U.S. patent application number 17/398902 was filed with the patent office on 2022-03-10 for inhibitors of integrated stress response pathway.
The applicant listed for this patent is Praxis Biotech LLC. Invention is credited to Sebastian BERNALES, Sarvajit CHAKRAVARTY, Luz Marina DELGADO OYARZO, Dayanand PANPATIL, Brahmam PUJALA, Gonzalo Andres URETA D AZ.
Application Number | 20220071966 17/398902 |
Document ID | / |
Family ID | |
Filed Date | 2022-03-10 |
United States Patent
Application |
20220071966 |
Kind Code |
A1 |
DELGADO OYARZO; Luz Marina ;
et al. |
March 10, 2022 |
INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
Abstract
The present disclosure relates generally to therapeutic agents
that may be useful as inhibitors of Integrated Stress Response
(ISR) pathway.
Inventors: |
DELGADO OYARZO; Luz Marina;
(Santiago, CL) ; URETA D AZ; Gonzalo Andres;
(Santiago, CL) ; PUJALA; Brahmam; (Greater Noida,
IN) ; PANPATIL; Dayanand; (Noida, IN) ;
BERNALES; Sebastian; (Piedmont, CA) ; CHAKRAVARTY;
Sarvajit; (Edmond, OK) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Praxis Biotech LLC |
San Francisco |
CA |
US |
|
|
Appl. No.: |
17/398902 |
Filed: |
August 10, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16432445 |
Jun 5, 2019 |
11166942 |
|
|
17398902 |
|
|
|
|
62681071 |
Jun 5, 2018 |
|
|
|
International
Class: |
A61K 31/428 20060101
A61K031/428; A61P 21/00 20060101 A61P021/00; A61P 25/28 20060101
A61P025/28; A61K 31/4468 20060101 A61K031/4468; A61K 31/4525
20060101 A61K031/4525; A61K 31/4709 20060101 A61K031/4709; A61K
31/495 20060101 A61K031/495; A61K 31/497 20060101 A61K031/497; A61K
31/538 20060101 A61K031/538; C07D 221/00 20060101 C07D221/00; C07D
241/04 20060101 C07D241/04; C07D 401/12 20060101 C07D401/12; C07D
403/12 20060101 C07D403/12; C07D 405/12 20060101 C07D405/12; C07D
413/12 20060101 C07D413/12; C07D 417/12 20060101 C07D417/12; C07K
16/00 20060101 C07K016/00; C12N 5/073 20060101 C12N005/073 |
Claims
1-20. (canceled)
21. A compound of formula (VI): ##STR00682## or a pharmaceutically
acceptable salt thereof, wherein: R.sup.24 is hydrogen or --C(O)OH;
R.sup.25 is hydrogen or halogen; L.sup.7 is selected from the group
consisting of ##STR00683## wherein the * represents the attachment
point to A.sup.7, and the # represents the attachment point to the
remainder of the molecule; L.sup.8 is selected from the group
consisting of ##STR00684## wherein the * represents the attachment
point to A.sup.8, and the # represents the attachment point to the
remainder of the molecule; A.sup.7 is selected from the group
consisting of phenyl, naphthyl, pyridyl, pyrazinyl, quinolinyl,
benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl, and
3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl;
A.sup.8 is selected from the group consisting of phenyl, naphthyl,
pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, and
3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl.
22. A compound of formula (VII): ##STR00685## or a pharmaceutically
acceptable salt thereof, wherein: R.sup.26 is hydrogen or --C(O)OH;
R.sup.27 is hydrogen or halogen; L.sup.9 is selected from the group
consisting of ##STR00686## wherein the * represents the attachment
point to A.sup.9, and the # represents the attachment point to the
remainder of the molecule; L.sup.10 is selected from the group
consisting of ##STR00687## wherein the * represents the attachment
point to A.sup.10, and the # represents the attachment point to the
remainder of the molecule; A.sup.9 is selected from the group
consisting of phenyl, naphthyl, pyridyl, pyrazinyl, quinolinyl,
benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl, and
3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl;
A.sup.10 is selected from the group consisting of phenyl, naphthyl,
pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, and
3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl.
23. A compound of formula (VIII): ##STR00688## or a
pharmaceutically acceptable salt thereof, wherein: R.sup.28 is
hydrogen or --C(O)OH; R.sup.29 is hydrogen or halogen; L.sup.11 is
selected from the group consisting of ##STR00689## wherein the *
represents the attachment point to A.sup.11, and the # represents
the attachment point to the remainder of the molecule; L.sup.12 is
selected from the group consisting of ##STR00690## wherein the *
represents the attachment point to A.sup.12, and the # represents
the attachment point to the remainder of the molecule; A.sup.11 is
selected from the group consisting of phenyl, naphthyl, pyridyl,
pyrazinyl, quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl,
benzothiazolyl, and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein
each of the phenyl, naphthyl, pyridyl, pyrazinyl, quinolinyl,
benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl;
A.sup.12 is selected from the group consisting of phenyl, naphthyl,
pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, and
3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl;
provided that the compound of formula (VIII) is not
##STR00691##
24-56. (canceled)
57. The compound of claim 21, or a pharmaceutically acceptable salt
thereof, wherein R.sup.24 and R.sup.25 are each hydrogen.
58. The compound of claim 21, or a pharmaceutically acceptable salt
thereof, wherein A.sup.7 is phenyl optionally substituted with 1,
2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl.
59. The compound of claim 21, or a pharmaceutically acceptable salt
thereof, wherein A.sup.7 is phenyl optionally substituted with 1,
2, 3, or 4 substituents selected from the group consisting of
halogen and C.sub.1-C.sub.6 haloalkyl.
60. The compound of claim 21, or a pharmaceutically acceptable salt
thereof, wherein L.sup.7 is selected from the group consisting of,
##STR00692## wherein the * represents the attachment point to
A.sup.7, and the # represents the attachment point to the remainder
of the molecule.
61. The compound of claim 21, or a pharmaceutically acceptable salt
thereof, wherein L.sup.7 is selected from the group consisting of
##STR00693## wherein the * represents the attachment point to
A.sup.7, and the # represents the attachment point to the remainder
of the molecule.
62. The compound of claim 21, or a pharmaceutically acceptable salt
thereof, wherein L.sup.8 is selected from the group consisting of
##STR00694## wherein the * represents the attachment point to
A.sup.8, and the # represents the attachment point to the remainder
of the molecule.
63. The compound of claim 21, or a pharmaceutically acceptable salt
thereof, wherein A.sup.8 is selected from the group consisting of
phenyl, naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl,
wherein each of the phenyl, naphthyl, pyridyl, pyrazinyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl.
64. The compound of claim 21, or a pharmaceutically acceptable salt
thereof, wherein A.sup.8 is selected from the group consisting of
phenyl, naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl,
wherein each of the phenyl, naphthyl, pyridyl, pyrazinyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6
haloalkyl.
65. The compound of claim 21, or a pharmaceutically acceptable salt
thereof, wherein the compound is selected from the group consisting
of ##STR00695## ##STR00696## ##STR00697## or a pharmaceutically
acceptable salt thereof.
66. The compound of claim 21, or a pharmaceutically acceptable salt
thereof, wherein the compound is ##STR00698## or a pharmaceutically
acceptable salt thereof.
67. The compound of claim 21, or a pharmaceutically acceptable salt
thereof, wherein the compound is ##STR00699## or a pharmaceutically
acceptable salt thereof.
68. The compound of claim 21, or a pharmaceutically acceptable salt
thereof, wherein the compound is ##STR00700## or a pharmaceutically
acceptable salt thereof.
69. The compound of claim 21, or a pharmaceutically acceptable salt
thereof, wherein the compound is ##STR00701## or a pharmaceutically
acceptable salt thereof.
70. A pharmaceutical composition comprising a compound of claim 21,
or a pharmaceutically acceptable salt thereof, and a
pharmaceutically acceptable carrier.
71. A method of treating a disease or disorder mediated by an
integrated stress response (ISR) pathway in an individual in need
thereof comprising administering to the individual a
therapeutically effective amount of a compound of claim 21, or a
pharmaceutically acceptable salt thereof.
72. The method of claim 71, wherein the compound, or the
pharmaceutically acceptable salt thereof, is administered in
combination with a therapeutically effective amount of one or more
additional anti-cancer agents.
73. The method of claim 71, wherein the disease or disorder is
mediated by phosphorylation of eIF2.alpha. and/or the guanine
nucleotide exchange factor (GEF) activity of eIF2B.
74. The method of claim 71, wherein the disease or disorder is
mediated by a decrease in protein synthesis.
75. The method of claim 71, wherein the disease or disorder is
mediated by the expression of ATF4, CHOP or BACE-1.
76. The method of claim 71, wherein the disease or disorder is a
neurodegenerative disease, an inflammatory disease, an autoimmune
disease, a metabolic syndrome, a cancer, a vascular disease, an
ocular disease, a musculoskeletal disease, or a genetic
disorder.
77. The method of claim 71, wherein the disease is vanishing white
matter disease, childhood ataxia with CNS hypomyelination,
intellectual disability syndrome, Alzheimer's disease, prion
disease, Creutzfeldt-Jakob disease, Parkinson's disease,
amyotrophic lateral sclerosis (ALS) disease, cognitive impairment,
frontotemporal dementia (FTD), traumatic brain injury,
postoperative cognitive dysfunction (PCD), neuro-otological
syndromes, hearing loss, Huntington's disease, stroke, chronic
traumatic encephalopathy, spinal cord injury, dementias or
cognitive impairment, arthritis, psoriatic arthritis, psoriasis,
juvenile idiopathic arthritis, asthma, allergic asthma, bronchial
asthma, tuberculosis, chronic airway disorder, cystic fibrosis,
glomerulonephritis, membranous nephropathy, sarcoidosis,
vasculitis, ichthyosis, transplant rejection, interstitial
cystitis, atopic dermatitis or inflammatory bowel disease, Crohn's
disease, ulcerative colitis, celiac disease, systemic lupus
erythematosus, type 1 diabetes, multiple sclerosis, rheumatoid
arthritis, alcoholic liver steatosis, obesity, glucose intolerance,
insulin resistance, hyperglycemia, fatty liver, dyslipidemia,
hyperlipidemia, type 2 diabetes, pancreatic cancer, breast cancer,
kidney cancer, bladder cancer, prostate cancer, testicular cancer,
urothelial cancer, endometrial cancer, ovarian cancer, cervical
cancer, renal cancer, esophageal cancer, gastrointestinal stromal
tumor (GIST), multiple myeloma, cancer of secretory cells, thyroid
cancer, gastrointestinal carcinoma, chronic myeloid leukemia,
hepatocellular carcinoma, colon cancer, melanoma, malignant glioma,
glioblastoma, glioblastoma multiforme, astrocytoma, dysplastic
gangliocytoma of the cerebellum, Ewing's sarcoma, rhabdomyosarcoma,
ependymoma, medulloblastoma, ductal adenocarcinoma, adenosquamous
carcinoma, nephroblastoma, acinar cell carcinoma, lung cancer,
non-Hodgkin's lymphoma, Burkitt's lymphoma, chronic lymphocytic
leukemia, monoclonal gammopathy of undetermined significance
(MGUS), plasmocytoma, lymphoplasmacytic lymphoma, acute
lymphoblastic leukemia, Pelizaeus-Merzbacher disease,
atherosclerosis, abdominal aortic aneurism, carotid artery disease,
deep vein thrombosis, Buerger's disease, chronic venous
hypertension, vascular calcification, telangiectasia or
lymphoedema, glaucoma, age-related macular degeneration,
inflammatory retinal disease, retinal vascular disease, diabetic
retinopathy, uveitis, rosacea, Sjogren's syndrome or
neovascularization in proliferative retinopathy,
hyperhomocysteinemia, skeletal muscle atrophy, myopathy, muscular
dystrophy, muscular wasting, sarcopenia, Duchenne muscular
dystrophy (DMD), Becker's disease, myotonic dystrophy, X-linked
dilated cardiomyopathy, spinal muscular atrophy (SMA), Down
syndrome, MEHMO syndrome, metaphyseal chondrodysplasia, Schmid type
(MCDS), depression, or social behavior impairment.
78. A method of producing a protein, comprising contacting a
eukaryotic cell comprising a nucleic acid encoding the protein with
the compound of claim 21, or salt thereof.
79. The method of claim 78, comprising culturing the cell in an in
vitro culture medium comprising the compound or salt.
80. A method of culturing a eukaryotic cell comprising a nucleic
acid encoding a protein, comprising contacting the eukaryotic cell
with an in vitro culture medium comprising the compound of claim
21, or salt thereof.
81. The method of claim 80, wherein the nucleic acid encoding the
protein is a recombinant nucleic acid.
82. The method of claim 80, wherein the cell is a human embryonic
kidney (HEK) cell or a Chinese hamster ovary (CHO) cell.
83. The method of claim 80, wherein the cell is a yeast cell, a
wheat germ cell, an insect cell, a rabbit reticulocyte, a cervical
cancer cell, a baby hamster kidney cell, a murine myeloma cell, an
HT-1080 cell, a PER.C6 cell, a plant cell, a hybridoma cell, or a
human blood derived leukocyte.
84. A method of producing a protein, comprising contacting a
cell-free protein synthesis (CFPS) system comprising eukaryotic
initiation factor 2 (eIF2) and a nucleic acid encoding a protein
with the compound of claim 21, or salt thereof.
85. The method of claim 84, wherein the protein is an antibody or a
fragment thereof.
86. The method of claim 84, wherein the protein is a recombinant
protein, an enzyme, an allergenic peptide, a cytokine, a peptide, a
hormone, erythropoietin (EPO), an interferon, a granulocyte-colony
stimulating factor (G-CSF), an anticoagulant, or a clotting
factor.
87. The method of claim 84, comprising purifying the protein.
88. An in vitro cell culture medium, comprising the compound of
claim 21, or salt thereof, and nutrients for cellular growth.
89. The cell culture medium of claim 88, comprising a eukaryotic
cell comprising a nucleic acid encoding a protein.
90. The cell culture medium of claim 88, further comprising a
compound for inducing protein expression.
91. The cell culture medium of claim 88, wherein the nucleic acid
encoding the protein is a recombinant nucleic acid.
92. The cell culture medium of claim 88, wherein the protein is an
antibody or a fragment thereof.
93. The cell culture medium of claim 88, wherein the protein is a
recombinant protein, an enzyme, an allergenic peptide, a cytokine,
a peptide, a hormone, erythropoietin (EPO), an interferon, a
granulocyte-colony stimulating factor (G-CSF), an anticoagulant, or
a clotting factor.
94. The cell culture medium of claim 88, wherein the eukaryotic
cell is a human embryonic kidney (HEK) cell or a Chinese hamster
ovary (CHO) cell.
95. The cell culture medium of claim 88, wherein the cell is a
yeast cell, a wheat germ cell, an insect cell, a rabbit
reticulocyte, a cervical cancer cell, a baby hamster kidney cell, a
murine myeloma cell, an HT-1080 cell, a PER.C6 cell, a plant cell,
a hybridoma cell, or a human blood derived leukocyte.
96. A cell-free protein synthesis (CFPS) system comprising
eukaryotic initiation factor 2 (eIF2) and a nucleic acid encoding a
protein with the compound of claim 21, or salt thereof.
97. The CFPS system of claim 96, comprising a eukaryotic cell
extract comprising eIF2.
98. The CFPS system of claim 96, further comprising eIF2B.
99. The CFPS system of claim 96, wherein the protein is an antibody
or a fragment thereof.
100. The CFPS system of claim 96, wherein the protein is a
recombinant protein, an enzyme, an allergenic peptide, a cytokine,
a peptide, a hormone, erythropoietin (EPO), an interferon, a
granulocyte-colony stimulating factor (G-CSF), an anticoagulant, or
a clotting factor.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the priority benefit of U.S.
Provisional Patent Application No. 62/681,071, filed Jun. 5, 2018,
the disclosure of which is hereby incorporated herein by reference
in its entirety.
FIELD
[0002] The present disclosure relates generally to therapeutic
agents that may be useful as inhibitors of Integrated Stress
Response (ISR) pathway.
BACKGROUND
[0003] Diverse cellular conditions and stresses activate a widely
conserved signaling pathway termed the Integrated Stress Response
(ISR) pathway. The ISR pathway is activated in response to
intrinsic and extrinsic stresses, such as viral infections,
hypoxia, glucose and amino acid deprivation, oncogene activation,
UV radiation, and endoplasmic reticulum stress. Upon activation of
ISR by one or more of these factors, the eukaryotic initiation
factor 2 (eIF2, which is comprised of three subunits, .alpha.,
.beta. and .gamma.) becomes phosphorylated in its .alpha.-subunit
and rapidly reduces overall protein translation by binding to the
eIF2B complex. This phosphorylation inhibits the eIF2B-mediated
exchange of GDP for GTP (i.e., a guanine nucleotide exchange factor
(GEF) activity), sequestering eIF2B in a complex with eIF2 and
reducing general protein translation of most mRNA in the cell.
Paradoxically, eIF2.alpha. phosphorylation also increases
translation of a subset of mRNAs that contain one or more upstream
open reading frames (uORFs) in their 5' untranslated region (UTR).
These transcripts include the transcriptional modulator activating
transcription factor 4 (ATF4), the transcription factor CHOP, the
growth arrest and DNA damage-inducible protein GADD34 and the
.beta.-secretase BACE-1.
[0004] In animals, the ISR modulates a broad translational and
transcriptional program involved in diverse processes such as
learning memory, immunity, intermediary metabolism, insulin
production and resistance to unfolded protein stress in the
endoplasmic reticulum, among others. Activation of the ISR pathway
has also been associated with numerous pathological conditions
including cancer, neurodegenerative diseases (such as amyotrophic
lateral sclerosis, Huntington disease, or prior disease), metabolic
diseases (metabolic syndrome), autoimmune diseases, inflammatory
diseases (such as cystic fibrosis), musculoskeletal diseases (such
as myopathy), vascular diseases, and ocular diseases.
BRIEF SUMMARY
[0005] Inhibitors of the Integrated Stress Response (ISR) pathway
are described, as are methods of making and using the compounds, or
salts thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[0006] FIG. 1 shows an IC.sub.50 titration for inhibition of ATF4
in stressed HEK293T cells using a luciferase assay for ISRIB
(trans-N,N'-1,4-cyclohexanediylbis[2-(4-chlorophenoxy)-acetamide).
ISRIB was found to have an IC.sub.50 of 5 nM.
[0007] FIG. 2 shows the percent recovery of protein translation in
stressed HEK293T cells after exposure to 10 nM, 31.6 nM, 100 nM,
316 nM, or 1000 nM of ISRIB.
[0008] FIG. 3 shows an IC.sub.50 titration for inhibition of ATF4
in stressed HEK293T cells using a luciferase assay for compound 4.
Compound 4 was found to have an IC.sub.50 of 3.1 nM.
[0009] FIG. 4 shows the percent recovery of protein translation in
stressed HEK293T cells after exposure to 1 .mu.M of ISRIB or
compound 4.
[0010] FIG. 5A shows long-term potentiation (LTP) of a stimulated
hippocampal slice from a WT C57BL/6 mouse or a transgenic APP/PS1
mouse with or without incubation with ISRIB. LTP was based on field
excitatory postsynaptic potential (fEPSP) slope, measured from 20
minutes prior to theta burst stimulation (TBS) to 60 minutes after
TBS.
[0011] FIG. 5B shows the LTP (based on fEPSP) for the stimulated
hippocampal slices after 60 minutes.
[0012] FIG. 6 shows ATF4 expression in unstressed condition (Veh)
or under Tg stress alone or in the presence of compound 58 at the
indicated concentration.
[0013] FIG. 7 shows ATF4 expression in SH-SY5Y cells after
incubation with CM from the 7PA2 CHO cells alone or in the presence
of compound 58 at the indicated concentrations.
[0014] FIG. 8A shows weight of fed mice and fasted mice treated
either with vehicle or compound 58.
[0015] FIG. 8B shows weight of quadriceps muscle in fed mice and in
fasted mice treated either with vehicle or compound 58.
[0016] FIG. 8C presents an immunoblot of puromycin labelling in
quadriceps samples of each mouse from fed or fasted animals treated
with vehicle or compound 58. Each lane corresponds to a sample
derived from each mouse.
[0017] FIG. 8D shows percent of protein synthesis in muscles from
fed or fasted animals treated with vehicle or compound 58.
[0018] FIG. 8E shows the expression of ATF4 and the muscle atrophy
marker, Atrogin-1, of quadriceps derived from fed mice or fasted
mice treated with vehicle or compound 58.
[0019] FIG. 8F shows percent of ATF4 expression of quadriceps
derived from fed mice or fasted mice treated with vehicle or
compound 58.
[0020] FIG. 8G shows percent of Atrogin expression of quadriceps
derived from fed mice or fasted mice treated with vehicle or
compound 58.
[0021] FIG. 9A presents an immunoblot of puromycin labelling in
gastrocnemius samples of mobile and immobile hind limb from mouse
treated with vehicle or compound 58. Each lane corresponds to a
sample derived from the indicated hind limb.
[0022] FIG. 9B shows percent of protein synthesis in mobile and
immobile hind limbs sections from gastrocnemius derived from mice
treated with vehicle or compound 58.
[0023] FIG. 9C shows the expression of ATF4 and the muscle atrophy
markers, Atrogin-1 and MuRF-1, of gastrocnemius derived from
mobilized and immobilized hind limbs of mice treated with vehicle
or compound 58.
[0024] FIG. 9D shows percent of ATF4 expression of gastrocnemius
derived from mobilized and immobilized hind limbs of mice treated
with vehicle or compound 58.
[0025] FIG. 9E shows percent of Atrogin-1 expression of
gastrocnemius derived from mobilized and immobilized hind limbs of
mice treated with vehicle or compound 58.
[0026] FIG. 9F shows percent of MuRF-1 expression of gastrocnemius
derived from mobilized and immobilized hind limbs of mice treated
with vehicle or compound 58.
[0027] FIG. 10A shows the expression of ATF4 and the muscle atrophy
markers, Atrogin-1 and MuRF-1, of gastrocnemius derived from
control and CT26 tumor-bearing mice treated with vehicle or
compound 58.
[0028] FIG. 10B shows percent of ATF4 expression of gastrocnemius
derived from control and CT26 tumor-bearing mice treated with
vehicle or compound 58.
[0029] FIG. 10C shows percent of Atrogin-1 expression of
gastrocnemius derived from control and CT26 tumor-bearing mice
treated with vehicle or compound 58.
[0030] FIG. 10D shows percent of MuRF-1 expression of gastrocnemius
derived from control and CT26 tumor-bearing mice treated with
vehicle or compound 58.
[0031] FIG. 11A shows the expression of ATF4 and the muscle atrophy
markers, Atrogin-1 and MuRF-1, of tibialis anterior derived from
control and denervated hind limbs of mice treated with vehicle or
compound 58.
[0032] FIG. 11B shows percent of ATF4 expression of tibialis
anterior derived from control and denervated hind limbs of mice
treated with vehicle or compound 58.
[0033] FIG. 11C shows percent of Atrogin-1 expression of tibialis
anterior derived from control and denervated hind limbs of mice
treated with vehicle or compound 58.
[0034] FIG. 11D shows percent of MuRF-1 expression of tibialis
anterior derived from control and denervated hind limbs of mice
treated with vehicle or compound 58.
[0035] FIG. 12A shows the expression of GFP after 24 hours in
untreated (Veh) or treated CHO cells with 1 .mu.M or 5 .mu.M
compound 58.
[0036] FIG. 12B shows percent expression of GFP after 24 hours in
untreated (Veh) or treated CHO cells with 1 .mu.M or 5 .mu.M
compound 58.
[0037] FIG. 13 shows the expression of PGRN after 48 hours in
untreated MEF cells (Unt), or MEF treated with transfection media
without siRNA mix (Veh) or treated with transfection media with
siRNA mix alone (GRN7) or in the presence of 1 NM or 5 .mu.M
compound 58.
DETAILED DESCRIPTION
[0038] Described herein are compounds, including therapeutic
agents, that can inhibit the ISR pathway. These compounds could be
used in the prevention and/or treatment of certain pathological
conditions as described herein, and/or in biotechnology
applications that would benefit from increased protein
translation.
Definitions
[0039] For use herein, unless clearly indicated otherwise, use of
the terms "a", "an" and the like refers to one or more.
[0040] Reference to "about" a value or parameter herein includes
(and describes) embodiments that are directed to that value or
parameter per se. For example, description referring to "about X"
includes description of "X".
[0041] "Alkyl" as used herein refers to and includes, unless
otherwise stated, a saturated linear (i.e., unbranched) or branched
univalent hydrocarbon chain or combination thereof, having the
number of carbon atoms designated (i.e., C.sub.1-C.sub.10 means one
to ten carbon atoms). Particular alkyl groups are those having 1 to
20 carbon atoms (a "C.sub.1-C.sub.20 alkyl"), having 1 to 10 carbon
atoms (a "C.sub.1-C.sub.10 alkyl"), having 6 to 10 carbon atoms (a
"C.sub.6-C.sub.10 alkyl"), having 1 to 6 carbon atoms (a
"C.sub.1-C.sub.6 alkyl"), having 2 to 6 carbon atoms (a
"C.sub.2-C.sub.6 alkyl"), or having 1 to 4 carbon atoms (a
"C.sub.1-C.sub.4 alkyl"). Examples of alkyl groups include, but are
not limited to, groups such as methyl, ethyl, n-propyl, isopropyl,
n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl,
n-octyl, n-nonyl, n-decyl, and the like.
[0042] "Alkylene" as used herein refers to the same residues as
alkyl, but having bivalency. Particular alkylene groups are those
having 1 to 20 carbon atoms (a "C.sub.1-C.sub.20 alkylene"), having
1 to 10 carbon atoms (a "C.sub.1-C.sub.10 alkylene"), having 6 to
10 carbon atoms (a "C.sub.6-C.sub.10 alkylene"), having 1 to 6
carbon atoms (a "C.sub.1-C.sub.6 alkylene"), 1 to 5 carbon atoms (a
"C.sub.1-C.sub.5 alkylene"), 1 to 4 carbon atoms (a
"C.sub.1-C.sub.4 alkylene") or 1 to 3 carbon atoms (a
"C.sub.1-C.sub.3 alkylene"). Examples of alkylene include, but are
not limited to, groups such as methylene (--CH.sub.2--), ethylene
(--CH.sub.2CH.sub.2--), propylene (--CH.sub.2CH.sub.2CH.sub.2--),
isopropylene (--CH.sub.2CH(CH.sub.3)--), butylene
(--CH.sub.2(CH.sub.2).sub.2CH.sub.2--), isobutylene
(--CH.sub.2CH(CH.sub.3)CH.sub.2--), pentylene
(--CH.sub.2(CH.sub.2).sub.3CH.sub.2--), hexylene
(--CH.sub.2(CH.sub.2).sub.4CH.sub.2--), heptylene
(--CH.sub.2(CH.sub.2).sub.5CH.sub.2--), octylene
(--CH.sub.2(CH.sub.2).sub.6CH.sub.2--), and the like.
[0043] "Alkenyl" as used herein refers to and includes, unless
otherwise stated, an unsaturated linear (i.e., unbranched) or
branched univalent hydrocarbon chain or combination thereof, having
at least one site of olefinic unsaturation (i.e., having at least
one moiety of the formula C.dbd.C) and having the number of carbon
atoms designated (i.e., C.sub.2-C.sub.10 means two to ten carbon
atoms). An alkenyl group may have "cis" or "trans" configurations,
or alternatively have "E" or "Z" configurations. Particular alkenyl
groups are those having 2 to 20 carbon atoms (a "C.sub.2-C.sub.20
alkenyl"), having 6 to 10 carbon atoms (a "C.sub.6-C.sub.10
alkenyl"), having 2 to 8 carbon atoms (a "C.sub.2-C.sub.8
alkenyl"), having 2 to 6 carbon atoms (a "C.sub.2-C.sub.6
alkenyl"), or having 2 to 4 carbon atoms (a "C.sub.2-C.sub.4
alkenyl"). Examples of alkenyl group include, but are not limited
to, groups such as ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or
allyl), 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl,
buta-1,3-dienyl, 2-methylbuta-1,3-dienyl, pent-1-enyl, pent-2-enyl,
hex-1-enyl, hex-2-enyl, hex-3-enyl, and the like.
[0044] "Alkenylene" as used herein refers to the same residues as
alkenyl, but having bivalency. Particular alkenylene groups are
those having 2 to 20 carbon atoms (a "C.sub.2-C.sub.20
alkenylene"), having 2 to 10 carbon atoms (a "C.sub.2-C.sub.10
alkenylene"), having 6 to 10 carbon atoms (a "C.sub.6-C.sub.10
alkenylene"), having 2 to 6 carbon atoms (a "C.sub.2-C.sub.6
alkenylene"), 2 to 4 carbon atoms (a "C.sub.2-C.sub.4 alkenylene")
or 2 to 3 carbon atoms (a "C.sub.2-C.sub.3 alkenylene"). Examples
of alkenylene include, but are not limited to, groups such as
ethenylene (or vinylene) (--CH.dbd.CH--), propenylene
(--CH.dbd.CHCH.sub.2--), 1,4-but-1-enylene
(--CH.dbd.CH--CH.sub.2CH.sub.2--), 1,4-but-2-enylene
(--CH.sub.2CH.dbd.CHCH.sub.2--), 1,6-hex-1-enylene
(--CH.dbd.CH--(CH.sub.2).sub.3CH.sub.2--), and the like.
[0045] "Alkynyl" as used herein refers to and includes, unless
otherwise stated, an unsaturated linear (i.e., unbranched) or
branched univalent hydrocarbon chain or combination thereof, having
at least one site of acetylenic unsaturation (i.e., having at least
one moiety of the formula C.ident.C) and having the number of
carbon atoms designated (i.e., C.sub.2-C.sub.10 means two to ten
carbon atoms). Particular alkynyl groups are those having 2 to 20
carbon atoms (a "C.sub.2-C.sub.20 alkynyl"), having 6 to 10 carbon
atoms (a "C.sub.6-C.sub.10 alkynyl"), having 2 to 8 carbon atoms (a
"C.sub.2-C.sub.8 alkynyl"), having 2 to 6 carbon atoms (a
"C.sub.2-C.sub.6 alkynyl"), or having 2 to 4 carbon atoms (a
"C.sub.2-C.sub.4 alkynyl"). Examples of alkynyl group include, but
are not limited to, groups such as ethynyl (or acetylenyl),
prop-1-ynyl, prop-2-ynyl (or propargyl), but-1-ynyl, but-2-ynyl,
but-3-ynyl, and the like.
[0046] "Alkynylene" as used herein refers to the same residues as
alkynyl, but having bivalency. Particular alkynylene groups are
those having 2 to 20 carbon atoms (a "C.sub.2-C.sub.20
alkynylene"), having 2 to 10 carbon atoms (a "C.sub.2-C.sub.10
alkynylene"), having 6 to 10 carbon atoms (a "C.sub.6-C.sub.10
alkynylene"), having 2 to 6 carbon atoms (a "C.sub.2-C.sub.6
alkynylene"), 2 to 4 carbon atoms (a "C.sub.2-C.sub.4 alkynylene")
or 2 to 3 carbon atoms (a "C.sub.2-C.sub.3 alkynylene"). Examples
of alkynylene include, but are not limited to, groups such as
ethynylene (or acetylenylene) (--C.ident.C--), propynylene
(--C.ident.CCH.sub.2--), and the like.
[0047] "Cycloalkyl" as used herein refers to and includes, unless
otherwise stated, saturated cyclic univalent hydrocarbon
structures, having the number of carbon atoms designated (i.e.,
C.sub.3-C.sub.10 means three to ten carbon atoms). Cycloalkyl can
consist of one ring, such as cyclohexyl, or multiple rings, such as
adamantyl. A cycloalkyl comprising more than one ring may be fused,
spiro or bridged, or combinations thereof. Particular cycloalkyl
groups are those having from 3 to 12 annular carbon atoms. A
preferred cycloalkyl is a cyclic hydrocarbon having from 3 to 8
annular carbon atoms (a "C.sub.3-C.sub.8 cycloalkyl"), having 3 to
6 carbon atoms (a "C.sub.3-C.sub.6 cycloalkyl"), or having from 3
to 4 annular carbon atoms (a "C.sub.3-C.sub.4 cycloalkyl").
Examples of cycloalkyl include, but are not limited to,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
norbornyl, and the like.
[0048] "Cycloalkylene" as used herein refers to the same residues
as cycloalkyl, but having bivalency. Cycloalkylene can consist of
one ring or multiple rings which may be fused, spiro or bridged, or
combinations thereof. Particular cycloalkylene groups are those
having from 3 to 12 annular carbon atoms. A preferred cycloalkylene
is a cyclic hydrocarbon having from 3 to 8 annular carbon atoms (a
"C.sub.3-C.sub.8 cycloalkylene"), having 3 to 6 carbon atoms (a
"C.sub.3-C.sub.6 cycloalkylene"), or having from 3 to 4 annular
carbon atoms (a "C.sub.3-C.sub.4 cycloalkylene"). Examples of
cycloalkylene include, but are not limited to, cyclopropylene,
cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene,
norbomylene, and the like. A cycloalkylene may attach to the
remaining structures via the same ring carbon atom or different
ring carbon atoms. When a cycloalkylene attaches to the remaining
structures via two different ring carbon atoms, the connecting
bonds may be cis- or trans- to each other. For example,
cyclopropylene may include 1,1-cyclopropylene and
1,2-cyclopropylene (e.g., cis-1,2-cyclopropylene or
trans-1,2-cyclopropylene), or a mixture thereof.
[0049] "Cycloalkenyl" refers to and includes, unless otherwise
stated, an unsaturated cyclic non-aromatic univalent hydrocarbon
structure, having at least one site of olefinic unsaturation (i.e.,
having at least one moiety of the formula C.dbd.C) and having the
number of carbon atoms designated (i.e., C.sub.2-C.sub.10 means two
to ten carbon atoms). Cycloalkenyl can consist of one ring, such as
cyclohexenyl, or multiple rings, such as norbornenyl. A preferred
cycloalkenyl is an unsaturated cyclic hydrocarbon having from 3 to
8 annular carbon atoms (a "C.sub.3-C.sub.8 cycloalkenyl"). Examples
of cycloalkenyl groups include, but are not limited to,
cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl,
norbornenyl, and the like.
[0050] "Cycloalkenylene" as used herein refers to the same residues
as cycloalkenyl, but having bivalency.
[0051] "Aryl" or "Ar" as used herein refers to an unsaturated
aromatic carbocyclic group having a single ring (e.g., phenyl) or
multiple condensed rings (e.g., naphthyl or anthryl) which
condensed rings may or may not be aromatic. Particular aryl groups
are those having from 6 to 14 annular carbon atoms (a
"C.sub.6-C.sub.14 aryl"). An aryl group having more than one ring
where at least one ring is non-aromatic may be connected to the
parent structure at either an aromatic ring position or at a
non-aromatic ring position. In one variation, an aryl group having
more than one ring where at least one ring is non-aromatic is
connected to the parent structure at an aromatic ring position.
[0052] "Arylene" as used herein refers to the same residues as
aryl, but having bivalency. Particular arylene groups are those
having from 6 to 14 annular carbon atoms (a "C.sub.6-C.sub.14
arylene").
[0053] "Heteroaryl" as used herein refers to an unsaturated
aromatic cyclic group having from 1 to 14 annular carbon atoms and
at least one annular heteroatom, including but not limited to
heteroatoms such as nitrogen, oxygen, and sulfur. A heteroaryl
group may have a single ring (e.g., pyridyl, furyl) or multiple
condensed rings (e.g., indolizinyl, benzothienyl) which condensed
rings may or may not be aromatic. Particular heteroaryl groups are
5 to 14-membered rings having 1 to 12 annular carbon atoms and 1 to
6 annular heteroatoms independently selected from nitrogen, oxygen,
and sulfur, 5 to 10-membered rings having 1 to 8 annular carbon
atoms and 1 to 4 annular heteroatoms independently selected from
nitrogen, oxygen, and sulfur, or 5, 6 or 7-membered rings having 1
to 5 annular carbon atoms and 1 to 4 annular heteroatoms
independently selected from nitrogen, oxygen, and sulfur. In one
variation, particular heteroaryl groups are monocyclic aromatic 5-,
6- or 7-membered rings having from 1 to 6 annular carbon atoms and
1 to 4 annular heteroatoms independently selected from nitrogen,
oxygen and sulfur. In another variation, particular heteroaryl
groups are polycyclic aromatic rings having from 1 to 12 annular
carbon atoms and 1 to 6 annular heteroatoms independently selected
from nitrogen, oxygen, and sulfur. A heteroaryl group having more
than one ring where at least one ring is non-aromatic may be
connected to the parent structure at either an aromatic ring
position or at a non-aromatic ring position. In one variation, a
heteroaryl group having more than one ring where at least one ring
is non-aromatic is connected to the parent structure at an aromatic
ring position. A heteroaryl group may be connected to the parent
structure at a ring carbon atom or a ring heteroatom.
[0054] "Heteroarylene" as used herein refers to the same residues
as heteroaryl, but having bivalency.
[0055] "Heterocycle", "heterocyclic", or "heterocyclyl" as used
herein refers to a saturated or an unsaturated non-aromatic cyclic
group having a single ring or multiple condensed rings, and having
from 1 to 14 annular carbon atoms and from 1 to 6 annular
heteroatoms, such as nitrogen, sulfur or oxygen, and the like. A
heterocycle comprising more than one ring may be fused, bridged or
spiro, or any combination thereof, but excludes heteroaryl. The
heterocyclyl group may be optionally substituted independently with
one or more substituents described herein. Particular heterocyclyl
groups are 3 to 14-membered rings having 1 to 13 annular carbon
atoms and 1 to 6 annular heteroatoms independently selected from
nitrogen, oxygen and sulfur, 3 to 12-membered rings having 1 to 11
annular carbon atoms and 1 to 6 annular heteroatoms independently
selected from nitrogen, oxygen and sulfur, 3 to 10-membered rings
having 1 to 9 annular carbon atoms and 1 to 4 annular heteroatoms
independently selected from nitrogen, oxygen and sulfur, 3 to
8-membered rings having 1 to 7 annular carbon atoms and 1 to 4
annular heteroatoms independently selected from nitrogen, oxygen
and sulfur, or 3 to 6-membered rings having 1 to 5 annular carbon
atoms and 1 to 4 annular heteroatoms independently selected from
nitrogen, oxygen and sulfur. In one variation, heterocyclyl
includes monocyclic 3-, 4-, 5-, 6- or 7-membered rings having from
1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6 annular carbon atoms and
1 to 2, 1 to 3, or 1 to 4 annular heteroatoms independently
selected from nitrogen, oxygen and sulfur. In another variation,
heterocyclyl includes polycyclic non-aromatic rings having from 1
to 12 annular carbon atoms and 1 to 6 annular heteroatoms
independently selected from nitrogen, oxygen and sulfur.
[0056] "Heterocyclylene" as used herein refers to the same residues
as heterocyclyl, but having bivalency.
[0057] "Halo" or "halogen" refers to elements of the Group 17
series having atomic number 9 to 85. Preferred halo groups include
the radicals of fluorine, chlorine, bromine and iodine. Where a
residue is substituted with more than one halogen, it may be
referred to by using a prefix corresponding to the number of
halogen moieties attached, e.g., dihaloaryl, dihaloalkyl,
trihaloaryl etc. refer to aryl and alkyl substituted with two
("di") or three ("tri") halo groups, which may be but are not
necessarily the same halogen; thus 4-chloro-3-fluorophenyl is
within the scope of dihaloaryl. An alkyl group in which each
hydrogen is replaced with a halo group is referred to as a
"perhaloalkyl." A preferred perhaloalkyl group is trifluoromethyl
(--CF.sub.3). Similarly, "perhaloalkoxy" refers to an alkoxy group
in which a halogen takes the place of each H in the hydrocarbon
making up the alkyl moiety of the alkoxy group. An example of a
perhaloalkoxy group is trifluoromethoxy (--OCF.sub.3).
[0058] "Carbonyl" refers to the group C.dbd.O.
[0059] "Thiocarbonyl" refers to the group C.dbd.S.
[0060] "Oxo" refers to the moiety .dbd.O.
[0061] "Optionally substituted" unless otherwise specified means
that a group may be unsubstituted or substituted by one or more
(e.g., 1, 2, 3, 4 or 5) of the substituents listed for that group
in which the substituents may be the same of different. In one
embodiment, an optionally substituted group has one substituent. In
another embodiment, an optionally substituted group has two
substituents. In another embodiment, an optionally substituted
group has three substituents. In another embodiment, an optionally
substituted group has four substituents. In some embodiments, an
optionally substituted group has 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2
to 3, 2 to 4, or 2 to 5 substituents. In one embodiment, an
optionally substituted group is unsubstituted.
[0062] Unless clearly indicated otherwise, "an individual" as used
herein intends a mammal, including but not limited to a primate,
human, bovine, horse, feline, canine, or rodent. In one variation,
the individual is a human.
[0063] As used herein, "treatment" or "treating" is an approach for
obtaining beneficial or desired results including clinical results.
For purposes of this disclosure, beneficial or desired results
include, but are not limited to, one or more of the following:
decreasing one more symptoms resulting from the disease,
diminishing the extent of the disease, stabilizing the disease
(e.g., preventing or delaying the worsening of the disease),
preventing or delaying the spread of the disease, delaying the
occurrence or recurrence of the disease, delay or slowing the
progression of the disease, ameliorating the disease state,
providing a remission (whether partial or total) of the disease,
decreasing the dose of one or more other medications required to
treat the disease, enhancing effect of another medication, delaying
the progression of the disease, increasing the quality of life,
and/or prolonging survival. The methods of the present disclosure
contemplate any one or more of these aspects of treatment.
[0064] As used herein, the term "effective amount" intends such
amount of a compound of the invention which should be effective in
a given therapeutic form. As is understood in the art, an effective
amount may be in one or more doses, i.e., a single dose or multiple
doses may be required to achieve the desired treatment endpoint. An
effective amount may be considered in the context of administering
one or more therapeutic agents (e.g., a compound, or
pharmaceutically acceptable salt thereof), and a single agent may
be considered to be given in an effective amount if, in conjunction
with one or more other agents, a desirable or beneficial result may
be or is achieved. Suitable doses of any of the co-administered
compounds may optionally be lowered due to the combined action
(e.g., additive or synergistic effects) of the compounds.
[0065] A "therapeutically effective amount" refers to an amount of
a compound or salt thereof sufficient to produce a desired
therapeutic outcome.
[0066] As used herein, "unit dosage form" refers to physically
discrete units, suitable as unit dosages, each unit containing a
predetermined quantity of active ingredient calculated to produce
the desired therapeutic effect in association with the required
pharmaceutical carrier. Unit dosage forms may contain a single or a
combination therapy.
[0067] As used herein, by "pharmaceutically acceptable" or
"pharmacologically acceptable" is meant a material that is not
biologically or otherwise undesirable, e.g., the material may be
incorporated into a pharmaceutical composition administered to a
patient without causing any significant undesirable biological
effects or interacting in a deleterious manner with any of the
other components of the composition in which it is contained.
Pharmaceutically acceptable carriers or excipients have preferably
met the required standards of toxicological and manufacturing
testing and/or are included on the Inactive Ingredient Guide
prepared by the U.S. Food and Drug administration.
[0068] "Pharmaceutically acceptable salts" are those salts which
retain at least some of the biological activity of the free
(non-salt) compound and which can be administered as drugs or
pharmaceuticals to an individual. Such salts, for example, include:
(1) acid addition salts, formed with inorganic acids such as
hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,
phosphoric acid, and the like; or formed with organic acids such as
acetic acid, oxalic acid, propionic acid, succinic acid, maleic
acid, tartaric acid and the like; (2) salts formed when an acidic
proton present in the parent compound either is replaced by a metal
ion, e.g., an alkali metal ion, an alkaline earth ion, or an
aluminum ion; or coordinates with an organic base. Acceptable
organic bases include ethanolamine, diethanolamine, triethanolamine
and the like. Acceptable inorganic bases include aluminum
hydroxide, calcium hydroxide, potassium hydroxide, sodium
carbonate, sodium hydroxide, and the like. Pharmaceutically
acceptable salts can be prepared in situ in the manufacturing
process, or by separately reacting a purified compound of the
present disclosure in its free acid or base form with a suitable
organic or inorganic base or acid, respectively, and isolating the
salt thus formed during subsequent purification.
[0069] The term "excipient" as used herein means an inert or
inactive substance that may be used in the production of a drug or
pharmaceutical, such as a tablet containing a compound of the
present disclosure as an active ingredient. Various substances may
be embraced by the term excipient, including without limitation any
substance used as a binder, disintegrant, coating,
compression/encapsulation aid, cream or lotion, lubricant,
solutions for parenteral administration, materials for chewable
tablets, sweetener or flavoring, suspending/gelling agent, or wet
granulation agent. Binders include, e.g., carbomers, povidone,
xanthan gum, etc.; coatings include, e.g., cellulose acetate
phthalate, ethylcellulose, gellan gum, maltodextrin, enteric
coatings, etc.; compression/encapsulation aids include, e.g.,
calcium carbonate, dextrose, fructose dc (dc="directly
compressible"), honey dc, lactose (anhydrate or monohydrate;
optionally in combination with aspartame, cellulose, or
microcrystalline cellulose), starch dc, sucrose, etc.;
disintegrants include, e.g., croscarmellose sodium, gellan gum,
sodium starch glycolate, etc.; creams or lotions include, e.g.,
maltodextrin, carrageenans, etc.; lubricants include, e.g.,
magnesium stearate, stearic acid, sodium stearyl fumarate, etc.;
materials for chewable tablets include, e.g., dextrose, fructose
dc, lactose (monohydrate, optionally in combination with aspartame
or cellulose), etc.; suspending/gelling agents include, e.g.,
carrageenan, sodium starch glycolate, xanthan gum, etc.; sweeteners
include, e.g., aspartame, dextrose, fructose dc, sorbitol, sucrose
dc, etc.; and wet granulation agents include, e.g., calcium
carbonate, maltodextrin, microcrystalline cellulose, etc.
[0070] The term "antibody" herein is used in the broadest sense and
encompasses various antibody structures, including but not limited
to monoclonal antibodies, polyclonal antibodies, multispecific
antibodies (e.g., bispecific antibodies), and antibody fragments so
long as they exhibit the desired antigen-binding activity.
[0071] An "antibody fragment" refers to a molecule other than an
intact antibody that comprises a portion of an intact antibody that
binds the antigen to which the intact antibody binds. Examples of
antibody fragments include but are not limited to Fv, Fab, Fab',
Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain
antibody molecules (e.g. scFv); and multispecific antibodies formed
from antibody fragments.
Compounds
[0072] In one aspect, provided is a compound of formula (I):
##STR00001##
or a pharmaceutically acceptable salt thereof, wherein: [0073]
m.sup.1, m.sup.2, n.sup.1, n.sup.2, p.sup.1, p.sup.2, q.sup.1, and
q.sup.2, independently of each other, are 0 or 1; [0074] r and s,
independently of each other, are 0, 1, or 2; [0075] X is N or
CR.sup.X; [0076] R.sup.X is selected from the group consisting of
hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, and
C.sub.2-C.sub.6 alkynyl; [0077] j is 0 or 1; [0078] R.sup.j-a and
R.sup.j-b are taken together to form an oxo (.dbd.O) substituent,
or R.sup.j-a and R.sup.j-b are both hydrogen; [0079] k is 0 or 1;
[0080] R.sup.N-k is H or C.sub.1-C.sub.6 alkyl; [0081] R.sup.N is H
or C.sub.1-C.sub.6 alkyl; [0082] A.sup.1 is selected from the group
consisting of: [0083] a substituent of formula (A.sup.1-a)
[0083] ##STR00002## [0084] wherein [0085] * represents the
attachment point to the remainder of the molecule; [0086] Z.sup.1
is selected from the group consisting of CR.sub.Z1-1R.sup.Z1-2,
NR.sup.Z1-2, C(R.sup.Z1-1R.sup.Z1-2)N(R.sup.Z1-2), O,
C(R.sup.Z1-1R.sup.Z1-2)O, S, C(R.sup.Z1-1R.sup.Z1-2)S, and
--CR.sup.Z1-1.dbd.CR.sup.Z1-1--; wherein R.sup.Z1-1 is H or
R.sup.14; and R.sup.Z1-2 is H or R.sup.14; [0087] Z.sup.2 is
selected from the group consisting of CR.sup.Z2-1R.sup.Z2-2,
NR.sup.Z2-2, C(R.sup.Z2-1R.sup.Z2-2)N(R.sup.Z2-2), O,
C(R.sup.Z2-1R.sup.Z2-2)O, S, C(R.sup.Z2-1R.sup.Z2-2)S, and
--CR.sup.Z2-1.dbd.CR.sup.Z2-1--; wherein R.sup.Z2-1 is H or
R.sup.14; and R.sup.Z2-2 is H or R.sup.14; [0088] Z.sup.3,
independently at each occurrence, is CH, CR.sup.14, or N; [0089]
R.sup.13 is hydrogen or R.sup.14, or R.sup.13 and R.sup.Z1-2 are
taken together to form a double bond between the carbon atom
bearing R.sup.13 and Z.sup.1, or R.sup.13 and R.sup.Z2-2 are taken
together to form a double bond between the carbon atom bearing
R.sup.13 and Z.sup.2; and [0090] x1 is 0, 1, 2, 3, or 4; [0091]
C.sub.6-C.sub.14 aryl optionally substituted with one or more
R.sup.14 substituents; and [0092] 5-14 membered heteroaryl
optionally substituted with one or more R.sup.14 substituents;
[0093] R.sup.14 is selected, independently at each occurrence, from
the group consisting of halogen, NO.sub.2, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6
haloalkyl, --OH, --O(C.sub.1-C.sub.6 alkyl), --O(C.sub.1-C.sub.6
haloalkyl), --SH, --S(C.sub.1-C.sub.6 alkyl), --S(C.sub.1-C.sub.6
haloalkyl), --NH.sub.2, --NH(C.sub.1-C.sub.6 alkyl),
--NH(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6 alkyl).sub.2,
--N(C.sub.1-C.sub.6 haloalkyl).sub.2, --NR.sup.14-aR.sup.14-b,
--CN, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), --C(O)NH.sub.2,
--C(O)NH(C.sub.1-C.sub.6 alkyl), --C(O)NH(C.sub.1-C.sub.6
haloalkyl), --C(O)N(C.sub.1-C.sub.6 alkyl).sub.2,
--C(O)N(C.sub.1-C.sub.6 haloalkyl).sub.2,
--C(O)NR.sup.14-aR.sup.14-b, --S(O).sub.2OH,
--S(O).sub.2O(C.sub.1-C.sub.6 alkyl), --S(O).sub.2O(C.sub.1-C.sub.6
haloalkyl), --S(O).sub.2NH.sub.2, --S(O).sub.2NH(C.sub.1-C.sub.6
alkyl), --S(O).sub.2NH(C.sub.1-C.sub.6haloalkyl),
--S(O).sub.2N(C.sub.1-C.sub.6 alkyl).sub.2,
--S(O).sub.2N(C.sub.1-C.sub.6 haloalkyl).sub.2,
--S(O).sub.2NR.sup.14-aR.sup.14-b, --OC(O)H,
--OC(O)(C.sub.1-C.sub.6 alkyl), --OC(O)(C.sub.1-C.sub.6 haloalkyl),
--N(H)C(O)H, --N(H)C(O)(C.sub.1-C.sub.6 alkyl),
--N(H)C(O)(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6
alkyl)C(O)H, --N(C.sub.1-C.sub.6 alkyl)C(O)(C.sub.1-C.sub.6 alkyl),
--N(C.sub.1-C.sub.6 alkyl)C(O)(C.sub.1-C.sub.6 haloalkyl),
--N(C.sub.1-C.sub.6 haloalkyl)C(O)H, --N(C.sub.1-C.sub.6
haloalkyl)C(O)(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
haloalkyl)C(O)(C.sub.1-C.sub.6 haloalkyl),
--OS(O).sub.2(C.sub.1-C.sub.6 alkyl), --OS(O).sub.2(C.sub.1-C.sub.6
haloalkyl), --N(H)S(O).sub.2(C.sub.1-C.sub.6 alkyl),
--N(H)S(O).sub.2(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6
alkyl)S(O).sub.2(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
alkyl)S(O).sub.2(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6
haloalkyl)S(O).sub.2(C.sub.1-C.sub.6 alkyl), and
--N(C.sub.1-C.sub.6 haloalkyl)S(O).sub.2(C.sub.1-C.sub.6
haloalkyl); [0094] wherein R.sup.14-a and R.sup.14-b are taken
together with the nitrogen atom to which they are attached to form
a 3-10 membered heterocycle; [0095] A.sup.2 is selected from the
group consisting of: [0096] a substituent of formula
(A.sup.2-a)
[0096] ##STR00003## [0097] wherein [0098] * represents the
attachment point to the remainder of the molecule; [0099] Z.sup.4
is selected from the group consisting of CR.sup.Z4-1R.sup.Z4-2,
NR.sup.Z4-2, C(R.sup.Z4-1R.sup.Z4-2)N(R.sup.Z4-2), O,
C(R.sup.Z4-1R.sup.Z4-2)O, S, C(R.sup.Z4-1R.sup.Z4-2)S, and
--CR.sup.Z4-1.dbd.CR.sup.Z4-1--; wherein R.sup.Z4-1 is H or
R.sup.16; and R.sup.Z4-2 is H or R.sup.16. [0100] Z.sup.5 is
selected from the group consisting of CR.sup.Z5-1R.sup.Z5-2,
NR.sup.Z5-2, C(R.sup.Z5-1R.sup.Z5-2)N(R.sup.Z5-2), O,
C(R.sup.Z5-1R.sup.Z5-2)O, S, C(R.sup.Z5-1R.sup.Z5-2)S, and
--CR.sup.Z5-1.dbd.CR.sup.Z5-1--; wherein R.sup.Z5-1 is H or
R.sup.16; and R.sup.Z5-2 is H or R.sup.16. [0101] Z.sup.6,
independently at each occurrence, is CH, CR.sup.16, or N; [0102]
R.sup.15 is hydrogen or R.sup.16, or R.sup.15 and R.sup.Z4-2 are
taken together to form a double bond between the carbon atom
bearing R.sup.15 and Z.sup.4, or R.sup.15 and R.sup.Z5-2 are taken
together to form a double bond between the carbon atom bearing
R.sup.15 and Z.sup.5; and [0103] x2 is 0, 1, 2, 3, or 4; [0104]
C.sub.6-C.sub.14 aryl optionally substituted with one or more
R.sup.16 substituents; and [0105] 5-14 membered heteroaryl
optionally substituted with one or more R.sup.16 substituents;
[0106] R.sup.16 is selected, independently at each occurrence, from
the group consisting of halogen, NO.sub.2, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6
haloalkyl, --OH, --O(C.sub.1-C.sub.6 alkyl), --O(C.sub.1-C.sub.6
haloalkyl), --SH, --S(C.sub.1-C.sub.6 alkyl), --S(C.sub.1-C.sub.6
haloalkyl), --NH.sub.2, --NH(C.sub.1-C.sub.6 alkyl),
--NH(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6 alkyl).sub.2,
--N(C.sub.1-C.sub.6 haloalkyl).sub.2, --NR.sup.16-aR.sup.16-b,
--CN, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), --C(O)NH.sub.2,
--C(O)NH(C.sub.1-C.sub.6 alkyl), --C(O)NH(C.sub.1-C.sub.6
haloalkyl), --C(O)N(C.sub.1-C.sub.6 alkyl).sub.2,
--C(O)N(C.sub.1-C.sub.6 haloalkyl).sub.2,
--C(O)NR.sup.16-aR.sup.16-b, --S(O).sub.2OH,
--S(O).sub.2O(C.sub.1-C.sub.6 alkyl), --S(O).sub.2O(C.sub.1-C.sub.6
haloalkyl), --S(O).sub.2NH.sub.2, --S(O).sub.2NH(C.sub.1-C.sub.6
alkyl), --S(O).sub.2NH(C.sub.1-C.sub.6 haloalkyl),
--S(O).sub.2N(C.sub.1-C.sub.6 alkyl).sub.2,
--S(O).sub.2N(C.sub.1-C.sub.6 haloalkyl).sub.2,
--S(O).sub.2NR.sup.16-aR.sup.16-b, --OC(O)H,
--OC(O)(C.sub.1-C.sub.6 alkyl), --OC(O)(C.sub.1-C.sub.6 haloalkyl),
--N(H)C(O)H, --N(H)C(O)(C.sub.1-C.sub.6 alkyl),
--N(H)C(O)(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6
alkyl)C(O)H, --N(C.sub.1-C.sub.6 alkyl)C(O)(C.sub.1-C.sub.6 alkyl),
--N(C.sub.1-C.sub.6 alkyl)C(O)(C.sub.1-C.sub.6 haloalkyl),
--N(C.sub.1-C.sub.6 haloalkyl)C(O)H, --N(C.sub.1-C.sub.6
haloalkyl)C(O)(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
haloalkyl)C(O)(C.sub.1-C.sub.6 haloalkyl),
--OS(O).sub.2(C.sub.1-C.sub.6 alkyl), --OS(O).sub.2(C.sub.1-C.sub.6
haloalkyl), --N(H)S(O).sub.2(C.sub.1-C.sub.6 alkyl),
--N(H)S(O).sub.2(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6
alkyl)S(O).sub.2(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
alkyl)S(O).sub.2(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6
haloalkyl)S(O).sub.2(C.sub.1-C.sub.6 alkyl), and
--N(C.sub.1-C.sub.6 haloalkyl)S(O).sub.2(C.sub.1-C.sub.6
haloalkyl); [0107] wherein R.sup.16-a and R.sup.16-b are taken
together with the nitrogen atom to which they are attached to form
a 3-10 membered heterocycle; [0108] R.sup.1a is selected from the
group consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH,
--C(O)O(C.sub.1-C.sub.6 alkyl), --C(O)O(C.sub.1-C.sub.6 haloalkyl),
and halogen, or R.sup.1a is taken together with R.sup.2a to form a
C.sub.1-C.sub.6 alkylene moiety, or R.sup.1a is taken together with
an R.sup.3a moiety to form a C.sub.1-C.sub.6 alkylene moiety;
[0109] R.sup.1b is selected from the group consisting of hydrogen,
C.sub.1-C.sub.6 alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; [0110] R.sup.2a is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; [0111] R.sup.2b is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; [0112] R.sup.3a
independently at each occurrence is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH,
--C(O)O(C.sub.1-C.sub.6 alkyl), --C(O)O(C.sub.1-C.sub.6 haloalkyl),
and halogen, or R.sup.3a is taken together with R.sup.4a to form a
C.sub.1-C.sub.6 alkylene moiety; [0113] R.sup.3b independently at
each occurrence is selected from the group consisting of hydrogen,
C.sub.1-C.sub.6 alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; [0114] R.sup.4a
independently at each occurrence is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH,
--C(O)O(C.sub.1-C.sub.6 alkyl), --C(O)O(C.sub.1-C.sub.6 haloalkyl),
and halogen; [0115] R.sup.4b independently at each occurrence is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; [0116] R.sup.5a
and R.sup.5b are taken together to form an oxo (.dbd.O) substituent
or an imido (.dbd.NH) substituent, or R.sup.5a and R.sup.5b are
both hydrogen; [0117] R.sup.6a is selected from the group
consisting of hydrogen, --OR.sup.6a-a, and --NR.sup.6a-bR.sup.6a-c;
[0118] R.sup.6b is hydrogen; [0119] or R.sup.6a and R.sup.6b are
taken together to form a moiety selected from the group consisting
of --O--CH.sub.2--CH.sub.2--, --CH.sub.2--O--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--, --O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--CH.sub.2--, and
--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--O--; [0120] R.sup.7a and
R.sup.7b are both hydrogen; [0121] R.sup.8a and R.sup.8b are taken
together to form an oxo (.dbd.O) substituent, or R.sup.8a and
R.sup.8b are both hydrogen; [0122] R.sup.9a and R.sup.9b are taken
together to form an oxo (.dbd.O) substituent or an imido (.dbd.NH)
substituent, or R.sup.9a and R.sup.9b are both hydrogen; [0123]
R.sup.10a is selected from the group consisting of hydrogen,
--OR.sup.10a-a, and --NR.sup.10a-bR.sup.10a-c and R.sup.10b is
hydrogen, or R.sup.10a and R.sup.10b are taken together to form a
moiety selected from the group consisting of
--O--CH.sub.2--CH.sub.2--, --CH.sub.2--O--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--, --O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--CH.sub.2--, and
--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--O--; [0124] R.sup.11a and
R.sup.11b are both hydrogen; [0125] R.sup.12a and R.sup.12b are
taken together to form an oxo (.dbd.O) substituent, or R.sup.12a
and R.sup.12b are both hydrogen; [0126] R.sup.6a-a is selected from
the group consisting of hydrogen, C.sub.1-C.sub.6 alkyl, and
C.sub.1-C.sub.6 haloalkyl, or R.sup.6a-a is taken together with
R.sup.N-k to form a carbonyl (C.dbd.O) moiety; [0127] R.sup.10a-a
is selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, and C.sub.1-C.sub.6 haloalkyl, or R.sup.10a-a is taken
together with R.sup.N to form a carbonyl (C.dbd.O) moiety; [0128]
R.sup.6a-b and R.sup.6a-c independently of each other, are selected
from the group consisting of hydrogen, C.sub.1-C.sub.6 alkyl, and
C.sub.1-C.sub.6 haloalkyl; and [0129] R.sup.10a-b and R.sup.10a-c,
independently of each other, are selected from the group consisting
of hydrogen, C.sub.1-C.sub.6 alkyl, and C.sub.1-C.sub.6
haloalkyl;
[0130] provided that: [0131] (i) when j is 1, then k is 1; [0132]
(ii) when m.sup.1 is 0, n.sup.1 is 0, q.sup.1 is 0, and p.sup.1 is
1, then R.sup.8a and R.sup.8b are taken together to form an oxo
(.dbd.O) substituent, and A.sup.1 is a substituent of formula
(A1-a)
[0132] ##STR00004## [0133] wherein [0134] * represents the
attachment point to the remainder of the molecule; [0135] Z.sup.1
is selected from the group consisting of CR.sup.Z1-1R.sup.Z1-2,
NR.sup.Z1-2, C(R.sup.Z1-1R.sup.Z1-2)N(R.sup.Z1-2), O,
C(R.sup.Z1-1R.sup.Z1-2)O, S, C(R.sup.Z1-1R.sup.Z1-2)S, and
--CR.sup.Z1-1.dbd.CR.sup.Z1-1--; [0136] wherein R.sup.Z1-1 is H or
R.sup.14; and R.sup.Z1-2 is H or R.sup.14; [0137] Z.sup.2 is
selected from the group consisting of CR.sup.Z2-1R.sup.Z2-2,
NR.sup.Z2-2, C(R.sup.Z2-1R.sup.Z2-2)N(R.sup.Z2-2), O,
C(R.sup.Z2-1R.sup.Z2-2)O, S, C(R.sup.Z2-1R.sup.Z2-2)S, and
--CR.sup.Z2-1.dbd.CR.sup.Z2-1--; [0138] wherein R.sup.Z2-1 is H or
R.sup.14; and R.sup.Z2-2 is H or R.sup.14; [0139] Z.sup.3,
independently at each occurrence, is CH, CR.sup.14, or N; R.sup.13
is hydrogen or R.sup.14, or R.sup.13 and R.sup.Z1-2 are taken
together to form a double bond between the carbon atom bearing
R.sup.13 and Z.sup.1, or R.sup.13 and R.sup.Z2-2 are taken together
to form a double bond between the carbon atom bearing R.sup.13 and
Z.sup.2; and [0140] x1 is 0, 1, 2, 3, or 4; and [0141] (iii) when
m.sup.2 is 0, n.sup.2 is 0, q.sup.2 is 0, and p.sup.2 is 1, then
R.sup.12a and R.sup.12b are taken together to form an oxo (.dbd.O)
substituent, and A.sup.2 is a substituent of formula
(A.sup.2-a)
[0141] ##STR00005## [0142] wherein [0143] * represents the
attachment point to the remainder of the molecule; [0144] Z.sup.4
is selected from the group consisting of CR.sup.Z4-1R.sup.Z4-2,
NR.sup.Z4-2, C(R.sup.Z4-1R.sup.Z4-2)N(R.sup.Z4-2), O,
C(R.sup.Z4-1R.sup.Z4-2)O, S, C(R.sup.Z4-1R.sup.Z4-2)S, and
--CR.sup.Z4-1.dbd.CR.sup.Z4-1--; [0145] wherein R.sup.Z4-1 is H or
R.sup.16; and R.sup.Z4-2 is H or R.sup.16. [0146] Z.sup.5 is
selected from the group consisting of CR.sup.Z5-1R.sup.Z5-2,
NR.sup.Z5-2, C(R.sup.Z5-1R.sup.Z5-2)N(R.sup.Z5-2), O,
C(R.sup.Z5-1R.sup.Z5-2)O, S, C(R.sup.Z5-1R.sup.Z5-2)S, and
--CR.sup.Z5-1.dbd.CR.sup.Z5-1--; [0147] wherein R.sup.Z5-1 is H or
R.sup.16; and R.sup.Z5-2 is H or R.sup.16. [0148] Z.sup.6,
independently at each occurrence, is CH, CR.sup.16, or N; [0149]
R.sup.15 is hydrogen or R.sup.16, or R.sup.15 and R.sup.Z5-2 are
taken together to form a double bond between the carbon atom
bearing R.sup.15 and Z.sup.4, or R.sup.15 and R.sup.Z5-2 are taken
together to form a double bond between the carbon atom bearing
R.sup.15 and Z.sup.5; and [0150] x2 is 0, 1, 2, 3, or 4; [0151]
(iv) when X is CR.sup.X, then k is 1; [0152] (v) when X is N, j is
1, and k is 1, then R.sup.j-a and R.sup.j-b are taken together to
form an oxo (.dbd.O) substituent; [0153] (vi) when X is N, j is 0
and k is 1; then at least one of (vi-a), (vi-b), (vi-c), or (vi-d)
applies: [0154] (vi-a) A.sup.1 is C.sub.6-C.sub.14 aryl substituted
with one or more R.sup.14 substituents; [0155] (vi-b) A.sup.1 is
5-14 membered heteroaryl optionally substituted with one or more
R.sup.14 substituents; [0156] (vi-c) A.sup.2 is C.sub.6-C.sub.14
aryl substituted with one or more R.sup.16 substituents; [0157]
(vi-d) A.sup.2 is 5-14 membered heteroaryl optionally substituted
with one or more R.sup.16 substituents; and [0158] (vii) when X is
N, j is 0, k is 0, m.sup.1 is 1, n.sup.1 is 0, p.sup.1 is 0, and
q.sup.1 is 0, then A.sup.1 is a substituent of formula
(A.sup.1-a).
[0159] In some embodiments of the compound of formula (I), X is
CR.sup.X and k is 1, and the compound of formula (I) is a compound
of formula (II):
##STR00006##
or a pharmaceutically acceptable salt thereof;
[0160] wherein m.sup.1, m.sup.2, n.sup.1, n.sup.2, p.sup.1,
p.sup.2, q.sup.1, q.sup.2, r, s, j, j, R.sup.j-a, R.sup.j-b,
R.sup.N-k, R.sup.N, A.sup.1, A.sup.2, R.sup.1a, R.sup.1b, R.sup.2a,
R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b, R.sup.5a,
R.sup.5b, R.sup.6a, R.sup.6b, R.sup.7a, R.sup.7b, R.sup.8a,
R.sup.8b, R.sup.9a, R.sup.9b, R.sup.10a, R.sup.10b, R.sup.11a,
R.sup.11b, R.sup.12a, and R.sup.12b are as defined in compounds of
formula (I).
[0161] In some embodiments of the compound of formula (I), X is N,
and the compound of formula (I) is a compound of formula (III):
##STR00007##
or a pharmaceutically acceptable salt thereof;
[0162] wherein m.sup.1, m.sup.2, n.sup.1, n.sup.2, p.sup.1,
p.sup.2, q.sup.1, q.sup.2, r, s, j, R.sup.j-a, R.sup.j-b, k,
R.sup.N-k, R.sup.N, A.sup.1, A.sup.2, R.sup.1a, R.sup.1b, R.sup.2a,
R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b, R.sup.5a,
R.sup.5b, R.sup.6a, R.sup.6b, R.sup.7a, R.sup.7b, R.sup.8a,
R.sup.8b, R.sup.9a, R.sup.9b, R.sup.10a, R.sup.10b, R.sup.11a,
R.sup.11b, R.sup.12a, and R.sup.12b are as defined in compounds of
formula (I).
[0163] In some embodiments of the compounds of formula (I), (II),
or (III), r is 0. In some embodiments of the compounds of formula
(I), (II), or (III), r is 1. In some embodiments of the compounds
of formula (I), (II), or (III), r is 2.
[0164] In some embodiments of the compounds of formula (I), (II),
or (III), s is 0. In some embodiments of the compounds of formula
(I), (II), or (III), s is 1. In some embodiments of the compounds
of formula (I), (II), or (III), s is 2.
[0165] In some embodiments of the compounds of formula (I), (II),
or (III), r is 1 and s is 1. In some embodiments, R.sup.1a is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen, or R.sup.1a is
taken together with R.sup.2a to form a C.sub.1-C.sub.6 alkylene
moiety, or R.sup.1a is taken together with an R.sup.3a moiety to
form a C.sub.1-C.sub.6 alkylene moiety; R.sup.1b is selected from
the group consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH,
--C(O)O(C.sub.1-C.sub.6 alkyl), --C(O)O(C.sub.1-C.sub.6 haloalkyl),
and halogen; R.sup.2a is selected from the group consisting of
hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6
alkyl), --C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; R.sup.2b
is selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; R.sup.3a is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; or R.sup.3a is
taken together with R.sup.4a to form a C.sub.1-C.sub.6 alkylene
moiety; R.sup.3b is selected from the group consisting of hydrogen,
C.sub.1-C.sub.6 alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; R.sup.4a is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; and R.sup.4b is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen. In some
embodiments, R.sup.1a is selected from the group consisting of
hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and halogen. In some
embodiments, R.sup.1a is hydrogen. In some embodiments, R.sup.1a is
C.sub.1-C.sub.6 alkyl. In some embodiments, R.sup.1a is methyl. In
some embodiments, R.sup.1a is --C(O)OH. In some embodiments,
R.sup.1a is halogen. In some embodiments, R.sup.1a is fluoro. In
some embodiments, R.sup.1b is selected from the group consisting of
hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and halogen. In some
embodiments, R.sup.1b is hydrogen. In some embodiments, R.sup.1b is
C.sub.1-C.sub.6 alkyl. In some embodiments, R.sup.1b is methyl. In
some embodiments, R.sup.1b is --C(O)OH. In some embodiments,
R.sup.1b is halogen. In some embodiments, R.sup.1b is fluoro. In
some embodiments, R.sup.2a is selected from the group consisting of
hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and halogen. In some
embodiments, R.sup.2a is hydrogen. In some embodiments, R.sup.2a is
C.sub.1-C.sub.6 alkyl. In some embodiments, R.sup.2a is methyl. In
some embodiments, R.sup.2a is --C(O)OH. In some embodiments,
R.sup.2a is halogen. In some embodiments, R.sup.2a is fluoro. In
some embodiments, R.sup.2b is selected from the group consisting of
hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and halogen. In some
embodiments, R.sup.2b is hydrogen. In some embodiments, R.sup.2b is
C.sub.1-C.sub.6 alkyl. In some embodiments, R.sup.2b is methyl. In
some embodiments, R.sup.2b is --C(O)OH. In some embodiments,
R.sup.2b is halogen. In some embodiments, R.sup.2b is fluoro. In
some embodiments, R.sup.3a is selected from the group consisting of
hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and halogen. In some
embodiments, R.sup.3a is hydrogen. In some embodiments, R.sup.3a is
C.sub.1-C.sub.6 alkyl. In some embodiments, R.sup.3a is methyl. In
some embodiments, R.sup.3a is --C(O)OH. In some embodiments,
R.sup.3a is halogen. In some embodiments, R.sup.3a is fluoro. In
some embodiments, R.sup.3b is selected from the group consisting of
hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and halogen. In some
embodiments, R.sup.3b is hydrogen. In some embodiments, R.sup.3b is
C.sub.1-C.sub.6 alkyl. In some embodiments, R.sup.3b is methyl. In
some embodiments, R.sup.3b is --C(O)OH. In some embodiments,
R.sup.3b is halogen. In some embodiments, R.sup.3b is fluoro. In
some embodiments, R.sup.4a is selected from the group consisting of
hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and halogen. In some
embodiments, R.sup.4a is hydrogen. In some embodiments, R.sup.4a is
C.sub.1-C.sub.6 alkyl. In some embodiments, R.sup.4a is methyl. In
some embodiments, R.sup.4a is --C(O)OH. In some embodiments,
R.sup.4a is halogen. In some embodiments, R.sup.4a is fluoro. In
some embodiments, R.sup.4b is selected from the group consisting of
hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and halogen. In some
embodiments, R.sup.4b is hydrogen. In some embodiments, R.sup.4b is
C.sub.1-C.sub.6 alkyl. In some embodiments, R.sup.4b is methyl. In
some embodiments, R.sup.4b is --C(O)OH. In some embodiments,
R.sup.4b is halogen. In some embodiments, R.sup.4b is fluoro. In
some embodiment, R.sup.1a is taken together with R.sup.2a to form a
C.sub.1-C.sub.6 alkylene moiety. In some embodiment, R.sup.1a is
taken together with R.sup.2a to form a methylene (--CH.sub.2--)
moiety. In some embodiment, R.sup.1a is taken together with
R.sup.2a to form an ethylene (--CH.sub.2--CH.sub.2--) moiety. In
some embodiment, R.sup.1a is taken together with R.sup.2a to form a
propylene (--CH.sub.2--CH.sub.2--CH.sub.2--) moiety. In some
embodiment, R.sup.1a is taken together with R.sup.3a to form a
C.sub.1-C.sub.6 alkylene moiety. In some embodiment, R.sup.1a is
taken together with R.sup.3a to form a methylene (--CH.sub.2--)
moiety. In some embodiment, R.sup.1a is taken together with
R.sup.3a to form an ethylene (--CH.sub.2--CH.sub.2--) moiety. In
some embodiment, R.sup.1a is taken together with R.sup.3a to form a
propylene (--CH.sub.2--CH.sub.2--CH.sub.2--) moiety. In some
embodiment, R.sup.3a is taken together with R.sup.4a to form a
C.sub.1-C.sub.6 alkylene moiety. In some embodiment, R.sup.3a is
taken together with R.sup.4a to form a methylene (--CH.sub.2--)
moiety. In some embodiment, R.sup.3a is taken together with
R.sup.4a to form an ethylene (--CH.sub.2--CH.sub.2--) moiety. In
some embodiment, R.sup.3a is taken together with R.sup.4a to form a
propylene (--CH.sub.2--CH.sub.2--CH.sub.2--) moiety. In some
embodiments, R.sup.1a, R.sup.1b, R.sup.2a, and R.sup.2b, are all
C.sub.1-C.sub.6 alkyl, and R3a R.sup.3b, R.sup.4a, and R.sup.4b are
all hydrogen. In some embodiments, R.sup.1a, R.sup.1b, R.sup.2a,
and R.sup.2b, are all methyl, and R3a R.sup.3b, R.sup.4a, and
R.sup.4b are all hydrogen. In some embodiments, R.sup.1a and
R.sup.2a are both C.sub.1-C.sub.6 alkyl, and Rib, R.sup.2b,
R.sup.3a, R.sup.3b, R.sup.4a, and R.sup.4b are all hydrogen. In
some embodiments, R.sup.1a and R.sup.2a are both methyl, and Rib,
R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4a, and R.sup.4b are all
hydrogen. In some embodiments, R.sup.1a is --C(O)OH and Rib,
R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4a, and R.sup.4b are
all hydrogen. In some embodiments, R3a is fluoro and R.sup.1a,
R.sup.1b, R.sup.2a, R.sup.2b, R.sup.3b, R.sup.4a, and R.sup.4b are
all hydrogen.
[0166] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.1 is 0, n.sup.1 is 0, p.sup.1 is 1, q.sup.1 is 0,
R.sup.8a and R.sup.8b are taken together to form an oxo (.dbd.O)
substituent, and A.sup.1 is a substituent of formula
(A.sup.1-a)
##STR00008## [0167] wherein [0168] * represents the attachment
point to the remainder of the molecule; [0169] Z.sup.1 is selected
from the group consisting of CR.sup.Z1-1R.sup.Z1-2, NR.sup.Z1-2,
C(R.sup.Z1-1R.sup.Z1-2)N(R.sup.Z1-2), O, C(R.sup.Z1-1R.sup.Z1-2)O,
S, C(R.sup.Z1-1R.sup.Z1-2)S, and --CR.sup.Z1-1.dbd.CR.sup.Z1-1--;
[0170] wherein R.sup.Z1-1 is H or R.sup.14; and R.sup.Z1-2 is H or
R.sup.14. [0171] Z.sup.2 is selected from the group consisting of
CR.sup.Z2-1R.sup.Z2-2, NR.sup.Z2-2,
C(R.sup.Z2-1R.sup.Z2-2)N(R.sup.Z2-2), O, C(R.sup.Z2-1R.sup.Z2-2)O,
S, C(R.sup.Z2-1R.sup.Z2-2)S, and --CR.sup.Z2-1.dbd.CR.sup.Z2-1--;
[0172] wherein R.sup.Z2-1 is H or R.sup.14; and R.sup.Z2-2 is H or
R.sup.14. [0173] Z.sup.3, independently at each occurrence, is CH,
CR.sup.14, or N; [0174] R.sup.13 is hydrogen or R.sup.14, or
R.sup.13 and R.sup.Z1-2 are taken together to form a double bond
between the carbon atom bearing R.sup.13 and Z.sup.1, or R.sup.13
and R.sup.Z2-2 are taken together to form a double bond between the
carbon atom bearing R.sup.13 and Z.sup.2; and [0175] x1 is 0, 1, 2,
3, or 4.
[0176] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.1 is 0, n.sup.1 is 0, p.sup.1 is 1, q.sup.1 is 0,
R.sup.8a and R.sup.8b are taken together to form an oxo (.dbd.O)
substituent, and A.sup.1 is a substituent of formula (A.sup.1-a)
selected from the group consisting of:
##STR00009##
[0177] In some embodiments, (A.sup.1-a) is (A.sup.1-b). In some
embodiments, (A.sup.1-a) is (A.sup.1-c). In some embodiments,
(A.sup.1-a) is (A.sup.1-d). In some embodiments, (A.sup.1-a) or
(A.sup.1-b) is selected from the group consisting of:
##STR00010##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b) is
selected from the group consisting of:
##STR00011##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b) is
selected from the group consisting of:
##STR00012##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b) is
selected from the group consisting of:
##STR00013##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b) is
selected from the group consisting of:
##STR00014##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00015##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00016##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00017##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00018##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00019##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00020##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00021##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00022##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00023##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00024##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00025##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-c) is
selected from the group consisting of:
##STR00026##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-c) is
selected from the group consisting of:
##STR00027##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-c)
is
##STR00028##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-c)
is
##STR00029##
wherein the * represents the attachment point to the remainder of
the molecule.
[0178] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.1 is 0, n.sup.1 is 0, p.sup.1 is 1, q.sup.1 is 1,
R.sup.8a and R.sup.8b are taken together to form an oxo (.dbd.O)
substituent.
[0179] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.1 is 1, n.sup.1 is 0, p.sup.1 is 0, and q.sup.1 is
1. In some embodiments, R.sup.5a, R.sup.5b, R.sup.6a, and R.sup.6b
are all hydrogen. In some embodiments, R.sup.5a and R.sup.5b are
taken together to form an oxo (.dbd.O) substituent or an imido
(.dbd.NH) substituent, and R.sup.6a and R.sup.6b are both hydrogen.
In some embodiments, R.sup.5a and R.sup.5b are taken together to
form an oxo (.dbd.O) substituent, and R.sup.6a and R.sup.6b are
both hydrogen. In some embodiments, R.sup.5a and R.sup.5b are taken
together to form an imido (.dbd.NH) substituent, and R.sup.6a and
R.sup.6b are both hydrogen. In some embodiments, R.sup.5a and
R.sup.5b are both hydrogen, and R.sup.6a and R.sup.6b are taken
together to form a moiety selected from the group consisting of
--O--CH.sub.2--CH.sub.2--, --CH.sub.2--O--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--, --O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--CH.sub.2--, and
--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--O--. In some embodiments,
R.sup.5a and R.sup.5b are both hydrogen, and R.sup.6a and R.sup.6b
are taken together to form a --CH.sub.2--O--CH.sub.2-- moiety.
[0180] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.1 is 1, n.sup.1 is 0, p.sup.1 is 0, and q.sup.1 is
0, R.sup.5a, R.sup.5b, R.sup.6a and R.sup.6b are all hydrogen, and
A.sup.1 is a substituent of formula (A.sup.1-a)
##STR00030## [0181] wherein [0182] * represents the attachment
point to the remainder of the molecule; [0183] Z.sup.1 is selected
from the group consisting of CR.sup.Z1-1R.sup.Z1-2, NR.sup.Z1-2,
C(R.sup.Z1-1R.sup.Z1-2)N(R.sup.Z1-2), O, C(R.sup.Z1-1R.sup.Z1-2)O,
S, C(R.sup.Z1-1R.sup.Z1-2)S, and --CR.sup.Z1-1.dbd.CR.sup.Z1-1--;
[0184] wherein R.sup.Z1-1 is H or R.sup.14; and R.sup.Z1-2 is H or
R.sup.14; [0185] Z.sup.2 is selected from the group consisting of
CR.sup.Z2-1R.sup.Z2-2, NR.sup.Z2-2,
C(R.sup.Z2-1R.sup.Z2-2)N(R.sup.Z2-2), O, C(R.sup.Z2-1R.sup.Z2-2)O,
S, C(R.sup.Z2-1R.sup.Z2-2)S, and --CR.sup.Z2-1.dbd.CR.sup.Z2-1--;
[0186] wherein R.sup.Z2-1 is H or R.sup.14; and R.sup.Z2-2 is H or
R.sup.14; [0187] Z.sup.3, independently at each occurrence, is CH,
CR.sup.14, or N; [0188] R.sup.13 is hydrogen or R.sup.14, or
R.sup.13 and R.sup.Z1-2 are taken together to form a double bond
between the carbon atom bearing R.sup.13 and Z.sup.1, or R.sup.13
and R.sup.Z2-2 are taken together to form a double bond between the
carbon atom bearing R.sup.13 and Z.sup.2; and [0189] x1 is 0, 1, 2,
3, or 4.
[0190] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.1 is 1, n.sup.1 is 0, p.sup.1 is 0, and q.sup.1 is
0, R.sup.5a, R.sup.5b, R.sup.6a, and R.sup.6b are all hydrogen, and
A.sup.1 is a substituent of formula (A.sup.1-a) selected from the
group consisting of:
##STR00031##
In some embodiments, (A.sup.1-a) is (A.sup.1-b). In some
embodiments, (A.sup.1-a) is (A.sup.1-c). In some embodiments,
(A.sup.1-a) is (A.sup.1-d). In some embodiments, (A.sup.1-a) or
(A.sup.1-b) is selected from the group consisting of:
##STR00032##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b) is
selected from the group consisting of:
##STR00033##
wherein the * represents the attachment point to remainder of the
molecule. In some embodiment, (A.sup.1-a) or (A.sup.1-b) is
selected from the group consisting of:
##STR00034##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b) is
selected from the group consisting of:
##STR00035##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b) is
selected from the group consisting of:
##STR00036##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00037##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00038##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00039##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00040##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00041##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00042##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00043##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00044##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00045##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00046##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00047##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-c) is
selected from the group consisting of:
##STR00048##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-c) is
selected from the group consisting of:
##STR00049##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-c)
is
##STR00050##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-c)
is
##STR00051##
wherein the * represents the attachment point to the remainder of
the molecule.
[0191] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.1 is 1, n.sup.1 is 0, p.sup.1 is 0, and q.sup.1 is
0; R5a, R.sup.5b, and R.sup.6b are all hydrogen, and R.sup.6a is
--OR.sup.6a-a or --NR.sup.6a-bR.sup.6a-c. In some embodiments,
R.sup.6a is --OR.sup.6a-a. In some embodiments, R.sup.6a is
--OR.sup.6a-a and R.sup.6a-a is hydrogen.
[0192] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.1 is 1, n.sup.1 is 0, p.sup.1 is 1, and q.sup.1 is
1. In some embodiments, R.sup.5a, R.sup.5b, R.sup.6b, R.sup.8a, and
R.sup.8b are all hydrogen, and R.sup.6a is selected from the group
consisting of hydrogen, --OR.sup.6a-a, and --NR.sup.6a-bR.sup.6a-c.
In some embodiments, R.sup.5a, R.sup.5b, R.sup.6a, R.sup.6b,
R.sup.8a, and R.sup.8b are all hydrogen. In some embodiments,
R.sup.5a, R.sup.5b, R.sup.6b, R.sup.8a, and R.sup.8b are all
hydrogen, and R.sup.6a is --OR.sup.6a-a. In some embodiments,
R.sup.5a, R.sup.5b, R.sup.6b, R.sup.8a, and R.sup.8b are all
hydrogen, R.sup.6a is --OR.sup.6a-a, and R.sup.6a-a is hydrogen. In
some embodiments, R.sup.5a, R.sup.5b, R.sup.6b, R.sup.8a, and
R.sup.8b are all hydrogen, and R.sup.6a is --NR.sup.6a-bR.sup.6a-c.
In some embodiments, R.sup.5a, R.sup.5b, R.sup.6b, R.sup.8a, and
R.sup.8b are all hydrogen, R.sup.6a is --NR.sup.6a-bR.sup.6a-c,
R.sup.6a-b and R.sup.6a-c are both hydrogen. In some embodiments,
R.sup.5a and R.sup.5b are taken together to form an oxo (.dbd.O)
substituent or an imido (.dbd.NH) substituent. In some embodiments,
R.sup.5a and R.sup.5b are taken together to form an oxo (.dbd.O)
substituent, R.sup.6b, R.sup.8a, and R.sup.8b are all hydrogen, and
R.sup.6a is selected from the group consisting of hydrogen,
--OR.sup.6a-a, and --NR.sup.6a-bR.sup.6a-c. In some embodiments,
R.sup.5a and R.sup.5b are taken together to form an oxo (.dbd.O)
substituent, and R.sup.6a, R.sup.6b, R.sup.8a, and R.sup.8b are all
hydrogen. In some embodiments, R.sup.5a and R.sup.5b are taken
together to form an oxo (.dbd.O) substituent, R.sup.6b, R.sup.8a,
and R.sup.8b are all hydrogen, and R.sup.6a is --OR.sup.6a-a. In
some embodiments, R.sup.5a and R.sup.5b are taken together to form
an oxo (.dbd.O) substituent, R.sup.6b, R.sup.8a, and R.sup.8b are
all hydrogen, R.sup.6a is --OR.sup.6a-a, and R.sup.6a-a is
hydrogen. In some embodiments, R.sup.5a and R.sup.5b are taken
together to form an oxo (.dbd.O) substituent, R.sup.6b, R.sup.8a,
and R.sup.8b are all hydrogen, and R.sup.6a is
--NR.sup.6a-bR.sup.6a-c. In some embodiments, R.sup.5a and R.sup.5b
are taken together to form an oxo (.dbd.O) substituent, R.sup.6b,
R.sup.8a, and R.sup.8b are all hydrogen, R.sup.6a is
--NR.sup.6a-bR.sup.6a-c, R.sup.6a-b and R.sup.6a-c are both
hydrogen. In some embodiments, R.sup.5a and R.sup.5b are taken
together to form an imido (.dbd.NH) substituent, R.sup.6b,
R.sup.8a, and R.sup.8b are all hydrogen, and R.sup.6a is selected
from the group consisting of hydrogen, --OR.sup.6a-a, and
--NR.sup.6a-bR.sup.6a-c. In some embodiments, R.sup.5a and R.sup.5b
are taken together to form an imido (.dbd.NH) substituent, and
R.sup.6a, R.sup.6b, R.sup.8a, and R.sup.8b are all hydrogen. In
some embodiments, R.sup.5a and R.sup.5b are taken together to form
an imido (.dbd.NH) substituent, R.sup.6b, R.sup.8a, and R.sup.8b
are all hydrogen, and R.sup.6a is --OR.sup.6a-a. In some
embodiments, R.sup.5a and R.sup.5b are taken together to form an
imido (.dbd.NH) substituent, R.sup.6b, R.sup.8a, and R.sup.8b are
all hydrogen, R.sup.6a is --OR.sup.6a-a, and R.sup.6a-a is
hydrogen. In some embodiments, R.sup.5a and R.sup.5b are taken
together to form an imido (.dbd.NH) substituent, R.sup.6b,
R.sup.8a, and R.sup.8b are all hydrogen, and R.sup.6a is
--NR.sup.6a-bR.sup.6a-c. In some embodiments, R.sup.5a and R.sup.5b
are taken together to form an imido (.dbd.NH) substituent,
R.sup.6b, R.sup.8a, and R.sup.8b are all hydrogen, R.sup.6a is
--NR.sup.6a-bR.sup.6a-c, R.sup.6a-b and R.sup.6a-c are both
hydrogen.
[0193] In some embodiments of the compounds of formula (I), (II),
or (III), k is 1, m.sup.1 is 1, n.sup.1 is 0, p.sup.1 is 1, q.sup.1
is 1, R.sup.6a is --OR.sup.6a-a, and R.sup.6a-a is taken together
with R.sup.N-k to form a carbonyl (C.dbd.O) moiety, and R.sup.5a,
R.sup.5b, R.sup.8a, and R.sup.8b are all hydrogen.
[0194] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.1 is 0, n.sup.1 is 1, p.sup.1 is 1, q.sup.1 is 1,
R.sup.7a, R.sup.7b, R.sup.8a, and R.sup.8b are all hydrogen.
[0195] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.2 is 0, n.sup.2 is 0, p.sup.2 is 1, q.sup.2 is 0,
R.sup.12a and R.sup.12b are taken together to form an oxo (.dbd.O)
substituent, and A.sup.2 is a substituent of formula
(A.sup.2-a)
##STR00052## [0196] wherein [0197] * represents the attachment
point to the remainder of the molecule; [0198] Z.sup.4 is selected
from the group consisting of CR.sup.Z4-1R.sup.Z4-2, NR.sup.Z4-2,
C(R.sup.Z4-1R.sup.Z4-2)N(R.sup.Z4-2), O, C(R.sup.Z4-1R.sup.Z4-2)O,
S, C(R.sup.Z4-1R.sup.Z4-2)S, and --CR.sup.Z4-1.dbd.CR.sup.Z4-1--;
[0199] wherein R.sup.Z4-1 is H or R.sup.16; and R.sup.Z4-2 is H or
R.sup.16. [0200] Z.sup.5 is selected from the group consisting of
CR.sup.Z5-1R.sup.Z4-2, NR.sup.Z4-2,
C(R.sup.Z5-1R.sup.Z5-2)N(R.sup.Z5-2), O, C(R.sup.Z5-1R.sup.Z5-2)O,
S, C(R.sup.Z5-1R.sup.Z5-2)S, and --CR.sup.Z5-1.dbd.CR.sup.Z5-1--;
[0201] wherein R.sup.Z5-1 is H or R.sup.16; and R.sup.Z5-2 is H or
R.sup.16. [0202] Z.sup.6, independently at each occurrence, is CH,
CR.sup.16, or N; [0203] R.sup.15 is hydrogen or R.sup.16, or
R.sup.15 and R.sup.Z4-2 are taken together to form a double bond
between the carbon atom bearing R.sup.15 and Z.sup.4, or R.sup.15
and R.sup.Z5-2 are taken together to form a double bond between the
carbon atom bearing R.sup.15 and Z.sup.5; and [0204] x2 is 0, 1, 2,
3, or 4;
[0205] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.2 is 0, n.sup.2 is 0, p.sup.2 is 1, q.sup.2 is 0,
R.sup.12a and R.sup.12b are taken together to form an oxo (.dbd.O)
substituent, and A.sup.2 is a substituent of formula (A.sup.2-a)
selected from the group consisting of:
##STR00053##
In some embodiments of the compounds of formula (1-1), (A.sup.2-a)
is (A.sup.2-b). In some embodiments of the compounds of formula
(1-1), (A.sup.2-a) is (A.sup.2-c). In some embodiments of the
compounds of formula (1-1), (A.sup.2-a) is (A.sup.2-d). In some
embodiments of the compounds of formula (1-1), (A.sup.2-a) or
(A.sup.2-b) is selected from the group consisting of:
##STR00054##
and wherein the * represents the attachment point to the remainder
of the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b) is
selected from the group consisting of:
##STR00055##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b) is
selected from the group consisting of:
##STR00056##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b) is
selected from the group consisting of:
##STR00057##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00058##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00059##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00060##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00061##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00062##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00063##
wherein the* represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00064##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00065##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00066##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00067##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00068##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00069##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments of the compounds of formula
(1-1), (A.sup.2-a) or (A.sup.2-c) is selected from the group
consisting of:
##STR00070##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-c) is
selected from the group consisting of:
##STR00071##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-c)
is
##STR00072##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-c)
is
##STR00073##
wherein the * represents the attachment point to the remainder of
the molecule.
[0206] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.2 is 0, n.sup.2 is 0, p.sup.2 is 1, q.sup.2 is 1,
R.sup.12a and R.sup.12b are taken together to form an oxo (.dbd.O)
substituent.
[0207] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.2 is 1, n.sup.2 is 0, p.sup.2 is 0, and q.sup.2 is
1. In some embodiments, R.sup.9a, R.sup.9b, R.sup.10a, and
R.sup.10b are all hydrogen. In some embodiments, R.sup.9a and
R.sup.9b are taken together to form an oxo (.dbd.O) substituent or
an imido (.dbd.NH) substituent, and R.sup.10a and R.sup.10b are
both hydrogen. In some embodiments, R.sup.9a and R.sup.9b are taken
together to form an oxo (.dbd.O) substituent, and R.sup.10a and
R.sup.10b are both hydrogen. In some embodiments, R.sup.9a and
R.sup.9b are taken together to form an imido (.dbd.NH) substituent,
and R.sup.10a and R.sup.10b are both hydrogen. In some embodiments,
R.sup.9a and R.sup.9b are both hydrogen, and R.sup.10a and
R.sup.10b are taken together to form a moiety selected from the
group consisting of --O--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--, --CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--CH.sub.2--, and
--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--O--. In some embodiments,
R.sup.9a and R.sup.9b are both hydrogen, and R.sup.10a and
R.sup.10b are taken together to form a --CH.sub.2--O--CH.sub.2--
moiety.
[0208] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.2 is 1, n.sup.2 is 0, p.sup.2 is 0, and q.sup.2 is
0. In some embodiments, R.sup.9a, R.sup.9b, and R.sup.10b are all
hydrogen, and R.sup.10a is selected from the group consisting of
hydrogen, --OR.sup.10a-a, and --NR.sup.10a-bR.sup.10a-c. In some
embodiments, R.sup.10a is hydrogen. In some embodiments, R.sup.10a
is --OR.sup.10a-a. In some embodiments, R.sup.10a is --OR.sup.10a-a
and R.sup.10a-a is hydrogen.
[0209] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.2 is 1, n.sup.2 is 0, p.sup.2 is 1, and q.sup.2 is
1. In some embodiments, R.sup.9a, R.sup.9b, R.sup.10b, R.sup.12a,
and R.sup.12b are all hydrogen, and R.sup.10a is selected from the
group consisting of hydrogen, --OR.sup.10a-a, and
--NR.sup.10a-bR.sup.10a-c. In some embodiments, R.sup.9a, R.sup.9b,
R.sup.10a, R.sup.10b, R.sup.12a, and R.sup.12b are all hydrogen. In
some embodiments, R.sup.9a, R.sup.9b, R.sup.10b, R.sup.12a, and
R.sup.12b are all hydrogen, and R.sup.10a is --OR.sup.10a-a. In
some embodiments, R.sup.9a, R.sup.9b, R.sup.10b, R.sup.12a, and
R.sup.12b are all hydrogen, R.sup.10a is --OR.sup.10a-a, and
R.sup.10a-a is hydrogen. In some embodiments, R.sup.9a, R.sup.9b,
R.sup.10b, R.sup.12a, and R.sup.12b are all hydrogen, and R.sup.10a
is --NR.sup.10a-bR.sup.10a-c. In some embodiments, R.sup.9a,
R.sup.9b, R.sup.10b, R.sup.12a, and R.sup.12b are all hydrogen,
R.sup.10a is --NR.sup.10a-bR.sup.10a-c, R.sup.10a-b and R.sup.10a-c
are both hydrogen. In some embodiments, R.sup.9a and R.sup.9b are
taken together to form an oxo (.dbd.O) substituent or an imido
(.dbd.NH) substituent. In some embodiments, R.sup.9a and R.sup.9b
are taken together to form an oxo (.dbd.O) substituent, R.sup.10b,
R.sup.12a, and R.sup.12b are all hydrogen, and R.sup.10a is
selected from the group consisting of hydrogen, --OR.sup.10a-a, and
--NR.sup.10a-bR.sup.10a-c. In some embodiments, R.sup.9a and
R.sup.9b are taken together to form an oxo (.dbd.O) substituent,
and R.sup.10a, R.sup.10b, R.sup.12a, and R.sup.12b are all
hydrogen. In some embodiments, R.sup.9a and R.sup.9b are taken
together to form an oxo (.dbd.O) substituent, R.sup.10b, R.sup.12a,
and R.sup.12b are all hydrogen, and R.sup.10a is --OR.sup.10a-a. In
some embodiments, R.sup.9a and R.sup.9b are taken together to form
an oxo (.dbd.O) substituent, R.sup.10b, R.sup.12a, and R.sup.12b
are all hydrogen, R.sup.10a is --OR.sup.10a-a, and R.sup.10a-a is
hydrogen. In some embodiments, R.sup.9a and R.sup.9b are taken
together to form an oxo (.dbd.O) substituent, R.sup.10b, R.sup.12a,
and R.sup.12b are all hydrogen, and R.sup.10a is
--NR.sup.10a-bR.sup.10a-c. In some embodiments, R.sup.9a and
R.sup.9b are taken together to form an oxo (.dbd.O) substituent,
R.sup.10b, R.sup.12a, and R.sup.12b are all hydrogen, R.sup.10a is
--NR.sup.10a-bR.sup.10a-c, R.sup.10a-b and R.sup.10a-c are both
hydrogen. In some embodiments, R.sup.9a and R.sup.9b are taken
together to form an imido (.dbd.NH) substituent, R.sup.10b,
R.sup.12a, and R.sup.12b are all hydrogen, and R.sup.10a is
selected from the group consisting of hydrogen, --OR.sup.10a-a, and
--NR.sup.10a-bR.sup.10a-c. In some embodiments, R.sup.9a and
R.sup.9b are taken together to form an imido (.dbd.NH) substituent,
and R.sup.10a, R.sup.10b, R.sup.12a, and R.sup.12b are all
hydrogen. In some embodiments, R.sup.9a and R.sup.9b are taken
together to form an imido (.dbd.NH) substituent, R.sup.10b,
R.sup.12a, and R.sup.12b are all hydrogen, and R.sup.10a is
--OR.sup.10a-a. In some embodiments, R.sup.9a and R.sup.9b are
taken together to form an imido (.dbd.NH) substituent, R.sup.10b,
R.sup.12a, and R.sup.12b are all hydrogen, R.sup.10a is
--OR.sup.10a-a, and R.sup.10a-a is hydrogen. In some embodiments,
R.sup.9a and R.sup.9b are taken together to form an imido (.dbd.NH)
substituent, R.sup.10b, R.sup.12a, and R.sup.12b are all hydrogen,
and R.sup.10a is --NR.sup.10a-bR.sup.10a-c. In some embodiments,
R.sup.9a and R.sup.9b are taken together to form an imido (.dbd.NH)
substituent, R.sup.10b, R.sup.12a, and R.sup.12b are all hydrogen,
R.sup.10a is --NR.sup.10a-bR.sup.10a-c, R.sup.10a-b and R.sup.10a-c
are both hydrogen.
[0210] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.2 is 1, n.sup.2 is 0, p.sup.2 is 1, q.sup.2 is 1,
R.sup.10a is --OR.sup.10a-a, and R.sup.10a-a is taken together with
R.sup.N to form a carbonyl (C.dbd.O) moiety, and R.sup.9a,
R.sup.9b, R.sup.12a, and R.sup.12b are all hydrogen.
[0211] In some embodiments of the compounds of formula (I), (II),
or (III), m.sup.2 is 0, n.sup.2 is 1, p.sup.2 is 1, q.sup.2 is 1,
R.sup.11a, R.sup.11b, R.sup.12a, and R.sup.12b are all
hydrogen.
[0212] In some embodiments of the compounds of formula (I), (II),
or (III), A.sup.1 is selected from the group consisting of
C.sub.6-C.sub.14 aryl optionally substituted with one or more
R.sup.14 substituents; and 5-14 membered heteroaryl optionally
substituted with one or more R.sup.14 substituents. In some
embodiments, A.sup.1 is C.sub.6-C.sub.14 aryl optionally
substituted with one or more R.sup.14 substituents. In some
embodiments, A.sup.1 is C.sub.6-C.sub.10 aryl optionally
substituted with one or more R.sup.14 substituents. In some
embodiments, A.sup.1 is selected from the group consisting of
##STR00074##
wherein the* represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is phenyl optionally
substituted with one or more R.sup.14 substituents. In some
embodiments, A.sup.1 is selected from the group consisting of
##STR00075##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00076##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00077##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00078##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00079##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00080##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00081##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is naphthyl optionally
substituted with one or more R.sup.14 substituents. In some
embodiments, A.sup.1 is selected from the group consisting of
##STR00082##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00083##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00084##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is 5-14 membered
heteroaryl optionally substituted with one or more R.sup.14
substituents. In some embodiments, A.sup.1 is 5-10 membered
heteroaryl optionally substituted with one or more R.sup.14
substituents. In some embodiments, A.sup.1 is selected from the
group consisting of
##STR00085##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is pyridyl optionally
substituted with one or more R.sup.14 substituents. In some
embodiments, A.sup.1 is
##STR00086##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00087##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00088##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is pyrazinyl optionally
substituted with one or more R.sup.14 substituents. In some
embodiments, A.sup.1 is
##STR00089##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is quinolinyl optionally
substituted with one or more R.sup.14 substituents. In some
embodiments, A.sup.1 is selected from the group consisting of
##STR00090##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00091##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is and
##STR00092##
wherein the * represents the attachment point to the remainder of
the molecule.
[0213] In some embodiments of the compounds of formula (I), (II),
or (III), A.sup.2 is selected from the group consisting of
C.sub.6-C.sub.14 aryl optionally substituted with one or more
R.sup.16 substituents; and 5-14 membered heteroaryl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is C.sub.6-C.sub.14 aryl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is C.sub.6-C.sub.10 aryl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is selected from the group consisting of
##STR00093##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is phenyl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is selected from the group consisting of
##STR00094##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00095##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00096##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00097##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00098##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00099##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00100##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is naphthyl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is selected from the group consisting of
##STR00101##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00102##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00103##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is 5-14 membered
heteroaryl optionally substituted with one or more R.sup.16
substituents. In some embodiments, A.sup.2 is 5-10 membered
heteroaryl optionally substituted with one or more R.sup.16
substituents. In some embodiments, A.sup.2 is selected from the
group consisting of
##STR00104##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is pyridyl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is
##STR00105##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00106##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00107##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is pyrazinyl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is
##STR00108##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is quinolinyl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is selected from the group consisting of
##STR00109##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00110##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is and
##STR00111##
wherein the * represents the attachment point to the remainder of
the molecule.
[0214] In some embodiments of the compound of formula (I) wherein X
is CR.sup.X and k is 1, and in some embodiments of the compound of
formula (II), j is 0 or 1. In some embodiments, j is 0. In some
embodiments, j is 1. In some embodiments, j is 1, and R.sup.j-a and
R.sup.j-b are taken together to form an oxo (.dbd.O) substituent.
In some embodiments, j is 1, and R.sup.j-a and R.sup.j-b are both
hydrogen.
[0215] In some embodiments of the compound of formula (I) wherein X
is CR.sup.X and k is 1, and in some embodiments of the compound of
formula (II), R.sup.X is selected from the group consisting of
hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, and
C.sub.2-C.sub.6 alkynyl. In some embodiments, R.sup.X is hydrogen
or C.sub.2-C.sub.6 alkynyl. In some embodiments, R.sup.X is
hydrogen. In some embodiments, R.sup.X is C.sub.2-C.sub.6 alkynyl.
In some embodiments, R.sup.X is ethynyl.
[0216] In some embodiments of the compound of formula (I) wherein X
is CR.sup.X and k is 1, and in some embodiments of the compound of
formula (II), r is 1, s is 1, R.sup.1a, R.sup.1b, R.sup.2a,
R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4a, and R.sup.4b are all
hydrogen, and R.sup.X is ethynyl.
[0217] In some embodiments of the compound of formula (I) wherein X
is CR.sup.X and k is 1, and in some embodiments of the compound of
formula (II), r is 1, s is 1, R.sup.1a, R.sup.1b, R.sup.2a,
R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4a, and R.sup.4b are all
hydrogen, and R.sup.X is hydrogen.
[0218] In some embodiments of the compound of formula (I) wherein X
is CR.sup.X and k is 1, and in some embodiments of the compound of
formula (II), r is 1, s is 1, R.sup.1a, R.sup.1b, R.sup.2a,
R.sup.2b, R.sup.3b, R.sup.4a, and R.sup.4b are all hydrogen,
R.sup.3a is fluoro, and R.sup.X is hydrogen.
[0219] In some embodiments of the compound of formula (I) wherein X
is CR.sup.X and k is 1, and in some embodiments of the compound of
formula (II), r is 1, s is 1, R.sup.1a is --C(O)OH, R.sup.1b,
R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4a, and R.sup.4b are
all hydrogen, and R.sup.X is hydrogen.
[0220] In some embodiments of the compound of formula (I) wherein X
is N, and in some embodiments of the compound of formula (III), j
is 0 and k is 0. In some embodiments, j is 0, k is 0, r is 1, s is
1, and R.sup.1a, R.sup.1b, R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b,
R.sup.4a, and R.sup.4b are all hydrogen.
[0221] In some embodiments of the compound of formula (I) wherein X
is N, and in some embodiments of the compound of formula (III), j
is 0 and k is 1. In some embodiments, j is 0, k is 1, r is 1, s is
1, and R.sup.1a, R.sup.1b, R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b,
R.sup.4a, and R.sup.4b are all hydrogen.
[0222] In some embodiments of the compound of formula (I) wherein X
is N, and in some embodiments of the compound of formula (III), j
is 1, R.sup.j-a and R.sup.j-b are taken together to form an oxo
(.dbd.O) substituent, and k is 1. In some embodiments, j is 1,
R.sup.j-a and R.sup.j-b are taken together to form an oxo (.dbd.O)
substituent, k is 1, r is 1, s is 1, and R.sup.1a, R.sup.1b,
R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4a, and R.sup.4b are
all hydrogen.
[0223] In some embodiments of the compounds of formula (II) is a
compound of formula (II-1-1), (II-1-2), or (II-1-3):
##STR00112##
[0224] In some embodiments of the compounds of formula (II) is a
compound of formula (II-2-1), (II-2-2), or (II-2-3):
##STR00113##
[0225] In some embodiments of the compounds of formula (II) is a
compound of formula (II-3-1), (II-3-2), or (II-3-3):
##STR00114##
[0226] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), and (II-3-3), R.sup.X is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, and C.sub.2-C.sub.6 alkynyl. In some embodiments, R.sup.X
is hydrogen or C.sub.2-C.sub.6 alkynyl. In some embodiments,
R.sup.X is hydrogen. In some embodiments, R.sup.X is
C.sub.2-C.sub.6 alkynyl. In some embodiments, R.sup.X is
ethynyl.
[0227] In some embodiments of the compounds of formula (III) is a
compound of formula (III-1-2) or (III-1-3):
##STR00115##
[0228] In some embodiments of the compounds of formula (III) is a
compound of formula (III-2-2) or (III-2-3):
##STR00116##
[0229] In some embodiments of the compounds of formula (III) is a
compound of formula (III-3-2) or (III-3-3):
##STR00117##
[0230] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.1a is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH,
--C(O)O(C.sub.1-C.sub.6 alkyl), --C(O)O(C.sub.1-C.sub.6 haloalkyl),
and halogen, or R.sup.1a is taken together with R.sup.2a to form a
C.sub.1-C.sub.6 alkylene moiety, or R.sup.1a is taken together with
an R.sup.3a moiety to form a C.sub.1-C.sub.6 alkylene moiety;
R.sup.1b is selected from the group consisting of hydrogen,
C.sub.1-C.sub.6 alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; R.sup.2a is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; R.sup.2b is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; R.sup.3a is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; or R.sup.3a is
taken together with R.sup.4a to form a C.sub.1-C.sub.6 alkylene
moiety; R.sup.3b is selected from the group consisting of hydrogen,
C.sub.1-C.sub.6 alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; R.sup.4a is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; and R.sup.4b is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen.
[0231] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.1a is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and
halogen. In some embodiments, R.sup.1a is hydrogen. In some
embodiments, R.sup.1a is C.sub.1-C.sub.6 alkyl. In some
embodiments, R.sup.1a is methyl. In some embodiments, R.sup.1a is
--C(O)OH. In some embodiments, R.sup.1a is halogen. In some
embodiments, R.sup.1a is fluoro.
[0232] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.1b is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and
halogen. In some embodiments, R.sup.1b is hydrogen. In some
embodiments, R.sup.1b is C.sub.1-C.sub.6 alkyl. In some
embodiments, R.sup.1b is methyl. In some embodiments, R.sup.1b is
--C(O)OH. In some embodiments, R.sup.1b is halogen. In some
embodiments, R.sup.1b is fluoro.
[0233] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.2a is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and
halogen. In some embodiments, R.sup.2a is hydrogen. In some
embodiments, R.sup.2a is C.sub.1-C.sub.6 alkyl. In some
embodiments, R.sup.2a is methyl. In some embodiments, R.sup.2a is
--C(O)OH. In some embodiments, R.sup.2a is halogen. In some
embodiments, R.sup.2a is fluoro.
[0234] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.2b is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and
halogen. In some embodiments, R.sup.2b is hydrogen. In some
embodiments, R.sup.2b is C.sub.1-C.sub.6 alkyl. In some
embodiments, R.sup.2b is methyl. In some embodiments, R.sup.2b is
--C(O)OH. In some embodiments, R.sup.2b is halogen. In some
embodiments, R.sup.2b is fluoro. In some embodiments, R.sup.3a is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, and halogen. In some embodiments, R.sup.3a is
hydrogen. In some embodiments, R.sup.3a is C.sub.1-C.sub.6 alkyl.
In some embodiments, R.sup.3a is methyl. In some embodiments,
R.sup.3a is --C(O)OH. In some embodiments, R.sup.3a is halogen.
[0235] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.3a is fluoro. In some embodiments,
R.sup.3b is selected from the group consisting of hydrogen,
C.sub.1-C.sub.6 alkyl, --C(O)OH, and halogen. In some embodiments,
R.sup.3b is hydrogen. In some embodiments, R.sup.3b is
C.sub.1-C.sub.6 alkyl. In some embodiments, R.sup.3b is methyl. In
some embodiments, R.sup.3b is --C(O)OH. In some embodiments,
R.sup.3b is halogen. In some embodiments, R.sup.3b is fluoro.
[0236] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.4a is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and
halogen. In some embodiments, R.sup.4a is hydrogen. In some
embodiments, R.sup.4a is C.sub.1-C.sub.6 alkyl. In some
embodiments, R.sup.4a is methyl. In some embodiments, R.sup.4a is
--C(O)OH. In some embodiments, R.sup.4a is halogen. In some
embodiments, R.sup.4a is fluoro.
[0237] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.4b is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH, and
halogen. In some embodiments, R.sup.4b is hydrogen. In some
embodiments, R.sup.4b is C.sub.1-C.sub.6 alkyl. In some
embodiments, R.sup.4b is methyl. In some embodiments, R.sup.4b is
--C(O)OH. In some embodiments, R.sup.4b is halogen. In some
embodiments, R.sup.4b is fluoro.
[0238] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.1a is taken together with R.sup.2a
to form a C.sub.1-C.sub.6 alkylene moiety. In some embodiment,
R.sup.1a is taken together with R.sup.2a to form a methylene
(--CH.sub.2--) moiety. In some embodiment, R.sup.1a is taken
together with R.sup.2a to form an ethylene (--CH.sub.2--CH.sub.2--)
moiety. In some embodiment, R.sup.1a is taken together with
R.sup.2a to form a propylene (--CH.sub.2--CH.sub.2--CH.sub.2--)
moiety.
[0239] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.1a is taken together with R.sup.3a
to form a C.sub.1-C.sub.6 alkylene moiety. In some embodiment,
R.sup.1a is taken together with R.sup.3a to form a methylene
(--CH.sub.2--) moiety. In some embodiment, R.sup.1a is taken
together with R.sup.3a to form an ethylene (--CH.sub.2--CH.sub.2--)
moiety. In some embodiment, R.sup.1a is taken together with
R.sup.3a to form a propylene (--CH.sub.2--CH.sub.2--CH.sub.2--)
moiety.
[0240] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.3a is taken together with R.sup.4a
to form a C.sub.1-C.sub.6 alkylene moiety. In some embodiment,
R.sup.3a is taken together with R.sup.4a to form a methylene
(--CH.sub.2--) moiety. In some embodiment, R.sup.3a is taken
together with R.sup.4a to form an ethylene (--CH.sub.2--CH.sub.2--)
moiety. In some embodiment, R.sup.3a is taken together with
R.sup.4a to form a propylene (--CH.sub.2--CH.sub.2--CH.sub.2--)
moiety.
[0241] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.1a, R.sup.1b, R.sup.2a, and
R.sup.2b, are all C.sub.1-C.sub.6 alkyl, and R.sup.3a, R.sup.3b,
R.sup.4a, and R.sup.4b are all hydrogen. In some embodiments,
R.sup.1a, R.sup.1b, R.sup.2a, and R.sup.2b, are all methyl, and
R.sup.3a, R.sup.3b, R.sup.4a, and R.sup.4b are all hydrogen.
[0242] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.1a and R.sup.2a are both
C.sub.1-C.sub.6 alkyl, and Rib, R.sup.2b, R.sup.3a, R.sup.3b,
R.sup.4a, and R.sup.4b are all hydrogen. In some embodiments,
R.sup.1a and R.sup.2a are both methyl, and Rib, R.sup.2b, R.sup.3a,
R.sup.3b, R.sup.4a, and R.sup.4b are all hydrogen.
[0243] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.1a is --C(O)OH and Rib, R.sup.2a,
R.sup.2b, R.sup.3a, R.sup.3b, R.sup.4a, and R.sup.4b are all
hydrogen.
[0244] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (II-2-1), (II-2-2), (II-2-3), (II-3-1),
(II-3-2), (II-3-3), (III-1-2), (III-1-3), (III-2-2), (III-2-3),
(III-3-2), and (III-3-3), R.sup.3a is fluoro and R.sup.1a,
R.sup.1b, R.sup.2a, R.sup.2b, R.sup.3b, R.sup.4a, and R.sup.4b are
all hydrogen.
[0245] In some embodiments of the compounds of formulae (II-1-2),
(II-2-2), (II-3-2), (III-1-2), (III-2-2), and (III-3-2), q.sup.1 is
1. In some embodiments, R.sup.5a, R.sup.5b, R.sup.6a, and R.sup.6b
are all hydrogen. In some embodiments, R.sup.5a and R.sup.8b are
taken together to form an oxo (.dbd.O) substituent or an imido
(.dbd.NH) substituent, and R.sup.6a and R.sup.6b are both hydrogen.
In some embodiments, R.sup.5a and R.sup.5b are taken together to
form an oxo (.dbd.O) substituent, and R.sup.6a and R.sup.6b are
both hydrogen. In some embodiments, R.sup.5a and R.sup.5b are taken
together to form an imido (.dbd.NH) substituent, and R.sup.6a and
R.sup.6b are both hydrogen. In some embodiments, R.sup.5a and
R.sup.5b are both hydrogen, and R.sup.6a and R.sup.6b are taken
together to form a moiety selected from the group consisting of
--O--CH.sub.2--CH.sub.2--, --CH.sub.2--O--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--, --O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--CH.sub.2--, and
--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--O--. In some embodiments,
R.sup.5a and R.sup.5b are both hydrogen, and R.sup.6a and R.sup.6b
are taken together to form a --CH.sub.2--O--CH.sub.2-- moiety.
[0246] In some embodiments of the compounds of formulae (II-1-2),
(II-2-2), (II-3-2), (III-1-2), (III-2-2), and (III-3-2), q.sup.1 is
0; R.sup.5a, R.sup.5b, and R.sup.6b are all hydrogen, and R.sup.6a
is --OR.sup.6a-a or --NR.sup.6a-bR.sup.6a-c. In some embodiments,
R.sup.6a is --OR.sup.6a-a. In some embodiments, R.sup.6a is
--OR.sup.6a-a and R.sup.6a-a is hydrogen.
[0247] In some embodiments of the compounds of formulae (II-1-3),
(II-2-3), (II-3-3), (III-1-3), (III-2-3), and (III-3-3), q.sup.1 is
1. In some embodiments, R.sup.5a, R.sup.5b, R.sup.6b, R.sup.8a, and
R.sup.8b are all hydrogen, and R.sup.6a is selected from the group
consisting of hydrogen, --OR.sup.6a-a, and --NR.sup.6a-bR.sup.6a-c
In some embodiments, R.sup.5a, R.sup.5b, R.sup.6a, R.sup.6b,
R.sup.8a, and R.sup.8b are all hydrogen. In some embodiments,
R.sup.5a, R.sup.5b, R.sup.6b, R.sup.8a, and R.sup.8b are all
hydrogen, and R.sup.6a is --OR.sup.6a-a. In some embodiments,
R.sup.5a, R.sup.5b, R.sup.6b, R.sup.8a, and R.sup.8b are all
hydrogen, R.sup.6a is --OR.sup.6a-a, and R.sup.6a-a is hydrogen. In
some embodiments, R.sup.5a, R.sup.5b, R.sup.6b, R.sup.8a, and
R.sup.8b are all hydrogen, and R.sup.6a is --NR.sup.6a-bR.sup.6a-c.
In some embodiments, R.sup.5a, R.sup.5b, R.sup.6b, R.sup.8a, and
R.sup.8b are all hydrogen, R.sup.6a is --NR.sup.6a-bR.sup.6a-c,
R.sup.6a-b and R.sup.6a-c are both hydrogen. In some embodiments,
R.sup.5a and R.sup.5b are taken together to form an oxo (.dbd.O)
substituent or an imido (.dbd.NH) substituent. In some embodiments,
R.sup.5a and R.sup.5b are taken together to form an oxo (.dbd.O)
substituent, R.sup.6b, R.sup.8a, and R.sup.8b are all hydrogen, and
R.sup.6a is selected from the group consisting of hydrogen,
--OR.sup.6a-a, and --NR.sup.6a-bR.sup.6a-c. In some embodiments,
R.sup.5a and R.sup.5b are taken together to form an oxo (.dbd.O)
substituent, and R.sup.6a, R.sup.6b, R.sup.8a, and R.sup.8b are all
hydrogen. In some embodiments, R.sup.5a and R.sup.5b are taken
together to form an oxo (.dbd.O) substituent, R.sup.6b, R.sup.8a,
and R.sup.8b are all hydrogen, and R.sup.6a is --OR.sup.6a-a. In
some embodiments, R.sup.5a and R.sup.5b are taken together to form
an oxo (.dbd.O) substituent, R.sup.6b, R.sup.8a, and R.sup.8b are
all hydrogen, R.sup.6a is --OR.sup.6a-a, and R.sup.6a-a is
hydrogen. In some embodiments, R.sup.5a and R.sup.5b are taken
together to form an oxo (.dbd.O) substituent, R.sup.6b, R.sup.8a,
and R.sup.8b are all hydrogen, and R.sup.6a is
--NR.sup.6a-bR.sup.6a-c. In some embodiments, R.sup.5a and R.sup.5b
are taken together to form an oxo (.dbd.O) substituent, R.sup.6b,
R.sup.8a, and R.sup.8b are all hydrogen, R.sup.6a is
--NR.sup.6a-bR.sup.6a-c, R.sup.6a-b and R.sup.6a-c are both
hydrogen. In some embodiments, R.sup.5a and R.sup.5b are taken
together to form an imido (.dbd.NH) substituent, R.sup.6b,
R.sup.8a, and R.sup.8b are all hydrogen, and R.sup.6a is selected
from the group consisting of hydrogen, --OR.sup.6a-a, and
--NR.sup.6a-bR.sup.6a-c. In some embodiments, R.sup.5a and R.sup.5b
are taken together to form an imido (.dbd.NH) substituent, and
R.sup.6a, R.sup.6b, R.sup.8a, and R.sup.8b are all hydrogen. In
some embodiments, R.sup.5a and R.sup.5b are taken together to form
an imido (.dbd.NH) substituent, R.sup.6b, R.sup.8a, and R.sup.8b
are all hydrogen, and R.sup.6a is --OR.sup.6a-a. In some
embodiments, R.sup.5a and R.sup.5b are taken together to form an
imido (.dbd.NH) substituent, R.sup.6b, R.sup.8a, and R.sup.8b are
all hydrogen, R.sup.6a is --OR.sup.6a-a, and R.sup.6a-a is
hydrogen. In some embodiments, R.sup.5a and R.sup.5b are taken
together to form an imido (.dbd.NH) substituent, R.sup.6b,
R.sup.8a, and R.sup.8b are all hydrogen, and R.sup.6a is
--NR.sup.6a-bR.sup.6a-c. In some embodiments, R.sup.5a and R.sup.5b
are taken together to form an imido (.dbd.NH) substituent,
R.sup.6b, R.sup.8a, and R.sup.8b are all hydrogen, R.sup.6a is
--NR.sup.6a-bR.sup.6a-c, R.sup.6a-b and R.sup.6a-c are both
hydrogen.
[0248] In some embodiments of the compounds of formulae (II-1-3),
(II-2-3), (II-3-3), (III-1-3), (III-2-3), and (III-3-3), q.sup.1 is
1, R.sup.6a is --OR.sup.6a-a, and R.sup.6a-a is taken together with
R.sup.N-k to form a carbonyl (C.dbd.O) moiety, and R.sup.5a,
R.sup.5b, R.sup.8a, and R.sup.8b are all hydrogen.
[0249] In some embodiments of the compounds of formulae (II-2-1),
(II-2-2), (II-2-3), (III-2-2), and (III-2-3), q.sup.2 is 1. In some
embodiments, R.sup.9a, R.sup.9b, R.sup.10a, and R.sup.10b are all
hydrogen. In some embodiments, R.sup.9a and R.sup.9b are taken
together to form an oxo (.dbd.O) substituent or an imido (.dbd.NH)
substituent, and R.sup.10a and R.sup.10b are both hydrogen. In some
embodiments, R.sup.9a and R.sup.9b are taken together to form an
oxo (.dbd.O) substituent, and R.sup.10a and R.sup.10b are both
hydrogen. In some embodiments, R.sup.9a and R.sup.9b are taken
together to form an imido (.dbd.NH) substituent, and R.sup.10a and
R.sup.10b are both hydrogen. In some embodiments, R.sup.9a and
R.sup.9b are both hydrogen, and R.sup.10a and R.sup.10b are taken
together to form a moiety selected from the group consisting of
--O--CH.sub.2--CH.sub.2--, --CH.sub.2--O--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--, --O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--CH.sub.2--, and
--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--O--. In some embodiments,
R.sup.9a and R.sup.9b are both hydrogen, and R.sup.10a and
R.sup.10b are taken together to form a --CH.sub.2--O--CH.sub.2--
moiety.
[0250] In some embodiments of the compounds of formulae (II-2-1),
(II-2-2), (II-2-3), (III-2-2), and (III-2-3), q.sup.2 is 0. In some
embodiments, R.sup.9a, R.sup.9b, and R.sup.10b are all hydrogen,
and R.sup.10a is selected from the group consisting of hydrogen,
--OR.sup.10a-a, and --NR.sup.10a-bR.sup.10a-c. In some embodiments,
R.sup.10a is hydrogen. In some embodiments, R.sup.10a is
--OR.sup.10a-a. In some embodiments, R.sup.10a is --OR.sup.10a-a
and R.sup.10a-a is hydrogen.
[0251] In some embodiments of the compounds of formulae (II-3-1),
(II-3-2), (II-3-3), (III-3-2), and (III-3-3), q.sup.2 is 1. In some
embodiments, R.sup.9a, R.sup.9b, R.sup.10b, R.sup.12a, and
R.sup.12b are all hydrogen, and R.sup.10a is selected from the
group consisting of hydrogen, --OR.sup.10a-a, and
--NR.sup.10a-bR.sup.10a-c. In some embodiments, R.sup.9a, R.sup.9b,
R.sup.10a, R.sup.10b, R.sup.12a, and R.sup.12b are all hydrogen. In
some embodiments, R.sup.9a, R.sup.9b, R.sup.10b, R.sup.12a, and
R.sup.12b are all hydrogen, and R.sup.10a is --OR.sup.10a-a. In
some embodiments, R.sup.9a, R.sup.9b, R.sup.10b, R.sup.12a, and
R.sup.12b are all hydrogen, R.sup.10a is --OR.sup.10a-a, and
R.sup.10a-a is hydrogen. In some embodiments, R.sup.9a, R.sup.9b,
R.sup.10b, R.sup.12a, and R.sup.12b are all hydrogen, and R.sup.10a
is --NR.sup.10a-bR.sup.10a-c. In some embodiments, R.sup.9a,
R.sup.9b, R.sup.10b, R.sup.12a, and R.sup.12b are all hydrogen,
R.sup.10a is --NR.sup.10a-bR.sup.10a-c, R.sup.10a-b and R.sup.10a-c
are both hydrogen. In some embodiments, R.sup.9a and R.sup.9b are
taken together to form an oxo (.dbd.O) substituent or an imido
(.dbd.NH) substituent. In some embodiments, R.sup.9a and R.sup.9b
are taken together to form an oxo (.dbd.O) substituent, R.sup.10,
R.sup.12a, and R.sup.12b are all hydrogen, and R.sup.10a is
selected from the group consisting of hydrogen, --OR.sup.10a-a, and
--NR.sup.10a-bR.sup.10a-c. In some embodiments, R.sup.9a and
R.sup.9b are taken together to form an oxo (.dbd.O) substituent,
and R.sup.10a, R.sup.10b, R.sup.12a, and R.sup.12b are all
hydrogen. In some embodiments, R.sup.9a and R.sup.9b are taken
together to form an oxo (.dbd.O) substituent, R.sup.10, R.sup.12a,
and R.sup.12b are all hydrogen, and R.sup.10a is --OR.sup.10a-a. In
some embodiments, R.sup.9a and R.sup.9b are taken together to form
an oxo (.dbd.O) substituent, R.sup.10b, R.sup.12a, and R.sup.12b
are all hydrogen, R.sup.10a is --OR.sup.10a-a, and R.sup.10a-a is
hydrogen. In some embodiments, R.sup.9a and R.sup.9b are taken
together to form an oxo (.dbd.O) substituent, R.sup.10b, R.sup.12a,
and R.sup.12b are all hydrogen, and R.sup.10a is
--NR.sup.10a-bR.sup.10a-c. In some embodiments, R.sup.9a and
R.sup.9b are taken together to form an oxo (.dbd.O) substituent,
R.sup.10b, R.sup.12a, and R.sup.12b are all hydrogen, R.sup.10a is
--NR.sup.10a-bR.sup.10a-c, R.sup.10a-b and R.sup.10a-c are both
hydrogen. In some embodiments, R.sup.9a and R.sup.9b are taken
together to form an imido (.dbd.NH) substituent, R.sup.10b,
R.sup.12a, and R.sup.12b are all hydrogen, and R.sup.10a is
selected from the group consisting of hydrogen, --OR.sup.10a-a, and
--NR.sup.10a-bR.sup.10a-c. In some embodiments, R.sup.9a and
R.sup.9b are taken together to form an imido (.dbd.NH) substituent,
and R.sup.10a, R.sup.10b, R.sup.12a, and R.sup.12b are all
hydrogen. In some embodiments, R.sup.9a and R.sup.9b are taken
together to form an imido (.dbd.NH) substituent, R.sup.10b,
R.sup.12a, and R.sup.12b are all hydrogen, and R.sup.10a is
--OR.sup.10a-a. In some embodiments, R.sup.9a and R.sup.9b are
taken together to form an imido (.dbd.NH) substituent, R.sup.10b,
R.sup.12a, and R.sup.12b are all hydrogen, R.sup.10a is
--OR.sup.10a-a, and R.sup.10a-a is hydrogen. In some embodiments,
R.sup.9a and R.sup.9b are taken together to form an imido (.dbd.NH)
substituent, R.sup.10b, R.sup.12a, and R.sup.12b are all hydrogen,
and R.sup.10a is --NR.sup.10a-bR.sup.10a-c. In some embodiments,
R.sup.9a and R.sup.9b are taken together to form an imido (.dbd.NH)
substituent, R.sup.10b, R.sup.12a, and R.sup.12b are all hydrogen,
R.sup.10a is --NR.sup.10a-bR.sup.10a-c, R.sup.10a-b and R.sup.10a-c
are both hydrogen.
[0252] In some embodiments of the compounds of formulae (II-3-1),
(II-3-2), (II-3-3), (III-3-2), and (III-3-3), q.sup.2 is 1,
R.sup.10a is --OR.sup.10a-a, and R.sup.10a-a is taken together with
R.sup.N to form a carbonyl (C.dbd.O) moiety, and R.sup.9a,
R.sup.9b, R.sup.12a, and R.sup.12b are all hydrogen.
[0253] In some embodiments of the compounds of formulae (II-1-1),
(II-2-1), and (II-3-1), A.sup.1 is a substituent of formula
(A.sup.1-a) selected from the group consisting of:
##STR00118##
In some embodiments, (A.sup.1-a) is (A.sup.1-b). In some
embodiments, (A.sup.1-a) is (A.sup.1-c). In some embodiments,
(A.sup.1-a) is (A.sup.1-d). In some embodiments, (A.sup.1-a) or
(A.sup.1-b) is selected from the group consisting of:
##STR00119##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b) is
selected from the group consisting of:
##STR00120##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b) is
selected from the group consisting of:
##STR00121##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b) is
selected from the group consisting of:
##STR00122##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b) is
selected from the group consisting of:
##STR00123##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00124##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00125##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00126##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00127##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00128##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00129##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00130##
Wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00131##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00132##
Wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00133##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-b)
is
##STR00134##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-c) is
selected from the group consisting of:
##STR00135##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-c) is
selected from the group consisting of:
##STR00136##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-c)
is
##STR00137##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.1-a) or (A.sup.1-c)
is
##STR00138##
wherein the * represents the attachment point to the remainder of
the molecule.
[0254] In some embodiments of the compounds of formulae (II-1-2),
(II-1-3), (II-2-2), (II-2-3), (II-3-2), (II-3-3), (III-1-2),
(III-1-3), (III-2-2), (III-2-3), (III-3-2), and (III-3-3), A.sup.1
is selected from the group consisting of C.sub.6-C.sub.14 aryl
optionally substituted with one or more R.sup.14 substituents; and
5-14 membered heteroaryl optionally substituted with one or more
R.sup.14 substituents. In some embodiments, A.sup.1 is
C.sub.6-C.sub.14 aryl optionally substituted with one or more
R.sup.14 substituents. In some embodiments, A.sup.1 is
C.sub.6-C.sub.10 aryl optionally substituted with one or more
R.sup.14 substituents. In some embodiments, A.sup.1 is selected
from the group consisting of
##STR00139##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is phenyl optionally
substituted with one or more R.sup.14 substituents. In some
embodiments, A.sup.1 is selected from the group consisting of
##STR00140##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00141##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00142##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00143##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1
##STR00144##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00145##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00146##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is naphthyl optionally
substituted with one or more R.sup.14 substituents. In some
embodiments, A.sup.1 is selected from the group consisting of
##STR00147##
wherein the represents the attachment point to the remainder of the
molecule. In some embodiments, A.sup.1 is
##STR00148##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00149##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is 5-14 membered
heteroaryl optionally substituted with one or more R.sup.14
substituents. In some embodiments, A.sup.1 is 5-10 membered
heteroaryl optionally substituted with one or more R.sup.14
substituents. In some embodiments, A.sup.1 is selected from the
group consisting of
##STR00150##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is pyridyl optionally
substituted with one or more R.sup.14 substituents. In some
embodiments, A.sup.1 is
##STR00151##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00152##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00153##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is pyrazinyl optionally
substituted with one or more R.sup.14 substituents. In some
embodiments, A.sup.1 is
##STR00154##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is quinolinyl optionally
substituted with one or more R.sup.14 substituents. In some
embodiments, A.sup.1 is selected from the group consisting of
##STR00155##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is
##STR00156##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.1 is and
##STR00157##
wherein the * represents the attachment point to the remainder of
the molecule.
[0255] In some embodiments of the compounds of formulae (II-1-1),
(II-1-2), (II-1-3), (III-1-3), and (III-2-2), A.sup.2 is a
substituent of formula (A.sup.2-a) selected from the group
consisting of:
##STR00158##
[0256] In some embodiments of the compounds of formula (1-1),
(A.sup.2-a) is (A.sup.2-b). In some embodiments of the compounds of
formula (1-1), (A.sup.2-a) is (A.sup.2-c). In some embodiments of
the compounds of formula (1-1), (A.sup.2-a) is (A.sup.2-d). In some
embodiments of the compounds of formula (1-1), (A.sup.2-a) or
(A.sup.2-b) is selected from the group consisting of:
##STR00159##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b) is
selected from the group consisting of:
##STR00160##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b) is
selected from the group consisting of:
##STR00161##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b) is
selected from the group consisting of:
##STR00162##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00163##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00164##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00165##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00166##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00167##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00168##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00169##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00170##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00171##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00172##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00173##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-b)
is
##STR00174##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments of the compounds of formula
(1-1), (A.sup.2-a) or (A.sup.2-c) is selected from the group
consisting of:
##STR00175##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-c) is
selected from the group consisting of:
##STR00176##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-c)
is
##STR00177##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, (A.sup.2-a) or (A.sup.2-c)
is
##STR00178##
wherein the * represents the attachment point to the remainder of
the molecule.
[0257] In some embodiments of the compounds of formulae (II-2-1),
(II-2-2), (II-2-3), (II-3-1), (II-3-2), (II-3-3), (III-2-2),
(III-2-3), (III-3-2), and (III-3-3), A.sup.2 is selected from the
group consisting of C.sub.6-C.sub.14 aryl optionally substituted
with one or more R.sup.16 substituents; and 5-14 membered
heteroaryl optionally substituted with one or more R.sup.16
substituents. In some embodiments, A.sup.2 is C.sub.6-C.sub.14 aryl
optionally substituted with one or more R.sup.16 substituents. In
some embodiments, A.sup.2 is C.sub.6-C.sub.10 aryl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is selected from the group consisting of
##STR00179##
wherein the represents the attachment point to the remainder of the
molecule. In some embodiments, A.sup.2 is phenyl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is selected from the group consisting of
##STR00180##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00181##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00182##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00183##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00184##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00185##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00186##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is naphthyl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is selected from the group consisting of
##STR00187##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00188##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2
##STR00189##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is 5-14 membered
heteroaryl optionally substituted with one or more R.sup.16
substituents. In some embodiments, A.sup.2 is 5-10 membered
heteroaryl optionally substituted with one or more R.sup.16
substituents. In some embodiments, A.sup.2 is selected from the
group consisting of
##STR00190##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is pyridyl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is
##STR00191##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00192##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00193##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is pyrazinyl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is
##STR00194##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is quinolinyl optionally
substituted with one or more R.sup.16 substituents. In some
embodiments, A.sup.2 is selected from the group consisting of
##STR00195##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is
##STR00196##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.2 is and
##STR00197##
wherein the * represents the attachment point to the remainder of
the molecule.
[0258] In one aspect, provided is a compound of formula (IV):
##STR00198##
or a pharmaceutically acceptable salt thereof, wherein: [0259]
R.sup.17 is hydrogen or --C(O)OH; [0260] R.sup.18 is hydrogen or
halogen; [0261] R.sup.19 is hydrogen or C.sub.2-C.sub.6 alkynyl;
[0262] L.sup.3 is selected from the group consisting of
[0262] ##STR00199## [0263] wherein the represents the attachment
point to A.sup.3, and the # represents the attachment point to the
remainder of the molecule; [0264] L.sup.4 is selected from the
group consisting of
[0264] ##STR00200## wherein the represents the attachment point to
A.sup.4, and the # represents the attachment point to the remainder
of the molecule; [0265] A.sup.3 is selected from the group
consisting of phenyl, naphthyl, pyridyl, pyrazinyl, quinolinyl,
benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl, and
3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl;
[0266] A.sup.4 is selected from the group consisting of phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, and
3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl.
[0267] In some embodiments of the compound of Formula (IV), A.sup.3
is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6
haloalkyl.
[0268] In some embodiments of the compound of Formula (IV), A.sup.4
is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6
haloalkyl.
[0269] In some embodiments, the compound of formula (IV) is a
compound of formula (IV-a):
##STR00201##
or a pharmaceutically acceptable salt thereof, wherein L.sup.3,
L.sup.4, A.sup.3, and A.sup.4 are as defined for the compound of
formula (IV).
[0270] In some embodiments, the compound of formula (IV) is a
compound of formula (IV-b):
##STR00202##
or a pharmaceutically acceptable salt thereof, wherein L.sup.3,
L.sup.4, A.sup.3, and A.sup.4 are as defined for the compound of
formula (IV).
[0271] In some embodiments, the compound of formula (IV) is a
compound of formula (IV-c):
##STR00203##
or a pharmaceutically acceptable salt thereof, wherein L.sup.3,
L.sup.4, A.sup.3, and A.sup.4 are as defined for the compound of
formula (IV).
[0272] In some embodiments, the compound of formula (IV) is a
compound of formula (IV-d):
##STR00204##
or a pharmaceutically acceptable salt thereof, wherein L.sup.3,
L.sup.4, A.sup.3, and A.sup.4 are as defined for the compound of
formula (IV).
[0273] In some embodiments of the compounds of formula (IV),
(IV-a), (IV-b), (IV-c), and (IV-a), L.sup.3 is selected from the
group consisting of
##STR00205##
wherein the * represents the attachment point to A.sup.3, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.3 is
##STR00206##
wherein the * represents the attachment point to A.sup.3, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.3 is
##STR00207##
wherein the * represents the attachment point to A.sup.3, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.3 is
##STR00208##
wherein the * represents the attachment point to A.sup.3, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.3 is
##STR00209##
wherein the * represents the attachment point to A.sup.3, and the #
represents the attachment point to the remainder of the molecule.
L.sup.3 is
##STR00210##
wherein the * represents the attachment point to A.sup.3, and the #
represents the attachment point to the remainder of the molecule.
L.sup.3 is
##STR00211##
wherein the * represents the attachment point to A.sup.3, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.3 is
##STR00212##
wherein the * represents the attachment point to A.sup.3, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.3 is
##STR00213##
#; wherein the * represents the attachment point to A.sup.3, and
the # represents the attachment point to the remainder of the
molecule.
[0274] In some embodiments of the compounds of formula (IV),
(IV-a), (IV-b), (IV-c), and (IV-a), L.sup.4 is selected from the
group consisting of
##STR00214##
wherein the * represents the attachment point to A.sup.4, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.4 is
##STR00215##
wherein the * represents the attachment point to A.sup.4, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.4 is
##STR00216##
wherein the * represents the attachment point to A.sup.4, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.4 is
##STR00217##
wherein the * represents the attachment point to A.sup.4, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.4 is
##STR00218##
wherein the * represents the attachment point to A.sup.4, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.4 is
##STR00219##
wherein the * represents the attachment point to A.sup.4, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.4 is
##STR00220##
wherein the * represents the attachment point to A.sup.4, and the #
represents the attachment point to the remainder of the
molecule.
[0275] In some embodiments of the compounds of formula (IV),
(IV-a), (IV-b), (IV-c), and (IV-a), A.sup.3 is selected from the
group consisting of
##STR00221##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is selected from the
group consisting of
##STR00222##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00223##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00224##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00225##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00226##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00227##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00228##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00229##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00230##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00231##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00232##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00233##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00234##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00235##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00236##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00237##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00238##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00239##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00240##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.3 is
##STR00241##
wherein the * represents the attachment point to the remainder of
the molecule.
[0276] In some embodiments of the compounds of formula (IV),
(IV-a), (IV-b), (IV-c), and (IV-a), A.sup.4 is selected from the
group consisting of
##STR00242##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is selected from the
group consisting of
##STR00243##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00244##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00245##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00246##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00247##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00248##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00249##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00250##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00251##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00252##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments. A.sup.4 is
##STR00253##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments. A.sup.4 is
##STR00254##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00255##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00256##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00257##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00258##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00259##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00260##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00261##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.4 is
##STR00262##
wherein the * represents the attachment point to the remainder of
the molecule.
[0277] In one aspect, provided is a compound of formula (V):
##STR00263##
or a pharmaceutically acceptable salt thereof, wherein: [0278]
R.sup.20 is hydrogen or --C(O)OH; [0279] R.sup.21 is hydrogen or
halogen; [0280] R.sup.22 and R.sup.23 are both hydrogen or R.sup.22
and R.sup.23 are taken together to form an oxo (.dbd.O)
substituent; [0281] L.sup.5 is selected from the group consisting
of
[0281] ##STR00264## wherein the represents the attachment point to
A.sup.5, and the # represents the attachment point to the remainder
of the molecule; [0282] L.sup.6 is selected from the group
consisting of
[0282] ##STR00265## wherein the represents the attachment point to
A.sup.6, and the # represents the attachment point to the remainder
of the molecule; [0283] A.sup.5 is selected from the group
consisting of phenyl, naphthyl, pyridyl, pyrazinyl, quinolinyl,
benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl, and
3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl;
[0284] A.sup.6 is selected from the group consisting of phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, and
3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl.
[0285] In some embodiments of the compound of Formula (V), A.sup.5
is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6
haloalkyl.
[0286] In some embodiments of the compound of Formula (V), A.sup.6
is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6
haloalkyl.
[0287] In some embodiments, the compound of formula (V) is a
compound of formula (V-a):
##STR00266##
or a pharmaceutically acceptable salt thereof, wherein L.sup.5,
L.sup.6, A.sup.5, and A.sup.6 are as defined for the compound of
formula (V).
[0288] In some embodiments, the compound of formula (V) is a
compound of formula (V-b):
##STR00267##
or a pharmaceutically acceptable salt thereof, wherein L.sup.5,
L.sup.6, A.sup.5, and A.sup.6 are as defined for the compound of
formula (V).
[0289] In some embodiments of the compounds of formula (V), (V-a),
and (V-b), L.sup.5 is selected from the group consisting of
##STR00268##
wherein the * represents the attachment point to A.sup.5, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.5 is
##STR00269##
wherein the * represents the attachment point to A.sup.5, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.5 is
##STR00270##
wherein the * represents the attachment point to A.sup.5, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.5 is
##STR00271##
wherein the * represents the attachment point to A.sup.5, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.5 is
##STR00272##
* wherein the * represents the attachment point to A.sup.5, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.5 is
##STR00273##
wherein the * represents the attachment point to A.sup.5, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.5 is
##STR00274##
wherein the * represents the attachment point to A.sup.5, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.5 is
##STR00275##
wherein the * represents the attachment point to A.sup.5, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.5 is
##STR00276##
wherein the * represents the attachment point to A.sup.5, and the #
represents the attachment point to the remainder of the
molecule.
[0290] In some embodiments of the compounds of formula (V), (V-a),
and (V-b), L.sup.6 is selected from the group consisting of
##STR00277##
wherein the * represents the attachment point to A.sup.6, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.6 is
##STR00278##
wherein the * represents the attachment point to A.sup.6, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.6 is
##STR00279##
wherein the * represents the attachment point to A.sup.6, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.6 is
##STR00280##
wherein the * represents the attachment point to A.sup.6, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.6 is
##STR00281##
wherein the * represents the attachment point to A.sup.6, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.6 is
##STR00282##
wherein the * represents the attachment point to A.sup.6, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.6 is
##STR00283##
wherein the * represents the attachment point to A.sup.6, and the #
represents the attachment point to the remainder of the
molecule.
[0291] In some embodiments of the compounds of formula (V), (V-a),
and (V-b), A.sup.5 is selected from the group consisting of
##STR00284##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is selected from the
group consisting of
##STR00285##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00286##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00287##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00288##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00289##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00290##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00291##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00292##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00293##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00294##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00295##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00296##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00297##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00298##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00299##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00300##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00301##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00302##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00303##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.5 is
##STR00304##
wherein the * represents the attachment point to the remainder of
the molecule.
[0292] In some embodiments of the compounds of formula (V), (V-a),
and (V-b), A.sup.6 is selected from the group consisting of
##STR00305##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is selected from the
group consisting of
##STR00306##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00307##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00308##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00309##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00310##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00311##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00312##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00313##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00314##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00315##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00316##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00317##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00318##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00319##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00320##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00321##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00322##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00323##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00324##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.6 is
##STR00325##
wherein the * represents the attachment point to the remainder of
the molecule.
[0293] In one aspect, provided is a compound of formula (VI):
##STR00326##
or a pharmaceutically acceptable salt thereof, wherein: [0294]
R.sup.24 is hydrogen or --C(O)OH; [0295] R.sup.25 is hydrogen or
halogen; [0296] L.sup.7 is selected from the group consisting
of
[0296] ##STR00327## wherein the represents the attachment point to
A.sup.7, and the # represents the attachment point to the remainder
of the molecule; [0297] L.sup.8 is selected from the group
consisting of
[0297] ##STR00328## wherein the * represents the attachment point
to A.sup.8, and the # represents the attachment point to the
remainder of the molecule; [0298] A.sup.7 is selected from the
group consisting of phenyl, naphthyl, pyridyl, pyrazinyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl;
[0299] A.sup.8 is selected from the group consisting of phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, and
3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl.
[0300] In some embodiments of the compound of Formula (VI), A.sup.7
is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6
haloalkyl.
[0301] In some embodiments of the compound of Formula (VI), A.sup.8
is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6
haloalkyl.
[0302] In some embodiments, the compound of formula (VI) is a
compound of formula (VI-a):
##STR00329##
or a pharmaceutically acceptable salt thereof, wherein L.sup.7,
L.sup.8, A.sup.7, and A.sup.8 are as defined for the compound of
formula (VI).
[0303] In some embodiments of the compounds of formula (VI) and
(VI-a), L.sup.7 is selected from the group consisting of
##STR00330##
wherein the represents the attachment point to A.sup.7, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.7 is
##STR00331##
wherein the * represents the attachment point to A.sup.7, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.7 is
##STR00332##
wherein the * represents the attachment point to A.sup.7, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.7 is
##STR00333##
wherein the * represents the attachment point to A.sup.7, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.7 is
##STR00334##
wherein the * represents the attachment point to A.sup.7, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.7 is
##STR00335##
wherein the * represents the attachment point to A.sup.7, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.7 is
##STR00336##
wherein the * represents the attachment point to A.sup.7, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.7 is
##STR00337##
wherein the * represents the attachment point to A.sup.7, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.7 is
##STR00338##
wherein the * represents the attachment point to A.sup.7, and the #
represents the attachment point to the remainder of the
molecule.
[0304] In some embodiments of the compounds of formula (VI) and
(VI-a), L.sup.8 is selected from the group consisting of
##STR00339##
wherein the * represents the attachment point to A.sup.8, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.8 is
##STR00340##
wherein the * represents the attachment point to A.sup.8, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.8 is
##STR00341##
wherein the * represents the attachment point to A.sup.8, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.8 is
##STR00342##
wherein the * represents the attachment point to A.sup.8, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.8 is
##STR00343##
wherein the * represents the attachment point to A.sup.8, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.8 is
##STR00344##
wherein the * represents the attachment point to A.sup.8, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.8 is
##STR00345##
wherein the * represents the attachment point to A.sup.8, and the #
represents the attachment point to the remainder of the
molecule.
[0305] In some embodiments of the compounds of formula (VI) and
(VI-a), A.sup.7 is selected from the group consisting of
##STR00346##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is selected from the
group consisting of
##STR00347##
wherein the * represent the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00348##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00349##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00350##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00351##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00352##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00353##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00354##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00355##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00356##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00357##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00358##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00359##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00360##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00361##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00362##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00363##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00364##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00365##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.7 is
##STR00366##
wherein the * represents the attachment point to the remainder of
the molecule.
[0306] In some embodiments of the compounds of formula (VI) and
(VI-a), A.sup.8 is selected from the group consisting of
##STR00367##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments. A.sup.8 is selected from the
group consisting of
##STR00368##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00369##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00370##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00371##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00372##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00373##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00374##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00375##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00376##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00377##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00378##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00379##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00380##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00381##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00382##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00383##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00384##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00385##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00386##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.8 is
##STR00387##
wherein the * represents the attachment point to the remainder of
the molecule.
[0307] In one aspect, provided is a compound of formula (VII):
##STR00388##
or a pharmaceutically acceptable salt thereof, wherein: [0308]
R.sup.26 is hydrogen or --C(O)OH; [0309] R.sup.27 is hydrogen or
halogen; [0310] L.sup.9 is selected from the group consisting of
*
[0310] ##STR00389## wherein the represents the attachment point to
A.sup.9, and the # represents the attachment point to the remainder
of the molecule; [0311] L.sup.10 is selected from the group
consisting of
[0311] ##STR00390## wherein the * represents the attachment point
to A.sup.10, and the # represents the attachment point to the
remainder of the molecule; [0312] A.sup.9 is selected from the
group consisting of phenyl, naphthyl, pyridyl, pyrazinyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl;
[0313] A.sup.10 is selected from the group consisting of phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, and
3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl.
[0314] In some embodiments of the compound of Formula (VII),
A.sup.9 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6
haloalkyl.
[0315] In some embodiments of the compound of Formula (VII),
A.sup.10 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6
haloalkyl.
[0316] In some embodiments, the compound of formula (VII) is a
compound of formula (VII-a):
##STR00391## [0317] or a pharmaceutically acceptable salt thereof,
[0318] wherein L.sup.9, L.sup.10, A.sup.9, and A.sup.10 are as
defined for the compound of formula (VII).
[0319] In some embodiments of the compounds of formula (VII) and
(VII-a), L.sup.9 is selected from the group consisting of
##STR00392##
wherein the represents the attachment point to A.sup.9, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.9 is
##STR00393##
wherein the * represents the attachment point to A.sup.9, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.9 is
##STR00394##
wherein the * represents the attachment point to A.sup.9, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.9 is
##STR00395##
wherein the * represents the attachment point to A.sup.9, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.9 is
##STR00396##
wherein the * represents the attachment point to A.sup.9, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.9 is
##STR00397##
wherein the * represents the attachment point to A.sup.9, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.9 is
##STR00398##
wherein the * represents the attachment point to A.sup.9, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.9 is
##STR00399##
wherein the * represents the attachment point to A.sup.9, and the #
represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.9 is
##STR00400##
wherein the * represents the attachment point to A.sup.9, and the #
represents the attachment point to the remainder of the
molecule.
[0320] In some embodiments of the compounds of formula (VII) and
(VII-a), L.sup.10 is selected from the group consisting of
##STR00401##
wherein the * represents the attachment point to A.sup.10, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.10 is
##STR00402##
wherein the * represents the attachment point to A.sup.10, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.10 is
##STR00403##
wherein the * represents the attachment point to A.sup.10, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.10 is
##STR00404##
wherein the * represents the attachment point to A.sup.10, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.10 is
##STR00405##
wherein the * represents the attachment point to A.sup.10, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.10 is
##STR00406##
wherein the * represents the attachment point to A.sup.10, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.10 is
##STR00407##
wherein the * represents the attachment point to A.sup.10, and the
# represents the attachment point to the remainder of the
molecule.
[0321] In some embodiments of the compounds of formula (VII) and
(VII-a), A.sup.9 is selected from the group consisting of
##STR00408##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is selected from the
group consisting of
##STR00409##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00410##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00411##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00412##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00413##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00414##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00415##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00416##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00417##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00418##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00419##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00420##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00421##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00422##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00423##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00424##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00425##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00426##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00427##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.9 is
##STR00428##
wherein the * represents the attachment point to the remainder of
the molecule.
[0322] In some embodiments of the compounds of formula (VII) and
(VII-a), A.sup.10 is selected from the group consisting of
##STR00429##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is selected from the
group consisting of
##STR00430##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00431##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00432##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00433##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00434##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00435##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00436##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00437##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00438##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00439##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00440##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00441##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00442##
Wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00443##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00444##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00445##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00446##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00447##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00448##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.10 is
##STR00449##
wherein the * represents the attachment point to the remainder of
the molecule.
[0323] In one aspect, provided is a compound of formula (VIII):
##STR00450##
or a pharmaceutically acceptable salt thereof, wherein: [0324]
R.sup.28 is hydrogen or --C(O)OH; [0325] R.sup.29 is hydrogen or
halogen; [0326] L.sup.11 is selected from the group consisting
of
[0326] ##STR00451## wherein the represents the attachment point to
A.sup.11, and the # represents the attachment point to the
remainder of the molecule; [0327] L.sup.12 is selected from the
group consisting of
[0327] ##STR00452## wherein the represents the attachment point to
A.sup.12, and the # represents the attachment point to the
remainder of the molecule; [0328] A.sup.11 is selected from the
group consisting of phenyl, naphthyl, pyridyl, pyrazinyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl;
[0329] A.sup.12 is selected from the group consisting of phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, and
3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the phenyl,
naphthyl, pyridyl, pyrazinyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, CN, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, --O--C.sub.1-C.sub.6 alkyl,
--O--C.sub.1-C.sub.6 haloalkyl, and C.sub.1-C.sub.6 haloalkyl;
[0330] provided that the compound of formula (VIII) is not
##STR00453##
[0331] In some embodiments of the compound of Formula (VIII),
A.sup.11 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6 haloalkyl;
provided that the compound of formula (VIII) is not
##STR00454##
[0332] In some embodiments of the compound of Formula (VIII),
A.sup.12 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6 haloalkyl;
provided that the compound of formula (VIII) is not
##STR00455##
[0333] In some embodiments, the compound of formula (VIII) is a
compound of formula (VIII-a):
##STR00456##
or a pharmaceutically acceptable salt thereof, wherein L.sup.D,
L.sup.12, A.sup.11, and A.sup.12 are as defined for the compound of
formula (VIII) provided that the compound of formula (VIII-a) is
not
##STR00457##
[0334] In some embodiments of the compounds of formula (VIII) and
(VIII-a), L.sup.11 is selected from the group consisting of
##STR00458##
wherein the * represents the attachment point to A.sup.11, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.11 is
##STR00459##
wherein the * represents the attachment point to A.sup.11, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.11 is
##STR00460##
wherein the * represents the attachment point to A.sup.11, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.11 is
##STR00461##
wherein the * represents the attachment point to A.sup.11, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.11 is
##STR00462##
wherein the * represents the attachment point to A.sup.11, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.11 is
##STR00463##
wherein the * represents the attachment point to A.sup.11, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.11 is
##STR00464##
wherein the * represents the attachment point to A.sup.11, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.11 is
##STR00465##
wherein the * represents the attachment point to A.sup.11, and the
# represents the attachment point to the remainder of the
molecule.
[0335] In some embodiments of the compounds of formula (VIII) and
(VIII-a), L.sup.12 is selected from the group consisting of
##STR00466##
wherein the * represents the attachment point to A.sup.12, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.12 is
##STR00467##
wherein the * represents the attachment point to A.sup.12, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.12 is
##STR00468##
wherein the * represents the attachment point to A.sup.12, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.12 is
##STR00469##
wherein the * represents the attachment point to A.sup.12, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.12 is
##STR00470##
wherein the * represents the attachment point to A.sup.12, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.12 is
##STR00471##
wherein the * represents the attachment point to A.sup.12, and the
# represents the attachment point to the remainder of the molecule.
In some embodiments, L.sup.12 is
##STR00472##
wherein the * represents the attachment point to A.sup.12, and the
# represents the attachment point to the remainder of the
molecule.
[0336] In some embodiments of the compounds of formula (VIII) and
(VIII-a), A.sup.11 is selected from the group consisting of
##STR00473##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is selected from the
group consisting of
##STR00474##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00475##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00476##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00477##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00478##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00479##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00480##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00481##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00482##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00483##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00484##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00485##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00486##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00487##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11
##STR00488##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00489##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00490##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00491##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00492##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.11 is
##STR00493##
wherein the * represents the attachment point to the remainder of
the molecule.
[0337] In some embodiments of the compounds of formula (VIII) and
(VIII-a), A.sup.12 is selected from the group consisting of
##STR00494##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is selected from the
group consisting of
##STR00495##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00496##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00497##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00498##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00499##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00500##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00501##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00502##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00503##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00504##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00505##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00506##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00507##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00508##
wherein the * represents the attachment-point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00509##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00510##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00511##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00512##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00513##
wherein the * represents the attachment point to the remainder of
the molecule. In some embodiments, A.sup.12 is
##STR00514##
wherein the * represents the attachment point to the remainder of
the molecule.
[0338] In the descriptions herein, it is understood that every
description, variation, embodiment or aspect of a moiety may be
combined with every description, variation, embodiment or aspect of
other moieties the same as if each and every combination of
descriptions is specifically and individually listed. For example,
every description, variation, embodiment or aspect provided herein
with respect to X of formula (I) may be combined with every
description, variation, embodiment or aspect of m.sup.1, m.sup.2,
n.sup.1, n.sup.2, p.sup.1, p.sup.2, q.sup.1, q.sup.2, r, s, j,
R.sup.j-a, R.sup.j-b, k, R.sup.N-k, R.sup.N, A.sup.1, A.sup.2,
R.sup.1a, R.sup.1b, R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b,
R.sup.4a, R.sup.4b, R.sup.5a, R.sup.5b, R.sup.6a, R.sup.6b,
R.sup.7a, R.sup.7b, R.sup.8a, R.sup.8b, R.sup.9a, R.sup.9b,
R.sup.10a, R.sup.10b, R.sup.11a, R.sup.11b, R.sup.12a, and
R.sup.12b the same as if each and every combination were
specifically and individually listed. It is also understood that
all descriptions, variations, embodiments or aspects of formula
(I), where applicable, apply equally to other formulae detailed
herein, and are equally described, the same as if each and every
description, variation, embodiment or aspect were separately and
individually listed for all formulae. For example, all
descriptions, variations, embodiments or aspects of formula (I),
where applicable, apply equally to any of formulae (II) and (III)
detailed herein, and are equally described, the same as if each and
every description, variation, embodiment or aspect were separately
and individually listed for all formulae. Similarly, every
description, variation, embodiment or aspect provided herein with
respect to A.sup.3 of formula (IV) may be combined with every
description, variation, embodiment or aspect of R.sup.17, R.sup.18,
R.sup.19, L.sup.3, L.sup.4, and A.sup.4 the same as if each and
every combination were specifically and individually listed. It is
also understood that all descriptions, variations, embodiments or
aspects of formula (IV), where applicable, apply equally to other
formulae detailed herein, and are equally described, the same as if
each and every description, variation, embodiment or aspect were
separately and individually listed for all formulae. For example,
all descriptions, variations, embodiments or aspects of formula
(IV) where applicable, apply equally to any of formulae (IV-a),
(IV-b), (IV-c), and (IV-d) detailed herein, and are equally
described, the same as if each and every description, variation,
embodiment or aspect were separately and individually listed for
all formulae. Similarly, every description, variation, embodiment
or aspect provided herein with respect to A.sup.5 of formula (V)
may be combined with every description, variation, embodiment or
aspect of R.sup.20, R.sup.21, R.sup.22, R.sup.23, L.sup.5, L.sup.6,
and A.sup.6 the same as if each and every combination were
specifically and individually listed. It is also understood that
all descriptions, variations, embodiments or aspects of formula
(V), where applicable, apply equally to other formulae detailed
herein, and are equally described, the same as if each and every
description, variation, embodiment or aspect were separately and
individually listed for all formulae. For example, all
descriptions, variations, embodiments or aspects of formula (V)
where applicable, apply equally to any of formulae (V-a) and (V-b)
detailed herein, and are equally described, the same as if each and
every description, variation, embodiment or aspect were separately
and individually listed for all formulae. Similarly, every
description, variation, embodiment or aspect provided herein with
respect to A.sup.7 of formula (VI) may be combined with every
description, variation, embodiment or aspect of R.sup.24, R.sup.25,
L.sup.7, L.sup.8, and A.sup.8 the same as if each and every
combination were specifically and individually listed. It is also
understood that all descriptions, variations, embodiments or
aspects of formula (VI), where applicable, apply equally to other
formulae detailed herein, and are equally described, the same as if
each and every description, variation, embodiment or aspect were
separately and individually listed for all formulae. For example,
all descriptions, variations, embodiments or aspects of formula
(VI) where applicable, apply equally to formula (VI-a) detailed
herein, and are equally described, the same as if each and every
description, variation, embodiment or aspect were separately and
individually listed for all formulae. Similarly, every description,
variation, embodiment or aspect provided herein with respect to
A.sup.9 of formula (VII) may be combined with every description,
variation, embodiment or aspect of R.sup.26, R.sup.27, L.sup.9,
L.sup.10, and A.sup.10 the same as if each and every combination
were specifically and individually listed. It is also understood
that all descriptions, variations, embodiments or aspects of
formula (VII), where applicable, apply equally to other formulae
detailed herein, and are equally described, the same as if each and
every description, variation, embodiment or aspect were separately
and individually listed for all formulae. For example, all
descriptions, variations, embodiments or aspects of formula (VII-a)
where applicable, apply equally to formula (VII) detailed herein,
and are equally described, the same as if each and every
description, variation, embodiment or aspect were separately and
individually listed for all formulae. Similarly, every description,
variation, embodiment or aspect provided herein with respect to
A.sup.11 of formula (VIII) may be combined with every description,
variation, embodiment or aspect of R.sup.28, R.sup.29, L.sup.11,
L.sup.12, and A.sup.12 the same as if each and every combination
were specifically and individually listed. It is also understood
that all descriptions, variations, embodiments or aspects of
formula (VIII), where applicable, apply equally to other formulae
detailed herein, and are equally described, the same as if each and
every description, variation, embodiment or aspect were separately
and individually listed for all formulae. For example, all
descriptions, variations, embodiments or aspects of formula
(VIII-a) where applicable, apply equally to formula (VIII) detailed
herein, and are equally described, the same as if each and every
description, variation, embodiment or aspect were separately and
individually listed for all formulae.
[0339] Also provided are salts of compounds referred to herein,
such as pharmaceutically acceptable salts. The present disclosure
also includes any or all of the stereochemical forms, including any
enantiomeric or diastereomeric forms, and any tautomers or other
forms of the compounds described.
[0340] A compound as detailed herein may in one aspect be in a
purified form and compositions comprising a compound in purified
forms are detailed herein. Compositions comprising a compound as
detailed herein or a salt thereof are provided, such as
compositions of substantially pure compounds. In some embodiments,
a composition containing a compound as detailed herein or a salt
thereof is in substantially pure form. Unless otherwise stated,
"substantially pure" intends a composition that contains no more
than 35% impurity, wherein the impurity denotes a compound other
than the compound comprising the majority of the composition or a
salt thereof. In some embodiments, a composition of substantially
pure compound or a salt thereof is provided wherein the composition
contains no more than 25%, 20%, 15%, 10%, or 5% impurity. In some
embodiments, a composition of substantially pure compound or a salt
thereof is provided wherein the composition contains or no more
than 3%, 2%, 1% or 0.5% impurity.
[0341] In some embodiments, provided is compound selected from
compounds in Table 1, or a stereoisomer, tautomer, solvate, prodrug
or salt thereof. Although certain compounds described in Table 1
are presented as specific stereoisomers and/or in a
non-stereochemical form, it is understood that any or all
stereochemical forms, including any enantiomeric or diastereomeric
forms, and any tautomers or other forms of any of the compounds of
Table 1 are herein described.
TABLE-US-00001 TABLE 1 Cpd No. Structure 1 ##STR00515## 2
##STR00516## 3 ##STR00517## 4 ##STR00518## 5 ##STR00519## 6
##STR00520## 7 ##STR00521## 8 ##STR00522## 9 ##STR00523## 10
##STR00524## 11 ##STR00525## 12 ##STR00526## 13 ##STR00527## 14
##STR00528## 15 ##STR00529## 16 ##STR00530## 17 ##STR00531## 18
##STR00532## 19 ##STR00533## 20 ##STR00534## 21 ##STR00535## 22
##STR00536## 23 ##STR00537## 24 ##STR00538## 25 ##STR00539## 26
##STR00540## 27 ##STR00541## 28 ##STR00542## 29 ##STR00543## 30
##STR00544## 31 ##STR00545## 32 ##STR00546## 33 ##STR00547## 34
##STR00548## 35 ##STR00549## 36 ##STR00550## 37 ##STR00551## 38
##STR00552## 39 ##STR00553## 40 ##STR00554## 41 ##STR00555## 42
##STR00556## 43 ##STR00557## 44 ##STR00558## 45 ##STR00559## 46
##STR00560## 47 ##STR00561## 48 ##STR00562## 49 ##STR00563## 50
##STR00564## 51 ##STR00565## 52 ##STR00566## 53 ##STR00567## 54
##STR00568## 55 ##STR00569## 56 ##STR00570## 57 ##STR00571## 58
##STR00572## 59 ##STR00573## 60 ##STR00574## 61 ##STR00575## 62
##STR00576## 63 ##STR00577## 64 ##STR00578## 65 ##STR00579## 66
##STR00580## 67 ##STR00581## 68 ##STR00582## 69 ##STR00583## 70
##STR00584## 71 ##STR00585## 72 ##STR00586## 73 ##STR00587## 74
##STR00588## ##STR00589##
Pharmaceutical Compositions and Formulations
[0342] Pharmaceutical compositions of any of the compounds detailed
herein are embraced by this disclosure. Thus, the present
disclosure includes pharmaceutical compositions comprising a
compound as detailed herein or a salt thereof and a
pharmaceutically acceptable carrier or excipient. In one aspect,
the pharmaceutically acceptable salt is an acid addition salt, such
as a salt formed with an inorganic or organic acid. Pharmaceutical
compositions may take a form suitable for oral, buccal, parenteral,
nasal, topical or rectal administration or a form suitable for
administration by inhalation.
[0343] A compound as detailed herein may in one aspect be in a
purified form and compositions comprising a compound in purified
forms are detailed herein. Compositions comprising a compound as
detailed herein or a salt thereof are provided, such as
compositions of substantially pure compounds. In some embodiments,
a composition containing a compound as detailed herein or a salt
thereof is in substantially pure form.
[0344] In one variation, the compounds herein are synthetic
compounds prepared for administration to an individual. In another
variation, compositions are provided containing a compound in
substantially pure form. In another variation, the present
disclosure embraces pharmaceutical compositions comprising a
compound detailed herein and a pharmaceutically acceptable carrier.
In another variation, methods of administering a compound are
provided. The purified forms, pharmaceutical compositions and
methods of administering the compounds are suitable for any
compound or form thereof detailed herein.
[0345] A compound detailed herein or salt thereof may be formulated
for any available delivery route, including an oral, mucosal (e.g.,
nasal, sublingual, vaginal, buccal or rectal), parenteral (e.g.,
intramuscular, subcutaneous or intravenous), topical or transdermal
delivery form. A compound or salt thereof may be formulated with
suitable carriers to provide delivery forms that include, but are
not limited to, tablets, caplets, capsules (such as hard gelatin
capsules or soft elastic gelatin capsules), cachets, troches,
lozenges, gums, dispersions, suppositories, ointments, cataplasms
(poultices), pastes, powders, dressings, creams, solutions,
patches, aerosols (e.g., nasal spray or inhalers), gels,
suspensions (e.g., aqueous or non-aqueous liquid suspensions,
oil-in-water emulsions or water-in-oil liquid emulsions), solutions
and elixirs.
[0346] One or several compounds described herein or a salt thereof
can be used in the preparation of a formulation, such as a
pharmaceutical formulation, by combining the compound or compounds,
or a salt thereof, as an active ingredient with a pharmaceutically
acceptable carrier, such as those mentioned above. Depending on the
therapeutic form of the system (e.g., transdermal patch vs. oral
tablet), the carrier may be in various forms. In addition,
pharmaceutical formulations may contain preservatives,
solubilizers, stabilizers, re-wetting agents, emulgators,
sweeteners, dyes, adjusters, and salts for the adjustment of
osmotic pressure, buffers, coating agents or antioxidants.
Formulations comprising the compound may also contain other
substances which have valuable therapeutic properties.
Pharmaceutical formulations may be prepared by known pharmaceutical
methods. Suitable formulations can be found, e.g., in Remington's
Pharmaceutical Sciences, Mack Publishing Company, Philadelphia,
Pa., 20.sup.th ed. (2000), which is incorporated herein by
reference.
[0347] Compounds as described herein may be administered to
individuals in a form of generally accepted oral compositions, such
as tablets, coated tablets, and gel capsules in a hard or in soft
shell, emulsions or suspensions. Examples of carriers, which may be
used for the preparation of such compositions, are lactose, corn
starch or its derivatives, talc, stearate or its salts, etc.
Acceptable carriers for gel capsules with soft shell are, for
instance, plant oils, wax, fats, semisolid and liquid poly-ols, and
so on. In addition, pharmaceutical formulations may contain
preservatives, solubilizers, stabilizers, re-wetting agents,
emulgators, sweeteners, dyes, adjusters, and salts for the
adjustment of osmotic pressure, buffers, coating agents or
antioxidants.
[0348] Any of the compounds described herein can be formulated in a
tablet in any dosage form described, for example, a compound as
described herein or a salt thereof can be formulated as a 10 mg
tablet.
[0349] Compositions comprising a compound provided herein are also
described. In one variation, the composition comprises a compound
or salt thereof and a pharmaceutically acceptable carrier or
excipient. In another variation, a composition of substantially
pure compound is provided. In some embodiments, the composition is
for use as a human or veterinary medicament. In some embodiments,
the composition is for use in a method described herein. In some
embodiments, the composition is for use in the treatment of a
disease or disorder described herein.
Methods of Use and Uses
[0350] Compounds and compositions detailed herein, such as a
pharmaceutical composition containing a compound of any formula
provided herein or a salt thereof and a pharmaceutically acceptable
carrier or excipient, may be used in methods of administration and
treatment as provided herein. The compounds and compositions may
also be used in in vitro methods, such as in vitro methods of
administering a compound or composition to cells for screening
purposes and/or for conducting quality control assays.
[0351] Provided herein is a method of treating a disease or
disorder in an individual in need thereof comprising administering
a compound describes herein or any embodiment, variation, or aspect
thereof, or a pharmaceutically acceptable salt thereof. In some
embodiments, the compound, pharmaceutically acceptable salt
thereof, or composition is administered to the individual according
to a dosage and/or method of administration described herein.
[0352] The compounds or salts thereof described herein and
compositions described herein are believed to be effective for
treating a variety of diseases and disorders. In some embodiments,
a compound or salt thereof described herein or a composition
described herein may be used in a method of treating a disease or
disorder mediated by an integrated stress response (ISR) pathway.
In some embodiments, the disease or disorder is mediated by
eukaryotic translation initiation factor 2.alpha. (eIF2.alpha.) or
eukaryotic translation initiation factor 2B (eIF2B). In some
embodiments, the disease or disorder is mediated by phosphorylation
of eIF2.alpha. and/or the guanine nucleotide exchange factor (GEF)
activity of eIF2B.
[0353] In some embodiments, a compound or salt thereof described
herein or a composition described herein may be used in a method of
treating a disease or disorder, wherein the disease or disorder is
a neurodegenerative disease, an inflammatory disease, an autoimmune
disease, a metabolic syndrome, a cancer, a vascular disease, a
musculoskeletal disease (such as a myopathy), an ocular disease, or
a genetic disorder.
[0354] In some embodiments, the disease or disorder is a
neurodegenerative disease. In some embodiments, the
neurodegenerative disease is vanishing white matter disease,
childhood ataxia with CNS hypomyelination, intellectual disability
syndrome, Alzheimer's disease, prion disease, Creutzfeldt-Jakob
disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS)
disease, Pelizaeus-Merzbacher disease, a cognitive impairment, a
traumatic brain injury, a postoperative cognitive dysfunction
(PCD), a neuro-otological syndrome, hearing loss, Huntington's
disease, stroke, chronic traumatic encephalopathy, spinal cord
injury, dementia, frontotemporal dementia (FTD), depression, or a
social behavior impairment. In some embodiments, the cognitive
impairment is triggered by ageing, radiation, sepsis, seizure,
heart attack, heart surgery, liver failure, hepatic encephalopathy,
anesthesia, brain injury, brain surgery, ischemia, chemotherapy,
cancer treatment, critical illness, concussion, fibromyalgia, or
depression. In some embodiments, the neurodegenerative disease is
Alzheimer's disease. In some embodiments, the neurodegenerative
disease is ageing-related cognitive impairment. In some
embodiments, the neurodegenerative disease is a traumatic brain
injury.
[0355] In some embodiments, a compound or salt thereof described
herein or a composition described herein may be used in a method of
treating Alzheimer's disease. In some embodiments,
neurodegeneration, cognitive impairment, and/or amyloidogenesis is
decreased.
[0356] In some embodiments, the disease or disorder is an
inflammatory disease. In some embodiments, the inflammatory disease
is arthritis, psoriatic arthritis, psoriasis, juvenile idiopathic
arthritis, asthma, allergic asthma, bronchial asthma, tuberculosis,
chronic airway disorder, cystic fibrosis, glomerulonephritis,
membranous nephropathy, sarcoidosis, vasculitis, ichthyosis,
transplant rejection, interstitial cystitis, atopic dermatitis, or
inflammatory bowel disease. In some embodiments, the inflammatory
bowel disease is Crohn' disease, ulcerative colitis, or celiac
disease.
[0357] In some embodiments, the disease or disorder is an
autoimmune disease. In some embodiments, the autoimmune disease is
systemic lupus erythematosus, type 1 diabetes, multiple sclerosis,
or rheumatoid arthritis.
[0358] In some embodiments, the disease or disorder is a metabolic
syndrome. In some embodiments, the metabolic syndrome is alcoholic
liver steatosis, obesity, glucose intolerance, insulin resistance,
hyperglycemia, fatty liver, dyslipidemia, hyperlipidemia,
hyperhomocysteinemia, or type 2 diabetes.
[0359] In some embodiments, the disease or disorder is a cancer. In
some embodiments, the cancer is pancreatic cancer, breast cancer,
kidney cancer, bladder cancer, prostate cancer, testicular cancer,
urothelial cancer, endometrial cancer, ovarian cancer, cervical
cancer, renal cancer, esophageal cancer, gastrointestinal stromal
tumor (GIST), multiple myeloma, cancer of secretory cells, thyroid
cancer, gastrointestinal carcinoma, chronic myeloid leukemia,
hepatocellular carcinoma, colon cancer, melanoma, malignant glioma,
glioblastoma, glioblastoma multiforme, astrocytoma, dysplastic
gangliocytoma of the cerebellum, Ewing's sarcoma, rhabdomyosarcoma,
ependymoma, medulloblastoma, ductal adenocarcinoma, adenosquamous
carcinoma, nephroblastoma, acinar cell carcinoma, neuroblastoma, or
lung cancer. In some embodiments, the cancer of secretory cells is
non-Hodgkin's lymphoma, Burkitt's lymphoma, chronic lymphocytic
leukemia, monoclonal gammopathy of undetermined significance
(MGUS), plasmacytoma, lymphoplasmacytic lymphoma or acute
lymphoblastic leukemia.
[0360] In some embodiments, the disease or disorder is a
musculoskeletal disease (such as a myopathy). In some embodiments,
the musculoskeletal disease is a myopathy, a muscular dystrophy, a
muscular atrophy, a muscular wasting, or sarcopenia. In some
embodiments, the muscular dystrophy is Duchenne muscular dystrophy
(DMD), Becker's disease, myotonic dystrophy, X-linked dilated
cardiomyopathy, spinal muscular atrophy (SMA), or metaphyseal
chondrodysplasia, Schmid type (MCDS). In some embodiments, the
myopathy is a skeletal muscle atrophy. In some embodiments, the
musculoskeletal disease (such as the skeletal muscle atrophy) is
triggered by ageing, chronic diseases, stroke, malnutrition,
bedrest, orthopedic injury, bone fracture, cachexia, starvation,
heart failure, obstructive lung disease, renal failure, Acquired
Immunodeficiency Syndrome (AIDS), sepsis, an immune disorder, a
cancer, ALS, a burn injury, denervation, diabetes, muscle disuse,
limb immobilization, mechanical unload, myositis, or a
dystrophy.
[0361] In some embodiments, the disease or disorder is a genetic
disorder, such as Down syndrome or MEHMO syndrome (Mental
retardation, Epileptic seizures, Hypogenitalism, Microcephaly, and
Obesity).
[0362] In some embodiments, a compound or salt thereof described
herein or a composition described herein may be used in a method of
treating musculoskeletal disease. In some embodiments, skeletal
muscle mass, quality and/or strength are increased. In some
embodiments, synthesis of muscle proteins is increased. In some
embodiments, skeletal muscle fiber atrophy is inhibited.
[0363] In some embodiments, the disease or disorder is a vascular
disease. In some embodiments, the vascular disease is
atherosclerosis, abdominal aortic aneurism, carotid artery disease,
deep vein thrombosis, Buerger's disease, chronic venous
hypertension, vascular calcification, telangiectasia or
lymphoedema.
[0364] In some embodiments, the disease or disorder is an ocular
disease. In some embodiments, the ocular disease is glaucoma,
age-related macular degeneration, inflammatory retinal disease,
retinal vascular disease, diabetic retinopathy, uveitis, rosacea,
Sjogren's syndrome, or neovascularization in proliferative
retinopathy.
[0365] In some embodiments, provided herein is a method of
inhibiting an ISR pathway. The compounds or salts thereof described
herein and compositions described herein are believed to be
effective for inhibiting an ISR pathway. In some embodiments, the
method of inhibiting an ISR pathway comprises inhibiting the ISR
pathway in a cell by administering or delivering to the cell a
compound described herein, or a pharmaceutically acceptable salt
thereof, or a pharmaceutical composition described herein. In some
embodiments, the method of inhibiting an ISR pathway comprises
inhibiting the ISR pathway in an individual by administering to the
individual a compound described herein, or a pharmaceutically
acceptable salt thereof, or a pharmaceutical composition described
herein. Inhibition of the ISR pathway can be determined by methods
known in the art, such as western blot, immunohistochemistry, or
reporter cell line assays.
[0366] In some embodiments, the inhibition of the ISR pathway
comprises binding eIF2B. In some embodiments, the inhibition of the
ISR pathway comprises increasing protein translation, increasing
guanine nucleotide exchange factor (GEF) activity of eIF2B,
delaying or preventing apoptosis in a cell, and/or inhibiting
translation of one or more mRNAs comprising a 5' untranslated
region (5'UTR) comprising at least one upstream open reading frame
(uORF).
[0367] In some embodiments, provided herein are methods of
increasing protein production using a compound or salt described
herein. The protein production is increased relative to the same
condition without the compound or salt. Protein production can be
increased either in vivo or in vitro. For example, protein
production can be increased in vivo by administering the compound
or salt to an individual. In some embodiments, protein production
is increased in vitro using the compound or salt with a cell-free
protein synthesis system (CFPS) or a cell-based protein expression
system. The protein produced can be a heterologous protein (e.g., a
recombinant protein) or a native protein. Heterologous protein
production can be achieved using a recombinant nucleic acid
encoding the protein. In some embodiments, the protein produced is
an antibody or a fragment thereof. Other exemplary proteins can
include, but are not limited to, enzymes, allergenic peptides or
proteins (for example, for use as a vaccine), recombinant protein,
cytokines, peptides, hormones, erythropoietin (EPO), interferons,
granulocyte-colony stimulating factor (G-CSF), anticoagulants, and
clotting factors. The increase in protein production can be
determined by methods known in the art, such as western blot or
immunohistochemistry.
[0368] Cell-free protein synthesis (CFPS) systems are generally
known, and include cellular machinery for protein expression in an
in vitro environment. In some embodiments, the CFPS system includes
a cellular extract (such as a eukaryotic cellular extract), which
includes protein expression machinery. In some embodiment, the
cellular machinery in the CFPS system comprises eukaryotic cellular
machinery, such as eukaryotic initiation factor 2 (eIF2) and/or
eukaryotic initiation factor 2B (eIF2B), or one or more subunits
thereof.
[0369] In some embodiments, there is a cell-free protein synthesis
(CFPS) system comprising eukaryotic initiation factor 2 (eIF2) and
a nucleic acid encoding a protein with a compound or salt as
described herein. In some embodiments, the protein is an antibody
or a fragment thereof. Other exemplary proteins can include, but
are not limited to, enzymes, allergenic peptides or proteins (for
example, for use as a vaccine), recombinant protein, cytokines,
peptides, hormones, erythropoietin (EPO), interferons,
granulocyte-colony stimulating factor (G-CSF), anticoagulants, and
clotting factors. In some embodiments, the CFPS system comprises a
cell extract comprising the eIF2. In some embodiments, the CFPS
system further comprises eIF2B.
[0370] In some embodiments, there is a method of producing a
protein, comprising contacting a cell-free protein synthesis (CFPS)
system comprising eukaryotic initiation factor 2 (eIF2) and a
nucleic acid encoding a protein with a compound or salt thereof as
described herein. In some embodiments, the protein is an antibody
or a fragment thereof. Other exemplary proteins can include, but
are not limited to, enzymes, allergenic peptides or proteins (for
example, for use as a vaccine), recombinant protein, cytokines,
peptides, hormones, erythropoietin (EPO), interferons,
granulocyte-colony stimulating factor (G-CSF), anticoagulants, and
clotting factors. In some embodiments, the CFPS system comprises a
cell extract comprising the eIF2. In some embodiments, the CFPS
system further comprises eIF2B. In some embodiments, the method
comprises purifying the protein.
[0371] In some embodiments, there is a method of producing a
protein, comprising contacting a eukaryotic cell comprising a
nucleic acid encoding the protein with a compound or salt as
described herein. In some embodiments, the method comprises
culturing the cell in an in vitro culture medium comprising the
compound or salt. In some embodiments, the nucleic acid encoding
the protein is a recombinant nucleic acid. In some embodiments, the
eukaryotic cell is a human embryonic kidney (HEK) cell or a Chinese
hamster ovary (CHO) cell. In other embodiments, the eukaryotic cell
is a yeast cell (such as Saccharomyces cerevisiae or Pichia
pastoris), a wheat germ cell, an insect cell, a rabbit
reticulocyte, a cervical cancer cell (such as a HeLa cell), a baby
hamster kidney cell (such as BHK21 cells), a murine myeloma cell
(such as NSO or Sp2/0 cells), an HT-1080 cell, a PER.C6 cell, a
plant cell, a hybridoma cell, or a human blood derived leukocyte.
In some embodiments, the protein is an antibody or a fragment
thereof. Other exemplary proteins can include, but are not limited
to, enzymes, allergenic peptides or proteins (for example, for use
as a vaccine), recombinant protein, cytokines, peptides, hormones,
erythropoietin (EPO), interferons, granulocyte-colony stimulating
factor (G-CSF), anticoagulants, and clotting factors. In some
embodiments, the method comprises purifying the protein.
[0372] In some embodiments, there is a method of culturing a
eukaryotic cell comprising a nucleic acid encoding a protein,
comprising contacting the eukaryotic cell with an in vitro culture
medium comprising a compound or salt as described herein. In some
embodiments, the nucleic acid encoding the protein is a recombinant
nucleic acid. In some embodiments, the eukaryotic cell is a human
embryonic kidney (HEK) cell or a Chinese hamster ovary (CHO) cell.
In other embodiments, the eukaryotic cell is a yeast cell (such as
Saccharomyces cerevisiae or Pichia pastoris), a wheat germ cell, an
insect cell, a rabbit reticulocyte, a cervical cancer cell (such as
a HeLa cell), a baby hamster kidney cell (such as BHK21 cells), a
murine myeloma cell (such as NSO or Sp2/0 cells), an HT-1080 cell,
a PER.C6 cell, a plant cell, a hybridoma cell, or a human blood
derived leukocyte. In some embodiments, the protein is an antibody
or a fragment thereof. Other exemplary proteins can include, but
are not limited to, enzymes, allergenic peptides or proteins (for
example, for use as a vaccine), recombinant protein, cytokines,
peptides, hormones, erythropoietin (EPO), interferons,
granulocyte-colony stimulating factor (G-CSF), anticoagulants, and
clotting factors. In some embodiments, the method comprises
purifying the protein.
[0373] In some embodiments, there is an in vitro cell culture
medium, comprising the compound or salt described herein, and
nutrients for cellular growth. In some embodiments, the culture
medium comprises a eukaryotic cell comprising a nucleic acid
encoding a protein. In some embodiments, the culture medium further
comprises a compound for inducing protein expression. In some
embodiments, the nucleic acid encoding the protein is a recombinant
nucleic acid. In some embodiments, the protein is an antibody or a
fragment thereof. Other exemplary proteins can include, but are not
limited to, enzymes, allergenic peptides or proteins (for example,
for use as a vaccine), recombinant protein, cytokines, peptides,
hormones, erythropoietin (EPO), interferons, granulocyte-colony
stimulating factor (G-CSF), anticoagulants, and clotting factors.
In some embodiments, the eukaryotic cell is a human embryonic
kidney (HEK) cell or a Chinese hamster ovary (CHO) cell. In other
embodiments, the eukaryotic cell is a yeast cell (such as
Saccharomyces cerevisiae or Pichia pastoris), a wheat germ cell, an
insect cell, a rabbit reticulocyte, a cervical cancer cell (such as
a HeLa cell), a baby hamster kidney cell (such as BHK21 cells), a
murine myeloma cell (such as NSO or Sp2/0 cells), an HT-1080 cell,
a PER.C6 cell, a plant cell, a hybridoma cell, or a human blood
derived leukocyte.
[0374] In some embodiments, provided herein is a method of
increasing protein translation in a cell or cell free expression
system. In some embodiments, the cell was stressed prior to
administration of the compound, salt thereof, or composition. In
some embodiments, protein translation is increased by at least
about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 100%,
125%, 150%, 175%, 200%, 250%, or 300% or more. In some embodiments,
protein translation is increased by about 10% to about 300% (such
as about 10% to about 20%, about 20% to about 30%, about 30% to
about 40%, about 40% to about 50%, about 50% to about 60%, about
60% to about 70%, about 70% to about 80%, about 80% to about 90%,
about 90% to about 100%, about 100% to about 125%, about 125% to
about 150%, about 150% to about 175%, about 175% to about 200%,
about 200% to about 250%, or about 250% to about 300%) In some
embodiments, protein translation is increased as compared to prior
to the administration of the compounds, salt thereof, or
composition. In some embodiments, protein translation is increased
as compared to an unstressed cell, a basal condition where cells
are not subjected to a specific stress that activates the ISR. In
some embodiments, protein translation is increased as compared to a
stressed cell where ISR is active.
[0375] Some of the compounds described herein increase protein
synthesis in a cell without full inhibition of ATF4 translation,
under ISR-stressed or non-ISR stressed conditions. Despite ATF4
participation in various pathologies, the ATF4 protein is an
important factor for restoring cellular homeostasis in stressed
cells, for example during oxidative stress response, cholesterol
metabolism, protein folding amino acid synthesis, and autophagy.
Thus, for certain treatments, it may be preferable to limit ATF4
inhibition. In some embodiments, the compound is used to increase
protein synthesis by about 10% or more, about 20% or more, about
30% or more, about 40% or more, about 50% or more, about 60% or
more, about 70% or more, about 80% or more, about 90% or more,
about 100% or more, about 125% or more, about 150% or more, about
175% or more, about 200% or more, about 250% or more, about 300% or
more, or about 350% or more, wherein ATF4 protein expression is
inhibited by about 75% or less, about 50% or less, about 40% or
less, about 30% or less, about 20% or less, about 10% or less, or
about 5% or less. In some embodiments the compound is used to
increase protein synthesis by about 10% to about 300% (such as
about 10% to about 20%, about 20% to about 30%, about 30% to about
40%, about 40% to about 50%, about 50% to about 60%, about 60% to
about 70%, about 70% to about 80%, about 80% to about 90%, about
90% to about 100%, about 100% to about 125%, about 125% to about
150%, about 150% to about 175%, about 175% to about 200%, about
200% to about 250%, or about 250% to about 300%), wherein ATF4
protein expression is inhibited by about 75% or less (such as about
50% or less, about 40% or less, about 30% or less, about 20% or
less, about 10% or less, or about 5% or less).
[0376] In some embodiments, provided herein is a method of
increasing protein translation in a cell. In some embodiments, the
cell was stressed prior to administration of the compound, salt
thereof, or composition. In some embodiments, protein translation
is increased by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%,
80%, 90%, 95%, 98%, 100%, 125%, 150%, 175%, 200%, 250%, or 300% or
more. In some embodiments, protein translation is increased as
compared to prior to the administration of the compounds, salt
thereof, or composition. In some embodiments, protein translation
is increased as compared to an unstressed cell, a basal condition
where cells are not subjected to a specific stress that activates
the ISR. In some embodiments, protein translation is increased as
compared to a stressed cell where ISR is active.
[0377] In some embodiments, provided herein is a method of
increasing guanine nucleotide exchange factor (GEF) activity of
eIF2B in cells. In some embodiments, provided herein is a method of
delaying or preventing apoptosis in a cell. In some embodiments,
provided herein is a method of inhibiting translation of one or
more mRNAs comprising a 5' untranslated region (5'UTR) that
contains at least one upstream open reading frame (uORF), encoding
proteins with translational preferences, including but not limited
to ATF4, ATF2, ATF5, CHOP, GADD34, BACE-1, C/EBP.alpha., or
MAP1LC3B. In some embodiments, the mRNA encodes ATF4, BACE-1,
GADD34, or CHOP. In some embodiments, the mRNA encodes ATF4.
[0378] In some embodiments, expression of ATF4, BACE-1, GADD34 or
CHOP is inhibited. In some embodiments, expression of ATF4 is
inhibited. In some embodiments, expression of A.beta. is inhibited.
ATF4 increases expression of, among others, GADD45A, CDKN1A, and
EIF4EBP1, which encode DDIT-1, p21, and 4E-BP1, respectively. These
proteins induce musculoskeletal disease and can be modulated by
inhibiting expression of ATF4. Accordingly, in some embodiments,
expression of one or more of CDKN1A, GADD45A, or EIF4EBP1 is
inhibited.
[0379] In some embodiments, the compound, salt thereof, or
composition inhibits translation of one or more mRNAs comprising a
5' untranslated region (5'UTR) comprising at least one upstream
open reading frame (uORF) with an IC.sub.50 of less than about 1
.mu.M, such as less than about 750 nM, 600 nM, 500 nM, 300 nM, 200
nM, 100 nM, 80 nM, 60 nM, 40 nM, 25 nM, 10 nM, 5 nM, 1 nM, 0.5 nM,
0.1 nM, 0.01 nM, or less. In some embodiments, the compound, salt
thereof, or composition inhibits translation of one or more mRNAs
comprising a 5' untranslated region (5'UTR) comprising at least one
upstream open reading frame (uORF) with an IC.sub.50 between about
0.01 nM and 1 .mu.M, such as between about 10 nM and 600 nM, about
0.01 nM and 10 nM, 15 nM and 200 nM, or 20 nM and 180 nM.
[0380] In some embodiments, the compound, salt thereof, or
composition inhibits expression of ATF4 with an IC.sub.50 of less
than about 1 .mu.M, such as less than about 750 nM, 600 nM, 500 nM,
300 nM, 200 nM, 100 nM, 80 nM, 60 nM, 40 nM, 25 nM, 10 nM, 5 nM, 1
nM, 0.5 nM, 0.1 nM, 0.01 nM, or less. In some embodiments, the
compound, salt thereof, or composition inhibits expression of ATF4
with an IC.sub.50 between about 0.01 nM and 1 .mu.M, such as
between about 2 nM and 800 nM, 10 nM and 600 nM, about 0.01 nM and
10 nM, 15 nM and 200 nM, or 20 nM and 180 nM.
[0381] In some aspects, the half maximal inhibitory concentration
(IC.sub.50) is a measure of the effectiveness of a substance in
inhibiting a specific biological or biochemical function. In some
aspects, the IC.sub.50 is a quantitative measure that indicates how
much of an inhibitor is needed to inhibit a given biological
process or component of a process such as an enzyme, cell, cell
receptor or microorganism by half. Methods of determining IC.sub.50
in vitro and in vivo are known in the art.
[0382] In some embodiments, the individual is a mammal. In some
embodiments, the individual is a primate, bovine, ovine, porcine,
equine, canine, feline, rabbit, or rodent. In some embodiments, the
individual is a human. In some embodiments, the individual has any
of the diseases or disorders disclosed herein. In some embodiments,
the individual is a risk for developing any of the diseases or
disorders disclosed herein.
[0383] In some embodiments, the individual is human. In some
embodiments, the human is at least about or is about any of 21, 25,
30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or 85 years old. In
some embodiments, the human is a child. In some embodiments, the
human is less than about or about any of 21, 18, 15, 12, 10, 8, 6,
5, 4, 3, 2, or 1 years old.
[0384] Also provided herein are uses of a compound described herein
or a pharmaceutically acceptable salt thereof, or a pharmaceutical
composition described herein, in the manufacture of a medicament.
In some embodiments, the manufacture of a medicament is for the
treatment of a disorder or disease described herein. In some
embodiments, the manufacture of a medicament is for the prevention
and/or treatment of a disorder or disease mediated by an ISR
pathway. In some embodiments, the manufacture of a medicament is
for the prevention and/or treatment of a disorder or disease
mediated by eIF2.alpha. or eIF2B. In some embodiments, the
manufacture of a medicament is for the prevention and/or treatment
of a disorder or disease mediated by phosphorylation of eIF2.alpha.
and/or the GEF activity of eIF2B.
Combinations
[0385] In certain aspects, a compound described herein is
administered to an individual for treatment of a disease in
combination with one or more additional pharmaceutical agents that
can treat the disease. For example, in some embodiments, an
effective amount of the compound is administered to an individual
for the treatment of cancer in combination with one or more
additional anticancer agents.
[0386] In some embodiments, activity of the additional
pharmaceutical agent (such as additional anticancer agent) is
inhibited by an activated ISR pathway. An ISR inhibitor, such as
one of the compounds described herein, can inhibit the ISR pathway
to enhance functionality of the additional pharmaceutical agent. By
way of example, certain BRAF inhibitors (e.g., vemurafenib or
dabrafenib) activate the ISR pathway in BRAF-mutated melanoma cells
(e.g., BRAF with a V600F mutation) through the expression of ATF4.
In some embodiments, there is a method of treating cancer
comprising administering to an individual with cancer an effective
amount of a compound described herein in combination with an
effective amount of a BRAF inhibitor. In some embodiments, there is
a method of treating a BRAF-mutated melanoma comprising
administering to an individual with a BRAF-mutated melanoma an
effective amount of a compound described herein in combination with
an effective amount of a BRAF inhibitor. In some embodiments, there
is a method of treating a BRAF-mutated melanoma comprising
administering to an individual with a BRAF-mutated melanoma an
effective amount of a compound described herein in combination with
an effective amount of vemurafenib or dabrafenib.
[0387] As another example, certain anticancer agents (such as
ubiquitin-proteasome pathway inhibitors (such as bortezomib), Cox-2
inhibitors (e.g., celecoxib), platinum-based antineoplastic drugs
(e.g., cisplatin), anthracyclines (e.g. doxorubicin), or
topoisomerase inhibitors (e.g., etoposide)) are used to treat
cancer, but may have limited functionality against solid tumors.
Resistance in certain solid tumors (e.g., breast cancers) has been
associated with ATF4 stabilization and induction of autophagy. In
some embodiments, an effective amount of an ISR inhibitor compound
as described herein is administered to an individual with cancer to
increase sensitivity to one or more anticancer agents. In some
embodiments, there is a method of treating a refractory cancer
(such as a solid tumor) in an individual, comprising administering
to the individual an effective amount of a compound described
herein in combination with an effective amount of an anticancer
agent. In some embodiments, there is a method of treating a
refractory cancer (such as a solid tumor) in an individual,
comprising administering to the individual an effective amount of a
compound described herein in combination with an effective amount
of an ubiquitin-proteasome pathway inhibitor (e.g., bortezomib), a
Cox-2 inhibitor (e.g., celecoxib), a platinum-based antineoplastic
drug (e.g., cisplatin), an anthracycline (e.g. doxorubicin), or a
topoisomerase inhibitor (e.g., etoposide). In some embodiments, the
refractory cancer is breast cancer. In some embodiments, the
refractory cancer is melanoma.
[0388] In some embodiments, a compound described herein is used to
treat cancer in combination with one or more anti-cancer agents,
such as an anti-neoplastic agent, an immune checkpoint inhibitor,
or any other suitable anti-cancer agent. Exemplary immune
checkpoint inhibitors include anti-PD-1, anti-PD-L1, anti GITR,
anti-OX-40, anti-LAG3, anti-TIM-3, anti-41BB, anti-CTLA-4
antibodies. Exemplary anti-neoplastic agents can include, for
example, anti-microtubule agents, platinum coordination complexes,
alkylating agents, topoisomerase II inhibitors, topoisomerase I
inhibitors, antimetabolites, antibiotic agents, hormones and
hormonal analogs, signal transduction pathway inhibitors,
non-receptor tyrosine kinase angiogenesis inhibitors, proteasome
inhibitors, and inhibitors of cancer metabolism. Other anti-cancer
agents can include one or more of an immuno-stimulant, an antibody
or fragment thereof (e.g., an anti-CD20, anti-HER2, anti-CD52, or
anti-VEGF antibody or fragment thereof), or an immunotoxin (e.g.,
an anti-CD33 antibody or fragment thereof, an anti-CD22 antibody or
fragment thereof, a calicheamicin conjugate, or a pseudomonas
exotoxin conjugate).
[0389] ATF4-mediated expression of CHOP has also been shown to
regulate the function and accumulation of myeloid-derived
suppressor cells (MDSCs) in tumors. MDSCs in tumors reduce the
ability to prime T cell function and reduce antitumoral or
anticancer responses. Certain immunotherapeutic agents (such as
anti-PD-1, anti PD-L.sup.1, anti-GITR, anti-OX-40, anti-LAG3,
anti-TIM-3, anti-41BB, or anti-CTLA-4 antibodies) have been used to
boost the immune response against cancer. ATF4-mediated expression
of AXL has been associated with poor response to anti-PD1 therapy
in melanoma. In some embodiments, an effective amount of an ISR
inhibitor compound as described herein is administered to an
individual with cancer to increase sensitivity to one or more
immunotherapeutic agents. In some embodiments, there is a method of
treating a refractory cancer (such as a melanoma) in an individual,
comprising administering to the individual an effective amount of a
compound described herein in combination with an effective amount
of an immunotherapeutic agent (e.g. anti-PD-1, anti PD-L.sup.1,
anti-GITR, anti-OX-40, anti-LAG3, anti-TIM-3, anti-41BB, or
anti-CTLA-4 antibodies). In some embodiments, the refractory cancer
is melanoma.
Dosing and Method of Administration
[0390] The dose of a compound administered to an individual (such
as a human) may vary with the particular compound or salt thereof,
the method of administration, and the particular disease, such as
type and stage of cancer, being treated. In some embodiments, the
amount of the compound or salt thereof is a therapeutically
effective amount.
[0391] The effective amount of the compound may in one aspect be a
dose of between about 0.01 and about 100 mg/kg. Effective amounts
or doses of the compounds of the present disclosure may be
ascertained by routine methods, such as modeling, dose escalation,
or clinical trials, taking into account routine factors, e.g., the
mode or route of administration or drug delivery, the
pharmacokinetics of the agent, the severity and course of the
disease to be treated, the subject's health status, condition, and
weight. An exemplary dose is in the range of about from about 0.7
mg to 7 g daily, or about 7 mg to 350 mg daily, or about 350 mg to
1.75 g daily, or about 1.75 to 7 g daily.
[0392] Any of the methods provided herein may in one aspect
comprise administering to an individual a pharmaceutical
composition that contains an effective amount of a compound
provided herein or a salt thereof and a pharmaceutically acceptable
excipient.
[0393] A compound or composition provided herein may be
administered to an individual in accordance with an effective
dosing regimen for a desired period of time or duration, such as at
least about one month, at least about 2 months, at least about 3
months, at least about 6 months, or at least about 12 months or
longer, which in some variations may be for the duration of the
individual's life. In one variation, the compound is administered
on a daily or intermittent schedule. The compound can be
administered to an individual continuously (for example, at least
once daily) over a period of time. The dosing frequency can also be
less than once daily, e.g., about a once weekly dosing. The dosing
frequency can be more than once daily, e.g., twice or three times
daily. The dosing frequency can also be intermittent, including a
`drug holiday` (e.g., once daily dosing for 7 days followed by no
doses for 7 days, repeated for any 14 day time period, such as
about 2 months, about 4 months, about 6 months or more). Any of the
dosing frequencies can employ any of the compounds described herein
together with any of the dosages described herein.
Articles of Manufacture and Kits
[0394] The present disclosure further provides articles of
manufacture comprising a compound described herein or a salt
thereof, a composition described herein, or one or more unit
dosages described herein in suitable packaging. In certain
embodiments, the article of manufacture is for use in any of the
methods described herein. Suitable packaging is known in the art
and includes, for example, vials, vessels, ampules, bottles, jars,
flexible packaging and the like. An article of manufacture may
further be sterilized and/or sealed.
[0395] The present disclosure further provides kits for carrying
out the methods of the present disclosure, which comprises one or
more compounds described herein or a composition comprising a
compound described herein. The kits may employ any of the compounds
disclosed herein. In one variation, the kit employs a compound
described herein or a salt thereof. The kits may be used for any
one or more of the uses described herein, and, accordingly, may
contain instructions for the treatment of any disease or described
herein, for example for the treatment of cancer.
[0396] Kits generally comprise suitable packaging. The kits may
comprise one or more containers comprising any compound described
herein. Each component (if there is more than one component) can be
packaged in separate containers or some components can be combined
in one container where cross-reactivity and shelf life permit.
[0397] The kits may be in unit dosage forms, bulk packages (e.g.,
multi-dose packages) or sub-unit doses. For example, kits may be
provided that contain sufficient dosages of a compound as disclosed
herein and/or an additional pharmaceutically active compound useful
for a disease detailed herein to provide effective treatment of an
individual for an extended period, such as any of a week, 2 weeks,
3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7
months, 8 months, 9 months, or more. Kits may also include multiple
unit doses of the compounds and instructions for use and be
packaged in quantities sufficient for storage and use in pharmacies
(e.g., hospital pharmacies and compounding pharmacies).
[0398] The kits may optionally include a set of instructions,
generally written instructions, although electronic storage media
(e.g., magnetic diskette or optical disk) containing instructions
are also acceptable, relating to the use of component(s) of the
methods of the present disclosure. The instructions included with
the kit generally include information as to the components and
their administration to an individual.
General Synthetic Methods
[0399] The compounds of the present disclosure may be prepared by a
number of processes as generally described below and more
specifically in the Examples hereinafter (such as the schemes
provided in the Examples below). In the following process
descriptions, the symbols when used in the formulae depicted are to
be understood to represent those groups described above in relation
to the formulae herein.
[0400] Where it is desired to obtain a particular enantiomer of a
compound, this may be accomplished from a corresponding mixture of
enantiomers using any suitable conventional procedure for
separating or resolving enantiomers. Thus, for example,
diastereomeric derivatives may be produced by reaction of a mixture
of enantiomers, e.g., a racemate, and an appropriate chiral
compound. The diastereomers may then be separated by any convenient
means, for example by crystallization and the desired enantiomer
recovered. In another resolution process, a racemate may be
separated using chiral High-Performance Liquid Chromatography.
Alternatively, if desired a particular enantiomer may be obtained
by using an appropriate chiral intermediate in one of the processes
described.
[0401] Chromatography, recrystallization and other conventional
separation procedures may also be used with intermediates or final
products where it is desired to obtain a particular isomer of a
compound or to otherwise purify a product of a reaction.
[0402] Solvates and/or polymorphs of a compound provided herein or
a salt thereof are also contemplated. Solvates contain either
stoichiometric or non-stoichiometric amounts of a solvent, and are
often formed during the process of crystallization. Hydrates are
formed when the solvent is water, or alcoholates are formed when
the solvent is alcohol. Polymorphs include the different crystal
packing arrangements of the same elemental composition of a
compound. Polymorphs usually have different X-ray diffraction
patterns, infrared spectra, melting points, density, hardness,
crystal shape, optical and electrical properties, stability, and/or
solubility. Various factors such as the recrystallization solvent,
rate of crystallization, and storage temperature may cause a single
crystal form to dominate.
[0403] Chromatography, recrystallization and other conventional
separation procedures may also be used with intermediates or final
products where it is desired to obtain a particular isomer of a
compound or to otherwise purify a product of a reaction.
[0404] General methods of preparing compounds according to the
present disclosure are depicted in the schemes below.
##STR00590## ##STR00591##
[0405] Compounds disclosed herein, such as compounds of formula
(C-6), (C-7), (C-8), and (C-9), for example, can be synthesized
according to the general method described in the scheme above. A
compound of formula (C-1) is reacted with a carboxylic acid (B-1a),
or a carboxylic acid derivative (e.g. an acyl chloride of formula
(B-1b)), under suitable conditions to give a compound of formula
(C-2). The compound of formula (C-2) is deprotected to give a
compound of formula (C-3). The compound of formula (C-3) is
subjected to nitrosation conditions (e.g. reacted with sodium
nitrite) under suitable conditions to give a compound of formula
(C-4). The compound of formula (C-4) is reduced (e.g. with Zn dust)
under suitable conditions to give a compound of formula (C-5). The
compound of formula (C-5) is reacted with a carboxylic acid (B-2a),
or a carboxylic acid derivative (e.g. an acyl chloride of formula
(B-2b), to give a compound of formula (C-6). The compound of
formula (C-5) is reacted with an oxirane derivative of formula
(B-3) to give a compound of formula (C-7). The compound of formula
(C-5) is reacted with a haloalkyl derivative, such as a bromoalkyl
compound of formula (B-4), to give a compound of formula (C-8). The
compound of formula (C-5) is reacted with a carboxylic acid (B-5a),
or a carboxylic acid derivative (e.g. an acyl chloride of formula
(B-5b)), to give a compound of formula (C-9).
##STR00592## ##STR00593##
[0406] Compounds disclosed herein, such as compounds of formula
(D-5), (D-6), (D-7), and (D-8), for example, can be synthesized
according to the general method described in the scheme above. A
compound of formula (C-1) is reacted with a carboxylic acid (B-6)
under suitable conditions to give a compound of formula (D-1). The
compound of formula (D-1) is deprotected to give a compound of
formula (D-2). The compound of formula (D-2) is subjected to
nitrosation conditions (e.g. reacted with sodium nitrite) under
suitable conditions to give a compound of formula (D-3). The
compound of formula (D-3) is reduced (e.g. with Zn dust) under
suitable conditions to give a compound of formula (D-4). The
compound of formula (D-4) is reacted with a carboxylic acid (B-2a),
or a carboxylic acid derivative (e.g. an acyl chloride of formula
(B-2b), to give a compound of formula (D-5). The compound of
formula (D-4) is reacted with an oxirane derivative of formula
(B-3) to give a compound of formula (D-6). The compound of formula
(D-4) is reacted with a haloalkyl derivative, such as a bromoalkyl
compound of formula (B-4), to give a compound of formula (D-7). The
compound of formula (D-4) is reacted with a carboxylic acid (B-5a),
or a carboxylic acid derivative (e.g. an acyl chloride of formula
(B-5b), to give a compound of formula (D-8).
##STR00594## ##STR00595##
[0407] Compounds disclosed herein, such as compounds of formula
(E-6), (E-7), (E-8), and (E-9), for example, can be synthesized
according to the general method described in the scheme above. A
compound of formula (E-1) is reacted with a carboxylic acid (B-1a),
or a carboxylic acid derivative (e.g. an acyl chloride of formula
(B-1b), under suitable conditions to give a compound of formula
(E-2). The compound of formula (E-2) is deprotected to give a
compound of formula (E-3). The compound of formula (E-3) is
subjected to nitrosation conditions (e.g. reacted with sodium
nitrite) under suitable conditions to give a compound of formula
(E-4). The compound of formula (E-4) is reduced (e.g. with Zn dust)
under suitable conditions to give a compound of formula (E-5). The
compound of formula (E-5) is reacted with a carboxylic acid (B-2a),
or a carboxylic acid derivative (e.g. an acyl chloride of formula
(B-2b), to give a compound of formula (E-6). The compound of
formula (E-5) is reacted with an oxirane derivative of formula
(B-3) to give a compound of formula (E-7). The compound of formula
(E-5) is reacted with a haloalkyl derivative, such as a bromoalkyl
compound of formula (B-4), to give a compound of formula (E-8). The
compound of formula (E-5) is reacted with a carboxylic acid (B-5a),
or a carboxylic acid derivative (e.g. an acyl chloride of formula
(B-5b), to give a compound of formula (E-9).
##STR00596## ##STR00597##
[0408] Compounds disclosed herein, such as compounds of formula
(F-5) and (F-6), for example, can be synthesized according to the
general method described in the scheme above. A compound of formula
(E-1) is reacted with an oxirane derivative of formula (B-7) under
suitable conditions to give a compound of formula (F-1). The
compound of formula (F-1) is deprotected to give a compound of
formula (F-2). The compound of formula (F-2) is subjected to
nitrosation conditions (e.g. reacted with sodium nitrite) under
suitable conditions to give a compound of formula (F-3). The
compound of formula (F-3) is reduced (e.g. with Zn dust) under
suitable conditions to give a compound of formula (F-4). The
compound of formula (F-4) is reacted with a carboxylic acid (B-2a),
or a carboxylic acid derivative (e.g. an acyl chloride of formula
(B-2b), to give a compound of formula (F-5). The compound of
formula (F-4) is reacted with a carboxylic acid (B-5a), or a
carboxylic acid derivative (e.g. an acyl chloride of formula
(B-5b), to give a compound of formula (F-6).
##STR00598## ##STR00599##
[0409] Compounds disclosed herein, such as compounds of formula
(G-5) and (G-6), for example, can be synthesized according to the
general method described in the scheme above. A compound of formula
(E-1) is reacted with a haloalkyl derivative, such as a bromoalkyl
compound of formula (B-8), to give a compound of formula (G-1). The
compound of formula (G-1) is deprotected to give a compound of
formula (G-2). The compound of formula (G-2) is subjected to
nitrosation conditions (e.g. reacted with sodium nitrite) under
suitable conditions to give a compound of formula (G-3). The
compound of formula (G-3) is reduced (e.g. with Zn dust) under
suitable conditions to give a compound of formula (G-4). The
compound of formula (G-4) is reacted with a carboxylic acid (B-2a),
or a carboxylic acid derivative (e.g. an acyl chloride of formula
(B-2b), to give a compound of formula (G-5). The compound of
formula (G-4) is reacted with a carboxylic acid (B-5a), or a
carboxylic acid derivative (e.g. an acyl chloride of formula
(B-5b), to give a compound of formula (G-6).
ENUMERATED EMBODIMENTS
[0410] The following enumerated embodiments are representative of
some aspects of the invention.
[0411] Embodiment 1. A compound of formula (I):
##STR00600##
or a pharmaceutically acceptable salt thereof, wherein: m.sup.1,
m.sup.2, n.sup.1, n.sup.2, p.sup.1, p.sup.2, q.sup.1, and q.sup.2,
independently of each other, are 0 or 1; r and s, independently of
each other, are 0, 1, or 2;
X is N or CR.sup.X;
[0412] R.sup.X is selected from the group consisting of hydrogen,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, and C.sub.2-C.sub.6
alkynyl; j is 0 or 1; R.sup.j-a and R.sup.j-b are taken together to
form an oxo (.dbd.O) substituent, or R.sup.j-a and R.sup.j-b are
both hydrogen; k is 0 or 1; R.sup.N-k is H or C.sub.1-C.sub.6
alkyl; R.sup.N is H or C.sub.1-C.sub.6 alkyl; A.sup.1 is selected
from the group consisting of: C.sub.6-C.sub.14 aryl optionally
substituted with one or more R.sup.14 substituents; and 5-14
membered heteroaryl optionally substituted with one or more
R.sup.14 substituents; R.sup.14 is selected, independently at each
occurrence, from the group consisting of halogen, NO.sub.2,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, C.sub.1-C.sub.6 haloalkyl, --OH, --O(C.sub.1-C.sub.6
alkyl), --O(C.sub.1-C.sub.6 haloalkyl), --SH, --S(C.sub.1-C.sub.6
alkyl), --S(C.sub.1-C.sub.6 haloalkyl), --NH.sub.2,
--NH(C.sub.1-C.sub.6 alkyl), --NH(C.sub.1-C.sub.6 haloalkyl),
--N(C.sub.1-C.sub.6 alkyl).sub.2, --N(C.sub.1-C.sub.6
haloalkyl).sub.2, --NR.sup.14-aR.sup.14-b, --CN, --C(O)OH,
--C(O)O(C.sub.1-C.sub.6 alkyl), --C(O)O(C.sub.1-C.sub.6 haloalkyl),
--C(O)NH.sub.2, --C(O)NH(C.sub.1-C.sub.6 alkyl),
--C(O)NH(C.sub.1-C.sub.6 haloalkyl), --C(O)N(C.sub.1-C.sub.6
alkyl).sub.2, --C(O)N(C.sub.1-C.sub.6 haloalkyl).sub.2,
--C(O)NR.sup.14-aR.sup.14-b, --S(O).sub.2OH,
--S(O).sub.2O(C.sub.1-C.sub.6 alkyl), --S(O).sub.2O(C.sub.1-C.sub.6
haloalkyl), --S(O).sub.2NH.sub.2, --S(O).sub.2NH(C.sub.1-C.sub.6
alkyl), --S(O).sub.2NH(C.sub.1-C.sub.6 haloalkyl),
--S(O).sub.2N(C.sub.1-C.sub.6 alkyl).sub.2,
--S(O).sub.2N(C.sub.1-C.sub.6 haloalkyl).sub.2,
--S(O).sub.2NR.sup.14-aR.sup.14-b, --OC(O)H,
--OC(O)(C.sub.1-C.sub.6 alkyl), --OC(O)(C.sub.1-C.sub.6 haloalkyl),
--N(H)C(O)H, --N(H)C(O)(C.sub.1-C.sub.6 alkyl),
--N(H)C(O)(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6
alkyl)C(O)H, --N(C.sub.1-C.sub.6 alkyl)C(O)(C.sub.1-C.sub.6 alkyl),
--N(C.sub.1-C.sub.6 alkyl)C(O)(C.sub.1-C.sub.6 haloalkyl),
--N(C.sub.1-C.sub.6 haloalkyl)C(O)H, --N(C.sub.1-C.sub.6
haloalkyl)C(O)(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
haloalkyl)C(O)(C.sub.1-C.sub.6 haloalkyl),
--OS(O).sub.2(C.sub.1-C.sub.6 alkyl), --OS(O).sub.2(C.sub.1-C.sub.6
haloalkyl), --N(H)S(O).sub.2(C.sub.1-C.sub.6 alkyl),
--N(H)S(O).sub.2(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6
alkyl)S(O).sub.2(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
alkyl)S(O).sub.2(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6
haloalkyl)S(O).sub.2(C.sub.1-C.sub.6 alkyl), and
--N(C.sub.1-C.sub.6 haloalkyl)S(O).sub.2(C.sub.1-C.sub.6
haloalkyl); wherein R.sup.14-a and R.sup.14-b are taken together
with the nitrogen atom to which they are attached to form a 3-10
membered heterocycle; A.sup.2 is selected from the group consisting
of: C.sub.6-C.sub.14 aryl optionally substituted with one or more
R.sup.16 substituents; and 5-14 membered heteroaryl optionally
substituted with one or more R.sup.16 substituents; R.sup.16 is
selected, independently at each occurrence, from the group
consisting of halogen, NO.sub.2, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.1-C.sub.6
haloalkyl, --OH, --O(C.sub.1-C.sub.6 alkyl), --O(C.sub.1-C.sub.6
haloalkyl), --SH, --S(C.sub.1-C.sub.6 alkyl), --S(C.sub.1-C.sub.6
haloalkyl), --NH.sub.2, --NH(C.sub.1-C.sub.6 alkyl),
--NH(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6 alkyl).sub.2,
--N(C.sub.1-C.sub.6 haloalkyl).sub.2, --NR.sup.16-aR.sup.16-b,
--CN, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), --C(O)NH.sub.2,
--C(O)NH(C.sub.1-C.sub.6 alkyl), --C(O)NH(C.sub.1-C.sub.6
haloalkyl), --C(O)N(C.sub.1-C.sub.6 alkyl).sub.2,
--C(O)N(C.sub.1-C.sub.6 haloalkyl).sub.2,
--C(O)NR.sup.16-aR.sup.16-b, --S(O).sub.2OH,
--S(O).sub.2O(C.sub.1-C.sub.6 alkyl), --S(O).sub.2O(C.sub.1-C.sub.6
haloalkyl), --S(O).sub.2NH.sub.2, --S(O).sub.2NH(C.sub.1-C.sub.6
alkyl), --S(O).sub.2NH(C.sub.1-C.sub.6 haloalkyl),
--S(O).sub.2N(C.sub.1-C.sub.6 alkyl).sub.2,
--S(O).sub.2N(C.sub.1-C.sub.6 haloalkyl).sub.2,
--S(O).sub.2NR.sup.16-aR.sup.16-b, --OC(O)H,
--OC(O)(C.sub.1-C.sub.6 alkyl), --OC(O)(C.sub.1-C.sub.6 haloalkyl),
--N(H)C(O)H, --N(H)C(O)(C.sub.1-C.sub.6 alkyl),
--N(H)C(O)(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6
alkyl)C(O)H, --N(C.sub.1-C.sub.6 alkyl)C(O)(C.sub.1-C.sub.6 alkyl),
--N(C.sub.1-C.sub.6 alkyl)C(O)(C.sub.1-C.sub.6 haloalkyl),
--N(C.sub.1-C.sub.6 haloalkyl)C(O)H, --N(C.sub.1-C.sub.6
haloalkyl)C(O)(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
haloalkyl)C(O)(C.sub.1-C.sub.6 haloalkyl),
--OS(O).sub.2(C.sub.1-C.sub.6 alkyl), --OS(O).sub.2(C.sub.1-C.sub.6
haloalkyl), --N(H)S(O).sub.2(C.sub.1-C.sub.6 alkyl),
--N(H)S(O).sub.2(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6
alkyl)S(O).sub.2(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
alkyl)S(O).sub.2(C.sub.1-C.sub.6 haloalkyl), --N(C.sub.1-C.sub.6
haloalkyl)S(O).sub.2(C.sub.1-C.sub.6 alkyl), and
--N(C.sub.1-C.sub.6 haloalkyl)S(O).sub.2(C.sub.1-C.sub.6
haloalkyl); wherein R.sup.16-a and R.sup.16-b are taken together
with the nitrogen atom to which they are attached to form a 3-10
membered heterocycle; R.sup.1a is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH,
--C(O)O(C.sub.1-C.sub.6 alkyl), --C(O)O(C.sub.1-C.sub.6 haloalkyl),
and halogen, or R.sup.1a is taken together with R.sup.2a to form a
C.sub.1-C.sub.6 alkylene moiety, or R.sup.1a is taken together with
an R.sup.3a moiety to form a C.sub.1-C.sub.6 alkylene moiety;
R.sup.1b is selected from the group consisting of hydrogen,
C.sub.1-C.sub.6 alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; R.sup.2a is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; R.sup.2b is
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; R.sup.3a
independently at each occurrence is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH,
--C(O)O(C.sub.1-C.sub.6 alkyl), --C(O)O(C.sub.1-C.sub.6 haloalkyl),
and halogen, or R.sup.3a is taken together with R.sup.4a to form a
C.sub.1-C.sub.6 alkylene moiety; R.sup.3b independently at each
occurrence is selected from the group consisting of hydrogen,
C.sub.1-C.sub.6 alkyl, --C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl),
--C(O)O(C.sub.1-C.sub.6 haloalkyl), and halogen; R.sup.4a
independently at each occurrence is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, --C(O)OH,
--C(O)O(C.sub.1-C.sub.6 alkyl), --C(O)O(C.sub.1-C.sub.6 haloalkyl),
and halogen; R.sup.4b independently at each occurrence is selected
from the group consisting of hydrogen, C.sub.1-C.sub.6 alkyl,
--C(O)OH, --C(O)O(C.sub.1-C.sub.6 alkyl), --C(O)O(C.sub.1-C.sub.6
haloalkyl), and halogen; R.sup.5a and R.sup.5b are taken together
to form an oxo (.dbd.O) substituent or an imido (.dbd.NH)
substituent, or R.sup.5a and R.sup.5b are both hydrogen; R.sup.6a
is selected from the group consisting of hydrogen, --OR.sup.6a-a,
and --NR.sup.6a-bR.sup.6a-c; R.sup.6b is hydrogen; or R.sup.6a and
R.sup.6b are taken together to form a moiety selected from the
group consisting of --O--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--, --CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--CH.sub.2--, and
--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--O--; R.sup.7a and
R.sup.7b are both hydrogen; R.sup.8a and R.sup.8b are taken
together to form an oxo (.dbd.O) substituent, or R.sup.8a and
R.sup.8b are both hydrogen; R.sup.9a and R.sup.9b are taken
together to form an oxo (.dbd.O) substituent or an imido (.dbd.NH)
substituent, or R.sup.9a and R.sup.9b are both hydrogen; R.sup.10a
is selected from the group consisting of hydrogen, --OR.sup.10a-a,
and --NR.sup.10a-bR.sup.10a-c and R.sup.10b is hydrogen, or
R.sup.10a and R.sup.10b are taken together to form a moiety
selected from the group consisting of --O--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--, --CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--O--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--O--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--CH.sub.2--, and
--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--O--; R.sup.11a and
R.sup.11b are both hydrogen; R.sup.12a and R.sup.12b are taken
together to form an oxo (.dbd.O) substituent, or R.sup.12a and
R.sup.12b are both hydrogen; R.sup.6a-a is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, and C.sub.1-C.sub.6
haloalkyl, or R.sup.6a-a is taken together with R.sup.N-k to form a
carbonyl (C.dbd.O) moiety; R.sup.10a-a is selected from the group
consisting of hydrogen, C.sub.1-C.sub.6 alkyl, and C.sub.1-C.sub.6
haloalkyl, or R.sup.10a-a is taken together with R.sup.N to form a
carbonyl (C.dbd.O) moiety; R.sup.6a-b and R.sup.6a-c independently
of each other, are selected from the group consisting of hydrogen,
C.sub.1-C.sub.6 alkyl, and C.sub.1-C.sub.6 haloalkyl; and
R.sup.10a-b and R.sup.10a-c, independently of each other, are
selected from the group consisting of hydrogen, C.sub.1-C.sub.6
alkyl, and C.sub.1-C.sub.6 haloalkyl; provided that: (i) when j is
1, then k is 1; (ii) when m.sup.1 is 0, n.sup.1 is 0, q.sup.1 is 0,
and p.sup.1 is 1, then R.sup.8a and R.sup.8b are taken together to
form an oxo (.dbd.O) substituent, and A.sup.1 is a substituent of
formula (A.sup.1-a)
##STR00601##
wherein * represents the attachment point to the remainder of the
molecule; Z.sup.1 is selected from the group consisting of
CR.sup.Z1-1R.sup.Z1-2, NR.sup.Z1-2,
C(R.sup.Z1-1R.sup.Z1-2)N(R.sup.Z1-2), O, C(R.sup.Z1-1R.sup.Z1-2)O,
S, C(R.sup.Z1-1R.sup.Z1-2)S, and --CR.sup.Z1-1.dbd.CR.sup.Z1-1--;
[0413] wherein R.sup.Z1-1 is H or R.sup.14; and R.sup.Z1-2 is H or
R.sup.14; Z.sup.2 is selected from the group consisting of
CR.sup.Z2-1R.sup.Z2-2, NR.sup.Z2-2,
C(R.sup.Z2-1R.sup.Z2-2)N(R.sup.Z2-2), O, C(R.sup.Z2-1R.sup.Z2-2)O,
S, C(R.sup.Z2-1R.sup.Z2-2)S, and --CR.sup.Z2-1.dbd.CR.sup.Z2-1--;
[0414] wherein R.sup.Z2-1 is H or R.sup.14; and R.sup.Z2-2 is H or
R.sup.14; Z.sup.3, independently at each occurrence, is CH,
CR.sup.14, or N; R.sup.13 is hydrogen or R.sup.14, or R.sup.13 and
R.sup.Z1-2 are taken together to form a double bond between the
carbon atom bearing R.sup.13 and Z.sup.1, or R.sup.13 and
R.sup.Z2-2 are taken together to form a double bond between the
carbon atom bearing R.sup.13 and Z.sup.2; and x1 is 0, 1, 2, 3, or
4; and (iii) when m.sup.2 is 0, n.sup.2 is 0, q.sup.2 is 0, and
p.sup.2 is 1, then R.sup.12a and R.sup.12b are taken together to
form an oxo (.dbd.O) substituent, and A.sup.2 is a substituent of
formula (A.sup.2-a)
##STR00602##
[0414] wherein * represents the attachment point to the remainder
of the molecule; Z.sup.4 is selected from the group consisting of
CR.sup.Z4-1R.sup.Z4-2, NR.sup.Z4-2,
C(R.sup.Z4-1R.sup.Z4-2)N(R.sup.Z4-2), O, C(R.sup.Z4-1R.sup.Z4-2)O,
S, C(R.sup.Z4-1R.sup.Z4-2)S, and --CR.sup.Z4-1.dbd.CR.sup.Z4-1--;
[0415] wherein R.sup.Z4-1 is H or R.sup.16; and R.sup.Z4-2 is H or
R.sup.16. Z.sup.5 is selected from the group consisting of
CR.sup.Z5-1R.sup.Z5-2, NR.sup.Z5-2,
C(R.sup.Z5-1R.sup.Z5-2)N(R.sup.Z5-2), O, C(R.sup.Z5-1R.sup.Z5-2)O,
S, C(R.sup.Z5-1R.sup.Z5-2)S, and --CR.sup.Z5-1.dbd.CR.sup.Z5-1--;
[0416] wherein R.sup.Z5-1 is H or R.sup.16; and R.sup.Z5-2 is H or
R.sup.16; Z.sup.6, independently at each occurrence, is CH,
CR.sup.16, or N; R.sup.15 is hydrogen or R.sup.16, or R.sup.15 and
R.sup.Z4-2 are taken together to form a double bond between the
carbon atom bearing R.sup.15 and Z.sup.4, or R.sup.15 and
R.sup.Z5-2 are taken together to form a double bond between the
carbon atom bearing R.sup.15 and Z.sup.5; and x2 is 0, 1, 2, 3, or
4; (iv) when X is CR.sup.X, then k is 1; (v) when X is N, j is 1,
and k is 1, then R.sup.j-a and R.sup.j-b are taken together to form
an oxo (.dbd.O) substituent; (vi) when X is N, j is 0 and k is 1;
then at least one of (vi-a), (vi-b), (vi-c), or (vi-d) applies:
(vi-a) A.sup.1 is C.sub.6-C.sub.14 aryl substituted with one or
more R.sup.14 substituents; (vi-b) A.sup.1 is 5-14 membered
heteroaryl optionally substituted with one or more R.sup.14
substituents; (vi-c) A.sup.2 is C.sub.6-C.sub.14 aryl substituted
with one or more R.sup.16 substituents; (vi-d) A.sup.2 is 5-14
membered heteroaryl optionally substituted with one or more
R.sup.16 substituents; and (vii) when X is N, j is 0, k is 0,
m.sup.1 is 1, n.sup.1 is 0, p.sup.1 is 0, and q.sup.1 is 0, then
A.sup.1 is a substituent of formula (A.sup.1-a). Embodiment 2. The
compound of embodiment 1, or a pharmaceutically acceptable salt
thereof, wherein k is 1, X is CR.sup.X and the compound of formula
(I) is a compound of formula (II):
##STR00603##
[0416] Embodiment 3. The compound of embodiment 1, or a
pharmaceutically acceptable salt thereof, wherein X is N and the
compound of formula (I) is a compound of formula (III):
##STR00604##
Embodiment 4. A compound of formula (IV):
##STR00605##
or a pharmaceutically acceptable salt thereof, wherein: R.sup.17 is
hydrogen or --C(O)OH; R.sup.18 is hydrogen or halogen; R.sup.19 is
hydrogen or C.sub.2-C.sub.6 alkynyl; L.sup.3 is selected from the
group consisting of
##STR00606##
wherein the * represents the attachment point to A.sup.3, and the #
represents the attachment point to the remainder of the
molecule;
[0417] L.sup.4 is selected from the group consisting of
##STR00607##
wherein the * represents the attachment point to A.sup.4, and the #
represents the attachment point to the remainder of the molecule;
A.sup.3 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6 haloalkyl;
A.sup.4 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6 haloalkyl.
Embodiment 5. A compound of formula (V):
##STR00608##
or a pharmaceutically acceptable salt thereof, wherein: R.sup.20 is
hydrogen or --C(O)OH; R.sup.21 is hydrogen or halogen; R.sup.22 and
R.sup.23 are both hydrogen or R.sup.22 and R.sup.23 are taken
together to form an oxo (.dbd.O) substituent; L.sup.5 is selected
from the group consisting of
##STR00609##
wherein the * represents the attachment point to A.sup.5, and the #
represents the attachment point to the remainder of the molecule;
L.sup.6 is selected from the group consisting of
##STR00610##
wherein the * represents the attachment point to A.sup.6, and the #
represents the attachment point to the remainder of the molecule;
A.sup.5 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6 haloalkyl;
A.sup.6 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6 haloalkyl.
Embodiment 6. A compound of formula (VI):
##STR00611##
or a pharmaceutically acceptable salt thereof, wherein: R.sup.24 is
hydrogen or --C(O)OH; R.sup.25 is hydrogen or halogen; L is
selected from the group consisting of
##STR00612##
wherein the * represents the attachment point to A.sup.7, and the #
represents the attachment point to the remainder of the molecule;
L.sup.8 is selected from the group consisting of
##STR00613##
wherein the * represents the attachment point to A.sup.8, and the #
represents the attachment point to the remainder of the molecule;
A.sup.7 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6 haloalkyl;
A.sup.8 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6 haloalkyl.
Embodiment 7. A compound of formula (VII):
##STR00614##
or a pharmaceutically acceptable salt thereof, wherein: R.sup.26 is
hydrogen or --C(O)OH; R.sup.27 is hydrogen or halogen; L.sup.9 is
selected from the group consisting of
##STR00615##
wherein the * represents the attachment point to A.sup.9, and the #
represents the attachment point to the remainder of the molecule;
L.sup.10 is selected from the group consisting of
##STR00616##
wherein the * represents the attachment point to A.sup.10, and the
# represents the attachment point to the remainder of the molecule;
A.sup.9 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6 haloalkyl;
A.sup.10 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6 haloalkyl.
Embodiment 8. A compound of formula (VIII):
##STR00617##
or a pharmaceutically acceptable salt thereof, wherein: R.sup.28 is
hydrogen or --C(O)OH; R.sup.29 is hydrogen or halogen; L.sup.11 is
selected from the group consisting of
##STR00618##
wherein the * represents the attachment point to A.sup.11, and the
# represents the attachment point to the remainder of the molecule;
L.sup.12 is selected from the group consisting of
##STR00619##
wherein the * represents the attachment point to A.sup.12, and the
# represents the attachment point to the remainder of the molecule;
A.sup.11 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6 haloalkyl;
A.sup.12 is selected from the group consisting of phenyl, naphthyl,
quinolinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzothiazolyl,
and 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, wherein each of the
phenyl, naphthyl, quinolinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, benzothiazolyl, or
3,4-dihydro-2H-benzo[b][1,4]oxazinyl is optionally substituted with
1, 2, 3, or 4 substituents selected from the group consisting of
halogen, --NO.sub.2, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, and C.sub.1-C.sub.6 haloalkyl;
provided that the compound of formula (VIII) is not
##STR00620##
Embodiment 9. A compound selected from the group consisting of a
compound of Table 1, or a pharmaceutically acceptable salt thereof.
Embodiment 10. A pharmaceutical composition comprising a compound
of any one of the preceeding embodiments, or a pharmaceutically
acceptable salt thereof, and a pharmaceutically acceptable carrier.
Embodiment 11. A method of treating a disease or disorder mediated
by an integrated stress response (ISR) pathway in an individual in
need thereof comprising administering to the individual a
therapeutically effective amount of a compound of any one of
embodiments 1 to 9, or a pharmaceutically acceptable salt thereof,
or a therapeutically effective amount of a pharmaceutical
composition of embodiment 10. Embodiment 12. The method of
embodiment 11, wherein the compound, the pharmaceutically
acceptable salt, or the pharmaceutical composition is administered
in combination with a therapeutically effective amount of one or
more additional anti-cancer agents. Embodiment 13. The method of
embodiment 11, wherein the disease or disorder is mediated by
phosphorylation of eIF2.alpha. and/or the guanine nucleotide
exchange factor (GEF) activity of eIF2B. Embodiment 14. The method
of any one of embodiments 11-13, wherein the disease or disorder is
mediated by a decrease in protein synthesis. Embodiment 15. The
method of any one of embodiments 11-14, wherein the disease or
disorder is mediated by the expression of ATF4, CHOP or BACE-1.
Embodiment 16. The method of any of embodiments 11-15, wherein the
disease or disorder is a neurodegenerative disease, an inflammatory
disease, an autoimmune disease, a metabolic syndrome, a cancer, a
vascular disease, an ocular disease, or a musculoskeletal disease.
Embodiment 17. The method of embodiment 20, wherein the disease is
vanishing white matter disease, childhood ataxia with CNS
hypomyelination, intellectual disability syndrome, Alzheimer's
disease, prion disease, Creutzfeldt-Jakob disease, Parkinson's
disease, amyotrophic lateral sclerosis (ALS) disease, cognitive
impairment, frontotemporal dementia (FTD), traumatic brain injury,
postoperative cognitive dysfunction (PCD), neuro-otological
syndromes, hearing loss, Huntington's disease, stroke, chronic
traumatic encephalopathy, spinal cord injury, dementias or
cognitive impairment, arthritis, psoriatic arthritis, psoriasis,
juvenile idiopathic arthritis, asthma, allergic asthma, bronchial
asthma, tuberculosis, chronic airway disorder, cystic fibrosis,
glomerulonephritis, membranous nephropathy, sarcoidosis,
vasculitis, ichthyosis, transplant rejection, interstitial
cystitis, atopic dermatitis or inflammatory bowel disease, Crohn's
disease, ulcerative colitis, celiac disease, systemic lupus
erythematosus, type 1 diabetes, multiple sclerosis, rheumatoid
arthritis, alcoholic liver steatosis, obesity, glucose intolerance,
insulin resistance, hyperglycemia, fatty liver, dyslipidemia,
hyperlipidemia, type 2 diabetes, pancreatic cancer, breast cancer,
kidney cancer, bladder cancer, prostate cancer, testicular cancer,
urothelial cancer, endometrial cancer, ovarian cancer, cervical
cancer, renal cancer, esophageal cancer, gastrointestinal stromal
tumor (GIST), multiple myeloma, cancer of secretory cells, thyroid
cancer, gastrointestinal carcinoma, chronic myeloid leukemia,
hepatocellular carcinoma, colon cancer, melanoma, malignant glioma,
glioblastoma, glioblastoma multiforme, astrocytoma, dysplastic
gangliocytoma of the cerebellum, Ewing's sarcoma, rhabdomyosarcoma,
ependymoma, medulloblastoma, ductal adenocarcinoma, adenosquamous
carcinoma, nephroblastoma, acinar cell carcinoma, lung cancer,
non-Hodgkin's lymphoma, Burkitt's lymphoma, chronic lymphocytic
leukemia, monoclonal gammopathy of undetermined significance
(MGUS), plasmocytoma, lymphoplasmacytic lymphoma, acute
lymphoblastic leukemia, Pelizaeus-Merzbacher disease,
atherosclerosis, abdominal aortic aneurism, carotid artery disease,
deep vein thrombosis, Buerger's disease, chronic venous
hypertension, vascular calcification, telangiectasia or
lymphoedema, glaucoma, age-related macular degeneration,
inflammatory retinal disease, retinal vascular disease, diabetic
retinopathy, uveitis, rosacea, Sjogren's syndrome or
neovascularization in proliferative retinopathy,
hyperhomocysteinemia, skeletal muscle atrophy, myopathy, muscular
dystrophy, muscular wasting, sarcopenia, Duchenne muscular
dystrophy (DMD), Becker's disease, myotonic dystrophy, X-linked
dilated cardiomyopathy, or spinal muscular atrophy (SMA).
Embodiment 18. A method of producing a protein, comprising
contacting a eukaryotic cell comprising a nucleic acid encoding the
protein with the compound or salt of any one of embodiments 1-9.
Embodiment 19. The method of embodiment 18, comprising culturing
the cell in an in vitro culture medium comprising the compound or
salt. Embodiment 20. A method of culturing a eukaryotic cell
comprising a nucleic acid encoding a protein, comprising contacting
the eukaryotic cell with an in vitro culture medium comprising a
compound or salt of any one of embodiments 1-9. Embodiment 21. The
method of any one of embodiments 18-20, wherein the nucleic acid
encoding the protein is a recombinant nucleic acid. Embodiment 22.
The method of any one of embodiments 18-21, wherein the cell is a
human embryonic kidney (HEK) cell or a Chinese hamster ovary (CHO)
cell. Embodiment 23. A method of producing a protein, comprising
contacting a cell-free protein synthesis (CFPS) system comprising
eukaryotic initiation factor 2 (eIF2) and a nucleic acid encoding a
protein with the compound or salt of any one of embodiments 1-9.
Embodiment 24. The method of any one of embodiments 18-23, wherein
the protein is an antibody or a fragment thereof. Embodiment 25.
The method of any one of embodiments 18-24, comprising purifying
the protein. Embodiment 26. An in vitro cell culture medium,
comprising the compound or salt of any one of embodiments 1-9 and
nutrients for cellular growth. Embodiment 27. The cell culture
medium of embodiment 26, comprising a eukaryotic cell comprising a
nucleic acid encoding a protein. Embodiment 28. The cell culture
medium of embodiment 26 or 27, further comprising a compound for
inducing protein expression. Embodiment 29. The cell culture medium
of any one of embodiments 26-28, wherein the nucleic acid encoding
the protein is a recombinant nucleic acid. Embodiment 30. The cell
culture medium of any one of embodiments 26-29, wherein the protein
is an antibody or a fragment thereof. Embodiment 31. The cell
culture medium of any one of embodiments 26-30, wherein the
eukaryotic cell is a human embryonic kidney (HEK) cell or a Chinese
hamster ovary (CHO) cell. Embodiment 32. A cell-free protein
synthesis (CFPS) system comprising eukaryotic initiation factor 2
(eIF2) and a nucleic acid encoding a protein with the compound or
salt of any one of embodiments 1-9. Embodiment 33. The CFPS system
of embodiment 32, comprising a eukaryotic cell extract comprising
eIF2. Embodiment 34. The CFPS system of embodiments 32 and 33,
further comprising eIF2B. Embodiment 35. The CFPS system of any one
of embodiments 32-34, wherein the protein is an antibody or a
fragment thereof.
EXAMPLES
[0418] Although the invention has been described and illustrated
with a certain degree of particularity, it is understood that the
present disclosure has been made only by way of example, and that
numerous changes in the combination and arrangement of parts can be
resorted to by those skilled in the art without departing from the
spirit and scope of the invention, as defined by the claims.
[0419] The chemical reactions in the Examples described can be
readily adapted to prepare a number of other compounds disclosed
herein, and alternative methods for preparing the compounds of this
disclosure are deemed to be within the scope of this disclosure.
For example, the synthesis of non-exemplified compounds according
to the present disclosure can be successfully performed by
modifications apparent to those skilled in the art, e.g., by
appropriately protecting interfering groups, by utilizing other
suitable reagents known in the art other than those described, or
by making routine modifications of reaction conditions, reagents,
and starting materials. Alternatively, other reactions disclosed
herein or known in the art will be recognized as having
applicability for preparing other compounds of the present
disclosure.
[0420] In some cases, stereoisomers are separated to give single
enantiomers or diastereomers as single, unknown stereoisomers, and
are arbitrarily drawn as single isomers. Where appropriate,
information is given on separation method and elution time and
order. In the biological examples, compounds tested were prepared
in accordance to the synthetic procedures described therein. For
any given compound of unknown absolute stereochemistry for which
specific rotation is available, biological data for that compound
was obtained using the enantiomer or diastereoisomer associated
with said specific rotation.
[0421] In some cases, optical rotation was determined on Jasco
DIP-360 digital polarimeter at a wavelength of 589 nm (sodium D
line) and are reported as [.alpha.].sub.D.sup.T for a given
temperature T (expressed in .degree. C.). Where appropriate,
information is given on solvent and concentration (expressed as
g/100 mL).
Abbreviations
[0422] br. s. Broad singlet [0423] chloroform-d Deuterated
chloroform [0424] methanol-d.sub.4 Deuterated methanol [0425] DIAD
Diisopropyl azodicarboxylate [0426] DCM Dichloromethane [0427] DEA
Diethylamine [0428] DIPEA Diisopropylethylamine [0429] DMF
N,N-Dimethylformamide [0430] DMSO-d.sub.6 Deuterated
dimethylsulfoxide [0431] d Doublet [0432] EDC.HCl
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloric acid
[0433] EtOAc Ethyl acetate [0434] EtOH Ethanol [0435] g Gram [0436]
HATU (O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate) [0437] HOBT Hydroxybenzotriazole [0438] HPLC
High Performance Liquid Chromatography [0439] L Litre [0440] LCMS
Liquid Chromatography Mass Spectrometry [0441] MeCN Acetonitrile
[0442] MeOH Methanol [0443] mg Milligram [0444] mL Millilitre
[0445] mmol Millimoles [0446] m multiplet [0447] NMR Nuclear
Magnetic Resonance [0448] q quartet [0449] RT Room temperature
[0450] s singlet [0451] SFC Supercritical Fluid Chromatography
[0452] TFA trifluoroacetic acid [0453] THF Tetrahydrofuran [0454]
TLC Thin layer chromatography [0455] t triplet
EXAMPLES
Example 1
Synthesis of
6-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-1-yl)quino-
line-2-carboxamide
##STR00621## ##STR00622##
[0456] Step 1--Synthesis of tert-butyl
4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidine-1-carboxylate
[0457] To a stirred solution of tert-butyl
4-aminopiperidine-1-carboxylate (0.500 g, 2.50 mmol, 1.0 equiv) in
DMF (10 mL) was added 2-(4-chloro-3-fluorophenoxy)acetic acid
(0.510 g, 2.50 mmol, 1.0 equiv) and HATU (1.90 g, 5.00 mmol, 2.0
equiv) at RT. The resulting reaction mixture was stirred for 10
minutes and DIPEA (1.4 mL, 7.5 mmol, 3.00 equiv) was added. The
reaction mixture was allowed to stir at RT for overnight. Product
formation was confirmed by LCMS. The reaction mixture was diluted
with water (50 mL) and extracted with ethyl acetate (100
mL.times.2). Combined organic extracts were washed with water (20
mL.times.4), dried over anhydrous Na.sub.2SO.sub.4 and concentrated
to obtain tert-butyl
4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidine-1-carboxylate
(1.00 g, quantitative yield) as a brown semisolid. LCMS: 387.2
[M+H].sup.+.
Step 2--Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(piperidin-4-yl)acetamide
2,2,2-trifluoroacetate
[0458] To a stirred solution of tert-butyl
4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidine-1-carboxylate
(1.00 g, 2.5 mmol) in DCM (15 mL) was added TFA (1 mL). The
resultant reaction mixture was stirred at RT for overnight.
Progress of the reaction was monitored by NMR spectroscopy. After
completion of the reaction, the reaction mixture was concentrated
under reduced pressure to obtain
2-(4-chloro-3-fluorophenoxy)-N-(piperidin-4-yl)acetamide
2,2,2-trifluoroacetate (1.00 g, quantitative yield) as a brown
semisolid. LCMS: 287 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.55 (br. s., 1H), 8.31-8.18 (m, 2H), 7.49
(t, J=9.0 Hz, 1H), 7.06 (dd, J=2.6, 11.4 Hz, 1H), 6.84 (dd, J=2.0,
9.0 Hz, 1H), 4.54 (s, 2H), 3.90 (d, J=7.0 Hz, 1H), 3.27 (d, J=12.7
Hz, 2H), 3.09-2.93 (m, 2H), 1.88 (d, J=11.4 Hz, 2H), 1.69-1.54 (m,
2H).
Step 3--Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(1-nitrosopiperidin-4-yl)acetamide
[0459] To a stirred solution of
2-(4-chloro-3-fluorophenoxy)-N-(piperidin-4-yl)acetamide
2,2,2-trifluoroacetate (6.0 g, 15.66 mmol, 1.0 equiv) in water (30
mL) was added acetic acid (10 mL) and sodium nitrite (4.3 g, 62.66
mmol, 4.0 equiv) at RT. The reaction mixture was allowed to stir at
RT overnight. Product formation was confirmed by LCMS. The reaction
mixture was diluted with water (50 mL). The resulting solid was
filtered off, washed with water (20 mL.times.4) and dried under
vacuum to obtain to
2-(4-chloro-3-fluorophenoxy)-N-(1-nitrosopiperidin-4-yl)acetamide
(2.8 g, 60% yield as an off white solid). LCMS: 316 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.13 (d, J=7.0 Hz, 1H),
7.50 (t, J=8.8 Hz, 1H), 7.07 (dd, J=2.6, 11.4 Hz, 1H), 6.94-6.75
(m, 1H), 4.68-4.58 (m, 1H), 4.58-4.47 (m, 2H), 4.18-4.01 (m, 1H),
3.99-3.82 (m, 1H), 3.03-2.82 (m, 1H), 1.98 (d, J=12.3 Hz, 1H), 1.78
(d, J=12.7 Hz, 1H), 1.70-1.53 (m, 1H), 1.35-1.23 (m, 1H).
Step 4--Synthesis of
N-(1-aminopiperidin-4-yl)-2-(4-chloro-3-fluorophenoxy)acetamide
[0460] To a solution of
2-(4-chloro-3-fluorophenoxy)-N-(1-nitrosopiperidin-4-yl)acetamide
(0.100 g, 0.31 mmol, 1.0 equiv) in water (5 mL) was added acetic
acid (1 mL) and Zn dust (0.208 g, 3.1 mmol, 10.0 equiv) at RT. The
reaction mixture was allowed to stir at RT overnight. Product
formation was confirmed by LCMS. The reaction mixture was filtered
through Celite.RTM.. The resulting filtrate was basified by liquid
ammonia and extracted with ethyl acetate (50 mL.times.2). Combined
organic layer was washed with water (20 mL.times.4), dried over
anhydrous Na.sub.2SO.sub.4 and concentrated to obtain
N-(1-aminopiperidin-4-yl)-2-(4-chloro-3-fluorophenoxy)acetamide
(0.100 g, quantitative yield) as an off white solid. LCMS: 302
[M+H].sup.+.
Step 5--Synthesis of
6-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-1-yl)quino-
line-2-carboxamide
[0461] To a solution of
N-(1-aminopiperidin-4-yl)-2-(4-chloro-3-fluorophenoxy) acetamide
(0.100 g, 0.33 mmol, 1.0 equiv) in DMF (5 mL) was added
6-chloroquinoline-2-carboxylic acid (0.070 g, 0.33 mmol, 1.0 equiv)
and HATU (0.208 g, 0.66 mmol, 2.0 equiv) at RT. The resulting
reaction mixture was stirred for 10 minutes and DIPEA (0.28 mL,
0.99 mmol, 3.0 equiv) was added. The reaction mixture was allowed
to stir at RT overnight. Product formation was confirmed by LCMS.
The reaction mixture was diluted with water (20 mL) and extracted
with ethyl acetate (50 mL.times.2). Combined organic layer was
washed with water (20 mL.times.4), dried over anhydrous
Na.sub.2SO.sub.4 and concentrated. The crude product was purified
by reverse phase HPLC to obtain
6-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-1-yl)quino-
line-2-carboxamide (Compound 1-10 mg, 6% yield) as an off white
solid. LCMS: 491 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.77 (s, 1H), 8.53 (d, J=8.3 Hz, 1H), 8.24 (d, J=1.8 Hz,
1H), 8.18-8.03 (m, 3H), 7.88 (dd, J=2.4, 9.0 Hz, 1H), 7.51 (t,
J=8.8 Hz, 1H), 7.09 (dd, J=2.9, 11.6 Hz, 1H), 6.87 (d, J=7.5 Hz,
1H), 4.54 (s, 2H), 3.68 (br. s., 1H), 3.03 (d, J=10.5 Hz, 2H), 2.87
(t, J=10.7 Hz, 2H), 1.79 (d, J=10.5 Hz, 2H), 1.75-1.58 (m, 2H).
Example 2
Synthesis of
5-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-1-yl)benzo-
furan-2-carboxamide
##STR00623##
[0463] To a solution of
N-(1-aminopiperidin-4-yl)-2-(4-chloro-3-fluorophenoxy) acetamide
(0.100 g, 0.33 mmol, 1.0 equiv) in DMF (5 mL) was added
5-chlorobenzofuran-2-carboxylic acid (0.065 g, 0.33 mmol, 1.0
equiv) and HATU (0.250 g, 0.66 mmol, 2.0 equiv) at RT. The
resulting reaction mixture was stirred for 10 minutes. DIPEA (0.28
mL, 0.99 mmol, 3.0 equiv) was added. The reaction mixture was
allowed to stir at RT overnight. Product formation was confirmed by
LCMS. The reaction mixture was diluted with water (25 mL) and
extracted with ethyl acetate (50 mL.times.2). Combined organic
layer was washed with water (20 mL.times.4), dried over anhydrous
Na.sub.2SO.sub.4 and concentrated. The crude product was purified
by reverse phase HPLC to obtain
5-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-1-yl)benzo-
furan-2-carboxamide (Compound 2-20 mg, 12% yield) as an off white
solid. LCMS 480 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.79 (s, 1H), 8.08 (d, J=7.5 Hz, 1H), 7.86 (s, 1H), 7.70
(d, J=9.2 Hz, 1H), 7.54-7.38 (m, 3H), 7.08 (d, J=8.8 Hz, 1H), 6.86
(d, J=11.8 Hz, 1H), 4.53 (s, 2H), 3.66 (br. s., 1H), 2.99 (br. s.,
2H), 2.78 (br. s., 2H), 1.75 (br. s., 2H), 1.66 (br. s., 2H).
##STR00624## ##STR00625##
Step 1--Synthesis of tert-butyl
4-(6-chloroquinoline-2-carboxamido)piperidine-1-carboxylate
[0464] To a stirred solution of tert-butyl
4-aminopiperidine-1-carboxylate (1.00 g, 5.00 mmol, 1.0 equiv) in
DMF (10 mL) was added 6-chloroquinoline-2-carboxylic acid (1.040 g,
5.00 mmol, 1.0 equiv) and HATU (3.800 g, 10.00 mmol, 2.0 equiv) at
RT. The resulting reaction mixture was stirred for 10 minutes and
DIPEA (2.6 mL, 15.00 mmol, 3.00 equiv) was added. The reaction
mixture was allowed to stir at RT for overnight. Product formation
was confirmed by LCMS. The reaction mixture was diluted with water
(50 mL) and extracted with ethyl acetate (100 mL.times.2). Combined
organic extracts were washed with water (20 mL.times.4), dried over
anhydrous Na.sub.2SO.sub.4 and concentrated to obtain tert-butyl
4-(6-chloroquinoline-2-carboxamido)piperidine-1-carboxylate (1.50
g, quantitative yield) as a brown semisolid. LCMS: 390.2
[M+H].sup.+.
Step 2--Synthesis of
6-chloro-N-(piperidin-4-yl)quinoline-2-carboxamide
2,2,2-trifluoroacetate
[0465] To a stirred solution of tert-butyl
4-(6-chloroquinoline-2-carboxamido)piperidine-1-carboxylate (1.50
g, 3.80 mmol) in DCM (15 mL) was added TFA (5 mL). The resultant
reaction mixture was stirred at RT for overnight. Progress of the
reaction was monitored by NMR spectroscopy. After completion of the
reaction, the reaction mixture was concentrated under reduced
pressure to obtain
6-chloro-N-(piperidin-4-yl)quinoline-2-carboxamide
2,2,2-trifluoroacetate (1.00 g, 65% yield) as a brown solid. LCMS:
290 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.98
(d, J=7.9 Hz, 1H), 8.64 (br. s., 1H), 8.55 (d, J=8.3 Hz, 1H), 8.38
(br. s., 1H), 8.25 (d, J=2.2 Hz, 1H), 8.18 (d, J=8.8 Hz, 2H), 7.89
(dd, J=2.2, 9.2 Hz, 1H), 4.21-4.08 (m, 1H), 3.36 (d, J=12.7 Hz,
2H), 3.16-3.01 (m, 2H), 2.05-1.96 (m, 2H), 1.96-1.82 (m, 2H).
Step 3--Synthesis of 6-chloro-N-(1-nitrosopiperidin-4-yl)
quinoline-2-carboxamide
[0466] To a stirred solution of
6-chloro-N-(piperidin-4-yl)quinoline-2-carboxamide
2,2,2-trifluoroacetate (1.0 g, 2.50 mmol, 1.0 equiv) in water (15
mL) was added acetic acid (5 mL) and sodium nitrite (0.730 g, 10.03
mmol, 4.0 equiv) at RT. The reaction mixture was allowed to stir at
RT overnight. Product formation was confirmed by LCMS. The reaction
mixture was diluted with water (50 mL). The resulting solid was
filtered off, washed with water (20 mL.times.4) and dried under
vacuum to obtain to 6-chloro-N-(1-nitrosopiperidin-4-yl)
quinoline-2-carboxamide (1.40 g, quantitative yield) as a white
solid). LCMS: 319 [M+H].sup.+.
Step 4--Synthesis of
N-(1-aminopiperidin-4-yl)-6-chloroquinoline-2-carboxamide
[0467] To a solution of 6-chloro-N-(1-nitrosopiperidin-4-yl)
quinoline-2-carboxamide (0.100 g, 0.31 mmol, 1.0 equiv) in water (5
mL) was added acetic acid (5 mL) and Zn dust (0.045 g, 0.62 mmol,
2.00 equiv). The reaction mixture was allowed to stir at RT
overnight. Product formation was confirmed by LCMS. The reaction
mixture was filtered through Celite.RTM.. The resulting filtrate
was basified by liquid ammonia and extracted with ethyl acetate (50
mL.times.2). Combined organic layer was washed with water (20
mL.times.4), dried over anhydrous Na.sub.2SO.sub.4 and concentrated
to obtain N-(1-aminopiperidin-4-yl)-6-chloroquinoline-2-carboxamide
(0.100 g, 96% yield) as a brown semisolid. LCMS: 305
[M+H].sup.+.
Step 5--Synthesis of
6-chloro-N-(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)quino-
line-2-carboxamide
[0468] To a solution of
N-(1-aminopiperidin-4-yl)-6-chloroquinoline-2-carboxamide (0.100 g,
0.32 mmol, 1.0 equiv) in DMF (5 mL) was added
2-(4-chloro-3-fluorophenoxy)acetic acid (0.068 g, 0.32 mmol, 1.0
equiv) and HATU (0.244 g, 0.64 mmol, 2.0 equiv) at RT. The
resulting reaction mixture was stirred for 10 minutes and DIPEA
(0.25 mL, 0.96 mmol, 3.0 equiv) was added. The reaction mixture was
allowed to stir at RT overnight. Product formation was confirmed by
LCMS. The reaction mixture was diluted with water (20 mL) and
extracted with ethyl acetate (50 mL.times.2). Combined organic
layer was washed with water (20 mL.times.4), dried over anhydrous
Na.sub.2SO.sub.4 and concentrated. The crude product was purified
by reverse phase HPLC to obtain
6-chloro-N-(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)quino-
line-2-carboxamide (Compound 3-7 mg, 5% yield) as a white solid.
LCMS: 491 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.18 (s, 1H), 8.79 (d, J=8.8 Hz, 1H), 8.54 (d, J=8.8 Hz, 1H), 8.25
(br. s., 1H), 8.23-8.11 (m, 2H), 7.89 (d, J=8.3 Hz, 1H), 7.58-7.41
(m, 1H), 7.03 (br. s., 1H), 6.78 (br. s., 1H), 4.94 (s, 1H), 4.50
(s, 1H), 3.11 (br. s., 1H), 2.95 (br. s., 2H), 2.73 (br. s., 2H),
1.85 (br. s., 4H).
Example 4
Synthesis of
N,N'-(piperidine-1,4-diyl)bis(2-(4-chloro-3-fluorophenoxy)acetamide)
##STR00626##
[0470] To a solution of
N-(1-aminopiperidin-4-yl)-2-(4-chloro-3-fluorophenoxy) acetamide
(0.100 g, 0.33 mmol, 1.0 equiv) in DMF (5 mL) was added
2-(4-chloro-3-fluorophenoxy)acetic acid (0.068 g, 0.33 mmol, 1.0
equiv) and HATU (0.250 g, 0.66 mmol, 2.0 equiv) at RT. The
resulting reaction mixture was stirred for 10 minutes and DIPEA
(0.28 mL, 0.99 mmol, 3.0 equiv) was added. The reaction mixture was
allowed to stir at RT overnight. Product formation was confirmed by
LCMS. The reaction mixture was diluted with water (20 mL) and
extracted with ethyl acetate (50 mL.times.2). Combined organic
layer was washed with water (20 mL.times.4), dried over anhydrous
Na.sub.2SO.sub.4 and concentrated. The crude product was purified
by reverse phase HPLC to obtain
N,N'-(piperidine-1,4-diyl)bis(2-(4-chloro-3-fluorophenoxy)acetamide)
(Compound 4-20 mg, 13% yield) as a white solid. LCMS: 488
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.15 (s,
1H), 8.79 (br. s., 1H), 8.05 (d, J=7.5 Hz, 1H), 7.54-7.42 (m, 2H),
7.05 (s, 1H), 7.08 (s, 1H), 6.85 (d, J=6.6 Hz, 1H), 4.90 (s, 1H),
4.58-4.40 (m, 3H), 3.59 (br. s., 2H), 3.05 (br. s., 1H), 2.88 (br.
s., 1H), 2.66 (d, J=11.0 Hz, 1H), 1.73 (br. s., 2H), 1.58 (d, J=9.2
Hz, 2H).
Example 5
Synthesis of
5-chloro-N-(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)benzo-
furan-2-carboxamide
##STR00627## ##STR00628##
[0471] Step 1--Synthesis of tert-butyl
4-(5-chlorobenzofuran-2-carboxamido)cyclohexane-1-carboxylate
[0472] To a stirred solution of tert-butyl
4-aminopiperidine-1-carboxylate (1.02 g, 5.10 mmol, 1.0 equiv) in
DMF (10 mL) was added 5-chlorobenzofuran-2-carboxylic acid (1.0 g,
5.1 mmol, 1.0 equiv) and HATU (3.800 g, 10.02 mmol, 2.0 equiv) at
RT. The resulting reaction mixture was stirred for 10 minutes and
DIPEA (2.5 mL, 15.00 mmol, 3.00 equiv) was added. The reaction
mixture was allowed to stir at RT for overnight. Product formation
was confirmed by LCMS. The reaction mixture was diluted with water
(50 mL) and extracted with ethyl acetate (100 mL.times.2). Combined
organic extracts were washed with water (20 mL.times.4), dried over
anhydrous Na.sub.2SO.sub.4 and concentrated. The crude product
obtained was treated with ether-hexane (50:50) to obtain tert-butyl
4-(5-chlorobenzofuran-2-carboxamido)piperidine-1-carboxylate (0.800
g, 43% yield) as an off-white solid. LCMS: 379.2 [M+H].sup.+.
Step 2--Synthesis of
5-chloro-N-(piperidin-4-yl)benzofuran-2-carboxamide
2,2,2-trifluoroacetate
[0473] To a stirred solution of tert-butyl
4-(5-chlorobenzofuran-2-carboxamido)piperidine-1-carboxylate (0.800
g, 2.32 mmol) in DCM (10 mL) was added TFA (3 mL). The resultant
reaction mixture was stirred at RT for overnight. Progress of the
reaction was monitored by NMR spectroscopy. After completion of the
reaction, the reaction mixture was concentrated under reduced
pressure. The crude product obtained was treated with diethyl ether
to obtain 5-chloro-N-(piperidin-4-yl)benzofuran-2-carboxamide
2,2,2-trifluoroacetate (0.960 g, quantitative yield) as an
off-white solid. LCMS: 279.3 [M+H].sup.+.
Step 3--Synthesis of
5-chloro-N-(1-nitrosopiperidin-4-yl)benzofuran-2-carboxamide
[0474] To a stirred solution of
5-chloro-N-(piperidin-4-yl)benzofuran-2-carboxamide
2,2,2-trifluoroacetate (0.500 g, 1.25 mmol, 1.0 equiv) in water (20
mL) was added acetic acid (5 mL) and sodium nitrite (0.345 g, 5.00
mmol, 4.0 equiv). The reaction mixture was allowed to stir at RT
overnight. Product formation was confirmed by LCMS. The reaction
mixture was diluted with water (50 mL). The resulting solid was
filtered off, washed with water (20 mL.times.4) and dried under
vacuum to obtain to
5-chloro-N-(1-nitrosopiperidin-4-yl)benzofuran-2-carboxamide (0.320
g, 81% yield) as an off-white solid). LCMS: 308.1 [M+H].sup.+.
Step 4--Synthesis of
N-(1-aminopiperidin-4-yl)-5-chlorobenzofuran-2-carboxamide
[0475] To a solution of
5-chloro-N-(1-nitrosopiperidin-4-yl)benzofuran-2-carboxamide (0.300
g, 0.97 mmol, 1.0 equiv) in MeOH (10 mL) was added concentrated HCl
(0.5 mL) and Zn dust (0.123 g, 1.89 mmol, 2.0 equiv). The reaction
mixture was allowed to stir at RT overnight. Product formation was
confirmed by LCMS. The reaction mixture was filtered through
Celite.RTM.. The resulting filtrate was basified by liquid ammonia
and extracted with ethyl acetate (50 mL.times.2). Combined organic
layer was washed with water (20 mL.times.4), dried over anhydrous
Na.sub.2SO.sub.4 and concentrated to obtain
N-(1-aminopiperidin-4-yl)-5-chlorobenzofuran-2-carboxamide (0.340
g, quantitative yield) as a brown semisolid. LCMS: 294.1
[M+H].sup.+.
Step 5--Synthesis of
5-chloro-N-(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)benzo-
furan-2-carboxamide
[0476] To a solution of
N-(1-aminopiperidin-4-yl)-5-chlorobenzofuran-2-carboxamide (0.200
g, 0.68 mmol, 1.0 equiv) in DMF (5 mL) was added
2-(4-chloro-3-fluorophenoxy)acetic acid (0.139 g, 0.68 mmol, 1.0
equiv) and HATU (0.512 g, 1.365 mmol, 2.0 equiv) at RT. The
resulting reaction mixture was stirred for 10 minutes and DIPEA
(0.3 mL, 2.04 mmol, 3.0 equiv) was added. The reaction mixture was
allowed to stir at RT overnight. Product formation was confirmed by
LCMS. The reaction mixture was diluted with water (20 mL) and
extracted with ethyl acetate (50 mL.times.2). Combined organic
layer was washed with water (20 mL.times.4), dried over anhydrous
Na.sub.2SO.sub.4 and concentrated. The crude product was purified
by reverse phase HPLC to obtain
5-chloro-N-(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)benzo-
furan-2-carboxamide (Compound 5-20 mg, 5% yield) as a white solid.
LCMS: 480.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.18 (s, 1H), 8.70 (d, J=7.5 Hz, 1H), 7.87 (br. s., 1H),
7.70 (d, J=8.8 Hz, 1H), 7.57-7.42 (m, 1H), 7.09-6.98 (m, 1H),
6.87-6.78 (m, 1H), 4.93-4.49 (s, 2H), 4.49 3.76 (br. s., 1H), 3.09
(br. s., 1H), 2.93 (d, J=10.5 Hz, 2H), 2.74-2.63 (m, 2H), 1.85-1.69
(m, 4H).
Example 6
Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxy-
propyl)piperazin-1-yl)acetamide
##STR00629##
[0477] Step 1--Synthesis of tert-butyl
4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazine-1-carboxylate
[0478] To a stirred solution of tert-butyl piperazine-1-carboxylate
(2.00 g, 10.05 mmol, 1 equiv) in DMF (10 mL) was added
2-((4-chloro-3-fluorophenoxy)methyl)oxirane (2.2 g, 11.0 mmol, 1.1
equiv) and K.sub.2CO.sub.3 (4.1 g, 30.0 mmol, 3 equiv) at RT. The
resultant reaction mixture was heated at 100.degree. C. for
overnight. Progress of the reaction was monitored by LCMS. After
completion of the reaction, the reaction mixture was diluted with
water (100 mL) and extracted with ethyl acetate (150 mL.times.2).
Combined organic layer was washed with water (50 mL.times.4), dried
over anhydrous Na.sub.2SO.sub.4 and concentrated under reduced
pressure. The crude product obtained was purified by flash
chromatography (0-5% MeOH in DCM as an eluent) to obtain tert-butyl
4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazine-1-carboxylate
(2.3 g, 55% yield) as an off white solid. LCMS: 389.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) 67.46 (t, J=9.0 Hz, 1H), 7.06
(dd, J=2.6, 11.8 Hz, 1H), 6.83 (dd, J=2.2, 8.8 Hz, 1H), 4.93 (d,
J=4.8 Hz, 1H), 4.10-3.81 (m, 5H), 2.47-2.21 (m, 8H), 1.39 (s,
9H).
Step 2--Synthesis of
1-(4-chloro-3-fluorophenoxy)-3-(piperazin-1-yl)propan-2-ol
2,2,2-trifluoroacetate
[0479] To a stirred solution of tert-butyl
4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazine-1-carboxylate
(1.500 g, 5.92 mmol) in DCM (30 mL) was added TFA (5 mL). The
resultant reaction mixture was stirred at RT for overnight.
Progress of the reaction was monitored by NMR spectroscopy. After
completion of the reaction, the reaction mixture was concentrated
under reduced pressure. The crude product obtained was treated with
diethyl ether to obtain
1-(4-chloro-3-fluorophenoxy)-3-(piperazin-1-yl)propan-2-ol
2,2,2-trifluoroacetate (2.30 g, quantitative yield) as an brown
semisolid. LCMS: 289.2 [M+H].sup.+.
Step 3--Synthesis of
1-(4-chloro-3-fluorophenoxy)-3-(4-nitrosopiperazin-1-yl)propan-2-ol
[0480] To a stirred solution of
1-(4-chloro-3-fluorophenoxy)-3-(piperazin-1-yl)propan-2-ol
2,2,2-trifluoroacetate (1.0 g, 2.48 mmol, 1.0 equiv) in water (50
mL) was added acetic acid (10 mL) and sodium nitrite (0.68 g, 9.90
mmol, 4.0 equiv). The reaction mixture was allowed to stir at RT
overnight. Product formation was confirmed by LCMS. The reaction
mixture was diluted with water (50 mL). The resulting solid was
filtered off, washed with water (20 mL.times.4) and dried under
vacuum to obtain to
1-(4-chloro-3-fluorophenoxy)-3-(4-nitrosopiperazin-1-yl)propan-2-ol
(0.690 g, 87% yield) as an off-white solid). LCMS: 318.08
[M+H].sup.+.
Step 4--Synthesis of
1-(4-aminopiperazin-1-yl)-3-(4-chloro-3-fluorophenoxy)propan-2-ol
[0481] To a solution of
1-(4-chloro-3-fluorophenoxy)-3-(4-nitrosopiperazin-1-yl)propan-2-ol
(0.600 g, 1.89 mmol, 1.0 equiv) in MeOH (10 mL) was added
concentrated HCl (0.5 mL) and Zn dust (00.369 g, 5.67 mmol, 3.0
equiv). The reaction mixture was allowed to stir at RT overnight.
Product formation was confirmed by LCMS. The reaction mixture was
filtered through Celite.RTM.. The resulting filtrate was basified
by liquid ammonia and extracted with ethyl acetate (50 mL.times.2).
Combined organic layer was washed with water (20 mL.times.4), dried
over anhydrous Na.sub.2SO.sub.4 and concentrated to obtain
1-(4-aminopiperazin-1-yl)-3-(4-chloro-3-fluorophenoxy)propan-2-ol
(0.690 g, quantitative yield) as an off-white solid. LCMS: 304
[M+H].sup.+.
Step 5--Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxy-
propyl)piperazin-1-yl)acetamide
[0482] To a solution of
1-(4-aminopiperazin-1-yl)-3-(4-chloro-3-fluorophenoxy)propan-2-ol
(0.200 g, 0.66 mmol, 1.0 equiv) in DMF (05 mL) was added
2-(4-chloro-3-fluorophenoxy)acetic acid_(0.134 g, 0.66 mmol, 1.0
equiv) and HATU (0.503 g, 1.32 mmol, 2.0 equiv) at RT. The
resulting reaction mixture was stirred for 10 minutes and DIPEA
(0.3 mL, 1.98 mmol, 3.0 equiv) was added. The reaction mixture was
allowed to stir at RT overnight. Product formation was confirmed by
LCMS. The reaction mixture was diluted with water (20 mL) and
extracted with ethyl acetate (50 mL.times.2). Combined organic
layer was washed with water (20 mL.times.4), dried over anhydrous
Na.sub.2SO.sub.4 and concentrated. The crude product was purified
by reverse phase HPLC to obtain
2-(4-chloro-3-fluorophenoxy)-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxy-
propyl)piperazin-1-yl)acetamide (Compound 6-0.040 g, 12% yield) as
an off-white solid. LCMS: 490.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.15 (br. s., 1H), 8.81 (br. s., 1H),
7.52-7.39 (m, 3H), 7.04 (s, 1H), 7.07 (s, 1H), 6.84 (d, J=7.9 Hz,
2H), 4.88 (s, 2H), 4.47 (s, 1H), 4.00 (d, J=7.5 Hz, 1H), 3.92-3.83
(m, 2H), 2.90 (br. s., 1H), 2.76 (br. s., 3H), 2.35 (d, J=18.0 Hz,
4H).
Example 7
Synthesis of
6-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-1-yl)-3,4--
dihydro-2H-benzo[b][1,4]oxazine-2-carboxamide
##STR00630##
[0484] To a solution of
N-(1-aminopiperidin-4-yl)-2-(4-chloro-3-fluorophenoxy) acetamide
(0.100 g, 0.33 mmol, 1.0 equiv) in DMF (05 mL) was added
6-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carboxylic acid
(0.071 g, 0.33 mmol, 1.0 equiv) and HATU (0.251 g, 0.66 mmol, 2.0
equiv) at RT. The resulting reaction mixture was stir for 10
minutes. DIPEA (0.28 mL, 0.99 mmol, 3.0 equiv) was added. The
reaction mixture was allowed to stir at RT overnight. Product
formation was confirmed by LCMS. The reaction mixture was diluted
with water (50 mL) and extracted with ethyl acetate (100
mL.times.2). Combined organic extracts were washed with water (50
mL.times.4), dried over anhydrous Na.sub.2SO.sub.4 and
concentrated. The crude product was purified by reversed phase HPLC
to obtain
6-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-1-yl)-3,4--
dihydro-2H-benzo[b][1,4]oxazine-2-carboxamide (Compound 31-05 mg,
3% Yield) as an off white solid. LCMS: 497 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.01 (s, 1H), 8.03 (d, J=7.9 Hz,
1H), 7.49 (t, J=8.8 Hz, 1H), 7.06 (d, J=11.4 Hz, 1H), 6.85 (d,
J=8.8 Hz, 1H), 6.76 (d, J=8.3 Hz, 1H), 6.67 (d, J=8.3 Hz, 1H), 6.57
(br. s., 1H), 6.54-6.40 (m, 1H), 6.17 (br. s., 1H), 4.51 (s, 2H),
3.60 (br. s., 1H), 3.40 (d, J=12.3 Hz, 1H), 3.20 (dd, J=7.9, 11.8
Hz, 2H), 2.88 (br. s., 1H), 2.72-2.59 (m, 2H), 1.70 (br. s., 2H),
1.58 (d, J=14.5 Hz, 2H).
Example 8
Synthesis of
5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-y-
l)benzofuran-2-carboxamide
##STR00631##
[0485] Step 1--Synthesis of tert-butyl
4-aminopiperazine-1-carboxylate
[0486] To a stirred solution of tert-butyl
4-nitrosopiperazine-1-carboxylate (0.500 g, 2.32 mmol, 1 equiv) in
THF: H2O (10:10 mL) was added NH.sub.4Cl (1.98 g, 37.17 mmol, 16.0
equiv) and then Zn dust (1.21 g, 18.58 mmol, 8.0 equiv) was added
portion wise. After completion of addition the reaction mixture was
stirred at RT for overnight. Progress of the reaction was monitored
by LCMS. Reaction mixture was diluted with water (100 mL) and
filtered off over Celite.RTM. bed and filtrate was extracted with
DCM (100 mL.times.2). Organic layer was separated and dried over
anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure
to obtain tert-butyl 4-aminopiperazine-1-carboxylate (0.420 g, 96%
Yield) as a yellow semi solid. LCMS 202.3 [M+H].sup.+; .sup.1H NMR
(400 MHz, Chloroform-d) .delta. 3.47 (br. s., 4H), 3.14 (br. s.,
2H), 2.56 (br. s., 4H), 1.45 (s, 9H).
Step 2--Synthesis of tert-butyl
4-(5-chlorobenzofuran-2-carboxamido)piperazine-1-carboxylate
[0487] To a stirred solution of 5-chlorobenzofuran-2-carboxylic
acid (0.100 g, 0.50 mmol, 1.0 equiv) in DMF (05 mL) was added HATU
(0.380 g, 1.01 mmol, 2.0 equiv) at RT and stirred for 10 minutes.
Then tert-butyl 4-aminopiperazine-1-carboxylate (0.112 g, 0.55
mmol, 1.1 equiv) was added followed by the addition of DIPEA (0.2
mL, 1.52 mmol, 3.0 equiv). The resulting reaction mixture was
allowed to stir at RT for overnight. Product formation was
confirmed by LCMS. The reaction mixture was diluted with water (50
mL) and extracted with EtOAc (50 mL.times.2). The combined organic
layer was washed with water (30 mL), brine solution (30
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure, to obtain tert-butyl
4-(5-chlorobenzofuran-2-carboxamido)piperazine-1-carboxylate (0.140
g, 66% Yield) as an off-white solid. LCMS 380.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.90 (s, 1H), 7.87 (s,
1H), 7.70 (d, J=8.8 Hz, 1H), 7.57-7.44 (m, 2H), 3.42 (br. s., 4H),
2.83 (br. s., 4H), 1.50-1.29 (m, 9H).
Step 3--Synthesis of
5-chloro-N-(piperazin-1-yl)benzofuran-2-carboxamide
2,2,2-trifluoroacetate
[0488] To a stirred solution of tert-butyl
4-(5-chlorobenzofuran-2-carboxamido)piperazine-1-carboxylate (0.140
g, 0.0.36 mmol, 1.0 equiv) in DCM (5 mL), was added TFA (1 mL) and
the resultant reaction mixture was stirred at RT for 1 h under
nitrogen atmosphere. Reaction was monitored by TLC and LCMS. After
completion of reaction, the reaction mixture was concentrated under
reduced pressure to obtain crude product which was crystallized in
diethyl ether to obtain
5-chloro-N-(piperazin-1-yl)benzofuran-2-carboxamide
2,2,2-trifluoroacetate (0.130 g, 90% Yield) as an off-white solid.
LCMS 280.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.20 (s, 1H), 8.73 (br. s., 2H), 7.88 (d, J=1.8 Hz, 1H), 7.71 (d,
J=8.8 Hz, 1H), 7.58-7.42 (m, 2H), 3.08-3.12 (m, 4H), 3.17-2.97 (m,
4H).
Step 4--Synthesis of
5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-y-
l)benzofuran-2-carboxamide
[0489] To a stirred solution of
5-chloro-N-(piperazin-1-yl)benzofuran-2-carboxamide
2,2,2-trifluoroacetate (0.130 g, 0.33 mmol, 1.0 equiv) and
2-((4-chloro-3-fluorophenoxy)methyl)oxirane (0.066 g, 0.33 mmol,
1.0 equiv) in DMF (05 mL), was added K.sub.2CO.sub.3 (0.091 g, 0.66
mmol, 2.0 equiv) and the resultant reaction mixture was heated at
100.degree. C. for overnight. Progress of the reaction was
monitored by LCMS. After completion of reaction, the reaction
mixture was diluted with water (50 mL) and extracted with EtOAc (50
mL.times.2). The combined organic layer was washed with water (30
mL), brine solution (30 mL.times.2), dried over anhydrous sodium
sulfate and concentrated under reduced pressure to obtain crude
product which was purified by reversed-phase HPLC to obtain
5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-y-
l)benzofuran-2-carboxamide (Compound 19--0.015 g, 09% Yield) as a
white solid. LCMS 482.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.21 (br. s., 1H), 9.64 (br. s., 1H), 7.89
(s, 1H), 7.71 (d, J=9.2 Hz, 1H), 7.61-7.44 (m, 2H), 7.11 (dd,
J=2.6, 11.4 Hz, 1H), 6.87 (d, J=8.3 Hz, 1H), 6.01 (br. s., 1H),
4.31 (br. s., 1H), 4.01 (d, J=4.4 Hz, 2H), 3.60 (br. s., 2H), 3.21
(br. s., 8H).
Example 9
Synthesis of
6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-y-
l)-2-naphthamide
##STR00632##
[0490] Step 1--Synthesis of tert-butyl
4-(6-chloro-2-naphthamido)piperazine-1-carboxylate
[0491] To a stirred solution of 6-chloro-2-naphthoic acid (0.100 g,
0.48 mmol, 1.0 equiv) in DMF (05 mL) was added HATU (0.368 g, 0.97
mmol, 2.0 equiv) at RT and stirred for 10 minutes. Then tert-butyl
4-aminopiperazine-1-carboxylate (0.097 g, 0.48 mmol, 1.0 equiv) was
added followed by the addition of DIPEA (0.2 mL, 1.45 mmol, 3.0
equiv). The resulting reaction mixture was allowed to stir at RT
for overnight. Product formation was confirmed by LCMS. the
reaction mixture was diluted with water (50 mL) and extracted with
EtOAc (50 mL.times.2). The combined organic layer was washed with
water (30 mL), brine solution (30 mL.times.2), dried over anhydrous
sodium sulfate and concentrated under reduced pressure, to obtain
tert-butyl 4-(6-chloro-2-naphthamido)piperazine-1-carboxylate
(0.160 g, 85% Yield) as an off-white solid. LCMS 390.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.69 (s, 1H), 8.39 (s,
1H), 8.18-8.03 (m, 2H), 7.97 (t, J=9.0 Hz, 1H), 7.90 (d, J=8.8 Hz,
1H), 7.60 (d, J=7.0 Hz, 2H), 3.44 (br. s., 3H), 2.94-2.84 (m, 4H),
1.53-1.32 (m, 9H).
Step 2--Synthesis of 6-chloro-N-(piperazin-1-yl)-2-naphthamide
2,2,2-trifluoroacetate
[0492] To a stirred solution of tert-butyl
4-(6-chloro-2-naphthamido)piperazine-1-carboxylate (0.160 g, 0.41
mmol, 1.0 equiv) in DCM (05 mL) was added TFA (1 mL) and the
resultant reaction mixture was stirred at RT for 1 h under nitrogen
atmosphere. Reaction was monitored by TLC and LCMS. After
completion of reaction, the reaction mixture was concentrated under
reduced pressure to obtain sticky crude product which was
crystallized in diethyl ether to obtain
6-chloro-N-(piperazin-1-yl)-2-naphthamide 2,2,2-trifluoroacetate
(0.140 g, 84% Yield) as an off-white solid. LCMS 290.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.98 (s, 1H), 8.65 (br.
s., 2H), 8.41 (s, 1H), 8.19-8.05 (m, 2H), 8.00 (d, J=8.3 Hz, 1H),
7.91 (d, J=7.0 Hz, 1H), 7.62 (dd, J=1.8, 8.8 Hz, 1H), 3.25 (br. s.,
4H), 3.16 (br. s., 4H).
Step 3--Synthesis of
6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-y-
l)-2-naphthamide
[0493] To a stirred solution of
6-chloro-N-(piperazin-1-yl)-2-naphthamide trifluoroacetate (0.140
g, 0.34 mmol, 1.0 equiv) and
2-((4-chloro-3-fluorophenoxy)methyl)oxirane (0.070 g, 0.34 mmol,
1.0 equiv) in DMF (05 mL), was added K.sub.2CO.sub.3 (0.095 g, 0.69
mmol, 2.0 equiv) and the resultant reaction mixture was heated at
100.degree. C. for overnight. Progress of the reaction was
monitored by LCMS. After completion of reaction, the reaction
mixture was diluted with water (50 mL) and extracted with EtOAc (50
mL.times.2). The combined organic layer was washed with water (30
mL), brine solution (30 mL.times.2), dried over anhydrous sodium
sulfate and concentrated under reduced pressure to obtain crude
which was purified by reversed-phase HPLC to obtain
6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-y-
l)-2-naphthamide (Compound 14-0.005 g, 04% Yield) as white solid.
LCMS 492.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.99 (br. s., 1H), 9.62 (br. s., 1H), 8.42 (s, 1H), 8.21-8.05 (m, 2
H), 8.00 (d, J=8.3 Hz, 1H), 7.91 (d, J=9.2 Hz, 1H), 7.62 (d, J=10.5
Hz, 1H), 7.55-7.42 (m, 1H), 7.11 (d, J=11.0 Hz, 1H), 6.88 (d, J=7.5
Hz, 1H), 6.01 (br. s., 1H), 4.32 (br. s., 2H), 4.01 (d, J=4.4 Hz,
2H), 3.62 (br. s., 2H), 3.26 (br. s., 6H).
Example 10
Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(4-((2-(4-chloro-3-fluorophenoxy)ethyl)ami-
no)piperidin-1-yl)acetamide
##STR00633##
[0495] To a stirred solution of
N-(4-aminopiperidin-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide
2,2,2-trifluoroacetate (0.100 g, 0.24 mmol, 1.0 equiv) and
4-(2-bromoethoxy)-1-chloro-2-fluorobenzene (0.062 g, 0.24 mmol, 1.0
equiv) in DMF (05 mL), was added K.sub.2CO.sub.3 (0.068 g, 0.49
mmol, 2.0 equiv) and the resultant reaction mixture was heated at
60.degree. C. for overnight. Progress of the reaction was monitored
by LCMS. The reaction mixture was diluted with water (20 mL) and
extracted with ethyl acetate (50 mL.times.2). Combined organic
layer was washed with water (20 mL.times.4), dried over anhydrous
Na.sub.2SO.sub.4 and concentrated. The crude product was purified
by reverse phase HPLC to obtain
2-(4-chloro-3-fluorophenoxy)-N-(4-((2-(4-chloro-3-fluorophenoxy)ethyl)ami-
no)piperidin-1-yl)acetamide (Compound 22-0.018 g, 16% Yield) as a
white solid. LCMS 474.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.12 (br. s., 1H), 8.78 (br. s., 1H),
7.45-7.54 (m, 2H), 7.04-7.13 (m, 2H), 6.84 (d, J=8.77 Hz, 2H), 4.88
(s, 2H), 4.46 (s, 2H), 4.05 (br. s., 2H), 2.65 (d, J=12.28 Hz, 2H),
1.87 (br. s., 2H), 1.39 (br. s., 3H), 1.23 (br. s., 2H).
Example 11
Synthesis of
6-chloro-N-(4-((2-(4-chloro-3-fluorophenoxy)ethyl)amino)piperidin-1-yl)qu-
inoline-2-carboxamide
##STR00634##
[0496] Step 1--Synthesis of tert-butyl
(1-(6-chloroquinoline-2-carboxamido)piperidin-4-yl)carbamate
[0497] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (0.170 g, 0.79 mmol, 1.0 equiv) in
DMF (5 mL) was added HATU (0.450 g, 1.18 mmol, 1.5 equiv) at RT and
stirred for 10 minutes. Then 6-chloroquinoline-2-carboxylic acid
(0.241 g, 1.18 mmol, 1.5 equiv) was added followed by the addition
of DIPEA (0.6 mL, 3.16 mmol, 4.0 equiv). The resulting reaction
mixture was allowed to stir at RT for overnight. Product formation
was confirmed by LCMS. The reaction mixture was diluted with water
(50 mL). The resulting solid was filtered off, washed with water
(20 mL.times.4) and dried under vacuum to obtain tert-butyl
(1-(6-chloroquinoline-2-carboxamido)piperidin-4-yl)carbamate (0.100
g, 32% Yield) as an off-white solid. LCMS 405.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.72 (s, 1H), 8.53 (d,
J=8.3 Hz, 1H), 8.24 (d, J=1.8 Hz, 1H), 8.14 (t, J=7.7 Hz, 1H),
7.96-7.81 (m, 1H), 6.85 (br. s., 1H), 2.97 (br. s., 2H), 2.91-2.74
(m, 2H), 1.75 (br. s., 2H), 1.56 (d, J=10.1 Hz, 2H), 1.47-1.28 (m,
9H).
Step 2--Synthesis of
N-(4-aminopiperidin-1-yl)-6-chloroquinoline-2-carboxamide
2,2,2-trifluoroacetate
[0498] To a stirred solution of tert-butyl
(1-(6-chloroquinoline-2-carboxamido)piperidin-4-yl)carbamate (0.100
g, 0.24 mmol, 1.0 equiv) in DCM (10 mL), was added trifluoroacetic
acid (0.2 mL) and the resultant reaction mixture was stirred at RT
for 1 h under nitrogen atmosphere. Reaction was monitored by TLC
and LCMS. After completion of reaction, the reaction mixture was
concentrated under reduced pressure to obtain sticky crude compound
which was triturated with hexane (10 mL) and diethyl ether and
dried under vacuum to obtain
N-(4-aminopiperidin-1-yl)-6-chloroquinoline-2-carboxamide
2,2,2-trifluoroacetate (0.100 g, 97% Yield) as an yellow solid.
LCMS 305.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.85 (s, 1H), 8.54 (d, J=8.3 Hz, 1H), 8.25 (s, 1H), 8.14 (dd,
J=3.9, 8.8 Hz, 2H), 8.01-7.73 (m, 3H), 3.04 (br. s., 2H), 2.89 (d,
J=12.3 Hz, 2H), 1.94 (br. s., 2H), 1.69 (d, J=12.3 Hz, 2H).
Step 3--Synthesis of
6-chloro-N-(4-((2-(4-chloro-3-fluorophenoxy)ethyl)amino)piperidin-1-yl)qu-
inoline-2-carboxamide
[0499] To a stirred solution of
N-(4-aminopiperidin-1-yl)-6-chloroquinoline-2-carboxamide
trifluoroacetate (0.100 g, 0.23 mmol, 1.0 equiv) and
4-(2-bromoethoxy)-1-chloro-2-fluorobenzene (0.060 g, 0.23 mmol, 1.0
equiv) in DMF (05 mL), was added K.sub.2CO.sub.3 (0.066 g, 0.47
mmol, 2.0 equiv) and the resultant reaction mixture was heated at
60.degree. C. for overnight. Progress of the reaction was monitored
by LCMS. Product formation was confirmed by LCMS. The reaction
mixture was diluted with water (50 mL). The resulting solid was
filtered off, washed with water (20 mL.times.4) and dried under
vacuum. The crude product was purified by reverse phase HPLC to
obtain
6-chloro-N-(4-((2-(4-chloro-3-fluorophenoxy)ethyl)amino)piperidin-1-yl)qu-
inoline-2-carboxamide (Compound 23-0.006 g, 04% Yield) as a white
solid. LCMS 477.2 [M+H].sup.+; .sup.1H NMR .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.92 (br. s., 1H), 8.72 (s, 1H), 8.54 (d,
J=8.33 Hz, 1H), 8.26 (s, 1H), 8.14 (dd, J=8.99, 5.04 Hz, 2H), 7.89
(d, J=7.02 Hz, 1H), 7.54 (d, J=8.77 Hz, 1H), 7.17 (d, J=9.21 Hz,
1H), 6.93 (d, J=7.89 Hz, 1H), 4.28 (br. s., 2H), 3.11 (d, J=9.65
Hz, 3H), 2.90 (d, J=12.28 Hz, 3H), 2.67 (br. s., 1H), 2.03-2.19 (m,
2H), 1.75 (s, 2H).
Example 12
Synthesis of
5-chloro-N-(4-((2-(4-chloro-3-fluorophenoxy)ethyl)amino)piperidin-1-yl)be-
nzofuran-2-carboxamide
##STR00635##
[0500] Step 1--Synthesis of tert-butyl
(1-(5-chlorobenzofuran-2-carboxamido)piperidin-4-yl)carbamate
[0501] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (0.100 g, 0.46 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (0.265 g, 0.69 mmol, 1.5 equiv) at RT
and stirred for 10 minutes. Then 5-chlorobenzofuran-2-carboxylic
acid (0.137 g, 0.69 mmol, 1.5 equiv) was added followed by the
addition of DIPEA (0.35 mL, 1.86 mmol, 4.0 equiv). The resulting
reaction mixture was allowed to stir at RT for overnight. Product
formation was confirmed by LCMS. The reaction mixture was diluted
with water (50 mL). The resulting solid was filtered off, washed
with water (20 mL.times.4) and dried under vacuum to obtain
tert-butyl
(1-(5-chlorobenzofuran-2-carboxamido)piperidin-4-yl)carbamate
(0.150 g, 82% Yield) as an yellow solid. LCMS 394.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.75 (s, 1H), 7.86 (s,
1H), 7.69 (d, J=8.8 Hz, 1H), 7.58-7.33 (m, 2H), 6.85 (d, J=7.5 Hz,
1H), 3.25 (br. s., 1H), 2.96 (d, J=11.0 Hz, 2H), 2.82-2.63 (m, 2H),
1.74 (d, J=11.8 Hz, 2H), 1.66-1.45 (m, 2H), 1.45-1.28 (m, 9H).
Step 2--Synthesis of
N-(4-aminopiperidin-1-yl)-5-chlorobenzofuran-2-carboxamide
2,2,2-trifluoroacetate
[0502] To a stirred solution of tert-butyl
(1-(5-chlorobenzofuran-2-carboxamido)piperidin-4-yl)carbamate
(0.150 g, 0.38 mmol, 1.0 equiv) in DCM (15 mL), was added
trifluoroacetic acid (0.3 mL) and the resultant reaction mixture
was stirred at RT for 1 h under nitrogen atmosphere. Reaction was
monitored by TLC and LCMS. After completion of reaction, the
reaction mixture was concentrated under reduced pressure to obtain
crude product which was crystallized in diethyl ether and dried
under vacuum to obtain
N-(4-aminopiperidin-1-yl)-5-chlorobenzofuran-2-carboxamide
2,2,2-trifluoroacetate (0.160 g, Quant. Yield) as an yellow solid.
LCMS 294.1 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.89 (s, 1H), 7.98 (br. s., 2H), 7.90-7.80 (m, 1H), 7.69 (d, J=8.8
Hz, 1H), 7.60-7.42 (m, 2H), 3.03 (d, J=10.5 Hz, 3H), 2.78 (t,
J=11.0 Hz, 2H), 1.94 (d, J=11.4 Hz, 2H), 1.66 (d, J=9.6 Hz,
2H).
Step 3--Synthesis of
5-chloro-N-(4-((2-(4-chloro-3-fluorophenoxy)ethyl)amino)piperidin-1-yl)be-
nzofuran-2-carboxamide
[0503] To a stirred solution of
N-(4-aminopiperidin-1-yl)-5-chlorobenzofuran-2-carboxamide
trifluoroacetate (0.160 g, 0.39 mmol, 1.0 equiv) and
4-(2-bromoethoxy)-1-chloro-2-fluorobenzene (0.100 g, 0.39 mmol, 1.0
equiv) in DMF (05 mL), was added K.sub.2CO.sub.3 (0.108 g, 0.78
mmol, 2.0 equiv) and the resultant reaction mixture was heated at
60.degree. C. for overnight. Progress of the reaction was monitored
by LCMS. Product formation was confirmed by LCMS. The reaction
mixture was diluted with water (50 mL). The resulting solid was
filtered off, washed with water (20 mL.times.4) and dried under
vacuum. The crude product was purified by reversed phase HPLC to
obtain
5-chloro-N-(4-((2-(4-chloro-3-fluorophenoxy)ethyl)amino)piperidin-1-yl)be-
nzofuran-2-carboxamide (Compound 24-0.020 g, 10% Yield) as an off
white solid. LCMS 466.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.73 (s, 1H), 7.86 (s, 1H), 7.69 (d, J=8.77
Hz, 1H), 7.38-7.58 (m, 4H), 7.08 (dd, J=11.40, 2.63 Hz, 1H), 6.84
(d, J=7.02 Hz, 1H), 4.03 (t, J=5.48 Hz, 2H), 2.99 (d, J=10.09 Hz,
2H), 2.89 (t, J=5.26 Hz, 2H), 2.73 (t, J=9.87 Hz, 2H), 1.86 (d,
J=16.66 Hz, 3H), 1.34-1.45 (m, 2H).
Example 13
Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydrox-
ypropyl)amino)piperidin-1-yl)acetamide
##STR00636##
[0504] Step 1--Synthesis of tert-butyl
(1-nitrosopiperidin-4-yl)carbamate
[0505] To a stirred solution of tert-butyl piperidin-4-ylcarbamate
(5.0 gm, 25 mmol, 1.0 equiv) in water (120 mL) was added acetic
acid (40 mL) and sodium nitrite (6.9 gm, 100 mmol, 4.0 equiv) at
RT. The reaction mixture was allowed to stir at RT overnight.
Product formation was confirmed by LCMS. The reaction mixture was
diluted with water (50 mL). The resulting solid was filtered off,
washed with water (20 mL.times.4) and dried under vacuum to obtain
to tert-butyl (1-nitrosopiperidin-4-yl)carbamate (5.6 gm, 97%
Yield) a white solid. LCMS 230.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 6.96 (d, J=6.1 Hz, 1H), 4.52 (d, J=13.2 Hz,
2H), 3.95-3.80 (m, 1H), 3.67 (br. s., 1H), 3.03-2.85 (m, 1H), 1.97
(d, J=11.0 Hz, 1H), 1.76 (d, J=10.5 Hz, 1H), 1.60-1.44 (m, 1H),
1.39 (s, 8H), 1.25-1.10 (m, 1H).
Step 2--Synthesis of tert-butyl
(1-aminopiperidin-4-yl)carbamate
[0506] To a stirred solution of tert-butyl
(1-nitrosopiperidin-4-yl)carbamate (0.500 g, 2.18 mmol, 1 equiv) in
THF: H2O (20:20 mL) was added NH.sub.4Cl (1.88 g, 39.9 mmol, 16.0
equiv) and then Zn dust (1.21 g, 17.4 mmol, 8.0 equiv) was added
portion wise. After addition, the reaction mixture was stirred at
RT for overnight. Progress of the reaction was monitored by LCMS.
The reaction mixture was diluted with water (100 mL), filtered over
celite bed and filtrate was extracted with DCM (100 mL.times.2).
Combined organic layer was dried over anhydrous Na.sub.2SO.sub.4
and concentrated under reduced pressure, to obtain tert-butyl
(1-aminopiperidin-4-yl)carbamate (0.400 g, 85% Yield) as an off
white solid. LCMS 216.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 6.70 (d, J=6.1 Hz, 1H), 3.37 (br. s., 2H),
3.14 (br. s., 1H), 2.84 (d, J=10.1 Hz, 2H), 2.04 (t, J=10.7 Hz,
2H), 1.64 (d, J=11.4 Hz, 2H), 1.51-1.26 (m, 10H).
Step 3--Synthesis of tert-butyl
(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)carbamate
[0507] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (0.200 g, 0.93 mmol, 1.0 equiv) in
DMF (10 mL) was added HATU (0.530 g, 1.39 mmol, 1.5 equiv) at RT
and stirred for 10 minutes. Then 2-(4-chloro-3-fluorophenoxy)acetic
acid (0.188 g, 0.93 mmol, 1.0 equiv) was added followed by the
addition of DIPEA (0.7 mL, 3.72 mmol, 4.0 equiv). The resulting
reaction mixture was allowed to stir at RT for overnight. Product
formation was confirmed by LCMS. The reaction mixture was diluted
with water (50 mL). The resulting solid was filtered off, washed
with water (20 mL.times.4) and dried under vacuum to obtain
tert-butyl
(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)carbamate
(0.250 g, 67% Yield) as an off-white solid. LCMS 402.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.71 (s, 1H), 8.53 (d,
J=8.8 Hz, 1H), 8.24 (s, 1H), 8.14 (t, J=7.7 Hz, 2H), 7.93-7.86 (m,
1H), 6.85 (d, J=7.5 Hz, 1H), 2.99 (d, J=10.1 Hz, 2H), 2.87-2.74 (m,
2H), 1.75 (br. s., 2H), 1.56 (d, J=9.6 Hz, 2H), 1.39 (s, 9H).
Step 4--Synthesis of
N-(4-aminopiperidin-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide
2,2,2-trifluoroacetate
[0508] To a stirred solution of tert-butyl
(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)carbamate
(0.250 g, 0.623 mmol, 1.0 equiv) in DCM (10 mL), was added
trifluoroacetic acid (0.1 mL) and the resultant reaction mixture
was stirred at RT for 1 h under nitrogen atmosphere. Reaction was
monitored by TLC and LCMS. After completion of reaction, the
reaction mixture was concentrated under reduced pressure to obtain
crude product which was crystallized in diethyl ether and dried
under vacuum to obtain
N-(4-aminopiperidin-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide
2,2,2-trifluoroacetate (0.130 g, 50% Yield) as an off white solid.
LCMS 302.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.26 (s, 1H), 8.00 (br. s., 2H), 7.55-7.39 (m, 1H), 7.14-6.92 (m,
1H), 6.88-6.72 (m, 1H), 4.90 (s, 1 H), 4.48 (s, 1H), 3.07 (br. s.,
1H), 2.99 (br. s., 1H), 2.91 (d, J=10.5 Hz, 1H), 2.75-2.53 (m, 2H),
1.89 (br. s., 2H), 1.76-1.51 (m, 2H).
Step 5--Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydrox-
ypropyl)amino)piperidin-1-yl)acetamide
[0509] To a stirred solution of
N-(4-aminopiperidin-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide
trifluoroacetate (0.100 g, 0.24 mmol, 1.0 equiv) and
2-((4-chloro-3-fluorophenoxy)methyl)oxirane (0.048 g, 0.24 mmol,
1.0 equiv) in DMF (05 mL), was added K.sub.2CO.sub.3 (0.066 g, 0.48
mmol, 2.0 equiv) and the resultant reaction mixture was heated at
60.degree. C. for overnight. Progress of the reaction was monitored
by LCMS. Product formation was confirmed by LCMS. The reaction
mixture was diluted with water (50 mL). The resulting solid was
filtered off, washed with water (20 mL.times.4) and dried under
vacuum. The crude product was purified by reverse phase HPLC to
obtain
2-(4-chloro-3-fluorophenoxy)-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydrox-
ypropyl)amino)piperidin-1-yl)acetamide (Compound 8-0.034 g, 28%
Yield) as a white solid. LCMS 504.2 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 9.08 (br. s., 1H), 8.76 (br. s., 1H),
7.39-7.50 (m, 2H), 7.00-7.11 (m, 2H), 6.83 (d, J=7.02 Hz, 2H), 5.00
(d, J=4.82 Hz, 2H), 4.87 (s, 2H), 4.46 (s, 2H), 3.99 (d, J=9.21 Hz,
1H), 3.71 (d, J=9.21 Hz, 1H), 3.00 (br. s., 1H), 2.88 (d, J=9.65
Hz, 1H), 1.80 (br. s., 2H), 1.61 (br. s., 2H), 1.32 (d, J=9.21 Hz,
2H).
Example 14
Synthesis of
5-chloro-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)
piperidin-1-yl)benzofuran-2-carboxamide
##STR00637##
[0510] Step 1--Synthesis of
5-chloro-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperi-
din-1-yl)benzofuran-2-carboxamide
[0511] To a stirred solution of
N-(4-aminopiperidin-1-yl)-5-chlorobenzofuran-2-carboxamide
2,2,2-trifluoroacetate (0.200 g, 0.49 mmol, 1.0 equiv) and
2-((4-chloro-3-fluorophenoxy)methyl)oxirane (0.99 g, 0.49 mmol, 1.0
equiv) in DMF (05 mL), was added K.sub.2CO.sub.3 (0.135 g, 0.98
mmol, 2.0 equiv) and the resultant reaction mixture was heated at
80.degree. C. for overnight. Progress of the reaction was monitored
by LCMS. Product formation was confirmed by LCMS. The reaction
mixture was diluted with water (20 mL) and extracted with ethyl
acetate (50 mL.times.2). Combined organic layer was washed with
water (20 mL.times.4), dried over anhydrous Na.sub.2SO.sub.4 and
concentrated. The crude product was purified by reverse phase HPLC
to obtain
5-chloro-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)
piperidin-1-yl)benzofuran-2-carboxamide (Compound 21-0.006 g, 04%
Yield) a white solid. LCMS 496.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.77 (s, 1H), 8.20 (br. s., 1H), 7.86 (d,
J=1.75 Hz, 1H), 7.69 (d, J=8.77 Hz, 1H), 7.39-7.57 (m, 3H), 7.08
(dd, J=11.62, 2.85 Hz, 1H), 6.84 (d, J=8.33 Hz, 1H), 4.01 (d,
J=5.26 Hz, 1H), 3.93 (d, J=6.14 Hz, 2H), 3.01 (d, J=10.52 Hz, 2H),
2.62-2.87 (m, 4H), 1.89 (br. s., 2H), 1.46 (br. s., 2H).
Example 15
Synthesis of
6-chloro-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperi-
din-1-yl)quinoline-2-carboxamide
##STR00638##
[0513] To a stirred solution of
N-(4-aminopiperidin-1-yl)-6-chloroquinoline-2-carboxamide
2,2,2-trifluoroacetate (0.230 g, 0.55 mmol, 1.0 equiv) and
2-((4-chloro-3-fluorophenoxy)methyl)oxirane (0.111 g, 0.55 mmol,
1.0 equiv) in DMF (05 mL), was added K.sub.2CO.sub.3 (0.150 g, 1.1
mmol, 2.0 equiv) and the resultant reaction mixture was heated at
80.degree. C. for overnight. Progress of the reaction was monitored
by LCMS. Product formation was confirmed by LCMS. The reaction
mixture was diluted with water (20 mL) and extracted with ethyl
acetate (50 mL.times.2). Combined organic layer was washed with
water (20 mL.times.4), dried over anhydrous Na.sub.2SO.sub.4 and
concentrated. The crude product was purified by reverse phase HPLC
to obtain
6-chloro-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperi-
din-1-yl)quinoline-2-carboxamide (Compound 20-0.044 g, 14% Yield) a
white solid. LCMS 507.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.75 (s, 1H), 8.53 (d, J=8.33 Hz, 1H), 8.24
(s, 1H), 8.08-8.21 (m, 3H), 7.88 (dd, J=8.77, 2.19 Hz, 1H), 7.48
(t, J=8.99 Hz, 1H), 7.09 (dd, J=11.62, 2.85 Hz, 1H), 6.86 (d,
J=7.02 Hz, 1H), 3.99-4.05 (m, 1H), 3.95 (d, J=6.14 Hz, 2H), 3.05
(d, J=10.09 Hz, 2H) 2.72-2.91 (m, 4H) 1.94 (br. s., 2H) 1.53 (br.
s., 2H).
Example 16
Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(4-(3-(4-chloro-3-fluorophenoxy)propyl)pip-
erazin-1-yl)acetamide
##STR00639##
[0515] To a stirred solution of
2-(4-chloro-3-fluorophenoxy)-N-(piperazin-1-yl)acetamide
2,2,2-trifluoroacetate (0.320 g, 0.98 mmol, 1.0 equiv) in DMF (5
mL) was added K.sub.2CO.sub.3 (0.220 g, 1.96 mmol, 2.0 equiv) and
4-(3-bromopropoxy)-1-chloro-2-fluorobenzene (0.213 g, 0.98 mmol,
1.0 equiv). The resultant reaction mixture was heated at 70.degree.
C. for overnight. Product formation was confirmed by LCMS. The
reaction mixture was diluted with water (50 mL). The resulting
solid was filtered off, washed with water (20 mL.times.4) and dried
under vacuum. The crude product was purified by reversed phase HPLC
to obtain
2-(4-chloro-3-fluorophenoxy)-N-(4-(3-(4-chloro-3-fluorophenoxy)propyl)pip-
erazin-1-yl)acetamide as a formate salt (Compound 16--0.03 g, 8%
Yield) as a white solid. LCMS 474.2 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.81 (br. s., 1H), 7.48-7.38 (m, 2H),
7.10-6.97 (m, 2H), 6.84-6.75 (m, 2H), 4.88 (s, 2H), 4.47 (s, 2H),
4.01 (t, J=5.9 Hz, 4H), 2.77 (br. s., 3H), 2.67 (br. s., 1H),
1.91-1.73 (m, 4H).
Example 17
Synthesis of 5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)
propyl)piperazin-1-yl)benzofuran-2-carboxamide
##STR00640##
[0517] To a stirred solution of
5-chloro-N-(piperazin-1-yl)benzofuran-2-carboxamide
2,2,2-trifluoroacetate (0.200 g, 0.50 mmol, 1.0 equiv) and
4-(3-bromopropoxy)-1-chloro-2-fluorobenzene (0.135 g, 0.50 mmol,
1.0 equiv) in DMF (07 mL), was added K.sub.2CO.sub.3 (0.140 g, 1.01
mmol, 2.0 equiv) and the resultant reaction mixture was heated at
70.degree. C. for overnight. Product formation was confirmed by
LCMS. The reaction mixture was diluted with water (50 mL). The
resulting solid was filtered off, washed with water (20 mL.times.4)
and dried under vacuum. The crude product was purified by reversed
phase HPLC to obtain 5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)
propyl)piperazin-1-yl)benzofuran-2-carboxamide (Compound 18--0.054
g, 20% Yield) as a white solid. LCMS 466.2 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.81 (s, 1H), 7.86 (br. s., 1H),
7.70 (d, J=8.77 Hz, 1H), 7.36-7.58 (m, 3H), 7.07 (d, J=12.28 Hz,
1H), 6.83 (d, J=7.89 Hz, 1H), 3.96-4.11 (m, 2H), 2.89 (br. s., 4H),
2.43 (br. s., 3H), 2.33 (br. s., 6H), 1.86 (br. s., 2H).
Example 18
Synthesis of
6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)propyl)piperazin-1-yl)quinolin-
e-2-carboxamide
##STR00641##
[0519] To a stirred solution of
6-chloro-N-(piperazin-1-yl)quinoline-2-carboxamide
2,2,2-trifluoroacetate (0.220 g, 0.54 mmol, 1.0 equiv) and
4-(3-bromopropoxy)-1-chloro-2-fluorobenzene (0.145 g, 0.54 mmol,
1.0 equiv) in DMF (07 mL), was added K.sub.2CO.sub.3 (0.150 g, 1.08
mmol, 2.0 equiv) and the resultant reaction mixture was heated at
70.degree. C. for overnight. Product formation was confirmed by
LCMS. The reaction mixture was diluted with water (50 mL). The
resulting solid was filtered off, washed with water (20 mL.times.4)
and dried under vacuum. The crude product was purified by reversed
phase HPLC to obtain
6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)propyl)piperazin-1-yl)quinolin-
e-2-carboxamide (Compound 17-0.070 g, 28% Yield) a white solid.
LCMS 477.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.31 (s, 1H), 9.34 (br. s., 1H), 8.55 (d, J=8.3 Hz, 1H), 8.27 (d,
J=2.2 Hz, 1H), 8.16 (t, J=8.3 Hz, 1H), 7.90 (dd, J=2.2, 9.2 Hz,
1H), 7.58-7.50 (m, 1H), 7.10 (dd, J=2.6, 11.4 Hz, 1H), 6.88-6.81
(m, 1H), 4.10 (t, J=5.7 Hz, 2H), 3.62 (d, J=6.6 Hz, 2H), 3.27-3.17
(m, 8H), 2.14 (br. s., 2H).
Example 19
Synthesis of
6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-y-
l)quinoline-2-carboxamide
##STR00642##
[0520] Step 1--Synthesis of tert-butyl
4-(6-chloroquinoline-2-carboxamido)piperazine-1-carboxylate
[0521] To a stirred solution of tert-butyl
4-aminopiperazine-1-carboxylate (0.200 g, 0.99 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (0.753 g, 1.98 mmol, 2.0 equiv) at RT
and stirred for 10 minutes. Then 6-chloroquinoline-2-carboxylic
acid (0.206 g, 0.99 mmol, 1.0 equiv) was added followed by the
addition of DIPEA (0.6 mL, 2.97 mmol, 3.0 equiv). The resulting
reaction mixture was allowed to stir at RT for overnight. Product
formation was confirmed by LCMS. The reaction mixture was diluted
with water (50 mL) and extracted with EtOAc (50 mL.times.2). The
combined organic layer was washed with water (30 mL.times.3), brine
solution (30 mL.times.2), dried over anhydrous sodium sulfate and
concentrated under reduced pressure, to obtain tert-butyl
4-(6-chloroquinoline-2-carboxamido)piperazine-1-carboxylate (0.140
g, 36% Yield) as a brown solid. LCMS 390 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.95 (br. s., 1H), 8.53 (d, J=8.3
Hz, 1H), 8.24 (br. s., 1H), 8.15 (d, J=5.3 Hz, 2H), 7.88 (d, J=7.5
Hz, 1H), 3.45 (br. s., 4H), 2.90 (d, J=11.0 Hz, 4H), 1.42 (s,
9H).
Step 2--Synthesis of
6-chloro-N-(piperazin-1-yl)quinoline-2-carboxamide
2,2,2-trifluoroacetate
[0522] To a stirred solution of tert-butyl
4-(6-chloroquinoline-2-carboxamido)piperazine-1-carboxylate (0.140
g, 0.35 mmol, 1.0 equiv) in DCM (10 mL), was added trifluoroacetic
acid (02 mL) and the resultant reaction mixture was stirred at RT
for 1 h under nitrogen atmosphere. Reaction was monitored by TLC
and LCMS. After completion of reaction, the reaction mixture was
concentrated under reduced pressure to obtain crude product which
was crystallized in diethyl ether and dried under vacuum to obtain
6-chloro-N-(piperazin-1-yl)quinoline-2-carboxamide
2,2,2-trifluoroacetate (0.100 g, 68% Yield) as a brown solid. LCMS
291.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.28 (br. s., 2H), 8.64 (br. s., 2H), 8.55 (d, J=8.3 Hz, 1H), 8.26
(br. s., 1H), 8.15 (t, J=8.1 Hz, 2H), 7.90 (d, J=9.2 Hz, 1H), 3.25
(br. s., 4H), 3.17 (br. s., 4H)
Step 3--Synthesis of
6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-y-
l)quinoline-2-carboxamide
[0523] To a stirred solution of
6-chloro-N-(piperazin-1-yl)quinoline-2-carboxamide trifluoroacetate
(0.100 g, 0.25 mmol, 1.0 equiv)
2-((4-chloro-3-fluorophenoxy)methyl)oxirane (0.063 g, 0.31 mmol,
1.2 equiv) in DMF (05 mL), was added K.sub.2CO.sub.3 (0.070 g, 0.50
mmol, 2.0 equiv) and the resultant reaction mixture was heated at
100.degree. C. for overnight. Progress of the reaction was
monitored by LCMS. After completion of reaction, the reaction
mixture was diluted with water (50 mL) and extracted with EtOAc (50
mL.times.2). The combined organic layer was washed with water (30
mL), brine solution (30 mL.times.2), dried over anhydrous sodium
sulfate and concentrated under reduced pressure to obtain crude
which was purified by reversed-phase HPLC to obtain
6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-y-
l)quinoline-2-carboxamide (Compound 15-0.015 g, 12% Yield) as an
off white solid. LCMS 493.3 [M+H].sup.+; .sup.1H NMR .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.79 (s, 1H), 8.53 (d, J=8.8 Hz,
2H), 8.24 (s, 1H), 8.14 (t, J=8.8 Hz, 2H), 7.88 (d, J=8.8 Hz, 1H),
7.47 (t, J=8.8 Hz, 1H), 7.08 (d, J=14.0 Hz, 1H), 6.86 (d, J=6.6 Hz,
1H), 4.95 (br. s., 1H), 4.03 (d, J=7.0 Hz, 2H), 3.92 (d, J=9.6 Hz,
2H), 2.94 (br. s., 4H), 2.67 (br. s., 2H), 2.33 (br. s., 2H).
Example 20
Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(4-(2-(4-chloro-3-fluorophenoxy)acetyl)pip-
erazin-1-yl)acetamide
##STR00643##
[0524] Step 1--Synthesis of tert-butyl
4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperazine-1-carboxylate
[0525] To a stirred solution of tert-butyl
4-aminopiperazine-1-carboxylate (0.200 g, 0.99 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (0.753 g, 1.98 mmol, 2.0 equiv) at RT
and stirred for 10 minutes. Then 2-(4-chloro-3-fluorophenoxy)acetic
acid (0.201 g, 0.99 mmol, 1.0 equiv) was added followed by the
addition of DIPEA (0.6 mL, 2.97 mmol, 3.0 equiv). The resulting
reaction mixture was allowed to stir at RT for overnight. Product
formation was confirmed by LCMS. The reaction mixture was diluted
with water (50 mL) and extracted with EtOAc (50 mL.times.2). The
combined organic layer was washed with water (30 mL), brine
solution (30 mL.times.2), dried over anhydrous sodium sulfate and
concentrated under reduced pressure, to obtain tert-butyl
4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperazine-1-carboxylate
(0.150 g, 38% Yield) as a semi solid. LCMS 388.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.57-7.36 (m, 1H),
7.11-6.94 (m, 1H), 6.92-6.69 (m, 1H), 5.76 (s, 1H), 5.04-4.79 (m,
1H), 4.48 (s, 1H), 3.85 (br. s., 1H), 2.92 (br. s., 2H), 2.70 (d,
J=11.8 Hz, 2H), 1.40 (s, 9H).
Step 2--2-(4-chloro-3-fluorophenoxy)-N-(piperazin-1-yl)acetamide
2,2,2-trifluoroacetate
[0526] To a stirred solution of tert-butyl
4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperazine-1-carboxylate
(0.150 g, 0.38 mmol, 1.0 equiv) in DCM (10 mL), was added
trifluoroacetic acid (02 mL) and the resultant reaction mixture was
stirred at RT for 1 h under nitrogen atmosphere. Reaction was
monitored by TLC and LCMS. After completion of reaction, the
reaction mixture was concentrated under reduced pressure to obtain
crude product which was crystallized in diethyl ether and dried
under vacuum to obtain
2-(4-chloro-3-fluorophenoxy)-N-(piperazin-1-yl)acetamide
2,2,2-trifluoroacetate (0.140 g, 90% Yield) as an off-white solid.
LCMS 288.1 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.58 (br. s., 1H), 9.12 (br. s., 1H), 8.62 (br. s., 1H), 7.60-7.35
(m, 1H), 7.17-6.95 (m, 1H), 6.82 (dd, J=8.8, 16.2 Hz, 1H), 4.94 (s,
1H), 4.51 (s, 2H), 3.63 (br. s., 2H), 3.31 (br. s., 2H), 3.00 (br.
s., 2H).
Step 3 Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(4-(2-(4-chloro-3-fluorophenoxy)acetyl)pip-
erazin-1-yl)acetamide
[0527] To a stirred solution of
2-(4-chloro-3-fluorophenoxy)-N-(piperazin-1-yl)acetamide
trifluoroacetate (0.140 g, 0.36 mmol, 1.0 equiv) in DMF (05 mL) was
added HATU (0.274 g, 0.72 mmol, 2.0 equiv) at RT and stirred for 10
minutes. Then 2-(4-chloro-3-fluorophenoxy)acetic acid (0.075 g,
0.36 mmol, 1.0 equiv) was added followed by the addition of DIPEA
(0.18 mL, 1.08 mmol, 3.0 equiv). The resulting reaction mixture was
allowed to stir at RT for overnight. Product formation was
confirmed by LCMS. the reaction mixture was diluted with water (50
mL) and extracted with EtOAc (50 mL.times.2). The combined organic
layer was washed with water (30 mL), brine solution (30
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure to obtain crude which was purified by
reversed-phase HPLC to obtain
2-(4-chloro-3-fluorophenoxy)-N-(4-(2-(4-chloro-3-fluorophenoxy)acetyl)pip-
erazin-1-yl)acetamide (Compound 30-0.050 g, 30% Yield) as white
solid. LCMS 474.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 7.55-7.36 (m, 2H), 7.14-6.97 (m, 2H), 6.91-6.75 (m, 2H),
4.94 (d, J=17.5 Hz, 3H), 4.50 (s, 1H), 4.25 (br. s., 1H), 3.50 (br.
s., 2H), 3.17 (br. s., 1H), 3.06 (br. s., 1H), 2.81 (br. s., 1H),
2.75 (br. s., 1H), 2.33 (br. s., 2H).
Example 21
Synthesis of
6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)propyl)piperazin-1-yl)-3,4-dih-
ydro-2H-benzo[b][1,4]oxazine-2-carboxamide
##STR00644##
[0529] To a stirred solution of
6-chloro-N-(piperazin-1-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carboxa-
mide 2,2,2-trifluoroacetate (0.300 g, 0.73 mmol, 1.0 equiv) and
4-(3-bromopropoxy)-1-chloro-2-fluorobenzene (0.195 g, 0.73 mmol,
1.0 equiv) in DMF (06 mL), was added K.sub.2CO.sub.3 (0.202 g, 1.46
mmol, 2.0 equiv) and the resultant reaction mixture was heated at
70.degree. C. for overnight. Product formation was confirmed by
LCMS. The reaction mixture was diluted with water (20 mL) and
extracted with ethyl acetate (50 mL.times.2). Combined organic
layer was washed with water (20 mL.times.4), dried over anhydrous
Na.sub.2SO.sub.4 and concentrated. The crude product was purified
by reverse phase HPLC to obtain
6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)propyl)piperazin-1-yl)-3,4-dih-
ydro-2H-benzo[b][1,4]oxazine-2-carboxamide (Compound 44-0.012 g,
09% Yield) as a white solid. LCMS 482.1 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.03 (s, 1H), 8.79 (s, 1H), 7.45
(t, J=8.77 Hz, 1H), 7.04 (d, J=2.63 Hz, 1H), 7.07 (d, J=2.63 Hz,
1H), 6.74-6.85 (m, 2H), 6.66 (s, 1H), 6.46-6.53 (m, 1H), 6.18 (br.
s., 1H), 4.40 (dd, J=7.24, 2.85 Hz, 1H), 4.01 (t, J=6.36 Hz, 2H),
3.41 (d, J=11.84 Hz, 1H), 3.18-3.23 (m, 1H), 2.72-2.83 (m, 4H),
2.33-2.43 (m, 4H), 1.76-1.88 (m, 3H).
Example 22
Synthesis of
7-chloro-N-(1-(2-(3-chloro-4-fluorophenoxy)acetamido)piperidin-4-yl)-6-fl-
uoro-3,4-dihydro-2H-benzo[b][1,4]oxazine-3-carboxamide
##STR00645##
[0531] To a stirred solution of
N-(4-aminopiperidine-1-yl)-2-(3-chloro-4-fluorophenoxy)acetamide
trifluoroacetate (0.340 g, 0.819 mmol, 1.0 equiv) and
6-chloro-3,4-dihyro-2H-benzo-1,4-oxazine-2-carboxylic acid (0.172
g, 0.819 mmol, 1.0 equiv), HATU (0.172 g, 0.819 mmol, 1.0 equiv) in
DMF (07 mL), was added DIPEA (0.422 g, 3.27 mmol, 4.0 equiv) and
the resultant reaction mixture was stir overnight at RT. Product
formation was confirmed by LCMS. The reaction mixture was diluted
with water (50 mL). The resulting solid was filtered off, washed
with methanol and dried under vacuum to obtain of
7-chloro-N-(1-(2-(3-chloro-4-fluorophenoxy)acetamido)piperidin-4-yl)-6-fl-
uoro-3,4-dihydro-2H-benzo[b][1,4]oxazine-3-carboxamide (Compound
32-0.026 g, 7.3% Yield) as a white solid. LCMS 497.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.13 (br. s., 1H), 7.92
(d, J=7.45 Hz, 1H), 7.42-7.49 (m, 1H), 6.99 (d, J=11.40 Hz, 1H),
6.77 (br. s., 1H), 6.59 (br. s., 1H), 6.49 (br. s., 1H), 6.19 (br.
s., 1H), 4.89 (s, 2H), 3.57 (br. s., 1H), 3.44 (d, J=9.21 Hz, 1H),
3.15-3.23 (m, 2H), 3.05 (br. s., 1H), 2.88 (br. s., 2H), 2.65 (d,
J=13.59 Hz, 2H), 1.65 (br. s., 3H).
Example 23
Synthesis of
N,N'-(piperidine-1,4-diyl)bis(2-(4-chlorophenoxy)acetamide)
##STR00646##
[0532] Step 1--Synthesis of tert-butyl
(1-(2-(4-chlorophenoxy)acetamido)piperidin-4-yl)carbamate
[0533] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (0.100 g, 0.46 mmol, 1.0 equiv) in
DCM (05 mL) was added 2-(4-chlorophenoxy)acetyl chloride (0.095 g,
0.46 mmol, 1.0 equiv) and followed by the addition of TEA (0.2 mL,
1.39 mmol, 3.0 equiv). The resulting reaction mixture was allowed
to stir at RT for overnight. Product formation was confirmed by
LCMS. The reaction mixture was diluted with water (20 mL) and
extracted with ethyl acetate (50 mL.times.2). Combined organic
layer was washed with water (20 mL.times.4), dried over anhydrous
Na.sub.2SO.sub.4 and concentrated under reduced pressure to obtain
tert-butyl
(1-(2-(4-chlorophenoxy)acetamido)piperidin-4-yl)carbamate (0.170 g,
95% Yield) as a white solid. LCMS 384.1 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.07 (s, 1H), 8.72 (br. s., 1H),
7.39-7.23 (m, 2H), 7.00-6.87 (m, 2H), 6.87-6.72 (m, 1H), 4.85-4.74
(m, 1H), 4.41 (s, 1H), 3.33 (br. s., 4H), 2.84 (d, J=10.5 Hz, 2H),
1.71 (br. s., 2H), 1.47 (d, J=10.1 Hz, 1H), 1.44-1.28 (m, 9H).
Step 2--Synthesis of
N-(4-aminopiperidin-1-yl)-2-(4-chlorophenoxy)acetamide
2,2,2-trifluoroacetate
[0534] To a stirred solution of tert-butyl
(1-(2-(4-chlorophenoxy)acetamido)piperidin-4-yl)carbamate (0.170 g,
0.44 mmol, 1.0 equiv) in DCM (05 mL), was added trifluoroacetic
acid (0.3 mL) and the resultant reaction mixture was stirred at RT
for 1 h under nitrogen atmosphere. Reaction was monitored by TLC
and LCMS. After completion of reaction, the reaction mixture was
concentrated under reduced pressure to obtain crude product which
was crystallized in diethyl ether and dried under vacuum to obtain
N-(4-aminopiperidin-1-yl)-2-(4-chlorophenoxy)acetamide
2,2,2-trifluoroacetate (0.290 g, Quant. Yield) as a brown semi
solid. LCMS 284.1 [M+H].sup.+;
Step 3--Synthesis of
N,N'-(piperidine-1,4-diyl)bis(2-(4-chlorophenoxy)acetamide)
[0535] To a stirred solution of
N-(4-aminopiperidin-1-yl)-2-(4-chlorophenoxy)acetamide.
trifluoroacetate (0.290 g, 0.73 mmol, 1.0 equiv) in DMF (05 mL) was
added HATU (0.416 g, 1.09 mmol, 1.5 equiv) at RT and stirred for 10
minutes. Then 2-(4-chloro-3-fluorophenoxy) acetic acid (0.136 g,
0.73 mmol, 1.0 equiv) was added followed by the addition of DIPEA
(0.5 mL, 2.92 mmol, 4.0 equiv). The resulting reaction mixture was
allowed to stir at RT for overnight. Product formation was
confirmed by LCMS. The reaction mixture was diluted with water (50
mL). The resulting solid was filtered off, washed with water (20
mL.times.4) and dried under vacuum. The crude product was purified
by reverse phase HPLC to obtain
N,N'-(piperidine-1,4-diyl)bis(2-(4-chlorophenoxy)acetamide)
(Compound 45-0.100 g, 30% Yield) as an off white solid. LCMS 452.2
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.12 (s,
1H), 8.03 (d, J=7.89 Hz, 1H), 7.28-7.39 (m, 4H), 6.92-7.03 (m, 4H),
4.84 (s, 1H), 4.40-4.50 (m, 3H), 3.61 (br. s., 1H), 3.04 (br. s.,
1H), 2.88 (d, J=7.02 Hz, 1H), 2.65 (d, J=12.28 Hz, 2H), 1.73 (br.
s., 2H), 1.59 (d, J=9.21 Hz, 2H).
Example 24
Chiral Resolution of
6-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-1-yl)-3,4--
dihydro-2H-benzo[b][1,4]oxazine-2-carboxamide
##STR00647##
[0537] The enantiomers,
(R)-6-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-1-yl)--
3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carboxamide (Compound
46--[.alpha.].sub.D.sup.20=-14.92.degree. (c=0.05, MeOH); elution
time: 6.89 min) and
(S)-6-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-1-yl)--
3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carboxamide (Compound
47--[.alpha.].sub.D.sup.20=1.28.degree. (c=0.05, MeOH); elution
time: 12.75 min), were separated by chiral SFC (Chiralcel.RTM.
OD-H, 250.times.20 mm, 5p). Isocratic program with analytical grade
liquid carbon dioxide and HPLC grade MeOH. LCMS: 497.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.02 (s, 1H), 8.04 (d,
J=7.5 Hz, 1H), 7.50 (t, J=8.8 Hz, 2H), 7.06 (d, J=11.0 Hz, 1H),
6.85 (d, J=8.8 Hz, 1H), 6.76 (d, J=8.3 Hz, 1H), 6.65-6.55 (m, 1H),
6.49 (d, J=6.1 Hz, 1H), 4.51 (s, 2H), 3.60 (br. s., 2H), 3.52-3.42
(m, 2H), 3.42-3.36 (m, 1H), 3.21 (d, J=5.7 Hz, 2H), 2.97-2.78 (m,
3H), 2.65 (d, J=14.0 Hz, 3H), 1.71 (d, J=5.7 Hz, 2H), 1.57 (d,
J=12.7 Hz, 2H).
Example 25
Chiral resolution of
5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-y-
l)benzofuran-2-carboxamide
##STR00648##
[0539] The enantiomers,
(R)-5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-
-1-yl)benzofuran-2-carboxamide (Compound
48--[.alpha.].sub.D.sup.20=-39.80.degree. (c=0.05, MeOH); elution
time: 29.6 min) and
(S)-5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-
-1-yl)benzofuran-2-carboxamide (Compound
49--[.alpha.].sub.D.sup.20=3.24.degree. (c=0.05, MeOH); elution
time: 34.8 min), were separated by chiral SFC (Chiralpak.RTM. IA,
250.times.20 mm, 5.mu.). Isocratic program with analytical grade
liquid carbon dioxide and HPLC grade MeOH (0.2% DEA). LCMS: 482.3
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.79 (br.
s., 1H), 7.86 (s, 1H), 7.70 (d, J=8.8 Hz, 1H), 7.52-7.41 (m, 2H),
7.16-7.06 (m, 1H), 6.86 (d, J=10.5 Hz, 1H), 4.94 (br. s., 1H), 4.01
(d, J=6.6 Hz, 1H), 3.92 (br. s., 2H), 2.89 (br. s., 4H), 2.67 (br.
s., 4H).
Example 26
Chiral Resolution of
2-(4-chloro-3-fluorophenoxy)-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxy-
propyl)piperazin-1-yl)acetamide
##STR00649##
[0541] The enantiomers,
(R)-2-(4-chloro-3-fluorophenoxy)-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hyd-
roxypropyl)piperazin-1-yl)acetamide (Compound
50--[.alpha.].sub.D.sup.20=-1.00.degree. (c=0.05, MeOH); elution
time: 15.99 min) and
(S)-2-(4-chloro-3-fluorophenoxy)-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hyd-
roxypropyl)piperazin-1-yl)acetamide (Compound
51--[.alpha.].sub.D.sup.20=1.92.degree. (c=0.05, MeOH); elution
time: 25.3 min), were separated by chiral SFC (Chiralpak.RTM. ADH,
250.times.20 mm, 5.mu.). Isocratic program with analytical grade
liquid carbon dioxide and HPLC grade EtOH (0.2% DEA in Hexane).
LCMS: 490.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.08 (br. s., 1H), 8.76 (br. s., 1H), 7.39-7.50 (m, 2H),
7.00-7.11 (m, 2H), 6.83 (d, J=7.02 Hz, 2H), 5.00 (d, J=4.82 Hz,
2H), 4.87 (s, 2H), 4.46 (s, 2H), 3.99 (d, J=9.21 Hz, 1H), 3.71 (d,
J=9.21 Hz, 1H), 3.00 (br. s., 1H), 2.88 (d, J=9.65 Hz, 1H), 1.80
(br. s., 2H), 1.61 (br. s., 2H), 1.32 (d, J=9.21 Hz, 2H).
Example 27
Chiral Resolution of
2-(4-chloro-3-fluorophenoxy)-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydrox-
ypropyl)amino)piperidin-1-yl)acetamide
##STR00650##
[0543] The enantiomers,
(R)-2-(4-chloro-3-fluorophenoxy)-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hy-
droxypropyl)amino)piperidin-1-yl)acetamide (Compound
52--[.alpha.].sub.D.sup.20=-27.04.degree. (c=0.05, MeOH); elution
time: 20.4 min) and
(S)-2-(4-chloro-3-fluorophenoxy)-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hy-
droxypropyl)amino)piperidin-1-yl)acetamide (Compound
53--[.alpha.].sub.D.sup.20=1.52.degree. (c=0.05, MeOH); elution
time: 25.4 min), were separated by chiral SFC (Chiralpak.RTM. IC,
250.times.20 mm, 5.mu.). Isocratic program with analytical grade
liquid carbon dioxide and HPLC grade EtOH (0.2% DEA in Hexane).
LCMS: 504.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.08 (br. s., 1H), 8.76 (br. s., 1H), 7.39-7.50 (m, 2H),
7.00-7.11 (m, 2H), 6.83 (d, J=7.02 Hz, 2H), 5.00 (d, J=4.82 Hz,
2H), 4.87 (s, 2H), 4.46 (s, 2H), 3.99 (d, J=9.21 Hz, 1H), 3.71 (d,
J=9.21 Hz, 1H), 3.00 (br. s., 1H), 2.88 (d, J=9.65 Hz, 1H), 1.80
(br. s., 2H), 1.61 (br. s., 2H), 1.32 (d, J=9.21 Hz, 2H).
Example 28
Synthesis of
(R)-5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)pip-
erazin-1-yl)benzofuran-2-carboxamide
##STR00651##
[0545] To a stirred solution of
N-(4-aminopiperidin-1-yl)-5-chlorobenzofuran-2-carboxamide
2,2,2-trifluoroacetate (0.200 g, 0.491 mmol, 1.0 equiv) in DMF (5
mL) was added K.sub.2CO.sub.3 (0.135 g, 0.98 mmol, 2.0 equiv) and
(R)-2-(4-chloro-3-fluorophenoxy)methyl)oxirane (0.09 g, 0.491 mmol,
1.0 equiv). The resultant reaction mixture was heated at 80.degree.
C. for overnight. Product formation was confirmed by LCMS. The
reaction mixture was diluted with water (10 mL) and extracted by
ethyl acetate (50 mL.times.2). The organic layer washed with
NaHCO.sub.3, brine, dried over NaSO.sub.4 filter conc. under
reduced pressure to obtain
(R)-5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hyroxypropyl)amino)pipe-
razin-1-yl)benzofuran-2-carboxamide (Compound 54-0.040 g, 16%
Yield) as a white solid. LCMS 496.4 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 9.72 (s, 1H), 7.86 (s, 1H), 7.68 (s,
1H), 7.55-7.38 (m, 3H), 7.06 (d, J=2.9 Hz, 1H), 7.09 (d, J=2.4 Hz,
1H), 6.84 (d, J=7.8 Hz, 1H), 5.02 (br. s., 1H), 4.01 (dd, J=3.7,
10.0 Hz, 1H), 3.96-3.81 (m, 3H), 2.99 (d, J=9.8 Hz, 2H), 2.77-2.62
(m, 3H), 1.82 (br. s., 2H), 1.38 (d, J=10.3 Hz, 2H).
Example 29
Synthesis of
(S)-5-chloro-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)pi-
peridin-1-yl)benzofuran-2-carboxamide
##STR00652##
[0547] To a stirred solution of
N-(4-aminopiperidin-1-yl)-5-chlorobenzofuran-2-carboxamide
2,2,2-trifluoroacetate (0.200 g, 0.491 mmol, 1.0 equiv) in DMF (5
mL) was added K.sub.2CO.sub.3 (0.135 g, 0.98 mmol, 2.0 equiv) and
(S)-2-(4-chloro-3-fluorophenoxy)methyl)oxirane (0.09 g, 0.491 mmol,
1.0 equiv). The resultant reaction mixture was heated at 80.degree.
C. for overnight. Product formation was confirmed by LCMS. The
reaction mixture was diluted with water (10 mL) and extracted by
ethyl acetate (50 mL.times.2). The organic layer washed with
NaHCO.sub.3, brine, dried over NaSO.sub.4 filter conc. under
reduced pressure to obtain
(S)-5-chloro-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)pi-
peridin-1-yl)benzofuran-2-carboxamide (Compound 55-0.010 g, 10%
Yield) as a white solid. LCMS 496.4 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 9.72 (s, 1H), 7.86 (s, 1H), 7.68 (s,
1H), 7.55-7.38 (m, 3H), 7.06 (d, J=2.9 Hz, 1H), 7.09 (d, J=2.4 Hz,
1H), 6.84 (d, J=7.8 Hz, 1H), 5.02 (br. s., 1H), 4.01 (dd, J=3.7,
10.0 Hz, 1H), 3.96-3.81 (m, 3H), 2.99 (d, J=9.8 Hz, 2H), 2.77-2.62
(m, 3H), 1.82 (br. s., 2H), 1.38 (d, J=10.3 Hz, 2H).
Example 30
Chiral Resolution of
6-chloro-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperi-
din-1-yl)quinoline-2-carboxamide
##STR00653##
[0549] The enantiomers,
(R)-6-chloro-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)pi-
peridin-1-yl)quinoline-2-carboxamide (Compound
56--[.alpha.].sub.D.sup.20=-1.60.degree. (c=0.05, MeOH); elution
time: 32.8 min) and
(S)-6-chloro-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)pi-
peridin-1-yl)quinoline-2-carboxamide (Compound
57--[.alpha.].sub.D.sup.20=6.76.degree. (c=0.05, MeOH); elution
time: 40.42 min), were separated by chiral SFC (Chiralpak.RTM. ADH,
250.times.20 mm, 5.mu.). Isocratic program with analytical grade
liquid carbon dioxide and HPLC grade EtOH (0.2% DEA in Hexane).
LCMS: 507.4 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.67 (s, 1H), 8.53 (d, J=8.8 Hz, 1H), 8.24 (d, J=2.0 Hz,
1H), 8.14 (dd, J=5.9, 8.8 Hz, 1H), 7.88 (d, J=9.3 Hz, 1H), 7.46 (t,
J=8.8 Hz, 1H), 7.08 (d, J=11.7 Hz, 1H), 6.85 (d, J=9.8 Hz, 1H),
5.02 (br. s., 1H), 4.02 (d, J=9.8 Hz, 1H), 3.97-3.71 (m, 2H), 3.01
(br. s., 2H), 2.91-2.71 (m, 2H), 2.67 (br. s., 2H), 2.61 (br. s.,
2H), 1.85 (br. s., 2H), 1.43 (br. s., 2H).
Example 31
Chiral resolution of
6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-y-
l)quinoline-2-carboxamide
##STR00654##
[0551] The enantiomers,
(R)-6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-
-1-yl)quinoline-2-carboxamide (Compound
58--[.alpha.].sub.D.sup.20=-14.80.degree. (c=0.05, MeOH); elution
time: 29.17 min) and
(S)-6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-
-1-yl)quinoline-2-carboxamide (Compound
59--[.alpha.].sub.D.sup.20=43.12.degree. (c=0.05, MeOH); elution
time: 39.19 min), were separated by chiral SFC (Chiralpak.RTM. IA,
250.times.20 mm, 5.mu.). Isocratic program with analytical grade
liquid carbon dioxide and HPLC grade MeOH. LCMS: 493.4 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.79 (s, 1H), 8.53 (d,
J=8.8 Hz, 1H), 8.24 (d, J=2.2 Hz, 1H), 8.14 (t, J=8.8 Hz, 2H), 7.88
(dd, J=2.4, 9.0 Hz, 1H), 7.47 (t, J=8.8 Hz, 1H), 7.08 (dd, J=2.6,
11.4 Hz, 1H), 6.86 (dd, J=1.8, 9.2 Hz, 1H), 4.95 (d, J=4.4 Hz, 1H),
4.08-3.98 (m, 1H), 3.98-3.83 (m, 2H), 2.94 (t, J=4.6 Hz, 4H), 2.59
(br. s., 4H).
Example 32
Chiral resolution of
6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-y-
l)-2-naphthamide
##STR00655##
[0553] The enantiomers,
(R)-6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-
-1-yl)-2-naphthamide (Compound
60--[.alpha.].sub.D.sup.20=-15.88.degree. (c=0.05, MeOH); elution
time: 29.55 min) and
(S)-6-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-
-1-yl)-2-naphthamide (Compound 61--[.alpha.].sub.D.sup.20=7.720
(c=0.05, MeOH); elution time: 35.21 min), were separated by chiral
SFC (Chiralpak.RTM. IA, 250.times.20 mm, 5.mu.). Isocratic program
with analytical grade liquid carbon dioxide and HPLC grade MeOH.).
LCMS: 492.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.59 (s, 1H), 8.38 (s, 1H), 8.16-8.06 (m, 2H), 7.98 (d,
J=8.3 Hz, 1H), 7.89 (d, J=8.8 Hz, 1H), 7.60 (dd, J=1.8, 8.8 Hz,
1H), 7.47 (t, J=8.8 Hz, 1H), 7.08 (dd, J=2.6, 11.4 Hz, 1H), 6.86
(d, J=7.5 Hz, 1H), 4.96 (d, J=4.4 Hz, 1H), 4.09-3.97 (m, 1H),
3.97-3.76 (m, 2H), 2.92 (br. s., 4H), 2.57 (br. s., 4H).
Example 33
Synthesis of
(R)--N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-yl)-4-
-(trifluoromethoxy)benzamide
##STR00656##
[0554] Step 1--Synthesis of tert-butyl
4-(4-(trifluoromethoxy)benzamido)piperazine-1-carboxylate
[0555] To a stirred solution of tert-butyl
4-aminopiperazine-1-carboxylate (487 mg, 2.4 mmol, 1.0 equiv) in
DMF (5 mL) was added HATU (1824 mg, 4.8 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. Then 4-(trifluoromethoxy)benzoic acid (500
mg, 2.4 mmol, 1.0 equiv) was added followed by the addition of
DIPEA (1.3 mL, 7.2 mmol, 3.0 equiv). The resulting reaction mixture
was allowed to stir at RT for overnight. Product formation was
confirmed by LCMS. The reaction mixture was diluted with water (50
mL) and extracted with EtOAc (50 mL.times.2). The combined organic
layer was washed with water (30 mL), brine solution (30
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure, to obtain tert-butyl
4-(4-(trifluoromethoxy)benzamido)piperazine-1-carboxylate (300 mg,
32% Yield) as an off white solid. LCMS 390.1 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 9.62 (s, 1H), 7.89 (m, J=8.77
Hz, 2H), 7.46 (m, J=8.33 Hz, 2H), 3.42 (br. s., 4H), 2.83 (t,
J=4.82 Hz, 4H), 1.41 (s, 9H).
Step 2--Synthesis of
N-(piperazin-1-yl)-4-(trifluoromethoxy)benzamide
2,2,2-trifluoroacetate
[0556] To a stirred solution of tert-butyl
4-(4-(trifluoromethoxy)benzamido)piperazine-1-carboxylate (300 mg,
0.77 mmol, 1.0 equiv) in DCM (10 mL), was added trifluoroacetic
acid (01 mL) and the resultant reaction mixture was stirred at RT
for overnight under nitrogen atmosphere. Reaction was monitored by
LCMS. After completion of reaction, the reaction mixture was
concentrated under reduced pressure. The crude product crystallized
in diethyl ether and dried under vacuum to obtain
N-(piperazin-1-yl)-4-(trifluoromethoxy)benzamide
2,2,2-trifluoroacetate (200 mg, 64% Yield) as an off white solid.
LCMS 290.1 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.91 (s, 1H), 8.73 (br. s., 2H), 7.91 (m, J=8.33 Hz, 2H), 7.47 (m,
J=7.89 Hz, 2H), 3.20 (br. s., 4H), 3.12 (br. s., 4H).
Step 3--Synthesis of
(R)--N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-yl)-4-
-(trifluoromethoxy)benzamide
[0557] To a stirred solution of
N-(piperazin-1-yl)-4-(trifluoromethoxy)benzamide
2,2,2-trifluoroacetate (200 mg, 0.49 mmol, 1.0 equiv)
(R)-2-((4-chloro-3-fluorophenoxy)methyl)oxirane (100 mg, 0.49 mmol,
1.0 equiv) in DMF (05 mL), was added TEA (0.3 mL, 1.96 mmol, 4.0
equiv) and the resultant reaction mixture was heated at 90.degree.
C. for overnight. Progress of the reaction was monitored by LCMS.
After completion of reaction, the reaction mixture was diluted with
water (50 mL) and extracted with EtOAc (50 mL.times.2). The
combined organic layer was washed with water (50 mL.times.4), dried
over anhydrous sodium sulfate and concentrated under reduced
pressure to obtain crude which was purified by reversed phase HPLC
to obtain
(R)--N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-yl)-4-
-(trifluoromethoxy)benzamide (Compound 62-70 mg, 30% Yield) as a
white solid. LCMS 492.4 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.91 (br. s., 1H), 9.51 (br. s., 1H), 7.90
(d, J=7.89 Hz, 3H), 7.46 (d, J=7.45 Hz, 3H), 7.09 (d, J=10.52 Hz,
1H), 6.86 (d, J=7.45 Hz, 1H), 5.99 (br. s., 1H), 4.95 (br. s., 1H),
4.34 (br. s., 1H), 3.98-4.03 (m, 2H), 3.94 (br. s., 1H), 3.59 (br.
s., 2H), 2.89 (br. s., 2H).
Example 34
Synthesis of
(R)-4-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-
-1-yl)benzamide
##STR00657##
[0558] Step 1--Synthesis of tert-butyl
4-(4-chlorobenzamido)piperazine-1-carboxylate
[0559] To a stirred solution of tert-butyl
4-aminopiperazine-1-carboxylate (644 mg, 3.2 mmol, 1.0 equiv) in
DMF (5 mL) was added HATU (2432 mg, 6.4 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. Then 4-chlorobenzoic acid (500 mg, 3.2
mmol, 1.0 equiv) was added followed by the addition of DIPEA (1.7
mL, 9.6 mmol, 3.0 equiv). The resulting reaction mixture was
allowed to stir at RT for overnight. Product formation was
confirmed by LCMS. The reaction mixture was diluted with water (50
mL) and extracted with EtOAc (50 mL.times.2). The combined organic
layer was washed with water (30 mL), brine solution (30
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure, to obtain tert-butyl
4-(4-chlorobenzamido)piperazine-1-carboxylate (300 mg, 28% Yield)
as an off white solid. LCMS 340.1 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 9.59 (s, 1H), 7.79 (m, J=8.33 Hz, 2H),
7.53 (m, J=8.77 Hz, 2H), 3.41 (br. s., 4H), 2.82 (t, J=4.60 Hz,
4H), 1.41 (s, 9H).
Step 2--Synthesis of 4-chloro-N-(piperazin-1-yl)benzamide
2,2,2-trifluoroacetate
[0560] To a stirred solution of tert-butyl
4-(4-chlorobenzamido)piperazine-1-carboxylate (300 mg, 0.88 mmol,
1.0 equiv) in DCM (10 mL), was added trifluoroacetic acid (01 mL)
and the resultant reaction mixture was stirred at RT for overnight
under nitrogen atmosphere. Reaction was monitored by LCMS. After
completion of reaction, the reaction mixture was concentrated under
reduced pressure. The crude product crystallized in diethyl ether
and dried under vacuum to obtain
4-chloro-N-(piperazin-1-yl)benzamide 2,2,2-trifluoroacetate (200
mg, 65% Yield) as an off white solid. LCMS 240.1 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.9.87 (s, 2H), 8.62 (br.
s., 2H), 7.80 (m, J=8.33 Hz, 2H), 7.55 (m, J=8.33 Hz, 2H), 3.22
(br. s., 4H), 3.11 (br. s., 4H).
Step 3--Synthesis of
(R)-4-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-
-1-yl)benzamide
[0561] To a stirred solution of
4-chloro-N-(piperazin-1-yl)benzamide 2,2,2-trifluoroacetate (200
mg, 0.56 mmol, 1.0 equiv)
(R)-2-((4-chloro-3-fluorophenoxy)methyl)oxirane (114 mg, 0.56 mmol,
1.0 equiv) in DMF (05 mL), was added TEA (0.3 mL, 2.24 mmol, 4.0
equiv) and the resultant reaction mixture was heated at 90.degree.
C. for overnight. Progress of the reaction was monitored by LCMS.
After completion of reaction, the reaction mixture was diluted with
water (50 mL) and extracted with EtOAc (50 mL.times.2). The
combined organic layer was washed with water (50 mL.times.4), dried
over anhydrous sodium sulfate and concentrated under reduced
pressure to obtain crude which was purified by reversed phase HPLC
to obtain
(R)-4-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-
-1-yl)benzamide (Compound 63--40 mg, 17% Yield) as a white solid.
LCMS 442.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta.9.48 (s, 1H), 7.78 (d, J=8.77 Hz, 2H), 7.36-7.61 (m, 3H),
7.07 (dd, J=11.84, 2.63 Hz, 1H), 6.76-6.92 (m, 1H), 4.94 (d, J=4.38
Hz, 1H), 4.01 (d, J=6.14 Hz, 1H), 3.79-3.96 (m, 2H), 2.87 (d,
J=4.82 Hz, 4H), 2.44 (d, J=5.26 Hz, 4H).
Example 35
Synthesis of
(R)-5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-
-1-yl)picolinamide
##STR00658##
[0562] Step 1--Synthesis of tert-butyl
4-(5-chloropicolinamido)piperazine-1-carboxylate
[0563] To a stirred solution of tert-butyl
4-aminopiperazine-1-carboxylate (384 mg, 1.9 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (1451 mg, 3.8 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. Then 5-chloropicolinic acid (300 mg, 1.9
mmol, 1.0 equiv) was added followed by the addition of DIPEA (1.0
mL, 5.7 mmol, 3.0 equiv). The resulting reaction mixture was
allowed to stir at RT for overnight. Product formation was
confirmed by LCMS. the reaction mixture was diluted with water (50
mL) and extracted with EtOAc (50 mL.times.2). The combined organic
layer was washed with water (30 mL), brine solution (30
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure, to obtain tert-butyl
4-(5-chloropicolinamido)piperazine-1-carboxylate (100 mg, 15%
Yield) as an off white solid. LCMS 341.1 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.86 (s, 1H), 8.67 (d, J=1.75 Hz,
1H), 8.12 (dd, J=8.55, 2.41 Hz, 1H), 8.01 (d, J=8.77 Hz, 1H), 3.40
(t, J=4.82 Hz, 4H), 2.81 (t, J=4.82 Hz, 4H), 1.34-1.47 (m, 9H).
Step 2--Synthesis of 5-chloro-N-(piperazin-1-yl)picolinamide
2,2,2-trifluoroacetate
[0564] To a stirred solution of tert-butyl
4-(5-chloropicolinamido)piperazine-1-carboxylate (100 mg, 0.29
mmol, 1.0 equiv) in DCM (05 mL), was added trifluoroacetic acid (01
mL) and the resultant reaction mixture was stirred at RT for
overnight under nitrogen atmosphere. Reaction was monitored by TLC
and LCMS. After completion of reaction, the reaction mixture was
concentrated under reduced pressure. The crude product crystallized
in diethyl ether and dried under vacuum to obtain
5-chloro-N-(piperazin-1-yl)picolinamide 2,2,2-trifluoroacetate (100
mg, 96% Yield) as an off white solid. LCMS 240.9 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.22 (br. s., 1H),
8.69 (br. s., 1H), 8.62 (br. s., 2H), 8.13 (d, J=6.58 Hz, 1H), 8.01
(d, J=7.89 Hz, 1H), 3.22 (br. s., 4H), 3.09 (br. s., 4H).
Step 3--Synthesis of
(R)-5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-
-1-yl)picolinamide
[0565] To a stirred solution of
5-chloro-N-(piperazin-1-yl)picolinamide 2,2,2-trifluoroacetate (100
mg, 0.28 mmol, 1.0 equiv)
(R)-2-((4-chloro-3-fluorophenoxy)methyl)oxirane (58 mg, 0.28 mmol,
1.0 equiv) in DMF (05 mL), was added TEA (0.2 mL, 1.12 mmol, 4.0
equiv) and the resultant reaction mixture was heated at 90.degree.
C. for overnight. Progress of the reaction was monitored by LCMS.
After completion of reaction, the reaction mixture was diluted with
water (100 mL) and extracted with EtOAc (50 mL.times.2). The
combined organic layer was washed with water (50 mL.times.4), dried
over anhydrous sodium sulfate and concentrated under reduced
pressure to obtain crude which was purified by reversed-phase HPLC
to obtain
(R)-5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-
-1-yl)picolinamide (Compound 64--80 mg, 65% Yield) as an off white
solid. LCMS 443.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.74 (br. s., 1H), 8.67 (d, J=2.63 Hz, 1H), 8.11 (dd,
J=8.55, 2.41 Hz, 1H), 8.00 (d, J=8.77 Hz, 1H), 7.47 (t, J=8.99 Hz,
1H), 7.09 (d, J=2.63 Hz, 1H), 6.86 (dd, J=8.99, 1.97 Hz, 1H), 4.96
(br. s., 1H), 3.97-4.05 (m, 1H), 3.84-3.94 (m, 2H), 2.88 (br. s.,
4H), 2.56 (br. s., 2H), 2.33 (br. s., 2H), 1.91 (s, 1H).
Example 36
Synthesis of
(R)--N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-yl)-5-
-(trifluoromethyl)picolinamide
##STR00659##
[0566] Step 1--Synthesis of tert-butyl
4-(5-(trifluoromethyl)picolinamido)piperazine-1-carboxylate
[0567] To a stirred solution of tert-butyl
4-aminopiperazine-1-carboxylate (315 mg, 1.5 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (1140 mg, 3.0 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. Then 5-(trifluoromethyl)picolinic acid (300
mg, 1.5 mmol, 1.0 equiv) was added followed by the addition of
DIPEA (0.8 mL, 4.5 mmol, 3.0 equiv). The resulting reaction mixture
was allowed to stir at RT for overnight. Product formation was
confirmed by LCMS. the reaction mixture was diluted with water (50
mL) and extracted with EtOAc (50 mL.times.2). The combined organic
layer was washed with water (30 mL), brine solution (30
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure, to obtain tert-butyl
4-(5-(trifluoromethyl)picolinamido)piperazine-1-carboxylate (100
mg, 17% Yield) as a brown solid. LCMS 375.1 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 10.04 (s, 1H), 9.00 (br. s.,
1H), 8.93 (s, 1H), 8.41 (d, J=7.89 Hz, 1H), 8.19 (d, J=8.33 Hz,
1H), 3.42 (br. s., 4H), 2.87-2.94 (m, 4H), 1.41 (d, J=3.51 Hz,
9H).
Step 2--Synthesis of
N-(piperazin-1-yl)-5-(trifluoromethyl)picolinamide
2,2,2-trifluoroacetate
[0568] To a stirred solution of tert-butyl
4-(5-(trifluoromethyl)picolinamido)piperazine-1-carboxylate (100
mg, 0.26 mmol, 1.0 equiv) in DCM (05 mL), was added trifluoroacetic
acid (01 mL) and the resultant reaction mixture was stirred at RT
for overnight under nitrogen atmosphere. Reaction was monitored by
TLC and LCMS. After completion of reaction, the reaction mixture
was concentrated under reduced pressure. The crude product
crystallized in diethyl ether and dried under vacuum to obtain
N-(piperazin-1-yl)-5-(trifluoromethyl)picolinamide
2,2,2-trifluoroacetate (100 mg) as an off white solid. LCMS 275
[M+H].sup.+;
Step 3--Synthesis of
(R)--N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-yl)-5-
-(trifluoromethyl)picolinamide
[0569] To a stirred solution of
N-(piperazin-1-yl)-5-(trifluoromethyl)picolinamide
2,2,2-trifluoroacetate (100 mg, 0.25 mmol, 1.0 equiv)
(R)-2-((4-chloro-3-fluorophenoxy)methyl)oxirane (52 mg, 0.25 mmol,
1.0 equiv) in DMF (05 mL), was added TEA (0.14 mL, 1.0 mmol, 4.0
equiv) and the resultant reaction mixture was heated at 90.degree.
C. for overnight. Progress of the reaction was monitored by LCMS.
After completion of reaction, the reaction mixture was diluted with
water (100 mL) and extracted with EtOAc (50 mL.times.2). The
combined organic layer was washed with water (50 mL.times.4), dried
over anhydrous sodium sulfate and concentrated under reduced
pressure to obtain crude which was purified by reversed-phase HPLC
to obtain
(R)--N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-yl)-5-
-(trifluoromethyl)picolinamide (Compound 65-50 mg, 42% Yield) as an
off white solid. LCMS 477.4 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.87 (br. s., 1H), 9.02 (br. s., 1H), 8.43
(d, J=8.77 Hz, 1H), 8.19 (d, J=7.89 Hz, 1H), 7.49 (t, J=8.77 Hz,
2H), 7.09 (d, J=11.84 Hz, 1H), 6.87 (d, J=6.58 Hz, 1H), 5.94 (br.
s., 1H), 4.00 (br. s., 4H), 3.58 (br. s., 2H), 2.67 (br. s., 3H),
2.33 (br. s., 3H).
Example 37
Synthesis of
(R)--N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-yl)-5-
-(difluoromethyl)pyrazine-2-carboxamide
##STR00660##
[0570] Step 1--Synthesis of tert-butyl
4-(5-(difluoromethyl)pyrazine-2-carboxamido)piperazine-1-carboxylate
[0571] To a stirred solution of tert-butyl
4-aminopiperazine-1-carboxylate (578 mg, 2.8 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (2128 mg, 5.6 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. Then
5-(difluoromethyl)pyrazine-2-carboxylic acid (500 mg, 2.8 mmol, 1.0
equiv) was added followed by the addition of DIPEA (1.5 mL, 8.4
mmol, 3.0 equiv). The resulting reaction mixture was allowed to
stir at RT for overnight. Product formation was confirmed by LCMS.
the reaction mixture was diluted with water (50 mL) and extracted
with EtOAc (50 mL.times.2). The combined organic layer was washed
with water (30 mL), brine solution (30 mL.times.2), dried over
anhydrous sodium sulfate and concentrated under reduced pressure,
to obtain tert-butyl
4-(5-(difluoromethyl)pyrazine-2-carboxamido)piperazine-1-carboxylate
(400 mg, 39% Yield) as a brown solid. LCMS 358.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.13 (s, 1H), 9.24 (s,
1H), 8.99 (s, 1H), 3.34-3.49 (m, 4H), 2.84 (t, J=5.04 Hz, 4H), 1.41
(s, 9H).
Step 2--Synthesis of
5-(difluoromethyl)-N-(piperazin-1-yl)pyrazine-2-carboxamide
2,2,2-trifluoroacetate
[0572] To a stirred solution of tert-butyl
4-(5-(difluoromethyl)pyrazine-2-carboxamido)piperazine-1-carboxylate
(400 mg, 1.12 mmol, 1.0 equiv) in DCM (10 mL), was added
trifluoroacetic acid (3 mL) and the resultant reaction mixture was
stirred at RT for overnight under nitrogen atmosphere. Reaction was
monitored by TLC and LCMS. After completion of reaction, the
reaction mixture was concentrated under reduced pressure. The crude
product crystallized in diethyl ether and dried under vacuum to
obtain 5-(difluoromethyl)-N-(piperazin-1-yl)pyrazine-2-carboxamide
2,2,2-trifluoroacetate (200 mg, 48% Yield) as an off white solid.
LCMS 258.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.46 (br. s., 1H), 9.25 (br. s., 1H), 9.01 (br. s., 1H), 8.73 (br.
s., 2H), 3.17 (br. s., 4H), 3.11 (br. s., 4H).
Step 3--Synthesis of
(R)--N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-yl)-5-
-(difluoromethyl)pyrazine-2-carboxamide
[0573] To a stirred solution of
5-(difluoromethyl)-N-(piperazin-1-yl)pyrazine-2-carboxamide
2,2,2-trifluoroacetate (200 mg, 0.53 mmol, 1.0 equiv)
(R)-2-((4-chloro-3-fluorophenoxy)methyl)oxirane (108 mg, 0.53 mmol,
1.0 equiv) in DMF (05 mL), was added TEA (0.3 mL, 2.12 mmol, 4.0
equiv) and the resultant reaction mixture was heated at 90.degree.
C. for overnight. Progress of the reaction was monitored by LCMS.
After completion of reaction, the reaction mixture was diluted with
water (100 mL) and extracted with EtOAc (50 mL.times.2). The
combined organic layer was washed with water (50 mL.times.4), dried
over anhydrous sodium sulfate and concentrated under reduced
pressure to obtain crude which was purified by reversed-phase HPLC
to obtain
(R)--N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-yl)-5-
-(difluoromethyl)pyrazine-2-carboxamide (Compound 66-100 mg, 42%
Yield) as a white solid. LCMS 460.3 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta.10.02 (s, 1H), 9.23 (s, 1H), 8.99 (s,
1H), 7.47 (t, J=8.99 Hz, 1H), 7.21 (s, 1H), 7.04-7.11 (m, 1H), 6.86
(dt, J=9.10, 1.37 Hz, 1H), 4.96 (d, J=4.38 Hz, 1H), 3.97-4.08 (m,
1H), 3.82-3.95 (m, 2H), 2.89 (t, J=4.82 Hz, 4H), 2.67 (br. s., 3H),
2.30-2.44 (m, 2H).
Example 38
Synthesis of
(R)--N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-yl)-5-
-cyanopicolinamide
##STR00661##
[0574] Step 1--Synthesis of tert-butyl
4-(5-cyanopicolinamido)piperazine-1-carboxylate
[0575] To a stirred solution of tert-butyl
4-aminopiperazine-1-carboxylate (679 mg, 3.37 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (2561 mg, 6.74 mmol, 2.0 equiv) at RT
and stirred for 10 minutes. Then 5-cyanopicolinic acid (500 mg,
3.37 mmol, 1.0 equiv) was added followed by the addition of DIPEA
(1.8 mL, 10.1 mmol, 3.0 equiv). The resulting reaction mixture was
allowed to stir at RT for overnight. Product formation was
confirmed by LCMS. the reaction mixture was diluted with water (50
mL) and extracted with EtOAc (50 mL.times.2). The combined organic
layer was washed with water (30 mL), brine solution (30
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure, to obtain tert-butyl
4-(5-cyanopicolinamido)piperazine-1-carboxylate (400 mg, 35% Yield)
as an yellow solid. LCMS 332.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.06 (s, 1H), 9.09 (s, 1H), 8.50 (dd,
J=8.33, 1.75 Hz, 1H), 8.14 (d, J=7.89 Hz, 1H), 3.42 (br. s., 4H),
2.82 (t, J=4.82 Hz, 4H), 1.41 (s, 9H).
Step 2--Synthesis of 5-cyano-N-(piperazin-1-yl)picolinamide
2,2,2-trifluoroacetate
[0576] To a stirred solution of tert-butyl
4-(5-cyanopicolinamido)piperazine-1-carboxylate (400 mg, 1.20 mmol,
1.0 equiv) in DCM (10 mL), was added trifluoroacetic acid (03 mL)
and the resultant reaction mixture was stirred at RT for overnight
under nitrogen atmosphere. Reaction was monitored by TLC and LCMS.
After completion of reaction, the reaction mixture was concentrated
under reduced pressure. The crude product crystallized in diethyl
ether and dried under vacuum to obtain
5-cyano-N-(piperazin-1-yl)picolinamide 2,2,2-trifluoroacetate (200
mg, 48% Yield) as an off white solid. LCMS 232.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.40 (s, 1H), 9.11 (s,
1H), 8.60 (br. s., 2H), 8.52 (dd, J=8.11, 1.97 Hz, 1H), 8.15 (d,
J=8.33 Hz, 1H), 3.23 (br. s., 4H), 3.10 (d, J=4.82 Hz, 4H)
Step 3--Synthesis of
(R)--N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-yl)-5-
-cyanopicolinamide
[0577] To a stirred solution of
5-cyano-N-(piperazin-1-yl)picolinamide 2,2,2-trifluoroacetate (200
mg, 0.57 mmol, 1.0 equiv)
(R)-2-((4-chloro-3-fluorophenoxy)methyl)oxirane (117 mg, 0.57 mmol,
1.0 equiv) in DMF (05 mL), was added TEA (0.32 mL, 2.28 mmol, 4.0
equiv) and the resultant reaction mixture was heated at 90.degree.
C. for overnight. Progress of the reaction was monitored by LCMS.
After completion of reaction, the reaction mixture was diluted with
water (100 mL) and extracted with EtOAc (50 mL.times.2). The
combined organic layer was washed with water (50 mL.times.4), dried
over anhydrous sodium sulfate and concentrated under reduced
pressure to obtain crude which was purified by reversed-phase HPLC
to obtain
(R)--N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-yl)-5-
-cyanopicolinamide (Compound 67--90 mg, 37% Yield) as a white
solid. LCMS 434.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.94 (s, 1H), 9.09 (s, 1H), 8.50 (dd, J=8.11, 1.97 Hz, 1H),
8.11-8.20 (m, 1H), 7.47 (t, J=8.99 Hz, 1H), 7.07 (dd, J=11.40, 2.63
Hz, 1H), 6.82-6.90 (m, 1H), 4.97 (br. s., 1H), 4.00 (d, J=6.58 Hz,
1H), 3.84-3.96 (m, 2H), 2.87 (t, J=4.60 Hz, 4H), 2.29-2.44 (m, 2H),
2.12 (m, 3H).
Example 39
Synthesis of
(R)-5-chloro-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)pi-
peridin-1-yl)picolinamide
##STR00662##
[0578] Step 1--Synthesis of tert-butyl
(1-(5-chloropicolinamido)piperidin-4-yl)carbamate
[0579] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (500 mg, 2.32 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (1763 mg, 4.64 mmol, 2.0 equiv) at RT
and stirred for 10 minutes. Then 5-chloropicolinic acid (365 mg,
2.32 mmol, 1.0 equiv) was added followed by the addition of DIPEA
(1.2 mL, 6.96 mmol, 3.0 equiv). The resulting reaction mixture was
allowed to stir at RT for overnight. Product formation was
confirmed by LCMS. the reaction mixture was diluted with water (50
mL) and extracted with EtOAc (50 mL.times.2). The combined organic
layer was washed with water (30 mL), brine solution (30
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure, to obtain tert-butyl
(1-(5-chloropicolinamido)piperidin-4-yl)carbamate (500 mg, 60%
Yield) as an off white solid. LCMS 355.1 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.61 (s, 1H), 8.66 (d, J=2.19 Hz,
1H), 8.11 (dd, J=8.33, 2.19 Hz, 1H), 7.99 (d, J=8.33 Hz, 1H), 6.83
(d, J=7.02 Hz, 1H), 3.23 (br. s., 1H), 2.84-3.00 (m, 3H), 2.62-2.84
(m, 2H), 1.73 (d, J=11.40 Hz, 2H), 1.47-1.66 (m, 2H), 1.38 (s,
9H).
Step 2--Synthesis of N-(4-aminopiperidin-1-yl)-5-chloropicolinamide
2,2,2-trifluoroacetate
[0580] To a stirred solution of tert-butyl
(1-(5-chloropicolinamido)piperidin-4-yl)carbamate (500 mg, 1.41
mmol, 1.0 equiv) in DCM (10 mL), was added trifluoroacetic acid (02
mL) and the resultant reaction mixture was stirred at RT for
overnight under nitrogen atmosphere. Reaction was monitored by TLC
and LCMS. After completion of reaction, the reaction mixture was
concentrated under reduced pressure. The crude product crystallized
in diethyl ether and dried under vacuum to obtain
N-(4-aminopiperidin-1-yl)-5-chloropicolinamide
2,2,2-trifluoroacetate (400 mg, 77% Yield) as an off white solid.
LCMS 255.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.79 (s, 1H), 8.67 (br. s., 1H), 8.12 (d, J=6.14 Hz, 1H), 8.00 (d,
J=8.77 Hz, 1H), 7.85 (br. s., 3H), 2.98 (d, J=10.96 Hz, 3H), 2.79
(t, J=11.62 Hz, 2H), 1.91 (d, J=10.96 Hz, 3H), 1.65 (d, J=8.77 Hz,
3H).
Step 3--Synthesis of
(R)-5-chloro-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)pi-
peridin-1-yl)picolinamide
[0581] To a stirred solution of
N-(4-aminopiperidin-1-yl)-5-chloropicolinamide
2,2,2-trifluoroacetate (200 mg, 0.54 mmol, 1.0 equiv)
(R)-2-((4-chloro-3-fluorophenoxy)methyl)oxirane (109 mg, 0.54 mmol,
1.0 equiv) in DMF (05 mL), was added TEA (0.3 mL, 2.16 mmol, 4.0
equiv) and the resultant reaction mixture was heated at 90.degree.
C. for overnight. Progress of the reaction was monitored by LCMS.
After completion of reaction, the reaction mixture was diluted with
water (100 mL) and extracted with EtOAc (50 mL.times.2). The
combined organic layer was washed with water (50 mL.times.4), dried
over anhydrous sodium sulfate and concentrated under reduced
pressure to obtain crude which was purified by reversed-phase HPLC
to obtain
(R)-5-chloro-N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)pi-
peridin-1-yl)picolinamide (Compound 68-60 mg, 25% Yield) as an off
white solid. LCMS 457.3 [M+H].sup.+; .sup.1H NMR .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 9.60 (s, 1H), 8.66 (d, J=2.19 Hz, 1H),
8.22 (br. s., 1H), 8.11 (dd, J=8.33, 2.63 Hz, 1H), 7.99 (d, J=8.33
Hz, 1H), 7.46 (t, J=8.77 Hz, 1H), 7.09 (d, J=2.63 Hz, 1H), 6.85 (d,
J=9.21 Hz, 1H), 4.01 (dd, J=9.87, 3.73 Hz, 1H), 3.83-3.93 (m, 2H),
2.96 (d, J=10.09 Hz, 2H), 2.62-2.78 (m, 4H), 1.85 (br. s., 2H),
1.42 (d, J=10.09 Hz, 3H).
Example 40
Synthesis of
(R)--N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperidin--
1-yl)-5-methoxybenzofuran-2-carboxamide
##STR00663##
[0582] Step 1--Synthesis of tert-butyl
(1-(5-methoxybenzofuran-2-carboxamido)piperidin-4-yl)carbamate
[0583] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (224 mg, 1.04 mmol, 1.0 equiv) in
DMF (5 mL) was added HATU (790 mg, 2.08 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. Then 5-methoxybenzofuran-2-carboxylic acid
(200 mg, 1.04 mmol, 1.0 equiv) was added followed by the addition
of DIPEA (0.6 mL, 3.12 mmol, 3.0 equiv). The resulting reaction
mixture was allowed to stir at RT for overnight. Product formation
was confirmed by LCMS. the reaction mixture was diluted with water
(50 mL) and extracted with EtOAc (50 mL.times.2). The combined
organic layer was washed with water (30 mL), brine solution (30
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure, to obtain tert-butyl
(1-(5-methoxybenzofuran-2-carboxamido)piperidin-4-yl)carbamate (300
mg, 74% Yield) as an off white solid. LCMS 390.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.62 (s, 1H), 7.53 (d,
J=8.77 Hz, 1H), 7.44 (s, 1H), 7.24 (br. s., 1H), 6.97-7.08 (m, 1H),
6.84 (d, J=6.58 Hz, 1H), 3.79 (s, 3H), 3.23 (br. s., 1H), 2.95 (d,
J=10.09 Hz, 2H), 2.62-2.81 (m, 2H), 1.74 (d, J=9.65 Hz, 2H), 1.53
(d, J=10.52 Hz, 2H), 1.38 (s, 9H).
Step 2--Synthesis of
N-(4-aminopiperidin-1-yl)-5-methoxybenzofuran-2-carboxamide
2,2,2-trifluoroacetate
[0584] To a stirred solution of tert-butyl
(1-(5-methoxybenzofuran-2-carboxamido)piperidin-4-yl)carbamate (300
mg, 0.77 mmol, 1.0 equiv) in DCM (05 mL), was added trifluoroacetic
acid (02 mL) and the resultant reaction mixture was stirred at RT
for overnight under nitrogen atmosphere. Reaction was monitored by
TLC and LCMS. After completion of reaction, the reaction mixture
was concentrated under reduced pressure. The crude product
crystallized in diethyl ether and dried under vacuum to obtain
N-(4-aminopiperidin-1-yl)-5-methoxybenzofuran-2-carboxamide
2,2,2-trifluoroacetate (300 mg) as an off white solid. LCMS 290.2
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.76 (br.
s., 1H), 7.88 (br. s., 2H), 7.54 (d, J=8.77 Hz, 1H), 7.45 (br. s.,
1H), 7.25 (br. s., 1H), 7.05 (d, J=7.45 Hz, 1H), 3.80 (s, 3H), 3.02
(d, J=8.77 Hz, 2H), 2.79 (t, J=10.74 Hz, 2H), 1.92 (d, J=11.40 Hz,
2H), 1.65 (d, J=10.52 Hz, 2H).
Step 3 Synthesis of
(R)--N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperidin--
1-yl)-5-methoxybenzofuran-2-carboxamide
[0585] To a stirred solution of
N-(4-aminopiperidin-1-yl)-5-methoxybenzofuran-2-carboxamide
trifluoroacetate (200 mg, 0.51 mmol, 1.0 equiv)
(R)-2-((4-chloro-3-fluorophenoxy)methyl)oxirane (104 mg, 0.51 mmol,
1.0 equiv) in DMF (05 mL), was added TEA (0.3 mL, 2.04 mmol, 4.0
equiv) and the resultant reaction mixture was heated at 90.degree.
C. for overnight. Progress of the reaction was monitored by LCMS.
After completion of reaction, the reaction mixture was diluted with
water (100 mL) and extracted with EtOAc (50 mL.times.2). The
combined organic layer was washed with water (50 mL.times.4), dried
over anhydrous sodium sulfate and concentrated under reduced
pressure to obtain crude which was purified by reversed-phase HPLC
to obtain
(R)--N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperidin--
1-yl)-5-methoxybenzofuran-2-carboxamide (Compound 69-60 mg, 24%
Yield) as a white solid. LCMS 491.16 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 9.65 (s, 1H), 8.24 (s, 1H), 7.41-7.59
(m, 3H), 7.24 (br. s., 1H), 6.98-7.09 (m, 2H), 6.85 (d, J=8.77 Hz,
1H), 4.01 (d, J=5.26 Hz, 1H), 3.86-3.96 (m, 2H), 3.79 (s, 3H), 3.00
(d, J=9.65 Hz, 3H), 2.61-2.83 (m, 4H), 1.88 (br. s., 2H), 1.46 (br.
s., 2H).
Example 41
Synthesis of 5-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy) acetamido)
piperidin-1-yl)-2,3-dihydrobenzofuran-2-carboxamide
##STR00664##
[0586] Step 1--Synthesis of tert-butyl
(1-(5-chloro-2,3-dihydrobenzofuran-2-carboxamido)piperidin-4-yl)carbamate
[0587] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (0.200 g, 0.93 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (0.706 g, 1.86 mmol, 2.0 equiv) at RT
and stirred for 10 minutes.
5-chloro-2,3-dihydrobenzofuran-2-carboxylic acid (0.184 g, 0.93
mmol, 1.0 equiv) was added followed by the addition of DIPEA (0.5
mL, 2.79 mmol, 3.0 equiv). The resulting reaction mixture was
allowed to stir at RT for overnight. Product formation was
confirmed by LCMS. The reaction mixture was diluted with water (50
mL). The resulting solid was filtered off, washed with water (20
mL.times.4) and dried under vacuum to obtain tert-butyl
(1-(5-chloro-2,3-dihydrobenzofuran-2-carboxamido)piperidin-4-yl)carbamate
(0.300 g, 81% yield) as an off white solid. LCMS 396.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.16 (s, 1H), 7.23-7.29
(m, 1H), 7.10-7.17 (m, 1H), 6.78-6.84 (m, 2H), 5.06 (dd, J=10.09,
7.02 Hz, 1H), 3.44 (d, J=10.52 Hz, 1H), 3.13-3.22 (m, 2H),
2.82-2.91 (m, 2H), 2.57-2.64 (m, 2H), 1.69 (br. s., 2H), 1.46 (d,
J=11.84 Hz, 2H), 1.37 (s, 9H).
Step 2--Synthesis of
N-(4-aminopiperidin-1-yl)-5-chloro-2,3-dihydrobenzofuran-2-carboxamide
2,2,2-trifluoroacetate
[0588] To a stirred solution of tert-butyl
(1-(5-chloro-2,3-dihydrobenzofuran-2-carboxamido)piperidin-4-yl)carbamate
(0.300 g, 0.75 mmol, 1.0 equiv) in DCM (10 mL), was added
trifluoroacetic acid (0.3 mL) and the resultant reaction mixture
was stirred at RT for 1 h under nitrogen atmosphere. Reaction was
monitored by TLC and LCMS. After completion of reaction, the
reaction mixture was concentrated under reduced pressure to obtain
sticky crude compound which was triturated with hexane (10 mL) and
diethyl ether and dried under vacuum to obtain
N-(4-aminopiperidin-1-yl)-5-chloro-2,3-dihydrobenzofuran-2-carboxamide
2,2,2-trifluoroacetate (0.200 g, 90% yield) as an off white solid.
LCMS 296.2 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.32 (br. s., 1H), 7.24-7.32 (m, 1H), 7.15 (d, J=7.89 Hz, 1H), 6.82
(d, J=7.89 Hz, 2H), 5.09 (d, J=7.45 Hz, 1H), 3.42-3.52 (m, 1H),
3.21 (dd, J=16.22, 6.58 Hz, 2H), 2.99 (br. s., 2H), 2.59-2.68 (m,
2H), 1.89 (br. s., 2H), 1.59 (d, J=10.96 Hz, 2H).
Step 3--Synthesis of 5-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)
acetamido) piperidin-1-yl)-2,3-dihydrobenzofuran-2-carboxamide
[0589] To a stirred solution of
N-(4-aminopiperidin-1-yl)-5-chloro-2,3-dihydrobenzofuran-2-carboxamide
2,2,2-trifluoroacetate salt (0.200 g, 0.48 mmol, 1.0 equiv) in DMF
(05 mL) was added HATU (0.364 g, 0.96 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. 2-(4-chloro-3-fluorophenoxy)acetic acid
(0.099 g, 0.48 mmol, 1.0 equiv) was added followed by the addition
of DIPEA (0.3 mL, 1.44 mmol, 3.0 equiv). The resulting reaction
mixture was allowed to stir at RT for overnight. Product formation
was confirmed by LCMS. The reaction mixture was diluted with water
(50 mL). The resulting solid was filtered off, washed with water
(20 mL.times.4) and dried under vacuum to obtain
5-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy) acetamido)
piperidin-1-yl)-2,3-dihydrobenzofuran-2-carboxamide (Compound
11-0.200 g, 86% Yield) as an off white solid. LCMS 482.3
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.23 (s,
1H), 8.04 (d, J=7.89 Hz, 1H), 7.48-7.54 (m, 1H), 7.24-7.33 (m, 1H),
7.05-7.20 (m, 2H), 6.76-6.88 (m, 2H), 5.07 (dd, J=10.09, 7.02 Hz,
1H), 4.51 (s, 2H), 3.60 (br. s., 1H), 3.43 (dd, J=16.22, 10.09 Hz,
1H), 3.19 (d, J=6.58 Hz, 1H), 2.87 (d, J=14.03 Hz, 3H), 2.65 (d,
J=12.72 Hz, 1H), 1.70 (br. s., 2H), 1.57 (d, J=8.77 Hz, 2H).
Example 42
Synthesis of
5-chloro-N-(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)-2,3--
dihydrobenzofuran-2-carboxamide
##STR00665##
[0590] Step 1--Synthesis of tert-butyl
(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)carbamate
[0591] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (0.200 g, 0.93 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (0.706 g, 1.86 mmol, 2.0 equiv) at RT
and stirred for 10 minutes. 2-(4-chloro-3-fluorophenoxy)acetic acid
(0.190 g, 0.93 mmol, 1.0 equiv) was added followed by the addition
of DIPEA (0.5 mL, 2.79 mmol, 3.0 equiv). The resulting reaction
mixture was allowed to stir at RT for overnight. Product formation
was confirmed by LCMS. The reaction mixture was diluted with water
(50 mL). The resulting solid was filtered off, washed with water
(20 mL.times.4) and dried under vacuum to obtain tert-butyl
(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)carbamate
(0.300 g, 80% yield) as an off white solid. LCMS 402.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.08 (s, 1H), 8.74 (s,
1H), 7.44-7.51 (m, 1H), 7.05 (dd, J=11.40, 2.63 Hz, 1H), 6.83 (dd,
J=9.43, 2.41 Hz, 1H), 4.88 (s, 2H), 4.46 (s, 1H), 3.20 (br. s.,
1H), 2.83-2.91 (m, 2H), 2.57-2.64 (m, 1H), 1.72 (br. s., 2H),
1.44-1.53 (m, 2H), 1.38 (s, 9H).
Step 2--Synthesis of
N-(4-aminopiperidin-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide
2,2,2-trifluoroacetate
[0592] To a stirred solution of tert-butyl
(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)carbamate
(0.300 g, 0.74 mmol, 1.0 equiv) in DCM (10 mL), was added
trifluoroacetic acid (0.3 mL) and the resultant reaction mixture
was stirred at RT for 1 h under nitrogen atmosphere. Reaction was
monitored by TLC and LCMS. After completion of reaction, the
reaction mixture was concentrated under reduced pressure to obtain
sticky crude compound which was triturated with hexane (10 mL) and
diethyl ether and dried under vacuum to obtain
N-(4-aminopiperidin-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide
2,2,2-trifluoroacetate (0.200 g, 90% yield) as an off white solid.
LCMS 302.1 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.08 (s, 1H), 8.74 (s, 1H), 7.44-7.51 (m, 1H), 7.05 (dd, J=11.40,
2.63 Hz, 1H), 6.83 (dd, J=9.43, 2.41 Hz, 1H), 4.88 (s, 2H), 4.46
(s, 1H), 3.20 (br. s., 1H), 2.83-2.91 (m, 2H), 2.57-2.64 (m, 1H),
1.72 (br. s., 2H), 1.44-1.53 (m, 2H).
Step 3--Synthesis of
5-chloro-N-(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)-2,3--
dihydrobenzofuran-2-carboxamide
[0593] To a stirred solution of
N-(4-aminopiperidin-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide
2,2,2-trifluoroacetate (0.200 g, 0.48 mmol, 1.0 equiv) in DMF (05
mL) was added HATU (0.364 g, 0.96 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. 5-chloro-2,3-dihydrobenzofuran-2-carboxylic
acid (0.095 g, 0.48 mmol, 1.0 equiv) was added followed by the
addition of DIPEA (0.3 mL, 1.44 mmol, 3.0 equiv). The resulting
reaction mixture was allowed to stir at RT for overnight. Product
formation was confirmed by LCMS. The reaction mixture was diluted
with water (50 mL). The resulting solid was filtered off, washed
with water (20 mL.times.4) and dried under vacuum to obtain
5-chloro-N-(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-y-
l)-2,3-dihydrobenzofuran-2-carboxamide (Compound 12--0.200 g, 86%
Yield) as an off white solid. LCMS 482.3 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.13 (s, 1H), 8.79 (br. s., 1H),
8.14 (br. s., 1H), 7.46-7.54 (m, 1H), 7.27 (s, 1H), 7.16 (d, J=8.33
Hz, 1H), 6.99 (dd, J=11.40, 2.63 Hz, 1H), 6.83 (d, J=2.63 Hz, 1H),
4.47 (s, 2H), 3.57 (br. s., 1H), 3.41-3.48 (m, 1H), 3.21 (dd,
J=16.01, 6.80 Hz, 2H), 3.04 (br. s., 1H), 2.88 (br. s., 1H),
2.59-2.71 (m, 2H), 1.64-1.77 (m, 4H).
Example 43
Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(1-((3-(4-chloro-3-fluorophenoxy)-2-hydrox-
ypropyl)amino)piperidin-4-yl)acetamide
##STR00666##
[0594] Step 1--Synthesis of tert-butyl
(1-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperidin-4-yl)ca-
rbamate
[0595] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (0.500 g, 2.3 mmol, 1.0 equiv) in
THF (05 mL) was added LiClO.sub.4 (0.487 g, 4.6 mmol, 2.0 equiv) at
RT and stirred for 10 minutes. Then
2-((4-chloro-3-fluorophenoxy)methyl)oxirane (0.469 g, 2.3 mmol, 1.0
equiv). The resulting reaction mixture was allowed to stir at RT
for overnight. Product formation was confirmed by LCMS. The
reaction mixture was diluted with water (50 mL) and extracted with
EtOAc (100 mL.times.2). The combined organic layer was washed with
water (50 mL), brine solution (50 mL.times.2), dried over anhydrous
sodium sulfate and concentrated under reduced pressure to obtain
tert-butyl
(1-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperidin-4-yl)ca-
rbamate (0.400 g, 41% Yield) as a white solid. LCMS 418.1
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.08 (br.
s., 1H), 7.52 (t, J=8.99 Hz, 1H), 7.11 (dd, J=11.40, 3.07 Hz, 1H),
6.88 (d, J=8.77 Hz, 1H), 6.09 (br. s., 1H), 5.78 (br. s., 1H), 4.60
(br. s., 1H), 4.01 (d, J=4.82 Hz, 1H), 3.86 (d, J=12.28 Hz, 2H),
3.71-3.81 (m, 1H), 3.66 (br. s., 1H), 3.58 (br. s., 1H), 3.50 (d,
J=13.15 Hz, 1H), 3.34 (br. s., 1H), 2.15 (d, J=14.03 Hz, 2H), 2.08
(s, 2H), 1.37 (s, 9H).
Step 2--Synthesis of
1-((4-aminopiperidin-1-yl)amino)-3-(4-chloro-3-fluorophenoxy)propan-2-ol
2,2,2-trifluoroacetate
[0596] To a stirred solution of tert-butyl
(1-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)
piperidin-4-yl)carbamate (0.400 g, 0.95 mmol, 1.0 equiv) in DCM (10
mL), was added trifluoroacetic acid (4 mL) and the resultant
reaction mixture was stirred at RT for 1 h under nitrogen
atmosphere. Reaction was monitored by TLC and LCMS. After
completion of reaction, the reaction mixture was concentrated under
reduced pressure to obtain sticky crude compound which was
triturated with hexane (10 mL) and diethyl ether and dried under
vacuum to obtain
1-((4-aminopiperidin-1-yl)amino)-3-(4-chloro-3-fluorophenoxy)propan-2-ol
2,2,2-trifluoroacetate (0.400 g, Quantitative yield) as an off
white solid. LCMS 318.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.08 (br. s., 1H), 7.52 (t, J=8.99 Hz, 1H),
7.11 (dd, J=11.40, 3.07 Hz, 1H), 6.88 (d, J=8.77 Hz, 1H), 6.09 (br.
s., 1H), 5.78 (br. s., 1H), 4.60 (br. s., 1H), 4.01 (d, J=4.82 Hz,
1H), 3.86 (d, J=12.28 Hz, 2H), 3.71-3.81 (m, 1H), 3.66 (br. s.,
1H), 3.58 (br. s., 1H), 3.50 (d, J=13.15 Hz, 1H), 3.34 (br. s.,
1H), 2.15 (d, J=14.03 Hz, 2H), 2.08 (s, 2H).
Step 3--Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(1-((3-(4-chloro-3-fluorophenoxy)-2-hydrox-
ypropyl)amino)piperidin-4-yl)acetamide
[0597] To a stirred solution of
1-((4-aminopiperidin-1-yl)amino)-3-(4-chloro-3-fluorophenoxy)propan-2-ol
2,2,2-trifluoroacetate (0.100 g, 0.23 mmol, 1.0 equiv) in DMF (05
mL) was added HATU (0.175 g, 0.46 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. 2-(4-chloro-3-fluorophenoxy)acetic acid
(0.048 g, 0.23 mmol, 1.0 equiv) was added followed by the addition
of DIPEA (0.2 mL, 0.69 mmol, 3.0 equiv). Product formation was
confirmed by LCMS. the reaction mixture was diluted with water (50
mL) and extracted with EtOAc (50 mL.times.2). The combined organic
layer was washed with water (50 mL), brine solution (50
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure to obtain crude which was purified by
reverse phase of HPLC to obtain
2-(4-chloro-3-fluorophenoxy)-N-(1-((3-(4-chloro-3-fluorophenoxy)-2-hydrox-
ypropyl)amino)piperidin-4-yl)acetamide (Compound 7-0.015 g, 13%
Yield) as an off white solid. LCMS 504.3 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 8.50 (br. s., 1H), 8.41 (br. s.,
1H), 7.50 (td, J=8.77, 3.07 Hz, 2H), 7.04-7.16 (m, 2H), 6.87 (t,
J=7.45 Hz, 2H), 6.07 (br. s., 1H), 4.58 (s, 2H), 4.01 (d, J=6.14
Hz, 3H), 3.84 (br. s., 2H), 3.75 (br. s., 1H), 3.53 (d, J=13.59 Hz,
3H), 2.02 (br. s., 3H), 1.94 (br. s., 1H).
Example 44
Synthesis of
6-chloro-N-(1-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperi-
din-4-yl)quinoline-2-carboxamide
##STR00667##
[0599] To a stirred solution of
1-((4-aminopiperidin-1-yl)amino)-3-(4-chloro-3-fluorophenoxy)propan-2-ol
2,2,2-trifluoroacetate salt (0.100 g, 0.23 mmol, 1.0 equiv) in DMF
(05 mL) was added HATU (0.175 g, 0.46 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. 6-chloroquinoline-2-carboxylic acid (0.048
g, 0.23 mmol, 1.0 equiv) was added followed by the addition of
DIPEA (0.2 mL, 0.69 mmol, 3.0 equiv). Product formation was
confirmed by LCMS. The reaction mixture was diluted with water (50
mL) and extracted with EtOAc (50 mL.times.2). The combined organic
layer was washed with water (50 mL), brine solution (50
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure to obtain crude which was purified by
reverse phase of HPLC to obtain
6-chloro-N-(1-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperi-
din-4-yl)quinoline-2-carboxamide (Compound 25-0.020 g, 17% Yield)
as an off white solid. LCMS 507.4 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.96 (d, J=8.77 Hz, 1H), 8.57 (d, J=8.77
Hz, 1H), 8.28 (d, J=2.63 Hz, 1H), 8.16 (d, J=9.21 Hz, 1H), 8.21 (d,
J=8.33 Hz, 1H), 7.91 (dd, J=9.21, 2.19 Hz, 1H), 7.52 (t, J=8.99 Hz,
1H), 7.14 (dd, J=11.18, 2.85 Hz, 1H), 6.84-6.97 (m, 2H), 6.16 (br.
s., 1H), 4.67 (br. s., 1H), 4.26 (br. s., 1H), 3.92-4.08 (m, 3H),
3.81 (d, J=13.15 Hz, 1H), 3.54-3.71 (m, 3H), 2.24-2.37 (m, 2H),
2.08 (br. s., 2H).
Example 45
Synthesis of
5-chloro-N-(1-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperi-
din-4-yl)-2,3-dihydrobenzofuran-2-carboxamide
##STR00668##
[0601] To a stirred solution of
1-((4-aminopiperidin-1-yl)amino)-3-(4-chloro-3-fluorophenoxy)propan-2-ol
2,2,2-trifluoroacetate salt (0.100 g, 0.23 mmol, 1.0 equiv) in DMF
(05 mL) was added HATU (0.175 g, 0.46 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. 5-chloro-2,3-dihydrobenzofuran-2-carboxylic
acid (0.046 g, 0.23 mmol, 1.0 equiv) was added followed by the
addition of DIPEA (0.2 mL, 0.69 mmol, 3.0 equiv). Product formation
was confirmed by LCMS. The reaction mixture was diluted with water
(50 mL) and extracted with EtOAc (50 mL.times.2). The combined
organic layer was washed with water (50 mL), brine solution (50
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure to obtain crude which was purified by
reverse phase of HPLC to obtain
5-chloro-N-(1-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperi-
din-4-yl)-2,3-dihydrobenzofuran-2-carboxamide (Compound 70-0.020 g,
17% Yield) as an off white solid. LCMS 498.3 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 8.48 (br. s., 1H), 8.38 (br.
s., 1H), 7.46-7.54 (m, 1H), 7.28 (s, 1H), 7.08-7.24 (m, 2H),
6.83-6.95 (m, 2H), 6.06 (br. s., 1H), 5.21 (dd, J=9.87, 6.80 Hz,
1H), 4.01 (dd, J=9.65, 4.38 Hz, 2H), 3.86 (d, J=12.28 Hz, 2H), 3.74
(br. s., 1H), 3.44-3.58 (m, 4H), 3.14-3.26 (m, 2H), 1.99 (br. s.,
4H).
Example 46
Synthesis of
5-chloro-N-(1-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperi-
din-4-yl)benzofuran-2-carboxamide
##STR00669##
[0603] To a stirred solution of
1-((4-aminopiperidin-1-yl)amino)-3-(4-chloro-3-fluorophenoxy)propan-2-ol
trifluoroacetate (0.100 g, 0.23 mmol, 1.0 equiv) in DMF (05 mL) was
added HATU (0.175 g, 0.46 mmol, 2.0 equiv) at RT and stirred for 10
minutes. 5-chlorobenzofuran-2-carboxylic acid (0.045 g, 0.23 mmol,
1.0 equiv) was added followed by the addition of DIPEA (0.2 mL,
0.69 mmol, 3.0 equiv). Product formation was confirmed by LCMS. The
reaction mixture was diluted with water (50 mL) and extracted with
EtOAc (50 mL.times.2). The combined organic layer was washed with
water (50 mL), brine solution (50 mL.times.2), dried over anhydrous
sodium sulfate and concentrated under reduced pressure to obtain
crude which was purified by reverse phase of HPLC to obtain
5-chloro-N-(1-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperi-
din-4-yl)benzofuran-2-carboxamide (Compound 26-0.020 g, 17% Yield)
as an off white solid. LCMS 496.3 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.93 (d, J=7.45 Hz, 1H), 7.89 (d, J=2.19
Hz, 1H), 7.71 (d, J=8.77 Hz, 1H), 7.62 (s, 1H), 7.43-7.55 (m, 2H),
7.13 (dd, J=11.40, 2.63 Hz, 1H), 6.89 (d, J=9.21 Hz, 1H), 6.15 (br.
s., 1H), 4.69 (br. s., 1H), 4.21 (br. s., 1H), 3.92-4.05 (m, 3H),
3.88 (d, J=10.52 Hz, 1H), 3.58 (d, J=13.15 Hz, 3H), 2.14 (br. s.,
4H).
Example 47
Synthesis of
5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)
piperazin-1-yl)-2,3-dihydrobenzofuran-2-carboxamide
##STR00670##
[0604] Step 1--Synthesis of tert-butyl
4-(5-chloro-2,3-dihydrobenzofuran-2-carboxamido)piperazine-1-carboxylate
[0605] To a stirred solution of tert-butyl
4-aminopiperazine-1-carboxylate (0.200 g, 0.99 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (0.752 g, 1.98 mmol, 2.0 equiv) at RT
and stirred for 10 minutes. Then
5-chloro-2,3-dihydrobenzofuran-2-carboxylic acid (0.197 g, 0.99
mmol, 1.0 equiv) was added followed by the addition of DIPEA (0.5
mL, 2.97 mmol, 3.0 equiv). The resulting reaction mixture was
allowed to stir at RT for overnight. Product formation was
confirmed by LCMS. After completion of the reaction the reaction
mixture was diluted with water (100 mL) and extracted with ethyl
acetate (150 mL.times.2). Combined organic layer was washed with
water (50 mL.times.4), dried over anhydrous sodium sulfate and
concentrated under reduced pressure to obtain tert-butyl
4-(5-chloro-2,3-dihydrobenzofuran-2-carboxamido)piperazine-1-carboxylate
(0.200 g, 52% yield) as an off white solid. LCMS 382.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.67 (s, 1H), 7.28 (br.
s., 1H), 7.16 (d, J=8.33 Hz, 1H), 6.84 (s, 1H), 5.10 (dd, J=10.09,
7.02 Hz, 1H), 3.23 (dd, J=16.01, 7.24 Hz, 4H), 2.92-3.07 (m, 4H),
2.03-2.14 (m, 2H), 1.37 (s, 9H).
Step 2--Synthesis of
5-chloro-N-(piperazin-1-yl)-2,3-dihydrobenzofuran-2-carboxamide
2,2,2-trifluoroacetate
[0606] To a stirred solution of tert-butyl
4-(5-chloro-2,3-dihydrobenzofuran-2-carboxamido)piperazine-1-carboxylate
(0.200 g, 0.52 mmol, 1.0 equiv) in DCM (10 mL), was added
trifluoroacetic acid (02 mL) and the resultant reaction mixture was
stirred at RT for 1 h under nitrogen atmosphere. Reaction was
monitored by TLC and LCMS. After completion of reaction, the
reaction mixture was concentrated under reduced pressure to obtain
sticky crude compound which was triturated with hexane (10 mL) and
diethyl ether and dried under vacuum to obtain
5-chloro-N-(piperazin-1-yl)-2,3-dihydrobenzofuran-2-carboxamide
2,2,2-trifluoroacetate (0.200 g, Quantitative yield) as a
semisolid. LCMS 282.2 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.67 (s, 1H), 8.64 (br. s., 1H), 7.28 (br.
s., 1H), 7.16 (d, J=8.33 Hz, 1H), 6.84 (s, 1H), 5.10 (dd, J=10.09,
7.02 Hz, 1H), 3.23 (dd, J=16.01, 7.24 Hz, 4H), 2.92-3.07 (m, 4H),
2.03-2.14 (m, 2H).
Step 3--Synthesis of
5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)piperazin-1-y-
l)-2,3-dihydrobenzofuran-2-carboxamide
[0607] To a stirred solution of
5-chloro-N-(piperazin-1-yl)-2,3-dihydrobenzofuran-2-carboxamide
2,2,2-trifluoroacetate (0.200 g, 0.50 mmol, 1 equiv) in DMF (05 mL)
was added 2-((4-chloro-3-fluorophenoxy)methyl)oxirane (0.102 g,
0.50 mmol, 1.0 equiv) and K.sub.2CO.sub.3 (0.276 g, 1.0 mmol, 2.0
equiv) at RT. The resultant reaction mixture was heated at
90.degree. C. for overnight. Progress of the reaction was monitored
by LCMS. After completion of the reaction the reaction mixture was
diluted with water (100 mL) and extracted with ethyl acetate (100
mL.times.2). Combined organic layer was washed with water (50
mL.times.4), dried over anhydrous sodium sulfate and concentrated
under reduced pressure. The crude product which was purified by
reverse phase of HPLC to obtain
5-chloro-N-(4-(3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)
piperazin-1-yl)-2,3-dihydrobenzofuran-2-carboxamide (Compound
13-0.040 g, 17% Yield) a white solid. LCMS 484.4 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.75 (br. s., 1H), 7.47
(br. s., 2H), 7.05-7.17 (m, 2H), 6.84 (t, J=7.89 Hz, 2H), 5.58 (s,
1H), 5.09 (br. s., 2H), 4.93 (br. s., 2H), 4.30 (s, 1H), 3.99 (br.
s., 2H), 3.90 (br. s., 2H), 3.54 (br. s., 1H), 3.47 (br. s., 1H),
2.76 (br. s., 2H), 2.18 (br. s., 2H).
Example 48
Synthesis of
6-chloro-N-(4-(2-hydroxy-3-(4-(trifluoromethyl)phenoxy)
propyl)piperazin-1-yl)quinoline-2-carboxamide
##STR00671##
[0608] Step 1--Synthesis of
2-((4-(trifluoromethyl)phenoxy)methyl)oxirane
[0609] To a stirred solution of 4-(trifluoromethyl)phenol (1.0 g,
6.1 mmol, 1.0 equiv) 2-(chloromethyl)oxirane (0.681 g, 7.4 mmol,
1.2 equiv) in ACN (20 mL), was added K.sub.2CO.sub.3 (1.68 g, 12.2
mmol, 2.0 equiv) and the resultant reaction mixture was heated at
90.degree. C. for overnight. Progress of the reaction was monitored
by .sup.1H NMR. After completion of reaction, the reaction mixture
was diluted with water (100 mL) and extracted with EtOAc (100
mL.times.2). The combined organic layer was washed with water (50
mL), brine solution (50 mL.times.2), dried over anhydrous sodium
sulfate and concentrated under reduced pressure to obtain
2-((4-(trifluoromethyl)phenoxy)methyl)oxirane (0.400 g, 30% Yield)
as a yellow oil. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.66
(m, J=8.33 Hz, 2H), 7.15 (m, J=8.77 Hz, 2H), 4.44 (dd, J=11.40,
2.63 Hz, 1H), 3.92 (dd, J=11.84, 6.58 Hz, 1H), 3.34-3.41 (m, 1H),
2.84-2.92 (m, 1H), 2.73 (dd, J=4.82, 2.63 Hz, 1H).
Step 2--Synthesis of
6-chloro-N-(4-(2-hydroxy-3-(4-(trifluoromethyl)phenoxy)propyl)piperazin-1-
-yl)quinoline-2-carboxamide
[0610] To a stirred solution of
6-chloro-N-(piperazin-1-yl)quinoline-2-carboxamide
2,2,2-trifluoroacetate (0.200 g, 0.49 mmol, 1.0 equiv)
2-((4-(trifluoromethyl)phenoxy)methyl)oxirane (0.108 g, 0.49 mmol,
1.0 equiv) in DMF (05 mL), was added TEA (0.3 mL, 1.96 mmol, 2.0
equiv) and the resultant reaction mixture was heated at 90.degree.
C. for overnight. Progress of the reaction was monitored by LCMS.
After completion of reaction, the reaction mixture was diluted with
water (50 mL) and extracted with EtOAc (50 mL.times.2). The
combined organic layer was washed with water (30 mL), brine
solution (30 mL.times.2), dried over anhydrous sodium sulfate and
concentrated under reduced pressure to obtain crude which was
purified by reversed-phase HPLC to obtain
6-chloro-N-(4-(2-hydroxy-3-(4-(trifluoromethyl)phenoxy)
propyl)piperazin-1-yl)quinoline-2-carboxamide (Compound 71-0.010 g,
05% Yield) as an off white solid. LCMS 509.4 [M+H].sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 9.79 (s, 1H), 8.53 (d, J=8.77
Hz, 1H), 8.24 (d, J=2.19 Hz, 1H), 8.14 (t, J=8.99 Hz, 2H), 7.88
(dd, J=9.21, 2.19 Hz, 1H), 7.66 (m, J=8.77 Hz, 2H), 7.15 (m, J=8.33
Hz, 2H), 4.11 (br. s., 1H), 3.92-4.03 (m, 2H), 2.94 (br. s., 4H),
2.66 (br. s., 1H), 2.60 (br. s., 3H), 2.38-2.47 (m, 2H).
Example 49
Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(4-(2-(4-chloro-3-nitrophenoxy)acetamido)p-
iperidin-1-yl)acetamide
##STR00672##
[0611] Step 1--Synthesis of tert-butyl
2-(4-chloro-3-nitrophenoxy)acetate
[0612] To a solution of 4-chloro-3-nitrophenol (1.0 g, 5.7 mmol,
1.0 equiv) in DMF (10 mL) was added tert-butyl 2-bromoacetate (1.33
g, 5.7 mmol, 1.2 equiv), K.sub.2CO.sub.3 (1.57 g, 11.4 mmol, 2.0
equiv). The resulting reaction mixture was heated at 80.degree. C.
for overnight. Product formation was confirmed by .sup.1H NMR.
After completion of reaction, the mixture was diluted with water
(50 mL) and extracted with ethyl acetate (100 mL.times.2). Combined
organic extracts were washed with water (50 mL.times.4), dried over
anhydrous Na.sub.2SO.sub.4 and concentrated to obtain tert-butyl
2-(4-chloro-3-nitrophenoxy)acetate (1.0 g, 61%) as colorless oil.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.62-7.75 (m, 2H), 7.29
(dd, J=8.77, 3.07 Hz, 1H), 4.82 (s, 2H), 1.42 (s, 9H).
Step 2--Synthesis of 2-(4-chloro-3-nitrophenoxy)acetic acid
[0613] To a stirred solution of tert-butyl
2-(4-chloro-3-nitrophenoxy)acetate (1.0 g, 3.4 mmol, 1.0 equiv) in
THF (10 mL) and water (5 mL), was added LiOH (0.168 g, 6.9 mmol,
2.0 equiv). The mixture was allowed to stir at RT for overnight.
Product formation was confirmed by .sup.1H NMR Spectroscopy. After
the completion of reaction, the reaction mixture was concentrated
and diluted with water (50 mL). Aqueous layer was acidify with 3N
HCl (pH.about.3.0), extracted with EtOAc (50 mL.times.3). Combined
organic extracts were washed with water (50 mL), dried over
anhydrous Na.sub.2SO.sub.4 and concentrated to obtain
2-(4-chloro-3-nitrophenoxy)acetic acid (Quantitative Yield) as a
brown solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.13.20 (br.
s., 1H), 7.64-7.71 (m, 2H), 7.30 (dd, J=8.77, 3.07 Hz, 1H), 4.84
(s, 2H).
Step 3--Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(4-(2-(4-chloro-3-nitrophenoxy)
acetamido)piperidin-1-yl)acetamide
[0614] To a stirred solution of
N-(4-aminopiperidin-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide
2,2,2-trifluoroacetate (0.200 g, 0.48 mmol, 1.0 equiv) in DMF (05
mL) was added HATU (0.364 g, 0.96 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. 2-(4-chloro-3-nitrophenoxy)acetic acid
(0.111 g, 0.48 mmol, 1.0 equiv) was added followed by the addition
of DIPEA (0.3 mL, 1.44 mmol, 3.0 equiv). The resulting reaction
mixture was allowed to stir at RT for overnight. Product formation
was confirmed by LCMS. The reaction mixture was diluted with water
(50 mL). The resulting solid was filtered off, washed with water
(20 mL.times.4) and dried under vacuum to obtain
2-(4-chloro-3-fluorophenoxy)-N-(4-(2-(4-chloro-3-nitrophenoxy)acetamido)p-
iperidin-1-yl)acetamide (Compound 39-0.100 g, 40% Yield) a white
solid. LCMS 515.3 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.15 (s, 1H), 8.80 (br. s., 1H), 8.11 (d, J=8.33 Hz, 1H),
7.68-7.74 (m, 1H), 7.46-7.52 (m, 1H), 7.31 (dd, J=8.77, 3.07 Hz,
1H), 7.06 (dd, J=11.18, 2.85 Hz, 1H), 6.84 (d, J=9.21 Hz, 1H), 4.90
(s, 2H), 4.47 (s, 2H), 3.61 (br. s., 1H), 3.07 (br. s., 1H), 2.90
(d, J=10.52 Hz, 1H), 2.57-2.71 (m, 2H), 1.73 (br. s., 2H),
1.48-1.67 (m, 2H).
Example 50
Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(1-(2-(4-chloro-3-nitrophenoxy)acetamido)p-
iperidin-4-yl)acetamide
##STR00673##
[0615] Step 1--Synthesis of tert-butyl
(1-(2-(4-chloro-3-nitrophenoxy)acetamido)piperidin-4-yl)carbamate
[0616] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (0.200 g, 0.93 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (0.706 g, 1.86 mmol, 2.0 equiv) at RT
and stirred for 10 minutes. Then 2-(4-chloro-3-nitrophenoxy)acetic
acid (0.213 g, 0.93 mmol, 1.0 equiv) was added followed by the
addition of DIPEA (0.5 mL, 2.79 mmol, 3.0 equiv). The resulting
reaction mixture was allowed to stir at RT for overnight. Product
formation was confirmed by LCMS. The reaction mixture was diluted
with water (50 mL). The resulting solid was filtered off, washed
with water (20 mL.times.4) and dried under vacuum to obtain
tert-butyl
(1-(2-(4-chloro-3-nitrophenoxy)acetamido)piperidin-4-yl)carbamate
(0.200 g, 50% yield) as a white solid. LCMS 429.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.14 (s, 1H), 8.80 (s,
1 H), 7.67-7.75 (m, 1H), 7.26-7.30 (m, 1H), 6.83 (br. s., 1H), 4.98
(s, 2H), 4.56 (s, 1H), 3.17 (br. s., 1H), 3.03 (br. s., 1H),
2.84-2.90 (m, 1H), 2.56-2.63 (m, 1H), 1.71 (br. s., 2H), 1.47 (d,
J=10.09 Hz, 2H), 1.38 (s, 9H).
Step 2--Synthesis of
N-(4-aminopiperidin-1-yl)-2-(4-chloro-3-nitrophenoxy)acetamide
trifluoroacetate
[0617] To a stirred solution of tert-butyl
(1-(2-(4-chloro-3-nitrophenoxy)acetamido)piperidin-4-yl)carbamate
(0.200 g, 0.46 mmol, 1.0 equiv) in DCM (10 mL), was added
trifluoroacetic acid (2 mL) and the resultant reaction mixture was
stirred at RT for 1 h under nitrogen atmosphere. Reaction was
monitored by TLC and LCMS. After completion of reaction, the
reaction mixture was concentrated under reduced pressure to obtain
sticky crude compound which was triturated with hexane (10 mL) and
diethyl ether and dried under vacuum to obtain
N-(4-aminopiperidin-1-yl)-2-(4-chloro-3-nitrophenoxy)acetamide
trifluoroacetate (0.200 g, Quantitative yield) as a white solid.
LCMS 329.1 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.14 (s, 1H), 8.80 (s, 1H), 7.67-7.75 (m, 1H), 7.26-7.30 (m, 1H),
6.83 (br. s., 1H), 4.98 (s, 2H), 4.56 (s, 1H), 3.17 (br. s., 1H),
3.03 (br. s., 1H), 2.84-2.90 (m, 1H), 2.56-2.63 (m, 1H), 1.71 (br.
s., 2H), 1.47 (d, J=10.09 Hz, 2H).
Step 3--Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(1-(2-(4-chloro-3-nitrophenoxy)
acetamido) piperidin-4-yl)acetamide
[0618] To a stirred solution of
N-(4-aminopiperidin-1-yl)-2-(4-chloro-3-nitrophenoxy)acetamide
2,2,2-trifluoroacetate (0.200 g, 0.45 mmol, 1.0 equiv) in DMF (05
mL) was added HATU (0.342 g, 0.90 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. 2-(4-chloro-3-fluorophenoxy)acetic acid
(0.093 g, 0.45 mmol, 1.0 equiv) was added followed by the addition
of DIPEA (0.3 mL, 1.35 mmol, 3.0 equiv). The resulting reaction
mixture was allowed to stir at RT for overnight. Product formation
was confirmed by LCMS. The reaction mixture was diluted with water
(50 mL). The resulting solid was filtered off, washed with water
(20 mL.times.4) and dried under vacuum to gives crude which was
purified by reverse phase of HPLC to obtain
2-(4-chloro-3-fluorophenoxy)-N-(1-(2-(4-chloro-3-nitrophenoxy)acetamido)p-
iperidin-4-yl)acetamide (Compound 75-0.100 g, 43% Yield) as a white
solid. LCMS 515.4 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.20 (s, 1H), 8.85 (br. s., 1H), 8.05 (d, J=7.45 Hz, 1H),
7.65-7.73 (m, 1H), 7.50 (t, J=8.77 Hz, 1H), 7.23 (dd, J=8.99, 2.85
Hz, 1H), 7.05-7.10 (m, 1H), 6.86 (d, J=2.19 Hz, 1H), 5.00 (s, 2H),
4.51 (s, 2H), 3.61 (br. s., 2H), 3.06 (br. s., 1H), 2.90 (d,
J=10.52 Hz, 1H), 2.67 (br. s., 1H), 1.74 (br. s., 2H), 1.61 (d,
J=11.84 Hz, 2H).
Example 51
Synthesis of
5-chloro-N-(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)benzo-
[d]thiazole-2-carboxamide
##STR00674##
[0620] To a stirred solution of
N-(4-aminopiperidin-1-yl)-2-(4-chloro-3-fluorophenoxy)acetamide
2,2,2-trifluoroacetate (0.200 g, 0.48 mmol, 1.0 equiv) in DMF (05
mL) was added HATU (0.364 g, 0.96 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. 5-chlorobenzo[d]thiazole-2-carboxylic acid
(0.102 g, 0.48 mmol, 1.0 equiv) was added followed by the addition
of DIPEA (0.3 mL, 1.44 mmol, 3.0 equiv). The resulting reaction
mixture was allowed to stir at RT for overnight. Product formation
was confirmed by LCMS. The reaction mixture was diluted with water
(50 mL). The resulting solid was filtered off, washed with water
(20 mL.times.4) and dried under vacuum to obtain
5-chloro-N-(1-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-4-yl)benzo-
[d]thiazole-2-carboxamide (Compound 10-0.100 g, 42% Yield) as a
white solid. LCMS 497.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.26 (d, J=8.33 Hz, 1H), 8.82 (s, 1H), 8.28
(d, J=8.77 Hz, 1H), 8.17 (s, 1H), 7.65 (dd, J=8.55, 1.97 Hz, 1H),
7.45-7.54 (m, 1H), 7.07 (d, J=14.03 Hz, 1H), 6.85 (d, J=10.96 Hz,
1H), 4.49 (s, 2H), 3.80 (br. s., 1H), 3.07-3.18 (m, 2H), 2.93 (d,
J=10.96 Hz, 1H), 2.71 (br. s., 1H), 1.82 (d, J=11.84 Hz, 4H).
Example 52
Synthesis of
5-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-1-yl)benzo-
[d]thiazole-2-carboxamide
##STR00675##
[0621] Step 1--Synthesis of tert-butyl
(1-(5-chlorobenzo[d]thiazole-2-carboxamido)piperidin-4-yl)carbamate
[0622] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (0.200 g, 0.93 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (0.706 g, 1.86 mmol, 2.0 equiv) at RT
and stirred for 10 minutes. 5-chlorobenzo[d]thiazole-2-carboxylic
acid (0.198 g, 0.93 mmol, 1.0 equiv) was added followed by the
addition of DIPEA (0.5 mL, 2.79 mmol, 3.0 equiv). The resulting
reaction mixture was allowed to stir at RT for overnight. Product
formation was confirmed by LCMS. The reaction mixture was diluted
with water (50 mL). The resulting solid was filtered off, washed
with water (20 mL.times.4) and dried under vacuum to obtain
tert-butyl
(1-(5-chlorobenzo[d]thiazole-2-carboxamido)piperidin-4-yl)carbamate
(0.200 g, 52% yield) as an off white solid. LCMS 411.1 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.23 (s, 1H), 8.27 (d,
J=8.77 Hz, 1H), 8.15 (d, J=2.19 Hz, 1H), 7.64 (dd, J=8.55, 1.97 Hz,
1H), 6.85 (d, J=8.33 Hz, 1H), 3.23 (br. s., 1H), 2.96 (d, J=11.84
Hz, 2H), 2.79 (t, J=10.30 Hz, 2H), 1.74 (d, J=10.52 Hz, 2H), 1.53
(d, J=10.52 Hz, 2H), 1.39 (s, 9H).
Step 2--Synthesis of
N-(4-aminopiperidin-1-yl)-5-chlorobenzo[d]thiazole-2-carboxamide
2,2,2-trifluoroacetate
[0623] To a stirred solution of tert-butyl
(1-(5-chlorobenzo[d]thiazole-2-carboxamido)piperidin-4-yl)carbamate
(0.200 g, 0.48 mmol, 1.0 equiv) in DCM (10 mL), was added
trifluoroacetic acid (0.2 mL) and the resultant reaction mixture
was stirred at RT for 1 h under nitrogen atmosphere. Reaction was
monitored by TLC and LCMS. After completion of reaction, the
reaction mixture was concentrated under reduced pressure to obtain
sticky crude compound which was triturated with hexane (10 mL) and
diethyl ether and dried under vacuum to obtain
N-(4-aminopiperidin-1-yl)-5-chlorobenzo[d]thiazole-2-carboxamide
2,2,2-trifluoroacetate (0.200 g, Quantitative yield) as an off
white solid. LCMS 310.9 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.38 (br. s., 1H), 8.28 (d, J=8.77 Hz, 1H),
8.16 (d, J=1.75 Hz, 2H), 7.64-7.71 (m, 1H), 3.03 (br. s., 2H),
2.82-2.88 (m, 1H), 1.93 (d, J=12.72 Hz, 2H), 1.64-1.73 (m, 2H),
1.53 (s, 2H).
Step 3--Synthesis of
5-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)
piperidin-1-yl)benzo[d]thiazole-2-carboxamide
[0624] To a stirred solution of
N-(4-aminopiperidin-1-yl)-5-chlorobenzo[d]thiazole-2-carboxamide
2,2,2-trifluoroacetate (0.200 g, 0.47 mmol, 1.0 equiv) in DMF (05
mL) was added HATU (0.350 g, 0.92 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. 2-(4-chloro-3-fluorophenoxy)acetic acid
(0.096 g, 0.47 mmol, 1.0 equiv) was added followed by the addition
of DIPEA (0.3 mL, 1.41 mmol, 3.0 equiv). The resulting reaction
mixture was allowed to stir at RT for overnight. Product formation
was confirmed by LCMS. The reaction mixture was diluted with water
(50 mL). The resulting solid was filtered off, washed with water
(20 mL.times.4) and dried under vacuum to gives crude. The crude
which was purified by reverse phase of HPLC to obtain
5-chloro-N-(4-(2-(4-chloro-3-fluorophenoxy)acetamido)piperidin-1-yl)benzo-
[d]thiazole-2-carboxamide (Compound 9-0.100 g, 42% Yield) as an off
white solid. LCMS 497.3 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.27 (s, 1H), 8.28 (d, J=8.77 Hz, 1H), 8.16
(d, J=1.75 Hz, 1H), 8.09 (d, J=7.89 Hz, 1H), 7.64 (dd, J=8.77, 1.75
Hz, 1H), 7.43-7.52 (m, 1H), 7.08 (dd, J=11.18, 2.85 Hz, 1H), 6.87
(d, J=9.21 Hz, 1H), 4.53 (s, 2H), 3.66 (br. s., 1H), 2.95-3.07 (m,
2H), 2.79-2.91 (m, 2H), 1.76 (d, J=10.09 Hz, 2H), 1.57-1.68 (m,
2H).
Example 53
Synthesis of
(S)-6-chloro-N-(1-(2-(4-chlorophenoxy)acetamido)piperidin-4-yl)-3,4-dihyd-
ro-2H-benzo[b][1,4]oxazine-2-carboxamide
##STR00676##
[0625] Step 1--Synthesis of tert-butyl
(1-(2-(4-chlorophenoxy)acetamido)piperidin-4-yl)carbamate
[0626] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (0.100 g, 0.46 mmol, 1.0 equiv) in
DCM (10 mL) was added 2-(4-chlorophenoxy)acetyl chloride (0.095 g,
0.46 mmol, 1.0 equiv) and followed by the addition of TEA (0.2 mL,
1.39 mmol, 3.0 equiv). The resulting reaction mixture was allowed
to stir at RT for overnight. Product formation was confirmed by
LCMS. The reaction mixture was diluted with water (20 mL) and
extracted with ethyl acetate (50 mL.times.2). Combined organic
layer was washed with water (20 mL.times.4), dried over anhydrous
Na.sub.2SO.sub.4 and concentrated under reduced pressure to obtain
tert-butyl
(1-(2-(4-chlorophenoxy)acetamido)piperidin-4-yl)carbamate (0.100 g,
56% Yield) as a white solid. LCMS 384.1 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.07 (s, 1H), 8.72 (br. s., 1H),
7.39-7.23 (m, 2H), 7.00-6.87 (m, 2H), 6.87-6.72 (m, 1H), 4.85-4.74
(m, 1H), 4.41 (s, 1H), 3.33 (br. s., 4H), 2.84 (d, J=10.5 Hz, 2H),
1.71 (br. s., 2H), 1.47 (d, J=10.1 Hz, 1H), 1.44-1.28 (m, 9H).
Step 2--Synthesis of
N-(4-aminopiperidin-1-yl)-2-(4-chlorophenoxy)acetamide
2,2,2-trifluoroacetate
[0627] To a stirred solution of tert-butyl
(1-(2-(4-chlorophenoxy)acetamido)piperidin-4-yl)carbamate (0.100 g,
0.26 mmol, 1.0 equiv) in DCM (10 mL), was added trifluoroacetic
acid (02 mL) and the resultant reaction mixture was stirred at RT
for 1 h under nitrogen atmosphere. Reaction was monitored by TLC
and LCMS. After completion of reaction, the reaction mixture was
concentrated under reduced pressure to obtain crude product which
was crystallized in diethyl ether and dried under vacuum to obtain
N-(4-aminopiperidin-1-yl)-2-(4-chlorophenoxy)acetamide
2,2,2-trifluoroacetate (0.100 g, Quant. Yield) as a brown semi
solid. LCMS 284.1 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.07 (s, 1H), 8.72 (br. s., 1H), 7.39-7.23 (m, 2H),
7.00-6.87 (m, 2H), 6.87-6.72 (m, 1H), 4.85-4.74 (m, 1H), 4.41 (s,
1H), 3.33 (br. s., 4H), 2.84 (d, J=10.5 Hz, 2H), 1.71 (br. s., 2H),
1.47 (d, J=10.1 Hz, 1H).
Step 3--Synthesis of
(S)-6-chloro-N-(1-(2-(4-chlorophenoxy)acetamido)piperidin-4-yl)-3,4-dihyd-
ro-2H-benzo[b][1,4]oxazine-2-carboxamide
[0628] To a stirred solution of
N-(4-aminopiperidin-1-yl)-2-(4-chlorophenoxy)acetamide
2,2,2-trifluoroacetate (0.100 g, 0.25 mmol, 1.0 equiv) in DMF (05
mL) was added HATU (0.190 g, 0.50 mmol, 2.0 equiv) at RT and
stirred for 10 minutes.
(S)-6-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carboxylic acid
(0.054 g, 0.25 mmol, 1.0 equiv) was added followed by the addition
of DIPEA (0.12 mL, 0.75 mmol, 3.0 equiv). The resulting reaction
mixture was allowed to stir at RT for overnight. Product formation
was confirmed by LCMS. After completion of reaction, the mixture
was diluted with water (50 mL) and extracted with ethyl acetate
(100 mL.times.2). Combined organic extracts were washed with water
(50 mL.times.4), dried over anhydrous Na.sub.2SO.sub.4 and
concentrated to gives crude which was purified by reverse phase of
HPLC to obtain
(S)-6-chloro-N-(1-(2-(4-chlorophenoxy)acetamido)piperidin-4-yl)-3,4-dihyd-
ro-2H-benzo[b][1,4]oxazine-2-carboxamide (Compound 72-0.025 g, 21%
Yield) as an off white solid. LCMS 479.3 [M+H].sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.11 (s, 1H), 8.76 (br. s., 1H),
7.92 (d, J=7.89 Hz, 1H), 7.30-7.39 (m, 2H), 6.96 (d, J=9.21 Hz,
1H), 6.88 (d, J=9.21 Hz, 1H), 6.78 (dd, J=8.33, 3.95 Hz, 1H), 6.60
(d, J=2.19 Hz, 1H), 6.50 (d, J=8.77 Hz, 1H), 4.42-4.49 (m, 2H),
3.58 (br. s., 1H), 3.45 (br. s., 1H), 3.18 (dd, J=12.28, 7.45 Hz,
2H), 3.02 (br. s., 1H), 2.88 (br. s., 1H), 2.60-2.70 (m, 2H), 1.72
(d, J=11.84 Hz, 2H), 1.61 (d, J=14.91 Hz, 2H).
Example 54
Synthesis of
N,N'-(piperidine-1,4-diyl)bis(2-(4-(trifluoromethyl)phenoxy)acetamide)
##STR00677## ##STR00678##
[0629] Step 1--Synthesis of tert-butyl
2-(4-(trifluoromethyl)phenoxy)acetate
[0630] To a solution of 4-(trifluoromethyl)phenol (1.0 g, 6.1 mmol,
1.0 equiv) in DMF (10 mL) was added tert-butyl 2-bromoacetate (1.44
g, 7.4 mmol, 1.2 equiv), K.sub.2CO.sub.3 (1.68 g, 12.2 mmol, 2.0
equiv). The resulting reaction mixture was heated at 80.degree. C.
for overnight. Product formation was confirmed by .sup.1H NMR.
After completion of reaction, the mixture was diluted with water
(50 mL) and extracted with ethyl acetate (100 mL.times.2). Combined
organic extracts were washed with water (50 mL.times.4), dried over
anhydrous Na.sub.2SO.sub.4 and concentrated to obtain tert-butyl
2-(4-(trifluoromethyl)phenoxy)acetate (1.0 g, 60%) as colorless
oil. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.66 (m, J=8.77
Hz, 2H), 7.09 (m, J=8.33 Hz, 2H), 4.78 (s, 2H), 1.42 (s, 9H).
Step 2--Synthesis of 2-(4-(trifluoromethyl)phenoxy)acetic acid
[0631] To a stirred solution of tert-butyl
2-(4-(trifluoromethyl)phenoxy)acetate (1.0 g, 3.6 mmol, 1.0 equiv)
in DCM (10 mL), was added trifluoroacetic acid (05 mL) and the
resultant reaction mixture was stirred at RT for 1 h under nitrogen
atmosphere. Reaction was monitored by TLC and LCMS. After
completion of reaction, the reaction mixture was concentrated under
reduced pressure to obtain sticky crude compound which was
triturated with hexane (10 mL) and diethyl ether and dried under
vacuum to obtain 2-(4-(trifluoromethyl)phenoxy)acetic acid (0.700
g, 88%) as an off white solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 13.11 (br. s., 1H), 7.64 (s, 2H), 7.10 (d, J=8.77 Hz, 2H),
4.80 (s, 2H).
Step 3--Synthesis of tert-butyl
(1-(2-(4-(trifluoromethyl)phenoxy)acetamido)piperidin-4-yl)carbamate
[0632] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (0.200 g, 0.93 mmol, 1.0 equiv) in
DMF (05 mL) was added HATU (0.706 g, 1.86 mmol, 2.0 equiv) at RT
and stirred for 10 minutes. 2-(4-(trifluoromethyl)phenoxy)acetic
acid (0.204 g, 0.93 mmol, 1.0 equiv) was added followed by the
addition of DIPEA (0.5 mL, 2.79 mmol, 3.0 equiv). The resulting
reaction mixture was allowed to stir at RT for overnight. Product
formation was confirmed by LCMS. The reaction mixture was diluted
with water (50 mL). The resulting solid was filtered off, washed
with water (20 mL.times.4) and dried under vacuum to obtain
tert-butyl
(1-(2-(4-(trifluoromethyl)phenoxy)acetamido)piperidin-4-yl)carbamate
(0.300 g, 77% Yield) as an off white solid. LCMS 418.3 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.13 (s, 1H), 8.78 (br.
s., 1H), 7.62-7.70 (m, 2H), 7.12 (s, 1H), 7.03 (d, J=8.33 Hz, 1H),
4.52 (s, 2H), 3.02 (br. s., 1H), 2.89 (s, 2H), 2.73 (s, 1H), 2.67
(br. s., 1H), 1.72 (br. s., 2H), 1.49 (br. s., 2H), 1.33-1.44 (m,
9H).
Step 4--Synthesis of
N-(4-aminopiperidin-1-yl)-2-(4-(trifluoromethyl)phenoxy)acetamide
2,2,2-trifluoroacetate
[0633] To a stirred solution of tert-butyl
(1-(2-(4-(trifluoromethyl)phenoxy)acetamido)piperidin-4-yl)carbamate
(0.300 g, 0.77 mmol, 1.0 equiv) in DCM (10 mL), was added
trifluoroacetic acid (03 mL) and the resultant reaction mixture was
stirred at RT for 1 h under nitrogen atmosphere. Reaction was
monitored by TLC and LCMS. After completion of reaction, the
reaction mixture was concentrated under reduced pressure to obtain
sticky crude compound which was triturated with hexane (10 mL) and
diethyl ether and dried under vacuum to obtain
N-(4-aminopiperidin-1-yl)-2-(4-(trifluoromethyl)phenoxy)acetamide
2,2,2-trifluoroacetate (0.200 g, Quantitative yield) as a semi
solid. LCMS 318.1 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.13 (s, 1H), 8.78 (br. s., 1H), 7.62-7.70 (m, 2H), 7.12
(s, 1H), 7.03 (d, J=8.33 Hz, 1H), 4.52 (s, 2H), 3.02 (br. s., 1H),
2.89 (s, 2H), 2.73 (s, 1H), 2.67 (br. s., 1H), 1.72 (br. s., 2H),
1.49 (br. s., 2H).
Step 5--Synthesis of
N,N'-(piperidine-1,4-diyl)bis(2-(4-(trifluoromethyl)phenoxy)acetamide)
[0634] To a stirred solution of
N-(4-aminopiperidin-1-yl)-2-(4-(trifluoromethyl)phenoxy)acetamide
2,2,2-trifluoroacetate (0.200 g, 0.46 mmol, 1.0 equiv) in DMF (05
mL) was added HATU (0.350 g, 0.92 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. 2-(4-(trifluoromethyl)phenoxy)acetic acid
(0.102 g, 0.46 mmol, 1.0 equiv) was added followed by the addition
of DIPEA (0.3 mL, 1.38 mmol, 3.0 equiv). The resulting reaction
mixture was allowed to stir at RT for overnight. Product formation
was confirmed by LCMS. The reaction mixture was diluted with water
(50 mL). The resulting solid was filtered off, washed with water
(20 mL.times.4) and dried under vacuum to obtain
N,N'-(piperidine-1,4-diyl)bis(2-(4-(trifluoromethyl)phenoxy)acetamide)
(Compound 35-0.150 g, 40% Yield) as an off white solid. LCMS 520.4
[M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.19 (s,
1H), 8.83 (br. s., 1H), 7.64-7.71 (m, 4H), 7.07-7.17 (m, 4H),
4.50-4.60 (m, 4H), 3.62 (br. s., 1H), 3.07 (br. s., 1H), 2.92 (br.
s., 1H), 2.66 (d, J=8.33 Hz, 2H), 1.73 (d, J=11.84 Hz, 2H),
1.57-1.68 (m, 2H).
Example 55
Synthesis of
5-chloro-N-(1-((2-(4-chloro-3-fluorophenoxy)ethyl)amino)piperidin-4-yl)-2-
,3-dihydrobenzofuran-2-carboxamide
##STR00679##
[0635] Step 1--Synthesis of tert-butyl
(1-((2-(4-chloro-3-fluorophenoxy)ethyl)amino)piperidin-4-yl)carbamate
[0636] To a stirred solution of tert-butyl
(1-aminopiperidin-4-yl)carbamate (1.00 g, 4.6 mmol, 1.0 equiv) in
THF (15 mL) was added LiClO.sub.4 (0.975 g, 9.2 mmol, 2.0 equiv) at
RT and stirred for 10 minutes.
4-(2-bromoethoxy)-1-chloro-2-fluorobenzene (1.10 g, 4.6 mmol, 1.0
equiv). The resulting reaction mixture was allowed to stir at RT
for overnight. Product formation was confirmed by LCMS. The
reaction mixture was diluted with water (50 mL) and extracted with
EtOAc (100 mL.times.2). The combined organic layer was washed with
water (50 mL), brine solution (50 mL.times.2), dried over anhydrous
sodium sulfate and concentrated under reduced pressure to obtain
tert-butyl
(1-((2-(4-chloro-3-fluorophenoxy)ethyl)amino)piperidin-4-yl)carbamate
(1.00 g, 55% Yield) as a yellow semi solid. LCMS 388.2 [M+H].sup.+;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.40-7.51 (m, 1H), 7.12
(dd, J=11.62, 2.85 Hz, 1H), 6.86 (d, J=9.21 Hz, 1H), 4.28-4.40 (m,
2H), 3.73-3.83 (m, 2H), 3.52-3.61 (m, 1H), 2.83 (br. s., 2H), 2.14
(br. s., 2H), 2.04 (d, J=10.52 Hz, 2H), 1.65 (br. s., 2H), 1.45 (s,
9H).
Step 2--Synthesis of
N1-(2-(4-chloro-3-fluorophenoxy)ethyl)piperidine-1,4-diamine
2,2,2-trifluoroacetate
[0637] To a stirred solution of tert-butyl
(1-((2-(4-chloro-3-fluorophenoxy)ethyl)amino)piperidin-4-yl)carbamate
(1.00 g, 2.57 mmol, 1.0 equiv) in DCM (10 mL), was added
trifluoroacetic acid (5 mL) and the resultant reaction mixture was
stirred at RT for 1 h under nitrogen atmosphere. Reaction was
monitored by TLC and LCMS. After completion of reaction, the
reaction mixture was concentrated under reduced pressure to obtain
sticky crude compound which was triturated with hexane (10 mL) and
diethyl ether and dried under vacuum to obtain
N1-(2-(4-chloro-3-fluorophenoxy)ethyl)piperidine-1,4-diamine
2,2,2-trifluoroacetate (0.700 g, 70% Yield) as a yellow semi solid.
LCMS 288.2 [M+H].sup.+;
Step 3--Synthesis of
5-chloro-N-(1-((2-(4-chloro-3-fluorophenoxy)ethyl)amino)piperidin-4-yl)-2-
,3-dihydrobenzofuran-2-carboxamide
[0638] To a stirred solution of
N1-(2-(4-chloro-3-fluorophenoxy)ethyl)piperidine-1,4-diamine
2,2,2-trifluoroacetate (0.200 g, 0.49 mmol, 1.0 equiv) in DMF (05
mL) was added HATU (0.343 g, 0.98 mmol, 2.0 equiv) at RT and
stirred for 10 minutes. 5-chloro-2,3-dihydrobenzofuran-2-carboxylic
acid (0.097 g, 0.49 mmol, 1.0 equiv) was added followed by the
addition of DIPEA (0.3 mL, 1.47 mmol, 3.0 equiv). Product formation
was confirmed by LCMS. The reaction mixture was diluted with water
(50 mL) and extracted with EtOAc (50 mL.times.2). The combined
organic layer was washed with water (50 mL), brine solution (50
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure to obtain crude which was purified by
reverse phase of HPLC to obtain
5-chloro-N-(1-((2-(4-chloro-3-fluorophenoxy)ethyl)amino)piperidin-4-yl)-2-
,3-dihydrobenzofuran-2-carboxamide (Compound 73-0.010 g, 4% Yield)
as an off white solid. LCMS 469.3 [M+H].sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.31 (d, J=7.89 Hz, 1H), 7.48 (t, J=8.99
Hz, 1H), 7.21-7.29 (m, 1H), 7.08-7.19 (m, 1H), 6.73-6.92 (m, 2H),
5.13 (dd, J=10.30, 6.80 Hz, 2H), 4.50-4.62 (m, 2H), 3.65-3.81 (m,
2H), 3.44-3.61 (m, 5H), 3.13-3.24 (m, 3H), 3.10 (br. s., 2H),
2.15-2.29 (m, 2H), 1.51-1.68 (m, 2H).
Example 56
Synthesis of
N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperidin-1-yl)-
-2-(4-chlorophenoxy)acetamide
##STR00680##
[0640] To a stirred solution of
N-(4-aminopiperidin-1-yl)-2-(4-chlorophenoxy)acetamide
2,2,2-trifluoroacetate (0.100 g, 0.25 mmol, 1.0 equiv)
2-((4-chloro-3-fluorophenoxy)methyl)oxirane (0.051 g, 0.25 mmol,
1.0 equiv) in DMF (5 mL), was added TEA (0.14 mL, 1.00 mmol, 4.0
equiv) and the resultant reaction mixture was heated at 90.degree.
C. for overnight. Progress of the reaction was monitored by LCMS.
After completion of reaction, the reaction mixture was diluted with
water (50 mL) and extracted with EtOAc (50 mL.times.2). The
combined organic layer was washed with water (30 mL), brine
solution (30 mL.times.2), dried over anhydrous sodium sulfate and
concentrated under reduced pressure to obtain crude which was
purified by flash chromatography (0-5% MeOH in DCM as an eluent) to
obtain
N-(4-((3-(4-chloro-3-fluorophenoxy)-2-hydroxypropyl)amino)piperidin-1-yl)-
-2-(4-chlorophenoxy)acetamide (Compound 74-0.060 g, 50% Yield) as
an off white solid. LCMS 486.1 [M+H].sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.75 (br. s., 1H), 7.46 (t, J=8.99 Hz, 1H),
7.30 (d, J=9.21 Hz, 1H), 7.34 (d, J=9.21 Hz, 1H), 7.07 (dd,
J=11.40, 2.63 Hz, 1H), 6.95 (d, J=9.21 Hz, 1H), 6.83 (d, J=9.21 Hz,
1H), 6.87 (d, J=8.77 Hz, 1H), 5.04 (br. s., 1H), 4.82 (s, 1H), 4.41
(s, 1H), 3.99 (dd, J=9.65, 3.95 Hz, 1H), 3.76-3.96 (m, 2H), 3.00
(br. s., 1H), 2.87 (d, J=10.52 Hz, 1H), 2.67 (br. s., 1H),
2.56-2.64 (m, 2H), 2.33 (br. s., 2H), 1.90 (s, 1H), 1.81 (br. s.,
2H), 1.33 (d, J=9.21 Hz, 2H).
Example 57
Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(4-(2-(4-ethynylphenoxy)acetamido)piperidi-
n-1-yl)acetamide
##STR00681##
[0641] Step 1--Synthesis of ethyl 2-(4-ethynylphenoxy)acetate
[0642] To a stirred solution of 4-ethynylphenol (0.100 g, 0.847
mmol, 1.0 equiv) in DMF (2 mL) was added K.sub.2CO.sub.3 (0.233 g,
1.694 mmol, 2.0 equiv) and Ethyl 2-Bromoacetate (0.212 g, 1.271
mmol, 1.5 equiv), resultant reaction mixture was stirred at RT for
overnight. Progress of the reaction was monitored by TLC and LCMS.
After completion of reaction, the reaction mixture was diluted with
water (30 mL) and extracted with EtOAc (50 mL.times.2). The
combined organic layer was washed with water (30 mL), brine
solution (30 mL.times.2), dried over anhydrous sodium sulfate and
concentrated under reduced pressure to obtain crude which was
purified by combi-flash chromatography (Silica gel 100-200 mesh:
Elution 0-10% EA in Hexane) to afford titled compound ethyl
2-(4-ethynylphenoxy)acetate (0.090 g, 52.32%) as a white solid.
LCMS 204.9 [M+H].sup.+; .sup.1H NMR (400 MHz, Chloroform-d) .delta.
7.43 (d, J=8.77 Hz, 2H), 6.85 (d, J=8.77 Hz, 2H), 4.62 (s, 2H),
4.27 (d, J=7.02 Hz, 2H), 3.00 (s, 1H), 1.29 (t, J=7.24 Hz, 3H).
Step 2--Synthesis of 2-(4-ethynylphenoxy) acetic acid
[0643] To a stirred solution of ethyl 2-(4-ethynylphenoxy)acetate
(0.090 g, 0.441 mmol, 1.0 equiv) in THF (3 ml) was added a solution
of LiOH.H.sub.2O (0.027 g, 0.661 mmol, 1.5 equiv) in water (2 ml).
The reaction mixture was stirred at RT for 12 hr. Product formation
was confirmed by TLC. Reaction mixture was diluted with water (20
ml) and washed with ethyl acetate (25 mL.times.3). Aqueous layer
was acidified with 1N HCl and extracted with ethyl acetate (25
mL.times.3). Combined organic extracts were washed with water (30
mL.times.2) & brine (30 mL), dried over anhydrous
Na.sub.2SO.sub.4 and concentrated to obtained
2-(4-ethynylphenoxy)acetic acid (0.075 g, 97.40% Yield) as a white
solid. LCMS 176.9 [M+H].sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta.13.06 (br. s., 1H), 7.40 (m, J=8.77 Hz, 2H), 6.91 (m, J=8.77
Hz, 2H), 4.64-4.77 (m, 2H), 4.02 (s, 1H).
Step 3--Synthesis of
2-(4-chloro-3-fluorophenoxy)-N-(4-(2-(4-ethynylphenoxy)acetamido)piperidi-
n-1-yl)acetamide
[0644] To a stirred solution of
N-(4-aminopiperidin-1-yl)-2-(4-chloro-3-fluorophenoxy) acetamide
2,2,2-trifluoroacetate (0.100 g, 0.240 mmol, 1.0 equiv) in DMF (2
mL) was added HATU (0.137 g, 0.361 mmol, 1.5 equiv) at RT and
stirred for 5 minutes. 2-(4-ethynylphenoxy)acetic acid (0.063 g,
0.361 mmol, 1.5 equiv) was added followed by the addition of DIPEA
(0.08 mL, 0.481 mmol, 2.0 equiv). The resulting reaction mixture
was allowed to stir at RT for overnight. Product formation was
confirmed by LCMS. The reaction mixture was diluted with water (30
mL) and extracted with EtOAc (30 mL.times.2). The combined organic
layer was washed with water (30 mL), brine solution (30
mL.times.2), dried over anhydrous sodium sulfate and concentrated
under reduced pressure. The crude product was purified by reversed
phase HPLC to
2-(4-chloro-3-fluorophenoxy)-N-(4-(2-(4-ethynylphenoxy)acetamido)-
piperidin-1-yl)acetamide (Compound 37). LCMS 460.2 [M+H]+
BIOLOGICAL EXAMPLES
Example B1--ATF4 Expression Inhibition Assay
[0645] The ATF4 reporter was prepared by fusing the human full
length 5'UTR of ATF4 (NCBI Accession No. BC022088.2) upstream of
the firefly luciferase coding sequence lacking the initiator
methionine. The fused sequence was cloned into
pLenti-EF1a-C-Myc-DDK-IRES-Puro cloning vector (Origen #PS100085)
using standard methods. Virus production was carried out by using
Lenti-X.TM. Packaging Single Shots Protocol (Clonetech #631276).
Viral particles were used to transduce HEK293T cells (ATCC
#CRL-3216, ATCC Manassas, Va.), which were subsequently selected
with puromycin to generate stable cell line. Cells were maintained
at 37.degree. C. and 5% C.sub.02 in DMEM-F12 (Hyclone #SH30023.02)
supplemented with 10% heat-inactivated fetal bovine serum (Gibco
#16000-044), 2 mM L-glutamine (Gibco #25030-081), 100 U/ml
penicillin, and 100 .mu.g/ml streptomycin (Gibco #15140-122).
[0646] HEK293T cells carrying the ATF4 luciferase reporter were
plated on 96-well plates (Nunc) at 10,000 cells per well. Cells
were treated two days after seeding with 100 nM thapsigargin (Tg)
(Sigma-Aldrich #T9033) in the presence of 100 nM or 1 .mu.M. For
the assessment of the half-maximal inhibitory concentration
(IC.sub.50) for selected compounds, dose-response assays were
performed. Compounds were serially diluted using DMSO ranging from
0.1 nM to 1 .mu.M. Cells without treatment or cells treated with Tg
alone were used as controls. Assay plates containing cells were
incubated for 3 hours at 37.degree. C.
[0647] Luciferase reactions were performed using Luciferase Assay
System (Promega #E1501) as specified by the manufacturer.
Luminescence was read with an integration time of 1 s and a gain of
110 using a Cytation-5 multi-mode microplate reader (BioTek).
Relative luminescence units were normalized to Tg treatment (0%
inhibition) and untreated cells (100% inhibition) and the
percentage of ATF4 inhibition was calculated.
[0648] Percentages of ATF4 inhibition after induction with Tg in
the presence of 100 nM or 1 .mu.M of certain test compounds are
shown in Table 2. Also shown in Table 2 is the calculated IC.sub.50
for certain test compounds. Under ISR stressed conditions
(resulting from treatment with Tg), ATF4 expression is generally
upregulated. Accordingly, inhibition of ATF4 expression as a result
of the test compound indicates suppression of the ISR pathway.
[0649] ISRIB
(trans-N,N'-1,4-cyclohexanediylbis[2-(4-chlorophenoxy)-acetamide)
was found to inhibit ATF4 expression with an IC.sub.50 of 5 nM
(FIG. 1). Despite the great potency on the inhibition of ATF4
expression, ISRIB is not able to completely restore protein
synthesis when the global protein translation is decreased under
these stress conditions. Even at higher concentration-up to
200-fold its IC.sub.50 value-ISRIB only partially restores protein
translation (FIG. 2). Compound 4 has a great potency for the
inhibition of ATF4 expression under stress condition (FIG. 3) and
is much better at restoring global protein translation under ER
stress-mediated repression and going beyond a 100% recovery (FIG.
4).
TABLE-US-00002 TABLE 2 Compound % ATF4 inhibition % ATF4 inhibition
ATF4 inhbition IC.sub.50 No. at 100 nM at l .mu.M (nM) 1 93.7 97.9
3.6 2 87.1 97.6 18.4 3 88.1 92.2 10.6 4 93.2 94.7 3.1 5 85.7 93.7
18.8 6 75.9 83.8 30.8 7 16.1 13.9 >1,000 8 44.2 70.9 152.6 9
77.1 86.8 <100 10 68.2 87.2 <100 11 67.8 90.5 <100 12 69.4
88.5 <100 13 60.7 86.7 <100 14 89.3 98.9 10.2 15 87.8 100
12.4 16 46.3 91.6 124.7 17 58.6 92.7 79.1 18 59.1 94.6 76.3 19 87.3
95.8 11.5 20 24.7 33.7 >10,000 21 68.6 86.9 61.9 22 87.5 92.8
10.3 23 67.2 89.3 55.6 24 88.0 99.5 32.2 25 8.1 8.5 >1,000 26
37.5 49.4 n/a 30 29.5 97.1 187.3 31 94.8 92.7 4.16 32 85.7 92.4
12.0 35 92.1 91.6 <100 39 91.0 91.5 <100 44 51.5 82.0 150.9
45 92.7 92.4 2.6 46 100 99.3 3.6 47 98.2 99.0 1.98 48 96.5 97.4
3.36 49 55.4 100 69.7 50 97.2 100 1.93 51 79.3 100 19.8 52 75.3
81.2 26.9 53 36.1 69.8 268 54 87.2 97.2 1.6 55 58.1 80.5 101.7 56
63.4 75.6 71.7 57 25.9 39.8 >10,000 58 86.5 97.6 5.7 59 38.8
66.0 569.6 60 92.6 94.6 1.5 61 72.4 86.6 29.4 62 85.9 88.8 <100
63 14.8 84.6 <1,000 64 20.0 56.6 n/a 65 22.6 80.5 <1,000 66 0
0 >1,000 67 3.6 27.8 >1,000 68 9.0 50.9 n/a 69 37.0 78.1
<1,000 70 0.4 21.4 >1,000 71 83.4 89.9 <100
Example B2--ATF4 Expression Inhibition Assay
[0650] HEK293T cells were maintained at 37.degree. C. and 5% CO2 in
Dulbecco's Modified Eagle's Media (DMEM) supplemented with 10%
fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin,
and 100 .mu.g/ml streptomycin. After reaching 80% of confluence,
cells were detached and seeded on 6 well plates in complete media,
allowed to recover overnight and treated for 3 hours with 100 nM
thapsigargin (Tg) in the presence of various concentrations ranging
from 0.1 nM to 10 .mu.M. Cells without treatment (Veh) or cells
treated with Tg alone were used as controls.
[0651] After 3 hours of treatment with Tg and the test compound,
cells were lysed with SDS-PAGE lysis buffer. Lysates were
transferred to 1.5 ml tubes and sonicated for 3 min, and total
protein amounts were quantified using BCA Protein Assay Kit
(Pierce). Equal amount of proteins was loaded on SDS-PAGE gels.
Proteins were transferred onto 0.2 m PVDF membranes (BioRad) and
probed with primary antibodies diluted in Tris-buffered saline
supplemented with 0.1% Tween 20 and 3% bovine serum albumin.
[0652] ATF4 (11815) antibody (Cell Signaling Technologies) and
R-actin (Sigma-Aldrich) antibodies were used as primary antibodies.
A horseradish peroxidase (HRP)-conjugated secondary antibody
(Rockland) was employed to detect immune-reactive bands using
enhanced chemiluminescence (ECL Western Blotting Substrate, Pierce)
and photographed by a gel imaging equipment (Chemidoc).
[0653] Under ISR stressed conditions (resulting from treatment with
Tg), ATF4 expression is generally upregulated. Accordingly,
inhibition of ATF4 expression as a result of the test compound
indicates suppression of the ISR pathway.
[0654] ATF4 expression in unstressed condition (Veh) or under Tg
stress alone or in the presence of compound 58 at the indicated
concentration is shown in FIG. 6. Actin expression was used as a
loading control. Compound 58 inhibits the expression of ATF4 under
Tg treatment in a dose dependent manner.
Example B3--Protein Translation Assay
[0655] Chinese hamster ovary (CHO) cells were maintained at
37.degree. C. and 5% CO.sub.2 in Dulbecco's Modified Eagle's Media
(DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine,
100 U/ml penicillin, and 100 .mu.g/ml streptomycin. After reaching
80% of confluence, cells were detached and seeded on 6 well plates
in complete media, allowed to recover overnight and treated for 2
hours with 1 .mu.M of the test compound (to assess protein
synthesis levels in unstressed condition), or for 1 hour with 100
nM or 1 .mu.M of the test compound and then co-treated with 300 nM
Tg and 100 nM or 1 .mu.M of the test compound (to assess the
recovery of protein synthesis in a stressed condition). Cells
treated with Tg alone were used as controls.
[0656] After the 2 hours treatments, media were replaced by adding
10 .mu.g/ml puromycin (Sigma Aldrich #P8833) in complete media for
30 min. Media were removed and cells were lysed with SDS-PAGE lysis
buffer. Lysates were transferred to 1.5 ml tubes and sonicated for
3 min and total protein amount were quantified using BCA Protein
Assay Kit (Pierce). Equal amount of protein (30 .mu.g) was loaded
on SDS-PAGE gels. Proteins were transferred onto 0.2 m PVDF
membranes (BioRad) and probed with primary antibodies diluted in
Tris-buffered saline supplemented with 0.1% Tween 20 (Merck
#S6996184 505) and 3% bovine serum albumin (Rockland #BSA-50).
[0657] Puromycin (12D10) (Merck #MABE343) and R-actin (Sigma
Aldrich #A.sup.5441) antibodies were used as primary antibody. A
HRP-conjugated secondary antibody (Rockland) was employed to detect
immune-reactive bands using enhanced chemiluminescence (ECL Western
Blotting Substrate, Pierce). Quantification of protein bands was
done by densitometry using ImageJ software.
[0658] Percent increase of protein synthesis in unstressed cells
(without Tg treatment) in the presence of media alone or certain
test compounds is shown in Table 3 The percentage levels were
normalized to the media alone condition, which correspond to 100%
protein synthesis. Certain compounds stimulated protein synthesis
above baseline, indicating that these test compounds result in
increased protein synthesis in unstressed cells.
[0659] Percent recovery of protein synthesis in stressed cells
(with Tg treatment) due to the test compounds at 100 nM or 1 .mu.M
is also shown in Table 3. The levels were normalized to the media
alone and to Tg alone conditions, which correspond to 100% and 0%
respectively.
TABLE-US-00003 TABLE 3 % Protein synthesis % Recovery of % Recovery
of in unstressed cells protein expression protein expression
Compound (1 .mu.M test (100 nM test (1 .mu.M test No. compound)
compound) compound) 1 111.9 88.6 218.3 2 87.5 40.2 123.2 3 152.3
81.6 190.0 4 105.4 83.5 169.2 5 134.6 -7.1 109.5 6 97.9 16.7 105.1
8 121.4 n/a 52.1 14 138.9 n/a 174.7 15 119.2 n/a 247.9 16 66.1 n/a
-5.5 17 117.3 n/a 188.2 18 89.3 n/a 142.7 19 115.4 n/a 174.7 20
154.7 n/a 358.4 21 129.3 n/a 236.3 22 94.8 n/a 105.4 23 177.9 n/a
249.0 24 143.6 n/a 183.0 30 49.3 n/a 31.7 31 155.4 n/a 146.2 32
115.7 n/a 74.8 44 146.3 n/a 120.0 45 114.1 n/a 82.3 46 114.4 n/a
63.3 47 89.4 n/a 46.7 48 85.3 n/a 76.2 49 82.3 n/a 70.7 50 96.8 n/a
7.4 51 110.4 n/a 22.1 52 113.1 n/a 75.8 53 83.7 n/a 46.2 54 99.7
n/a 69.9 55 109.9 n/a 49.6 56 154.7 n/a 46.1 57 138.6 n/a 69.6 58
164.4 n/a 118.4 59 179.7 n/a 98.7 60 140.4 n/a 126 61 195.2 n/a 171
62 99.5 n/a 40.2 63 107.4 n/a 16.4 64 109.2 n/a 34.7 65 99.0 n/a
51.1 66 84.9 n/a 17.6 67 80.0 n/a 27.6 68 81.8 n/a 49.3 69 128.8
n/a 43.1
Example B4--ATF4 Inhibition Assay Under A.beta. Stimulation
[0660] Chinese hamster ovary (CHO) cells that stably express human
APP751 incorporating the familial Alzheimer's disease mutation
V717F were used as a source of A.beta. monomer and low-n oligomers.
These cells, referred to as 7PA2 CHO cells, were cultured in 100 mm
dishes with Dulbecco's modified Eagle's medium (DMEM) containing
10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and
100 .mu.g/ml penicillin, streptomycin and 200 .mu.g/ml G418. Upon
reaching 90-100% confluency, cells were washed with 5 mL of
glutamine- and serum-free DMEM and incubated for approximately 16 h
in 5 mL of the same DMEM. Conditioned media (CM) was collected.
[0661] SH-SY5Y cells were maintained at 37.degree. C. and 5% CO2 in
RPMI 1640 media supplemented with 10% fetal bovine serum (FBS),
penicillin and streptomycin. After reaching 80% of confluence,
cells were detached and seeded on 6 well plates in complete media,
allowed to recover 48 h and treated for 16 hours with CM from WT
CHO cells (wtCM) or 7PA2 CHO cells (7PA2CM) in the presences of
various concentrations ranging from 1 nM to 10 .mu.M of compound
58.
[0662] After 16 hours treatment, culture media were removed and
cells were lysed with SDS-PAGE lysis buffer. Lysates were
transferred to 1.5 ml tubes and sonicated for 3 min. Total protein
amount was quantified using BCA Protein Assay Kit (Pierce). Equal
amount of proteins (30 .mu.g) were loaded on SDS-PAGE gels.
Proteins were transferred onto 0.2 .mu.m PVDF membranes (BioRad)
and probed with primary antibodies diluted in Tris-buffered saline
supplemented with 0.1% Tween 20 and 3% bovine serum albumin.
[0663] ATF4 (11815) antibody (Cell Signaling Technologies) and
R-actin (Sigma-Aldrich) antibodies were used as primary antibodies.
A HRP-conjugated secondary antibody (Rockland) was employed to
detect immune-reactive bands using enhanced chemiluminescence (ECL
Western Blotting Substrate, Pierce) and photographed by a gel
imaging equipment (Chemidoc).
[0664] ATF4 expression in SH-SY5Y cells after incubation with CM
from the 7PA2 CHO cells alone or in the presence of compound 58 at
the indicated concentrations is shown in FIG. 7. Actin expression
was used as a loading control. Compound 58 inhibits the expression
of ATF4 in the presence of AR oligomers treatment in a dose
dependent manner.
Example B5--Electrophysiology and Long-Term Potentiation
[0665] Hippocampal slices were prepared as described in Ardiles et
al., Pannexin 1 regulates bidirectional hippocampal synaptic
plasticity in adult mice. Front Cell Neurosci, vol. 8, art. 326
(2014). Six to nine-month-old WT C57BL/6 or transgenic APP/PS1 mice
(Jackson Lab 34829-JAX) were deeply anesthetized with isoflurane
and their brains were quickly removed. 5-10 slices (350 .mu.m) from
each animal were dissected in ice-cold dissection buffer using a
vibratome (Leica VT1200S, Leica Microsystems, Nussloch, Germany).
Slices were incubated with 5 .mu.M ISRIB
(trans-N,N'-1,4-cyclohexanediylbis[2-(4-chlorophenoxy)-acetamide)
or a vehicle (complete medium containing 0.1% DMSO) 20 min before
conditioning stimulation. Synaptic responses were evoked by
stimulating the Schaffer collaterals with 0.2 ms pulses delivered
through concentric bipolar stimulating electrodes, and recorded
extracellularly in the stratum radiatum of the CA1 subfield.
Long-term potentiation (LTP) was induced by four-theta burst
stimulation (TBS) (10 trains of four pulses at 100 Hz; 5 Hz
inter-burst interval) delivered at 0.1 Hz. LTP magnitude based on
field excitatory postsynaptic potential (fEPSP) was calculated as
the average (normalized to baseline) of the responses recorded 60
min after conditioning stimulation. Similar experiments can be
performed using a test compound in place of ISRIB.
[0666] Results for ISRIB are shown in FIGS. 5A and 5B. Treatment of
the slices from both the WT C57BL/6 and APP/PS1 mice treated with
the vehicle resulted in LTP 60 minutes after stimulation, with the
APP/PS1 sample showing significantly reduced LTP. Treatment of the
slices from the APP/PS1 mouse with ISRIB, however, resulted in
partial LTP recovery.
Example B6--Learning Memory in Aged Mice
[0667] Wild type 19-month old male C57Bl/6J mice are used in an
8-arm radial water maze (RAWM) to measure the hippocampal-mediated
learning memory. The maze involves a pool 118.5 cm in diameter and
25 cm high with 8 arms, each 41 cm in length, and an escape
platform that can be moved. The pool is filled with water that is
rendered opaque by adding white paint (Crayola, 54-2128-053). The
escape platform remains hidden during the experiment. Visual cues
are placed around the room such that they are visible to animals
exploring the maze.
[0668] Nine mice are intraperitoneally injected with 5 mg/kg of a
test compound formulated in 50% Polyethylene glycol (PEG-400) in
distilled water and other 9 animals are intraperitoneally injected
with the vehicle 50% PEG-400 in distilled water as a control group.
Animals run 6 trials a day for two days. Animals are allowed 1 min
to locate the escape platform. On successfully finding the
platform, animals will remain for 10 seconds before being returned
to their holding cage. On a failed trial, animals are guided to the
escape platform and then will be returned to their holding cage 10
seconds later.
[0669] Behavioral tests are recorded and scored using a video
tracking and analysis setup (Ethovision XT 8.5, Noldus Information
Technology). The program automatically analyzes the number of
incorrect arm entries (termed number of errors) made per trial. The
last three trials are averaged to determine learning memory after
training.
[0670] At the end of the behavioral test, animals are sacrificed
and the hippocampi are extracted and immediately frozen in liquid
nitrogen and are stored at -80.degree. C. The frozen samples are
then homogenized with a T 10 basic ULTRA-TURRAX (IKa) in ice-cold
buffer lysis (Cell Signaling 9803) and protease and phosphatase
inhibitors (Roche). Lysates are sonicated for 3 min and centrifuged
at 13,000 rpm for 20 minutes at 4.degree. C. Protein concentration
in supernatants is determined using BCA Protein Assay Kit (Pierce).
Equal amount of protein is loaded on SDS-PAGE gels. Proteins are
transferred onto 0.2 .mu.m PVDF membranes (BioRad) and probed with
primary antibodies diluted in Tris-buffered saline supplemented
with 0.1% Tween 20 and 3% bovine serum albumin.
[0671] ATF4 (11815) antibody (Cell Signaling Technologies) and
R-actin (Sigma-Aldrich) antibodies are used as primary antibodies.
A HRP-conjugated secondary antibody (Rockland) is employed to
detect immune-reactive bands using enhanced chemiluminescence (ECL
Western Blotting Substrate, Pierce). Quantification of protein
bands is done by densitometry using ImageJ software.
[0672] Results of RAWM task and levels of ATF4 expression
normalized to R-actin expression in hippocampi can be reported.
Example B7--Learning Memory, Long-Term Memory and Social Behavior
after Traumatic Brain Injury (TBI)
[0673] Wild type three-month-old male C57Bl/6J mice are randomly
assigned to TBI or sham surgeries. Animals are anesthetized and
maintained at 2% isoflurane and secured to a stereotaxic frame with
nontraumatic ear bars. The hair on their scalp is removed, and eye
ointment and betadine are applied to their eyes and scalp,
respectively. A midline incision is made to expose the skull. A
unilateral TBI is induced in the right parietal lobe using the
controlled cortical impact model (Nat Neurosci. 2014 August; 17(8):
1073-82). Mice receive a 3.5-mm diameter craniectomy, a removal of
part of the skull, using an electric microdrill. The coordinates of
the craniectomy are: anteroposterior, -2.00 mm and mediolateral,
+2.00 mm with respect to bregma. After the craniectomy, the
contusion is induced using a 3-mm convex tip attached to an
electromagnetic impactor (Leica). The contusion depth is set to
0.95 mm from dura with a velocity of 4.0 m/s sustained for 300 ms.
These injury parameters are chosen to target, but not penetrate,
the hippocampus. Sham animals received craniectomy surgeries but
without the focal injury. After focal TBI surgery, the scalp was
sutured and the animal is allowed to recover in an incubation
chamber set to 37.degree. C. Animals are returned to their home
cage after showing normal walking and grooming behavior. Recovery
from the surgical procedures as exhibited by normal behavior and
weight maintenance is monitored throughout the duration of the
experiments.
[0674] After 28 days post injury (dpi), animals are tested on the
RAWM assay (see Example B6, above). Animals run 12 trials during
learning test and 4 trials during memory test. Last three trials
from learning test and all four trials from memory test are
averaged to determine learning memory (learning test) and long-term
memory (memory test).
[0675] Animals are intraperitoneally injected with 5 mg/kg of a
test compound formulated in 50% PEG-400 in distilled water (n=10)
or vehicle (50% PEG-400 in distilled water; n=10 for TBI group and
n=8 for sham group) starting the day prior to behavior tests (27
dpi), after each of the final trials of the learning-test days (28
and 29 dpi) and before the social behavior test (42 dpi, see below)
for a total of four injections. No injections is given when
long-term memory was tested on day 35 dpi.
[0676] To quantitate social tendencies of the treated mice, the
time spent with a novel conspecific mouse was measured in a
Crawley's three-chamber box (J Vis Exp. 2011; (48): 2473). Treated
animals are left to explore all three empty chambers freely for 10
min for habituation. A social pair mouse is placed in the housing
cage at one side of the apparatus and treated animals in opposite
chamber so that the mouse can freely explore the entire apparatus
for 10 min. The time spent with the never-before-met animal is
recorded. Direct contact between the treated mouse and the housing
cage or stretching of the body of the subject mouse in an area 3-5
cm around the housing cage is counted as an active contact.
[0677] Learning memory, long-term memory, and social behavior after
TBI in mice can be reported.
Example B8--Fasting-Induced Muscle Atrophy
[0678] Wild type eight-weeks-old male Balb/c mice obtained from the
vivarium Fundacion Ciencia & Vida Chile (Santiago, Chile) were
used. Mice were housed in independent plastic cages in a room
maintained at 25.degree. C. with a 12-h:12-h light:dark cycle.
[0679] Twenty-four hours before and during the 2 days of fasted
procedures, animals were weighed and receive oral administration
via feeding tubes (15 gauge) of vehicle (50% Polyethylene glycol
400 (Sigma-Aldrich P3265) in distilled water or 10 mg/kg of test
compound formulated in vehicle solution.
[0680] After 2 days of fasting the animals were weighed and
sacrificed. Quadriceps were removed from both hindlimbs and
weighed. Mice with feed and water ad libitum were used as
control.
[0681] For in vivo measurements of protein synthesis, puromycin
(Sigma-Aldrich, P8833) was prepared at 0.04 .mu.mol/g body weight
in a volume of 200 .mu.L of PBS, and subsequently administered into
the animals via IP injection, 30 min prior to muscle
collection.
[0682] Upon collection, muscles were immediately frozen in liquid
nitrogen and then stored at -80.degree. C. The frozen muscles were
then homogenized with a T 10 basic ULTRA-TURRAX (IKa) in ice-cold
buffer lysis (Cell Signaling 9803) and protease and phosphatase
inhibitors (Roche). Lysates were sonicated for 3 min and
centrifuged at 13,000 rpm for 20 minutes at 4.degree. C. Protein
concentration in supernatants was determined using BCA Protein
Assay Kit (Pierce). Equal amount of proteins was loaded on SDS-PAGE
gels. Proteins were transferred onto 0.2 um PVDF membranes (BioRad)
and probed with primary antibodies diluted in Tris-buffered saline
supplemented with 0.1% Tween 20 and 3% bovine serum albumin.
[0683] Puromycin (12D10) (Merck Millipore) ATF4 (Abcam), Atrogin-1
(ECM Biosciences), MuRF-1 (Santa Cruz Biotechnology) and R-actin
(Sigma-Aldrich) antibodies were used as primary antibodies. A
HRP-conjugated secondary antibody (Rockland) was employed to detect
immune-reactive bands using enhanced chemiluminescence (ECL Western
Blotting Substrate, Pierce). Quantification of protein bands was
done by densitometry using ImageJ software.
[0684] Weight of fed mice and fasted mice treated either with
vehicle or compound 58 is shown in FIG. 8A. Percentage of mice
weight was calculated as the percentage of weight at the end of the
study relative to the weight at the beginning of the study (day 0),
where the weight of fed mice at day 0 corresponds to 100%.
[0685] Weight of quadriceps from different groups is shown in FIG.
8B.
[0686] Immunoblot of puromycin labelling in quadriceps samples of
each mouse from fed or fasted animals treated with vehicle or
compound 58 is shown in FIG. 8C. Each lane corresponds to a sample
derived from each mouse. Percent of protein synthesis in muscles
from each group is shown in FIG. 8D. Percentage was calculated from
FIG. 8C as the percent relative to protein synthesis levels from
control mice (Fed) which correspond to 100%.
[0687] Expression of ATF4 and the muscle atrophy marker, Atrogin-1,
of quadriceps derived from fed mice or fasted mice treated with
vehicle or compound 58 are shown in FIG. 8E. Percent of ATF4 and
Atrogin expression from FIG. 8E are shown in FIGS. 8F and 8G
respectively. The levels were normalized to R-actin expression and
percentage was calculated as the percent relative to the expression
from control mice (Fed) which corresponds to 100%. Treatment of
fasted mice with compound 58 results in a reduction of both ATF4
and Atrogin-1 expression compared to vehicle-treated fasted mice
and it was comparable to levels observed in control mice (Fed).
Example B9--Immobilization-Induced Muscle Atrophy
[0688] Wild type eight-weeks-old male Balb/c mice obtained from the
vivarium Fundacion Ciencia & Vida Chile (Santiago, Chile) were
used. Mice were housed in independent plastic cages, fed ad libitum
in a room maintained at 25.degree. C. with a 12-h:12-h light:dark
cycle.
[0689] Twenty-four hours before and during the 3 days of
immobilization procedures, animals receive oral administration via
feeding tubes (15 gauge) of vehicle (50% Polyethylene glycol 400
(Sigma-Aldrich P3265) in distilled water or 10 mg/kg of test
compound formulated in vehicle.
[0690] One hindlimb is immobilized with a plastic stick placed over
and under the limb and fixed with a medical adhesive bandage.
Animals were daily monitored. The immobilization procedure prevents
movement of the immobilized leg alone. After 3 days, the animals
were sacrificed and gastrocnemius muscle is removed from both
hindlimbs, the contralateral, non-immobilized leg being used as an
internal control.
[0691] For in vivo measurements of protein synthesis, puromycin
(Sigma-Aldrich, P8833) is prepared at 0.04 .mu.mol/g body weight in
a volume of 200 .mu.l of PBS, and subsequently administered into
the animals via intraperitoneal injection, 30 min prior to muscle
collection.
[0692] Upon collection, muscles were immediately frozen in liquid
nitrogen and stored at -80.degree. C. The frozen muscles were then
homogenized with a T 10 basic ULTRA-TURRAX (IKa) in ice-cold buffer
lysis (Cell Signaling 9803) and protease and phosphatase inhibitors
(Roche). Lysates were sonicated for 3 min and centrifuged at 13,000
rpm for 20 minutes at 4.degree. C. Protein concentration in
supernatants is determined using BCA Protein Assay Kit (Pierce).
Equal amount of protein is loaded on SDS-PAGE gels. Proteins were
transferred onto 0.2 um PVDF membranes (BioRad) and probed with
primary antibodies diluted in Tris-buffered saline supplemented
with 0.1% Tween 20 and 3% bovine serum albumin.
[0693] Puromycin (12D10) (Merck Millipore), ATF4 (Abcam), Atrogin-1
(ECM Biosciences), MuRF-1 (Santa Cruz Biotechnology) and R-actin
(Sigma-Aldrich) antibodies were used as primary antibodies. A
HRP-conjugated secondary antibody (Rockland) is employed to detect
immune-reactive bands using enhanced chemiluminescence (ECL Western
Blotting Substrate, Pierce). Quantification of protein bands is
done by densitometry using ImageJ software.
[0694] Immunoblot of puromycin labelling in gastrocnemius samples
of mobile and immobile hind limb from mouse treated with vehicle or
compound 58 is shown in FIG. 9A. Each lane corresponds to a sample
derived from the indicated hind limb.
[0695] Percent of protein synthesis in mobile and immobile hind
limbs sections from gastrocnemius derived from mice treated with
vehicle or compound 58 is shown in FIG. 9B. The levels were
normalized to R-actin expression and percentage was calculated as
the percent relative to protein synthesis levels from mobile limb
of control mice (vehicle-treated) which correspond to 100%.
[0696] Expression of ATF4 and the muscle atrophy markers, Atrogin-1
and MuRF-1, of gastrocnemius derived from mobilized and immobilized
hind limbs of mice treated with vehicle or compound 58 are shown in
FIG. 9C. Percent of ATF4, Atrogin-1 and MuRF-1 expression from FIG.
9C are shown in FIGS. 9D, 9E and 9F respectively. The levels were
normalized to 0-actin expression and percentage is calculated as
the percent relative to the expression of mobile hind limb from
control mice (Vehicle) which corresponds to 100%. Treatment of
immobilized animals with compound 58 promotes a reduction of ATF4,
Atrogin-1 and MuRF-1 expression compared to immobilized animals
treated with vehicle.
Example B10--Cachexia-Induced Muscle Atrophy
[0697] Wild type six-weeks-old male Balb/c mice obtained from the
vivarium Fundacion Ciencia & Vida Chile (Santiago, Chile) were
used. Mice were housed in independent plastic cages in a room
maintained at 25.degree. C. with a 12-h:12-h light:dark cycle.
[0698] 1.times.10.sup.6 CT26 colon carcinoma cell line (ATCC
#CRL-2638, ATCC Manassas, Va.) were injected subcutaneously in the
right lower flank of each animal for induction of cachexia-induced
muscle atrophy as described (Nat Commun. 2012 Jun. 12; 3:896).
Non-injected animals were used as controls. At day 7 post
tumor-cell injection, animals were randomized into two groups and
treated with 10 mg/kg of test compound formulated in 50%
Polyethylene glycol (PEG-400) in distilled water, or with vehicle
(50% PEG-400 in distilled water) by daily oral gavage for 12
days.
[0699] After 12 treatments, animals were sacrificed and
gastrocnemius were removed from both hindlimbs. Muscles derived
from non-tumor-bearing mice were used as control.
[0700] Upon collection, muscles were immediately frozen in liquid
nitrogen and then stored at -80.degree. C. The frozen muscles were
then homogenized with a T 10 basic ULTRA-TURRAX (IKa) in ice-cold
buffer lysis (Cell Signaling 9803) and protease and phosphatase
inhibitors (Roche). Lysates were sonicated for 3 min and
centrifuged at 13,000 rpm for 20 minutes at 4.degree. C. Protein
concentration in supernatants was determined using BCA Protein
Assay Kit (Pierce). Equal amount of protein was loaded on SDS-PAGE
gels. Proteins were transferred onto 0.2 um PVDF membranes (BioRad)
and probed with primary antibodies diluted in Tris-buffered saline
supplemented with 0.1% Tween 20 and 3% bovine serum albumin.
[0701] ATF4 (Abcam), Atrogin-1 (ECM Biosciences), MuRF-1 (Santa
Cruz Biotechnology) and R-actin (Sigma-Aldrich) antibodies were
used as primary antibodies. A HRP-conjugated secondary antibody
(Rockland) was employed to detect immune-reactive bands using
enhanced chemiluminescence (ECL Western Blotting Substrate,
Pierce). Quantification of protein bands was done by densitometry
using ImageJ software.
[0702] Expression of ATF4 and the muscle atrophy markers, Atrogin-1
and MuRF-1, of gastrocnemius derived from control and CT26
tumor-bearing mice treated with vehicle or compound 58 are shown in
FIG. 10A. Percent of ATF4, Atrogin-1 and MuRF-1 expression from
FIG. 10A are shown in FIGS. 10B, 10C and 10D respectively. The
levels were normalized to 0-actin expression and percentage was
calculated as the percent relative to the expression of
non-tumor-bearing mice (Control) which corresponds to 100%.
Treatment of tumor-bearing animals with compound 58 results in a
reduction of ATF4, Atrogin-1 and MuRF-1 expression in muscles
compared to those of tumor-bearing animals treated with
vehicle.
Example B11--Denervation-Induced Muscle Atrophy
[0703] Wild type eight-weeks-old male Balb/c mice obtained from the
vivarium Fundacion Ciencia & Vida Chile (Santiago, Chile) were
used. Mice were housed in independent plastic cages in a room
maintained at 25.degree. C. with a 12-h:12-h light:dark cycle.
[0704] After a deeply anesthetized (isoflurane inhaled in medical
oxygen), mice were denervated by surgical removal of -2 mm of
sciatic nerve from one hindlimb. The incisions were closed using
sutures. All procedures were performed under sterile conditions and
the mice were daily monitored.
[0705] After seven days of denervation, animals receive oral
administration every day via feeding tubes (15 gauge) of vehicle
(50% Polyethylene glycol 400 (Sigma-Aldrich P3265) in distilled
water) or 10 mg/kg of compound 58 formulated in vehicle
solution.
[0706] After 14 days of denervation, animals were sacrificed and
tibialis anterior were removed from both hindlimbs. Muscles derived
from non-denervated hind limb were used as control.
[0707] Upon collection, muscles were immediately frozen in liquid
nitrogen and stored at -80.degree. C. The frozen muscles were then
homogenized with a T 10 basic ULTRA-TURRAX (IKa) in ice-cold buffer
lysis (Cell Signaling 9803) and protease and phosphatase inhibitors
(Roche). Lysates were sonicated for 3 min and centrifuged at 13,000
rpm for 20 minutes at 4.degree. C. Protein concentration in
supernatants was determined using BCA Protein Assay Kit (Pierce).
Equal amount of protein was loaded on SDS-PAGE gels. Proteins were
transferred onto 0.2 um PVDF membranes (BioRad) and probed with
primary antibodies diluted in Tris-buffered saline supplemented
with 0.1% Tween 20 and 3% bovine serum albumin.
[0708] ATF4 (Abcam), Atrogin-1 (ECM Biosciences), MuRF-1 (Santa
Cruz Biotechnology) and .beta.-actin (Sigma-Aldrich) antibodies
were used as primary antibodies. A HRP-conjugated secondary
antibody (Rockland) was employed to detect immune-reactive bands
using enhanced chemiluminescence (ECL Western Blotting Substrate,
Pierce). Quantification of protein bands was done by densitometry
using ImageJ software.
[0709] Expression of ATF4 and the muscle atrophy markers, Atrogin-1
and MuRF-1, of tibialis anterior derived from control and
denervated hind limbs of mice treated with vehicle or compound 58
are shown in FIG. 11A. Percent of ATF4, Atrogin-1 and MuRF-1
expression from FIG. 11A are shown in FIGS. 11B, 11C and 11D
respectively. The levels were normalized to .beta.-actin expression
and percentage was calculated as the percent relative to the
expression of non-denervated hind limbs from control mice (Vehicle)
which corresponds to 100%. Treatment of denervated animals with
compound 58 results in a reduction of ATF4, Atrogin-1 and MuRF-1
expression in muscles compared to those of denervated animals
treated with vehicle.
Example B12--Protein Production by Transient Gene Expression
[0710] CHO cells were maintained at 37.degree. C. and 5% CO2 in
DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM
L-glutamine, 100 U/ml penicillin, and 100 .mu.g/ml streptomycin.
After reaching 80% of confluence, cells were detached and seeded on
6-well plates in complete media and allowed to recover for 48 h.
Cells were then washed three times with PBS and transfected with 1
.mu.g of plasmid pIRES2-AcGFP1 (Clonetech 632435) using
Lipofectamine LTX (Thermofisher Scientific) according to
manufacturer instructions. Transfection media was supplemented with
culture medium alone (vehicle) or 1 .mu.M or 5 .mu.M compound 58 in
culture medium.
[0711] After 24 hours treatment, culture media were removed and
cells were lysed with SDS-PAGE lysis buffer. Lysates were
transferred to 1.5 ml tubes and sonicated for 3 min. Total protein
amount was quantified using BCA Protein Assay Kit (Pierce). Equal
amount of proteins (30 .mu.g) was loaded on SDS-PAGE gels. Proteins
were transferred onto 0.2 .mu.m PVDF membranes (BioRad) and probed
with primary antibodies diluted in Tris-buffered saline
supplemented with 0.1% Tween 20 and 3% bovine serum albumin.
[0712] GFP (cell Signaling) and R-actin (Sigma-Aldrich) antibodies
were used as primary antibodies. A HRP-conjugated secondary
antibody (Rockland) was employed to detect immune-reactive bands
using enhanced chemiluminescence (ECL Western Blotting Substrate,
Pierce). Quantification of protein bands was done by densitometry
using ImageJ software.
[0713] Expression of GFP after 24 hours in untreated (Veh) or
treated CHO cells with 1 .mu.M or 5 .mu.M compound 58 is shown in
FIG. 12A. Figure shows 2 sections of the same gel prepared at same
conditions for each antibody. Percent expression of GFP from FIG.
12A is shown in FIG. 12B. The levels were normalized to R-actin
expression and percentage was calculated as the percent relative to
the expression of GFP in untreated condition (Veh) which
corresponds to 100%. Treatment with compound 58 results in an
increased expression of GFP after transient transfection of the
pIRES-AcGFP which encodes GFP protein.
Example B13--Frontotemporal Dementia Cellular Model
[0714] MEF cells were maintained at 37.degree. C. and 5% CO2 in
DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM
L-glutamine, 100 U/ml penicillin, and 100 .mu.g/ml streptomycin.
After reaching 80% of confluence, cells were detached and seeded on
6-well plates in complete media at a density of 3.times.10.sup.5
cells/well and allowed to recover for 48 h. To perform a knockdown
expression of the progranulin protein, cells were then washed three
times with PBS and treated with small interference RNA (siRNA) mix,
that target progranulin (PGRN) gene (Qiagen FlexiTube siRNA mix,
Cat No 1027416), according to manufacturer instructions.
[0715] Transfection media with siRNA mix was supplemented with
OPTIMEM medium alone (GRN7) or 1 .mu.M or 5 .mu.M compound 58 in
OPTIMEM medium. Transfection media without siRNA mix (Veh) and
cells cultured in OPTIMEM medium alone (Unt) were used as
controls.
[0716] After 48 hours treatment, culture media were removed and
cells were lysed with SDS-PAGE lysis buffer. Lysates were
transferred to 1.5 ml tubes and sonicated for 3 min. Total protein
amount was quantified using BCA Protein Assay Kit (Pierce). Equal
amount of proteins (30 .mu.g) was loaded on SDS-PAGE gels. Proteins
were transferred onto 0.2 .mu.m PVDF membranes (BioRad) and probed
with primary antibodies diluted in Tris-buffered saline
supplemented with 0.1% Tween 20 and 3% bovine serum albumin.
[0717] PGRN (R&D Systems) and R-actin (Sigma-Aldrich)
antibodies were used as primary antibodies. A HRP-conjugated
secondary antibody (Rockland) was employed to detect
immune-reactive bands using enhanced chemiluminescence (ECL Western
Blotting Substrate, Pierce). Quantification of protein bands was
done by densitometry using ImageJ software.
[0718] Expression of PGRN after 48 hours in untreated MEF cells
(Unt), or MEF treated with transfection media without siRNA mix
(Veh) or treated with transfection media with siRNA mix alone
(GRN7) or in the presence of 1 .mu.M or 5 .mu.M compound 58 is
shown in FIG. 13. Figure shows 2 sections of the same gel prepared
at same conditions for each antibody. The levels were normalized to
R-actin expression and the fold change was calculated as the
expression relative to the expression of PGRN in the presence of
siRNA alone condition (GRN7) which corresponds to 1. Treatment with
compound 58 results in an increased expression of progranulin in a
knockdown condition.
[0719] All references throughout, such as publications, patents,
patent applications and published patent applications, are
incorporated herein by reference in their entireties.
* * * * *